[go: up one dir, main page]

KR20060079121A - Quinazolin Derivatives Effective in Preventing Diabetes and Obesity - Google Patents

Quinazolin Derivatives Effective in Preventing Diabetes and Obesity Download PDF

Info

Publication number
KR20060079121A
KR20060079121A KR1020050134722A KR20050134722A KR20060079121A KR 20060079121 A KR20060079121 A KR 20060079121A KR 1020050134722 A KR1020050134722 A KR 1020050134722A KR 20050134722 A KR20050134722 A KR 20050134722A KR 20060079121 A KR20060079121 A KR 20060079121A
Authority
KR
South Korea
Prior art keywords
quinazolin
amine compound
alkyl
benzyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020050134722A
Other languages
Korean (ko)
Inventor
이남규
이준원
이석호
임광진
한혜영
김태곤
김용혁
곽의종
김상웅
하주헌
김언겸
이정규
유충열
이대연
Original Assignee
에스케이케미칼주식회사
(주) 리드제넥스
경희대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에스케이케미칼주식회사, (주) 리드제넥스, 경희대학교 산학협력단 filed Critical 에스케이케미칼주식회사
Publication of KR20060079121A publication Critical patent/KR20060079121A/en
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/93—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

본 발명은 혈당 강하, 체중 감소를 나타내는 신규의 퀴나졸린 유도체와, 이 화합물을 유효성분으로 함유하는 당뇨 및 비만 치료예방제에 관한 것이다.The present invention relates to a novel quinazoline derivative that exhibits blood sugar drop and weight loss, and a diabetes and obesity treatment preventive agent containing the compound as an active ingredient.

당뇨병 치료제, 비만 치료제, 퀴나졸린 Diabetes treatment, obesity treatment, quinazoline

Description

당뇨 및 비만 치료예방에 유효한 퀴나졸린 유도체{Quinazoline derivatives for the treatment or prevention of diabetes and obesity}Quinazolin derivatives for the treatment or prevention of diabetes and obesity

도 1은 본 발명에 따른 화합물을 세린79 잔기의 인산화 정도를 웨스턴 블롯(Western blot) 분석한 결과이다.1 is a result of Western blot analysis of phosphorylation degree of the serine 79 residue of the compound according to the present invention.

도 2a 내지 도 2g는 본 발명에 따른 화합물을 세린79잔기와 트레오닌172 잔기의 인산화 정도를 웨스턴 블롯(Western blot) 분석한 결과이다.2A to 2G show Western blot analysis of phosphorylation levels of 79 residues and threonine 172 residues serine compounds according to the present invention.

도 3a 및 도 3b는 본 발명에 따른 화합물을 db/db 마우스에 복강 투여함에 따른 혈당변화를 보여주는 그래프이다.Figure 3a and Figure 3b is a graph showing the change in blood glucose by intraperitoneal administration of the compound according to the invention to db / db mice.

도 4a 및 도 4b는 본 발명에 따른 화합물을 db/db 마우스에 복강 투여함에 따른 체중변화를 보여주는 그래프이다.Figures 4a and 4b is a graph showing the weight change by the abdominal administration of the compound according to the invention to db / db mice.

도 5a, 도 5b 및 도 5c는 본 발명에 따른 화합물을 db/db 마우스에 경구 투여함에 따른 혈당변화를 보여주는 그래프이다.Figures 5a, 5b and 5c is a graph showing the change in blood glucose by oral administration of the compound according to the invention to db / db mice.

도 6a, 도 6b 및 도 6c는 본 발명에 따른 화합물을 db/db 마우스에 경구 투여함에 따른 체중변화를 보여주는 그래프이다.6a, 6b and 6c is a graph showing the weight change by oral administration of the compound according to the invention to db / db mice.

도 7a 및 도 7b는 본 발명에 따른 화합물을 ob/ob 마우스에 복강 투여함에　따른 체중변화를 보여주는 그래프이다.Figures 7a and 7b is a graph showing the weight change following the intraperitoneal administration of the compound according to the invention to ob / ob mice.

도 8a 및 도 8b는 본 발명에 따른 화합물을 ob/ob 마우스에 복강 투여함에 따른 혈당변화를 보여주는 그래프이다.8A and 8B are graphs showing changes in blood glucose by intraperitoneal administration of a compound according to the present invention to ob / ob mice.

도 9는 본 발명에 따른 화합물을 ob/ob 마우스에 경구 투여함에 따른 체중변화를 보여주는 그래프이다.Figure 9 is a graph showing the weight change by oral administration of the compound according to the invention to ob / ob mice.

본 발명은 혈당 강하, 체중 감소를 나타내는 신규의 퀴나졸린 유도체와, 이 화합물을 유효성분으로 함유하는 당뇨 및 비만 치료예방제에 관한 것이다.The present invention relates to a novel quinazoline derivative that exhibits blood sugar drop and weight loss, and a diabetes and obesity treatment preventive agent containing the compound as an active ingredient.

오늘날 가장 흔한 문화병의 하나인 당뇨병은 우리 나라에서도 발생 빈도가 점차 증가되고 있으며 그 병태의 심각성과 후유증으로 말미암아 심각한 사회문제로 대두되고 있다. 경제 발전에 따른 생활 수준의 향상으로 인하여 생활 여건이 향상되면서 운동 부족 현상을 초래하고, 전반적인 식생활의 향상으로 섭취 열량이 크게 증가하여 심각한 비만이 발생됨으로써 제2형 당뇨병이 증가하고 있다. 당뇨병이 오래 지속되면 혈당의 증가 이외에도 혈중 지질 농도가 증가하여 동맥 경화, 관상 심장 질환 등의 심혈관 질환, 당뇨병성 신장 및 망막 질환 등의 합병증을 유발하므로 이의 치료제의 개발이 시급한 실정이다. Diabetes, one of the most common cultural illnesses today, is increasing in frequency in our country and is a serious social problem due to its seriousness and sequelae. As living conditions improve due to the improvement of living standards according to the economic development, the lack of exercise is caused, and the caloric intake is greatly increased due to the improvement of the overall diet, and type 2 diabetes is increasing due to severe obesity. If diabetes is prolonged, blood lipid concentrations are increased in addition to increasing blood sugar, thereby causing complications such as atherosclerosis, coronary heart disease such as coronary heart disease, diabetic kidney and retinal disease, and thus, development of therapeutic agents thereof is urgent.

당뇨병은 크게 인슐린 의존형 당뇨병(Insulin dependent diabetes mellitus, 이하, "IDDM"라 함)과 인슐린 비의존형 당뇨병(Non insulin dependent diabetes mellitus, 이하, "NIDDM"라 함)으로 대별된다. 인슐린 의존형 당뇨병(IDDM) 즉, 제1형 당뇨병은 면역학적인 원인에 의하여 췌장의 베타세포가 파괴되어 인슐린 합성이 이루어지지 않는 질환이다. 반면에 인슐린 비의존형 당뇨병(NIDDM) 즉, 제2형 당뇨병은 인슐린 분비 장애와 인슐린 저항성의 복합 장애라는 두 가지 원인에 발생되는 질환으로, 당뇨병의 95% 이상을 차지한다. 인슐린 분비 장애란 혈당 농도에 따라 췌장의 베타세포에서 적절한 양의 인슐린이 분비되지 않는 상황을 일컬으며, 이는 인슐린을 분비하는 베타세포의 양적인 감소나 기능적인 분배장애를 모두 포함한다. 인슐린 저항성은 분비된 인슐린이 혈류를 타고 표적장기에 도달했으나 그 표적세포에서 인슐린의 작용이 저하된 상황을 의미하는데, 일반적으로 세포막 수용체 결합 후의 신호전달 장애로 생각하며, 그 원인으로는 유전적인 소인, 비만, 육체적 활동저하 및 고혈당 또는 이상지질혈증 등을 들 수 있다. 여기서 중요한 사실은 이 두 가지의 병인이 서로 맞물려 있다는 것이다. 즉, 인슐린 저항성이 있으면 저항성을 극복하기 위해 더 많은 양의 인슐린이 분비되어야 하고, 반대로 인슐린 분비가 충분하지 않아 생긴 고혈당 자체가 다시 인슐린 저항성을 악화시킬 수 있다는 것이다. 따라서 NIDDM의 병인을 이해하기 위해 국내외적으로 인슐린 신호전달체계, 글루코스 이송 및 대사과정에 관한 연구가 방대하게 이루어지고 있으나 NIDDM의 병인이 매우 복잡하고 다양하여 정확한 병리 기전이 밝혀지지 않고 있어 그에 따른 적절한 치료 방법의 개선이 이루어지지 않고 있다.Diabetes is roughly divided into insulin dependent diabetes mellitus (hereinafter referred to as "IDDM") and insulin independent diabetes mellitus (hereinafter referred to as "NIDDM"). Insulin-dependent diabetes mellitus (IDDM), that is, type 1 diabetes, is a disease in which beta cells of the pancreas are destroyed by immunological causes and insulin synthesis is not achieved. On the other hand, insulin independent diabetes mellitus (NIDDM), namely type 2 diabetes, is caused by two disorders, insulin secretion disorder and insulin resistance complex, and accounts for more than 95% of diabetes. Insulin secretion disorder refers to a situation in which an appropriate amount of insulin is not secreted from the beta cells of the pancreas according to the blood glucose level, which includes both a quantitative decrease in insulin secreting beta cells and a functional distribution disorder. Insulin resistance refers to a situation in which secreted insulin reaches the target organ in the bloodstream but the action of insulin in the target cell is degraded. In general, it is regarded as a signaling disorder after membrane membrane receptor binding. , Obesity, decreased physical activity and hyperglycemia or dyslipidemia. The important fact here is that these two etiologies are interlocked. In other words, if insulin resistance is required, more insulin must be secreted to overcome resistance, and conversely, hyperglycemia caused by insufficient insulin secretion may worsen insulin resistance again. Therefore, in order to understand the etiology of NIDDM, researches on insulin signaling system, glucose transport and metabolism have been conducted at home and abroad, but the pathogenesis of NIDDM is very complicated and diverse. Improvements in treatment have not been made.

한편, 제2형 당뇨병(NIDDM)이 비만과 관련되어 있음은 잘 알려져 있으나, 아직 정확한 상호 작용이나 연관성에 관한 기전이 정확히 밝혀지지 않았다. 하지 만 비만과 그에 따른 지방산 대사장애가 대사질환의 발병과 불가분의 관계가 있을 것이라는 전제를 두고, 최근 당뇨병 병인연구의 초점이 '포도당 대사'에서 '지방산 대사' 중심으로 옮겨지고 있다. 제2형 당뇨병 환자에서 고혈당 이외에 지질대사의 이상, 즉 혈중 지방산의 증가, 중성지방 증가, 고밀도 지단백 콜레스테롤 감소, 근육 내 지방의 축적, 복부 지방량 증가, 지방간의 발생 등을 흔히 발견할 수 있다. 물론 이런 지질 항상성의 장애가 당뇨병으로 인한 고혈당의 결과인지 아니면 당뇨병 발생의 원인으로 작용한 것인지는 아직 확실하지 않다. 그러나 인슐린 저항성 발생에 선행하여 인슐린 표적장기인 골격근, 심장 근육, 간조직 등에 중성지방의 비정상적인 축적이나 지방조직에서 지방산 유리 증가 등 지방산 대사장애가 선행하여 나타나고, 이런 현상이 지속될 때 인슐린 저항성이 악화되면서, 식후 또는 공복 시 고혈당이 나타나기 시작하고, 이는 다시 인슐린 저항성 및 지방산 대사장애를 더욱 악화시키게 되는 악순환을 거치게 되면서 결국 다른 대사질환들을 유발하게 된다. 이러한 병리현상은 생체밖 실험 또는 동물실험 뿐 아니라 사람을 대상으로 한 연구에서 비교적 일관되게 증명되고 있다. 하지만 무엇이 이런 지방대사 장애를 유발하는지 또는 어떤 기전에 의해서 인슐린 저항성이 초래되어 생리적 항상성을 파괴하는지에 대해서는 아직도 명확하지 않은 실정이다. It is well known that type 2 diabetes mellitus (NIDDM) is associated with obesity, but the mechanisms for precise interactions and associations are not yet known. However, under the premise that obesity and subsequent fatty acid metabolic disorders are inextricably linked to the development of metabolic diseases, the focus of diabetes etiology research has recently shifted from 'glucose metabolism' to 'fatty acid metabolism'. In patients with type 2 diabetes, abnormalities of lipid metabolism other than hyperglycemia, such as an increase in blood fatty acids, an increase in triglycerides, a decrease in high-density lipoprotein cholesterol, accumulation of muscle fat, an increase in abdominal fat, and fatty liver, are commonly found. Of course, it is not yet clear whether this disorder of lipid homeostasis is the result of diabetes or hyperglycemia. However, prior to the development of insulin resistance, fatty acid metabolic disorders such as abnormal accumulation of triglycerides and increased fatty acid release in fatty tissues, such as skeletal muscle, heart muscle, and liver tissues, which are targets of insulin, are preceded. Hyperglycemia begins to appear after meals or on an empty stomach, which in turn leads to a vicious cycle that further exacerbates insulin resistance and fatty acid metabolism, eventually leading to other metabolic disorders. This pathology has been demonstrated relatively consistently in human studies as well as in vitro or animal studies. However, it is still unclear what causes these fat metabolism disorders or which mechanisms cause insulin resistance to destroy physiological homeostasis.

이런 상황 속에서 현재 인슐린 저항성(insulin resistance)이 NIDDM의 가장 중요한 병리 기전으로 인식되고 있으며, 이는 체내인슐린이 충분하다 해도 당을 제대로 활용하지 못하는 현상을 의미하고 있으며, 이를 치료하기 위해 다양한 혈당 강하제가 사용되고 있다. 혈당 강하제는 치료기전 및 작용 약물의 작용점에 따 라 다음과 같이 분류된다 :In this situation, insulin resistance is currently recognized as the most important pathological mechanism of NIDDM, which means that even if the body's insulin is sufficient, it does not utilize sugar properly. It is used. Hypoglycemic agents are classified as follows according to the mechanism of action and the point of action of the acting drug:

1) 설포닐우레아계 약물은 주로 췌장의 베타세포 안에 있는 인슐린을 함유한 과립포의 이동을 촉진하여 간접적으로 인슐린을 분비시키는 약물로, 저혈당 유발 등의 심각한 부작용이 보고되고 있으나 최근에는 부작용을 최소화한 약물이 개발되기도 하였다.1) Sulfonylurea drugs are drugs that indirectly secrete insulin by promoting the movement of granules containing insulin in the beta cells of the pancreas, and serious side effects such as hypoglycemia have been reported. A drug has been developed.

2) 비구아나이드계 약물은 근육세포로 당을 이동시키고 간에서 당의 합성(gluconeogenesis)을 억제하는 약물로, 저혈당을 일으키지 않는 장점을 갖고 있으나 고령자와 심 혈관 질환 환자에게는 사용 시 주의가 요구되고 있다.2) Biguanide-based drugs transfer drugs to muscle cells and inhibit glucose synthesis (gluconeogenesis) in the liver. They have the advantage of not causing hypoglycemia, but they require caution when used in elderly and cardiovascular patients.

3) 알파 글루코시다아제 저해제는 소장에서 포도당을 만드는 효소 활동을 억제시켜 식후에 일시적으로 혈당이 급상승하는 것을 막아주고, 부작용이 심하지 않은 편이어서 경증 당뇨병 치료에 이용된다.3) Alpha glucosidase inhibitors inhibit the activity of glucose-producing enzymes in the small intestine to prevent blood glucose spikes temporarily after meals, and they are used for the treatment of mild diabetes because of their moderate side effects.

4) 티아졸리디온(TZD)계 약물은 최근에 개발된 것으로, 지방세포의 분화에 관계되는 피피에알 감마를 활성화하는 것으로 알려져 있다.4) Thiazolidion (TZD) -based drugs have recently been developed and are known to activate PPIE gamma, which is involved in the differentiation of adipocytes.

이러한 경구용 혈당 강하제 만으로는 혈당이 효과적으로 떨어지지 않고 이미 알려진 대부분의 약물에서 부작용이 나타나므로 보다 안전한 당뇨병 치료제 개발이 시급한 실정이다. 또한 제2형 당뇨병은 인슐린 신호 전달 체계 및 탄수화물과 지질대사 과정에서의 다양한 문제점으로 인해 발생하기 때문에 새로운 치료제 개발을 위해서는 이러한 신호전달 및 대사 과정을 전반적으로 조절하는 새로운 목표 단백질의 발굴이 절실한 실정이다.Since oral blood glucose lowering agents alone do not drop blood sugar effectively and most of the known side effects occur in the drug, it is urgent to develop a safer diabetes treatment. In addition, since type 2 diabetes is caused by various problems in the insulin signaling system and carbohydrate and lipid metabolism processes, it is urgent to discover new target proteins that regulate these signaling and metabolic processes in general for the development of new therapeutics. .

최근 5'AMP 활성화 단백질 인산화 효소(5'AMP-activated protein kinase, 이 하, "AMPK"라 함)가 탄수화물 및 지질대사 그리고 포도당 흡수를 조절하는 역할이 밝혀지면서 이의 활성물질이 제2형 당뇨병 치료제로서의 개발 가능성이 제시되고 있으며 이러한 근거는 다음과 같다.Recently, 5'AMP-activated protein kinase (hereinafter referred to as "AMPK") has been shown to regulate carbohydrate, lipid metabolism and glucose absorption, its active substance is a type 2 diabetes treatment The possibility of development is proposed as follows.

1) 운동을 시킨 쥐의 근육세포에서 ATP 소모의 결과로 AMP의 양이 증가하고, 이로 인해 AMPK의 활성도가 증가하고, 그 결과 포도당 흡수가 증가하는 사실이 관찰되었다.1) It was observed that the amount of AMP increased as a result of ATP depletion in exercised rat muscle cells, which resulted in increased AMPK activity and increased glucose uptake.

2) AMPK에 의해 포도당 흡수가 증가되는 기전은 인슐린 신호 전달 체계와 독립적이며, 이 사실은 인슐린 신호 전달체계에 이상이 발견되는 대부분의 제2형 당뇨병 환자에서 새로운 치료 목표 물질이 될 수 있다는 사실을 의미한다.2) The mechanism by which AMPK increases glucose uptake is independent of the insulin signaling system, suggesting that it may be a new therapeutic target in most patients with type 2 diabetes who have found abnormalities in the insulin signaling system. it means.

3) 실제로 제2형 당뇨 환자들의 대부분이 운동을 함으로써 혈당량을 감소할 수 있으며, 당뇨 모델 동물실험 결과 운동에 의해 AMPK가 활성화되며 동시에 혈당량이 감소되는 사실도 보고되고 있다.3) In fact, most of the patients with type 2 diabetes can reduce blood sugar levels by exercising, and according to the animal experiments of diabetes, AMPK is activated and blood glucose levels are also reduced.

4) 이 뿐 아니라 AMPK는 생체 내에서 다양할 역할을 수행하는데 췌장세포에서 인슐린의 분비를 조절할 뿐만 아니라 지방세포에서 아세틸 CoA 카르복시라제(ACC)와 HMG-CoA 환원효소의 활성을 저해하여 지방생성 및 콜레스테롤 합성을 억제하여 비만의 조절에도 중요한 역할을 한다.4) In addition, AMPK plays a variety of roles in vivo. It not only regulates insulin secretion in pancreatic cells but also inhibits the activity of acetyl CoA carboxylase (ACC) and HMG-CoA reductase in adipocytes. It inhibits cholesterol synthesis and plays an important role in the control of obesity.

결론적으로, AMPK는 그 이름에서 시사하는 바와 같이 근육수축이나 운동 후 세포내의 에너지 고갈의 결과로 축적된 AMP에 의해 활성화되어 에너지 항상성 조절과 탄수화물 및 지질 대사 조절의 중추적인 역할을 하고 있다. 또한 에너지 불균형으로 인하여 초래되는 당뇨 및 비만 등 대사성 질환 치료를 위한 새로운 목표 물질로 인식되고 있다. 운동에 의한 포도당 흡수 과정에서 AMPK의 중요성은 현재 널리 인식되고 있으며, 이 기전은 인슐린 신호 전달 체계와 독립적으로 일어나고 있으며, 이 사실은 인슐린 신호 전달 체계에 이상이 발견되는 대부분의 제2형 당뇨병 환자에서 새로운 치료 목표 물질이 될 수 있다는 사실을 의미한다. 실제로 제2형 당뇨 환자들의 대부분이 운동을 함으로써 혈당량을 감소할 수 있으며 당뇨 모델 동물에서 운동에 의해 AMPK가 활성화되며 동시에 혈당량이 감소되는 사실도 보고되고 있다. 또한 현재 당뇨 치료제로서 널리 사용되는 메트포민(Metformin) 혹은 티아졸리딘디온(TZD) 계열의 약물도 그 효과가 부분적으로 AMPK를 통해 혈당을 강하시킨다는 보고가 있다. 이러한 사실을 종합적으로 볼 때 AMPK를 활성화시킬 수 있는 약물 발굴은 운동으로 인한 다양한 대사성 질환 개선 효과를 모방할 수 있는 신 개념의 치료제 개발로 이어지리라 예상된다. In conclusion, AMPK, as its name suggests, is activated by AMP accumulated as a result of intracellular energy depletion after muscle contraction or exercise, and plays a pivotal role in regulating energy homeostasis and carbohydrate and lipid metabolism. It is also recognized as a new target for the treatment of metabolic diseases such as diabetes and obesity caused by energy imbalance. The importance of AMPK in the process of glucose uptake by exercise is now widely recognized, and this mechanism occurs independently of the insulin signaling system, which is found in most patients with type 2 diabetes who have abnormalities in the insulin signaling system. It means that it can be a new therapeutic target substance. In fact, most of the patients with type 2 diabetes can reduce blood glucose levels by exercising, and it has been reported that AMPK is activated and blood glucose levels are reduced by exercise in a diabetic model animal. In addition, it is reported that the drug of metformin or thiazolidinedione (TZD) family, which is widely used as a diabetes treatment agent, partially lowers blood sugar through AMPK. Based on these findings, the discovery of drugs that can activate AMPK will lead to the development of new therapeutics that can mimic the effects of exercise on various metabolic diseases.

그러나 AMPK의 활성제로서 제2형 당뇨병과 비만증에 선택적으로 효과가 있으면서 당뇨병 실험동물에 대하여 현저히 혈당을 감소시키는 저해물질에 대해서는 보고가 미비하다.However, there are few reports on inhibitors that significantly reduce blood sugar levels in diabetic experimental animals, while being selectively active against type 2 diabetes and obesity as an active agent of AMPK.

따라서, 본 발명은 AMPK 효소의 활성증가, 비만 및 당뇨 예방 및 치료 등에 뚜렷한 효과가 있는 신규 물질을 합성하여, 그 효과를 확인함으로써 완성하게 되었다.Accordingly, the present invention has been completed by synthesizing a novel substance having a marked effect on increasing the activity of the AMPK enzyme, preventing and treating obesity and diabetes, and confirming its effect.

본 발명자들은 상기한 여러 문제를 해결하기 위하여 퀴나졸린 골격을 가진 여러 화합물들을 합성하여 혈당 강하 활성과 체중 감소를 측정한 결과 탁월한 활성과 체중 감소를 나타내는 것을 확인하였다. The present inventors synthesized various compounds having a quinazoline skeleton in order to solve the above-described problems, and as a result of measuring the blood glucose lowering activity and weight loss, it was confirmed that it shows excellent activity and weight loss.

따라서 본 발명은 당뇨병 및 비만 치료에 필수적인 혈당 강하 효과와 체중 감소 효과가 우수한 신규의 퀴나졸린 화합물을 제공하는데 그 목적이 있다.Accordingly, an object of the present invention is to provide a novel quinazoline compound having excellent hypoglycemic effect and weight loss effect, which are essential for treating diabetes and obesity.

또한, 본 발명은 신규의 퀴나졸린 화합물, 약제학적으로 허용 가능한 이의 염, 또는 약제학적으로 허용 가능한 이의 프로드럭을 유효성분으로 함유하는, 독성 및 부작용이 없는 당뇨병 및 비만 치료제를 제공하는데 다른 목적이 있다.The present invention also provides a novel quinazoline compound, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable prodrug thereof as an active ingredient, wherein the present invention provides a therapeutic agent for diabetes and obesity without toxicity and side effects. have.

본 발명은 당뇨 및 비만 치료제로 유효한 다음 화학식 1로 표시되는 퀴나졸린 유도체, 약제학적으로 허용 가능한 이의 염, 또는 약제학적으로 허용 가능한 이의 프로드럭을 그 특징으로 한다.The present invention is characterized by a quinazoline derivative represented by the following formula (1), a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable prodrug thereof, which is effective as a therapeutic agent for diabetes and obesity.

Figure 112005078193254-PAT00001
Figure 112005078193254-PAT00001

상기 화학식 1에서, In Chemical Formula 1,

Ra은 수소, (C1-C18)알킬, (C2-C8)알케닐, (C2-C8)알키닐, 할로게노-(C1-C6)알킬, 히드록시-(C1-C6)알킬, (C1-C6)알콕시-(C1-C6)알킬, 시아노-(C1-C6)알킬, 아미노- (C1-C6)알킬, (C1-C6)알킬아미노-(C1-C6)알킬, 디-[(C1-C6)알킬]아미노-(C1-C6)알킬, (C1-C6)알킬티오-(C1-C6)알킬, (C1-C6)알킬설피닐-(C1-C6)알킬 또는 (C1-C6)알킬설포닐-(C1-C6)알킬에서 선택된 치환체이거나, 화학식 -X1-Q1 [여기서, X1는 직접 결합이거나, O, S, SO, SO2, N(R4), CO, CO2, CH(OR4), CON(R4), N(R4)CO, SO2N(R4), N(R4)SO2, C(R4)2O, C(R4)2S, N(R4)C(R4)2 , N(R4)CON(R4), N(R4)CSN(R4)]에서 선택되고, R4은 수소, (C1-C6)알킬, 아릴, 아릴-(C1-C6)알킬, (C3-C7)싸이클로알킬, (C3-C7)싸이클로알킬-(C1-C6)알킬, (C3-C7)싸이클로알케닐, (C3-C7)싸이클로알케닐-(C1-C6)알킬, 헤테로아릴, 헤테로아릴-(C1-C6)알킬, 헤테로싸이클릴 또는 헤테로싸이클릴-(C1-C6)알킬의 기이고, Q1은 R4 와 동일하거나 상이한 치환기에서 선택될 수 있으며, R a is hydrogen, (C 1 -C 18 ) alkyl, (C 2 -C 8 ) alkenyl, (C 2 -C 8 ) alkynyl, halogeno- (C 1 -C 6 ) alkyl, hydroxy- ( C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy- (C 1 -C 6 ) alkyl, cyano- (C 1 -C 6 ) alkyl, amino- (C 1 -C 6 ) alkyl, ( C 1 -C 6 ) alkylamino- (C 1 -C 6 ) alkyl, di-[(C 1 -C 6 ) alkyl] amino- (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkylthio At-(C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkylsulfinyl- (C 1 -C 6 ) alkyl or (C 1 -C 6 ) alkylsulfonyl- (C 1 -C 6 ) alkyl Is a selected substituent or is of the formula -X 1 -Q 1 wherein X 1 is a direct bond or is O, S, SO, SO 2 , N (R 4 ), CO, CO 2 , CH (OR 4 ), CON (R 4 ), N (R 4 ) CO, SO 2 N (R 4 ), N (R 4 ) SO 2 , C (R 4 ) 2 O, C (R 4 ) 2 S, N (R 4 ) C (R 4 ) 2 , N (R 4 ) CON (R 4 ), N (R 4 ) CSN (R 4 )], and R 4 is hydrogen, (C 1 -C 6 ) alkyl, aryl, aryl- (C 1 -C 6 ) alkyl, (C 3 -C 7 ) cycloalkyl, (C 3 -C 7 ) cycloalkyl- (C 1 -C 6 ) alkyl, (C 3 -C 7 ) cycloalkenyl, (C 3 -C 7 ) cycloalkenyl- (C 1 Is a group of -C 6 ) alkyl, heteroaryl, heteroaryl- (C 1 -C 6 ) alkyl, heterocyclyl or heterocyclyl- (C 1 -C 6 ) alkyl, Q 1 is R 4 and May be selected from the same or different substituents,

그리고, 여기서 Ra 기내에서의 (C2-C6)알킬렌 기에서 인접 탄소 원자는 O, S, SO, SO2 , N(R5), CO, CH(OR5), CON(R5), N(R5)CO, SO2N(R5), N(R5)SO2, C(R5)=C(R5) 및 C≡C에서 선택된 기의 삽입에 의해서 분리될 수 있고, 여기서 R5는 수소 또는 (C1-C6)알킬이고 And wherein adjacent carbon atoms in the (C 2 -C 6 ) alkylene group in the group R a are O, S, SO, SO 2 , N (R 5 ), CO, CH (OR 5 ), CON (R 5 ), N (R 5 ) CO, SO 2 N (R 5 ), N (R 5 ) SO 2 , C (R 5 ) = C (R 5 ) and C≡C can be separated by insertion of a group selected Wherein R 5 is hydrogen or (C 1 -C 6 ) alkyl

여기서 Ra 기내에서의 임의의 CH2=CH- 또는 HC≡C- 기는 말단 CH2= 또는 HC≡ 위치에서 할로게노, 카르복시, 카르바모일, (C1-C6)알콕시카르보닐, N-(C1-C6)알킬카르바모일, N,N-디-[(C1-C6)알킬]카르바모일, 아미노-(C1-C6)알킬, (C1-C6)알킬아미노-(C1-C6)알킬 및 디-[(C1-C6)알킬]아미노-(C1-C6)알킬에서 선택되거나 또는 화학식 Q2-X2-[여기서, X2는 직접 결합이거나, CO 및 N(R6)CO에서 선택되고, 여기서 R6는 수소 또는 (C1-C6)알킬이고, Q2는 아릴, 아릴-(C1-C6)알킬, 헤테로아릴, 헤테로아릴-(C1-C6)알킬, 헤테로싸이클릴 또는 헤테로싸이클릴-(C1-C6)알킬임]의 기에서 선택된 치환체를 포함할 수 있고,Wherein any CH 2 ═CH— or HC≡C— group in the R a group is halogeno, carboxy, carbamoyl, (C 1 -C 6 ) alkoxycarbonyl, N— at the terminal CH 2 = or HC≡ position (C 1 -C 6 ) alkylcarbamoyl, N, N- di-[(C 1 -C 6 ) alkyl] carbamoyl, amino- (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkylamino, - (C 1 -C 6) alkyl and di - [(C 1 -C 6) alkyl] amino - (C 1 -C 6) alkyl selected from or the formula Q 2 -X 2 - [wherein, X 2 Is a direct bond or is selected from CO and N (R 6 ) CO, wherein R 6 is hydrogen or (C 1 -C 6 ) alkyl, Q 2 is aryl, aryl- (C 1 -C 6 ) alkyl, hetero Aryl, heteroaryl- (C 1 -C 6 ) alkyl, heterocyclyl or heterocyclyl- (C 1 -C 6 ) alkyl], and

여기서 Ra 기내에서의 임의의 CH2 또는 CH3기는 각각의 CH2 또는 CH3기에서 1 이상의 할로게노, (C1-C6)알킬 치환체, 히드록시, 시아노, 아미노, 카르복시, 카르바모일, (C1-C6)알콕시, (C1-C6)알킬티오, (C1-C6)알킬설피닐, (C1-C6)알킬설포닐, (C1-C6)알킬아미노, 디-[(C1-C6)알킬]아미노, (C1-C6)알콕시카르보닐, N-(C1-C6)알킬카르바모일, N,N-디-[(C1-C6)알킬]카르바모일, (C2-C6)알카노일, (C2-C6)알카노일옥시, (C2-C6)알카노일아미노, N-(C1-C6)알킬-(C2-C6)알카노일아미노, N-(C1-C6)알킬설 파모일, N,N-디-[(C1-C6)알킬]설파모일, (C1-C6)알칸설포닐아미노 및 N-(C1-C6)알킬-(C1-C6)알칸설포닐아미노에서 선택된 치환체 또는, 화학식 -X3-Q3 [여기서, X3는 직접 결합이거나, O, S, SO, SO2, N(R7), CO, CH(OR7), CON(R7), N(R7)CO, SO2N(R7), N(R7)SO2, C(R7)2O, C(R7)2S, N(R7)C(R7)2, N(R7)CON(R7) 및 N(R7)CSN(R7)에서 선택되고, R7 은 수소, (C1-C6)알킬, 아릴, 아릴-(C1-C6)알킬, (C3-C7)싸이클로알킬, (C3-C7)싸이클로알킬-(C1-C6)알킬, (C3-C7)싸이클로알케닐, (C3-C7)싸이클로알케닐-(C1-C6)알킬, 헤테로아릴, 헤테로아릴-(C1-C6)알킬, 헤테로싸이클릴 또는 헤테로싸이클릴-(C1-C6)알킬의 기이고, Q3 은 R7 와 동일하거나 상이한 치환기에서 선택될 수 있으며Wherein any CH 2 or CH 3 group in the R a group is at least one halogeno, (C 1 -C 6 ) alkyl substituent, hydroxy, cyano, amino, carboxy, carba at each CH 2 or CH 3 group together, (C 1 -C 6) alkoxy, (C 1 -C 6) alkylthio, (C 1 -C 6) alkylsulfinyl, (C 1 -C 6) alkylsulfonyl, (C 1 -C 6) alkylamino, di - [(C 1 -C 6) alkyl] amino, (C 1 -C 6) alkoxycarbonyl, N- (C 1 -C 6) alkyl-carbamoyl, N, N- di - [( C 1 -C 6 ) alkyl] carbamoyl, (C 2 -C 6 ) alkanoyl, (C 2 -C 6 ) alkanoyloxy, (C 2 -C 6 ) alkanoylamino, N- (C 1- C 6 ) alkyl- (C 2 -C 6 ) alkanoylamino, N- (C 1 -C 6 ) alkylsulfamoyl, N, N- di-[(C 1 -C 6 ) alkyl] sulfamoyl, ( C 1 -C 6) alkane sulfonyl amino, N- (C 1 -C 6) alkyl, - (C 1 -C 6) alkane-sulfonyl-amino or a substituent selected from the formula -X 3 -Q 3 [wherein, X 3 Is a direct bond or O, S, SO, SO 2 , N (R 7 ), CO, CH (OR 7 ), CON (R 7 ), N (R 7 ) CO, SO 2 N (R 7 ), N ( R 7 ) SO 2 , C (R 7 ) 2 O, C (R 7 ) 2 S, N (R 7 ) C (R 7 ) 2 , N (R 7 ) CON (R 7 ) and N (R 7 ) CSN (R 7 ), R 7 is hydrogen, (C 1 -C 6 ) alkyl, aryl, aryl- (C 1 -C 6 ) Alkyl, (C 3 -C 7 ) cycloalkyl, (C 3 -C 7 ) cycloalkyl- (C 1 -C 6 ) alkyl, (C 3 -C 7 ) cycloalkenyl, (C 3 -C 7 ) cyclo Is a group of alkenyl- (C 1 -C 6 ) alkyl, heteroaryl, heteroaryl- (C 1 -C 6 ) alkyl, heterocyclyl or heterocyclyl- (C 1 -C 6 ) alkyl, Q 3 is With R 7 May be selected from the same or different substituents,

여기서, Ra 상의 치환체내에서의 임의의 아릴, 헤테로아릴 또는 헤테로싸이클릴기는 0 내지 3개의 치환체를 포함할 수 있고, 이 치환체는 동일하거나 상이할 수 있으며, 할로게노, 트리플루오로메틸, 시아노, 니트로, 히드록시, 아미노, 카르복시, 카르바모일, (C1-C6)알킬, (C2-C8)알케닐, (C2-C8)알키닐, (C1-C6)알콕시, (C2-C6)알케닐옥시, (C2-C6)알키닐옥시, (C1-C6)알킬티오, (C1-C6)알킬설피닐, (C1-C6)알킬설포닐, (C1-C6)알킬아미노, 디-[(C1-C6)알킬]아미노, (C1-C6)알콕시카르보닐, N-(C1- C6)알킬카르바모일, N,N-디-[(C1-C6)알킬]카르바모일, (C2-C6)알카노일, (C2-C6)알카노일옥시, (C2-C6)알카노일아미노, N-(C1-C6)알킬-(C2-C6)알카노일아미노, N-(C1-C6)알킬설파모일, N,N-디-[(C1-C6)알킬]설파모일, (C1-C6)알칸설포닐아미노 및 N-(C1-C6)알킬-(C1-C6)알칸설포닐아미노에서 선택되거나 또는, 화학식 -X4-R8 [여기서, X4는 직접 결합이거나, O 및 N(R9)에서 선택되고, 여기서 R9는 수소 또는 (C1-C6)알킬이고, R8은 할로게노-(C1-C6)알킬, 히드록시-(C1-C6)알킬, (C1-C6)알콕시-(C1-C6)알킬, 시아노-(C1-C6)알킬, 아미노-(C1-C6)알킬, (C1-C6)알킬아미노-(C1-C6)알킬, 디-[(C1-C6)알킬]아미노-(C1-C6)알킬, (C2-C6)알카노일아미노-(C1-C6)알킬 또는 (C1-C6)알콕시카르보닐아미노-(C1-C6)알킬 임]의 기에서 선택되거나, 또는 화학식-X5-Q4 [여기서, X5는 직접 결합이거나 O, CO 및 N(R10)에서 선택되고, 여기서 R10은 수소 또는 (C1-C6)알킬이고, Q4은 아릴, 아릴-(C1-C6)알킬, 헤테로아릴, 헤테로아릴-(C1-C6)알킬, 헤테로싸이클릴 또는 헤테로싸이클릴-(C1-C6)알킬이고, 이것은 1 또는 2개의 치환체를 포함할 수 있으며, 이 치환체는 동일하거나 상이할 수 있으며, 할로게노, (C1-C6)알킬 및 (C1-C6)알콕시에서 선택되는 것임]의 기에서 선택되고,Wherein any aryl, heteroaryl, or heterocyclyl group in the substituent on R a may comprise 0 to 3 substituents, which substituents may be the same or different and include halogeno, trifluoromethyl, cya Furnace, nitro, hydroxy, amino, carboxy, carbamoyl, (C 1 -C 6 ) alkyl, (C 2 -C 8 ) alkenyl, (C 2 -C 8 ) alkynyl, (C 1 -C 6 ) Alkoxy, (C 2 -C 6 ) alkenyloxy, (C 2 -C 6 ) alkynyloxy, (C 1 -C 6 ) alkylthio, (C 1 -C 6 ) alkylsulfinyl, (C 1- C 6 ) alkylsulfonyl, (C 1 -C 6 ) alkylamino, di-[(C 1 -C 6 ) alkyl] amino, (C 1 -C 6 ) alkoxycarbonyl, N- (C 1 -C 6 ) alkyl carbamoyl, N, N- di - [(C 1 -C 6) alkyl] carbamoyl, (C 2 -C 6) alkanoyl, (C 2 -C 6) alkanoyloxy, (C 2 -C 6 ) alkanoylamino, N- (C 1 -C 6 ) alkyl- (C 2 -C 6 ) alkanoylamino, N- (C 1 -C 6 ) alkylsulfamoyl, N, N- di- [ (C 1 -C 6) alkyl] sulfamoyl, (C 1 -C 6) alkane sulfonylamino N- (C 1 -C 6) alkyl, - (C 1 -C 6) alkane sulfonyl selected or in the amino, the formula -X 4 -R 8 [wherein, X 4 is either a direct bond, O or N (R 9 ), Where R 9 is hydrogen or (C 1 -C 6 ) alkyl, R 8 is halogeno- (C 1 -C 6 ) alkyl, hydroxy- (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy- (C 1 -C 6 ) alkyl, cyano- (C 1 -C 6 ) alkyl, amino- (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkylamino- ( C 1 -C 6 ) alkyl, di-[(C 1 -C 6 ) alkyl] amino- (C 1 -C 6 ) alkyl, (C 2 -C 6 ) alkanoylamino- (C 1 -C 6 ) alkyl Or (C 1 -C 6 ) alkoxycarbonylamino- (C 1 -C 6 ) alkyl], or a compound of formula-X 5 -Q 4 , wherein X 5 is a direct bond or O, CO and N (R 10 ), wherein R 10 is hydrogen or (C 1 -C 6 ) alkyl, Q 4 is aryl, aryl- (C 1 -C 6 ) alkyl, heteroaryl, heteroaryl- (C 1 -C 6 ) alkyl, heterocyclyl or heterocyclyl- (C 1 -C 6 ) alkyl , Which may comprise one or two substituents, which substituents may be the same or different and are selected from halogeno, (C 1 -C 6 ) alkyl and (C 1 -C 6 ) alkoxy] Is selected from,

그리고, 여기서 Ra 상의 치환체내에서 헤테로싸이클릴기는 1 또는 2개의 옥소 또는 티옥소 치환체를 포함할 수 있으며;And wherein the heterocyclyl group in the substituent on R a may comprise one or two oxo or thioxo substituents;

Rb은 수소, (C1-C18)알킬, (C2-C8)알케닐, (C2-C8)알키닐, 할로게노-(C1-C6)알킬, 히드록시-(C1-C6)알킬, (C1-C6)알콕시-(C1-C6)알킬, 시아노-(C1-C6)알킬, 아미노-(C1-C6)알킬, (C1-C6)알킬아미노-(C1-C6)알킬, 디-[(C1-C6)알킬]아미노-(C1-C6)알킬, (C1-C6)알킬티오-(C1-C6)알킬, (C1-C6)알킬설피닐-(C1-C6)알킬 또는 (C1-C6)알킬설포닐-(C1-C6)알킬에서 선택된 치환체이거나, 화학식 -X1-Q1 [여기서, X1는 직접 결합이거나, O, S, SO, SO2, N(R4), CO, CO2(R4), CH(OR4), CON(R4), N(R4)CO, SO2N(R4), N(R4)SO2, C(R4)2O, C(R4)2S, N(R4)C(R4)2 , N(R4)CON(R4), N(R4)CSN(R4)]에서 선택되고, R4은 수소, (C1-C6)알킬, 아릴, 아릴-(C1-C6)알킬, (C3-C7)싸이클로알킬, (C3-C7)싸이클로알킬-(C1-C6)알킬, (C3-C7)싸이클로알케닐, (C3-C7)싸이클로알케닐-(C1-C6)알킬, 헤테로아릴, 헤테로아릴-(C1-C6)알킬, 헤테로싸이클릴 또는 헤테로싸이클릴-(C1-C6)알킬의 기이고, Q1은 R4 와 동일하거나 상이한 치환기에서 선택될 수 있으며, R b is hydrogen, (C 1 -C 18 ) alkyl, (C 2 -C 8 ) alkenyl, (C 2 -C 8 ) alkynyl, halogeno- (C 1 -C 6 ) alkyl, hydroxy- ( C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy- (C 1 -C 6 ) alkyl, cyano- (C 1 -C 6 ) alkyl, amino- (C 1 -C 6 ) alkyl, ( C 1 -C 6 ) alkylamino- (C 1 -C 6 ) alkyl, di-[(C 1 -C 6 ) alkyl] amino- (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkylthio At-(C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkylsulfinyl- (C 1 -C 6 ) alkyl or (C 1 -C 6 ) alkylsulfonyl- (C 1 -C 6 ) alkyl Is a selected substituent or is of the formula -X 1 -Q 1 wherein X 1 is a direct bond or is O, S, SO, SO 2 , N (R 4 ), CO, CO 2 (R 4 ), CH (OR 4 ) , CON (R 4 ), N (R 4 ) CO, SO 2 N (R 4 ), N (R 4 ) SO 2 , C (R 4 ) 2 O, C (R 4 ) 2 S, N (R 4 ) C (R 4 ) 2 , N (R 4 ) CON (R 4 ), N (R 4 ) CSN (R 4 )], and R 4 is hydrogen, (C 1 -C 6 ) alkyl, aryl, Aryl- (C 1 -C 6 ) alkyl, (C 3 -C 7 ) cycloalkyl, (C 3 -C 7 ) cycloalkyl- (C 1 -C 6 ) alkyl, (C 3 -C 7 ) cycloalkenyl , (C 3 -C 7 ) cycloalkenyl - (C 1 -C 6) alkyl, heteroaryl, heteroaryl - (C 1 -C 6) alkyl, heteroaryl or heteroaryl cycle the cycle reel reel - a group of (C 1 -C 6) alkyl, Q 1 is R 4 Wow May be selected from the same or different substituents,

그리고, 여기서 Rb 기내에서의 (C2-C6)알킬렌 기에서 인접 탄소 원자는 O, S, SO, SO2 , N(R5), CO, CH(OR5), CON(R5), N(R5)CO, SO2N(R5), N(R5)SO2, CH=CH 및 C≡C에서 선택된 기의 삽입에 의해서 분리될 수 있고, 여기서 R5는 수소 또는 (C1-C6)알킬이고 And wherein adjacent carbon atoms in the (C 2 -C 6 ) alkylene group in the group R b are O, S, SO, SO 2 , N (R 5 ), CO, CH (OR 5 ), CON (R 5 ), N (R 5 ) CO, SO 2 N (R 5 ), N (R 5 ) SO 2 , CH═CH and C≡C can be separated by insertion of a group wherein R 5 is hydrogen or (C 1 -C 6 ) alkyl

여기서 Rb 기내에서의 임의의 CH2=CH- 또는 HC≡C- 기는 말단 CH2= 또는 HC≡위치에서 할로게노, 카르복시, 카르바모일, (C1-C6)알콕시카르보닐, N-(C1-C6)알킬카르바모일, N,N-디-[(C1-C6)알킬]카르바모일, 아미노-(C1-C6)알킬, (C1-C6)알킬아미노-(C1-C6)알킬 및 디-[(C1-C6)알킬]아미노-(C1-C6)알킬에서 선택되거나 또는 화학식 Q2-X2-[여기서, X2는 직접 결합이거나, CO 및 N(R6)CO에서 선택되고, 여기서 Rb 상의 치환체내에서의 임의의 아릴, 헤테로아릴 또는 헤테로싸이클릴기 R6는 수소 또는 (C1-C6)알킬이고, Q2는 아릴, 아릴-(C1-C6)알킬, 헤테로아릴, 헤테로아릴-(C1-C6)알킬, 헤테로싸이클릴 또는 헤테로싸이클릴-(C1-C6)알킬임]의 기에서 선택된 치환체를 포함할 수 있고,Wherein any CH 2 ═CH— or HC≡C— group in the R b group is halogeno, carboxy, carbamoyl, (C 1 -C 6 ) alkoxycarbonyl, N— at the terminal CH 2 = or HC≡ position (C 1 -C 6 ) alkylcarbamoyl, N, N- di-[(C 1 -C 6 ) alkyl] carbamoyl, amino- (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkylamino, - (C 1 -C 6) alkyl and di - [(C 1 -C 6) alkyl] amino - (C 1 -C 6) alkyl selected from or the formula Q 2 -X 2 - [wherein, X 2 Is a direct bond or is selected from CO and N (R 6 ) CO, wherein any aryl, heteroaryl or heterocyclyl group R 6 in the substituent on R b is hydrogen or (C 1 -C 6 ) alkyl, Q 2 is aryl, aryl- (C 1 -C 6 ) alkyl, heteroaryl, heteroaryl- (C 1 -C 6 ) alkyl, heterocyclyl or heterocyclyl- (C 1 -C 6 ) alkyl] May include a substituent selected from a group,

여기서 Rb 기내에서의 임의의 CH2 또는 CH3기는 각각의 CH2 또는 CH3기에서 1 이상의 할로게노 또는 (C1-C6)알킬 치환체, 또는 히드록시, 시아노, 아미노, 카르복 시, 카르바모일, (C1-C6)알콕시, (C1-C6)알킬티오, (C1-C6)알킬설피닐, (C1-C6)알킬설포닐, (C1-C6)알킬아미노, 디-[(C1-C6)알킬]아미노, (C1-C6)알콕시카르보닐, N-(C1-C6)알킬카르바모일, N,N-디-[(C1-C6)알킬]카르바모일, (C2-C6)알카노일, (C2-C6)알카노일옥시, (C2-C6)알카노일아미노, N-(C1-C6)알킬-(C2-C6)알카노일아미노, N-(C1-C6)알킬설파모일, N,N-디-[(C1-C6)알킬]설파모일, (C1-C6)알칸설포닐아미노 및 N-(C1-C6)알킬-(C1-C6)알칸설포닐아미노에서 선택된 치환체 또는, 화학식 -X3-Q3 [여기서, X3는 직접 결합이거나, O, S, SO, SO2, N(R7), CO, CH(OR7), CON(R7), N(R7)CO, SO2N(R7), N(R7)SO2, C(R7)2O, C(R7)2S, N(R7)C(R7)2, N(R7)CON(R7) 및 N(R7)CSN(R7)에서 선택되고, R7 은 수소, (C1-C6)알킬, 아릴, 아릴-(C1-C6)알킬, (C3-C7)싸이클로알킬, (C3-C7)싸이클로알킬-(C1-C6)알킬, (C3-C7)싸이클로알케닐, (C3-C7)싸이클로알케닐-(C1-C6)알킬, 헤테로아릴, 헤테로아릴-(C1-C6)알킬, 헤테로싸이클릴 또는 헤테로싸이클릴-(C1-C6)알킬의 기이고, Q3 은 R7 와 동일하거나 상이한 치환기에서 선택될 수 있으며Wherein any CH 2 or CH 3 group in the R b group is at least one halogeno or (C 1 -C 6 ) alkyl substituent at each CH 2 or CH 3 group, or hydroxy, cyano, amino, carboxy , Carbamoyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) alkylthio, (C 1 -C 6 ) alkylsulfinyl, (C 1 -C 6 ) alkylsulfonyl, (C 1- C 6 ) alkylamino, di-[(C 1 -C 6 ) alkyl] amino, (C 1 -C 6 ) alkoxycarbonyl, N- (C 1 -C 6 ) alkylcarbamoyl, N, N- di - [(C 1 -C 6) alkyl] carbamoyl, (C 2 -C 6) alkanoyl, (C 2 -C 6) alkanoyloxy, (C 2 -C 6) alkanoylamino, N- ( C 1 -C 6 ) alkyl- (C 2 -C 6 ) alkanoylamino, N- (C 1 -C 6 ) alkylsulfamoyl, N, N- di-[(C 1 -C 6 ) alkyl] sulfamoyl , (C 1 -C 6) alkane sulfonyl amino, N- (C 1 -C 6) alkyl, - (C 1 -C 6) alkane sulfonyl amino substituent selected from or the formula -X 3 -Q 3 [wherein, X 3 is a direct bond or O, S, SO, SO 2 , N (R 7 ), CO, CH (OR 7 ), CON (R 7 ), N (R 7 ) CO, SO 2 N (R 7 ), N (R 7 ) SO 2 , C (R 7 ) 2 O, C (R 7 ) 2 S, N (R 7 ) C (R 7 ) 2 , N (R 7 ) CON (R 7 ) and N (R 7 ) CSN (R 7 ), R 7 is hydrogen, (C 1 -C 6 ) alkyl, aryl, aryl- (C 1 -C 6 ) Alkyl, (C 3 -C 7 ) cycloalkyl, (C 3 -C 7 ) cycloalkyl- (C 1 -C 6 ) alkyl, (C 3 -C 7 ) cycloalkenyl, (C 3 -C 7 ) cyclo Is a group of alkenyl- (C 1 -C 6 ) alkyl, heteroaryl, heteroaryl- (C 1 -C 6 ) alkyl, heterocyclyl or heterocyclyl- (C 1 -C 6 ) alkyl, Q 3 is With R 7 May be selected from the same or different substituents,

Rb 기내에서의 임의의 아릴, 헤테로아릴 또는 헤테로싸이클릴기는 1, 2 또는 3개의 치환체를 포함할 수 있고, 이 치환체는 동일하거나 상이할 수 있으며, 수소, 할로게노, 트리플루오로메틸, 시아노, 니트로, 히드록시, 아미노, 카르복시, 카르바모일, (C1-C6)알킬, (C2-C8)알케닐, (C2-C8)알키닐, (C1-C6)알콕시, (C2-C6)알케닐옥시, (C2-C6)알키닐옥시, (C1-C6)알킬티오, (C1-C6)알킬설피닐, (C1-C6)알킬설포닐, (C1-C6)알킬아미노, 디-[(C1-C6)알킬]아미노, (C1-C6)알콕시카르보닐, N-(C1-C6)알킬카르바모일, N,N-디-[(C1-C6)알킬]카르바모일, (C2-C6)알카노일, (C2-C6)알카노일옥시, (C2-C6)알카노일아미노, N-(C1-C6)알킬-(C2-C6)알카노일아미노, (C3-C6)알케노일아미노, N-(C1-C6)알킬-(C3-C6)알케노일아미노, (C3-C6)알키노일아미노, N-(C1-C6)알킬-(C3-C6)알키노일아미노, N-(C1-C6)알킬설파모일, N,N-디-[(C1-C6)알킬]설파모일, (C1-C6)알칸설포닐아미노 및 N-(C1-C6)알킬-(C1-C6)알칸설포닐아미노에서 선택되거나 화학식 -X4-R8 [여기서, X4 은 직접 결합이거나, O 및 N(R9)에서 선택되고, 여기서 R9는 수소 또는 (C1-C6)알킬이고, R8 은 할로게노-(C1-C6)알킬, 히드록시-(C1-C6)알킬, (C1-C6)알콕시-(C1-C6)알킬, 시아노-(C1-C6)알킬, 아미노-(C1-C6)알킬, (C1-C6)알킬아미노-(C1-C6)알킬 또는 디-[(C1-C6)알킬]아미노-(C1-C6)알킬임]의 기에서 선택되거나 또는 화학식-X5-Q4 [여기서, X5는 직접 결합이거나 O, CO 및 N(R10)에서 선택되 고, 여기서 R10은 수소 또는 (C1-C6)알킬이고, Q4은 아릴, 아릴-(C1-C6)알킬, 헤테로아릴, 헤테로아릴-(C1-C6)알킬, 헤테로싸이클릴 또는 헤테로싸이클릴-(C1-C6)알킬이고, 이것은 1 또는 2개의 치환체를 포함할 수 있으며, 이 치환체는 동일하거나 상이할 수 있으며, 할로게노, (C1-C6)알킬 및 (C1-C6)알콕시에서 선택되는 것임]의 기에서 선택되고,Any aryl, heteroaryl, or heterocyclyl group in the group R b may contain 1, 2 or 3 substituents, which substituents may be the same or different and include hydrogen, halogeno, trifluoromethyl, cya Furnace, nitro, hydroxy, amino, carboxy, carbamoyl, (C 1 -C 6 ) alkyl, (C 2 -C 8 ) alkenyl, (C 2 -C 8 ) alkynyl, (C 1 -C 6 ) Alkoxy, (C 2 -C 6 ) alkenyloxy, (C 2 -C 6 ) alkynyloxy, (C 1 -C 6 ) alkylthio, (C 1 -C 6 ) alkylsulfinyl, (C 1- C 6 ) alkylsulfonyl, (C 1 -C 6 ) alkylamino, di-[(C 1 -C 6 ) alkyl] amino, (C 1 -C 6 ) alkoxycarbonyl, N- (C 1 -C 6 ) alkyl carbamoyl, N, N- di - [(C 1 -C 6) alkyl] carbamoyl, (C 2 -C 6) alkanoyl, (C 2 -C 6) alkanoyloxy, (C 2 -C 6 ) alkanoylamino, N- (C 1 -C 6 ) alkyl- (C 2 -C 6 ) alkanoylamino, (C 3 -C 6 ) alkenoylamino, N- (C 1 -C 6 ) Alkyl- (C 3 -C 6 ) alkenoylamino, (C 3 -C 6 ) alkynoylamino, N- ( C 1 -C 6 ) alkyl- (C 3 -C 6 ) alkynoylamino, N- (C 1 -C 6 ) alkylsulfamoyl, N, N- di-[(C 1 -C 6 ) alkyl] sulfa Moyl, (C 1 -C 6 ) alkanesulfonylamino and N- (C 1 -C 6 ) alkyl- (C 1 -C 6 ) alkanesulfonylamino, or a compound of formula -X 4 -R 8 [where X 4 is a direct bond or is selected from O and N (R 9 ) wherein R 9 is hydrogen or (C 1 -C 6 ) alkyl and R 8 is halogeno- (C 1 -C 6 ) alkyl, hydroxy - (C 1 -C 6) alkyl, (C 1 -C 6) alkoxy - (C 1 -C 6) alkyl, cyano, - (C 1 -C 6) alkyl, amino, - (C 1 -C 6) alkyl , (C 1 -C 6 ) alkylamino- (C 1 -C 6 ) alkyl or di-[(C 1 -C 6 ) alkyl] amino- (C 1 -C 6 ) alkyl]; or Formula -X 5 -Q 4 , wherein X 5 is a direct bond or is selected from O, CO and N (R 10 ), wherein R 10 is hydrogen or (C 1 -C 6 ) alkyl and Q 4 is aryl , Aryl- (C 1 -C 6 ) alkyl, heteroaryl, heteroaryl- (C 1 -C 6 ) alkyl, heterocyclyl or he Interrogating cycle reel - (C 1 -C 6) alkyl, which may include one or two substituents, the substituents may be the same or different, halogeno, (C 1 -C 6) alkyl and (C 1- C 6 ) alkoxy], and

여기서 Rb 상의 치환체내에서 헤테로싸이클릴기는 1 또는 2개의 옥소 또는 티옥소 치환체를 포함할 수 있으며,Wherein the heterocyclyl group in the substituent on R b may comprise one or two oxo or thioxo substituents,

그리고 Rb 기내에서의 임의의 아릴, 헤테로아릴 또는 헤테로싸이클릴기의 동일하거나 상이한 치환기는 서로 결합하여 화학식 CH=CH-CH=CH-, -N=CH-CH=CH-, -CH=N-CH=CH-, -CH=CH-N=CH-, CH=CH-CH=N-, -N=CH-N=CH-, -CH=N-CH=N-, -N=CH-CH=N-, -N=N-CH=CH-, -CH=CH-N=N-, -CH=CH-O-, -O-CH=CH-, -CH=CH-S-, -S-CH=CH-, -C(R11)2-C(R11)2-O-, -O-C(R11)2-C(R11)2-, -C(R11)2-C(R11)2-S-, -S-C(R11)2-C(R11)2-, -O-C(R11)2-O-, -O-C(R11)2-C(R11)2-O-, -S-C(R11)2-S-, -S-C(R11)2-C(R11)2-S-, -CH=CH-NH-, -NH-CH=CH-, -C(R11)2-C(R11)2-NH-, -NH-C(R11)2-C(R11)2-, -N=CH-NH-, -NH-CH=N-, -NH-C(R11)2-NH-, -O-CH=N-, -N=CH-O-, -S-CH=N-, -N=CH-S-, -O-C(R11)2-NH-, -NH- C(R11)2-O-, -S-C(R11)2-NH-, -NH-C(R11)2-S-, -O-N=CH-, -CH=N-O-, -S-N=CH-, -CH=N-S-, -O-NH-C(R11)2-, -C(R11)2-NH-O-, -S-NH-C(R11)2-, -C(R11)2-NH-S-, -NH-N=CH-, -CH=N-NH-, -NH-NH-C(R11)2-, -C(R11)2-NH-NH, -N=N-NH- 또는 -NH-N=N-의 기 [여기서, R11은 수소 또는 (C1-C6)알킬]를 형성할 수 있고, And the same or different substituents of any aryl, heteroaryl, or heterocyclyl group in the group R b are bonded to each other to formula CH = CH-CH = CH-, -N = CH-CH = CH-, -CH = N- CH = CH-, -CH = CH-N = CH-, CH = CH-CH = N-, -N = CH-N = CH-, -CH = N-CH = N-, -N = CH-CH = N-, -N = N-CH = CH-, -CH = CH-N = N-, -CH = CH-O-, -O-CH = CH-, -CH = CH-S-, -S -CH = CH-, -C (R 11 ) 2 -C (R 11 ) 2 -O-, -OC (R 11 ) 2 -C (R 11 ) 2- , -C (R 11 ) 2 -C ( R 11 ) 2 -S-, -SC (R 11 ) 2 -C (R 11 ) 2- , -OC (R 11 ) 2 -O-, -OC (R 11 ) 2 -C (R 11 ) 2- O-, -SC (R 11 ) 2 -S-, -SC (R 11 ) 2 -C (R 11 ) 2 -S-, -CH = CH-NH-, -NH-CH = CH-, -C (R 11 ) 2 -C (R 11 ) 2 -NH-, -NH-C (R 11 ) 2 -C (R 11 ) 2- , -N = CH-NH-, -NH-CH = N-, -NH-C (R 11 ) 2 -NH-, -O-CH = N-, -N = CH-O-, -S-CH = N-, -N = CH-S-, -OC (R 11 ) 2 -NH-, -NH-C (R 11 ) 2 -O-, -SC (R 11 ) 2 -NH-, -NH-C (R 11 ) 2 -S-, -ON = CH-,- CH = NO-, -SN = CH-, -CH = NS-, -O-NH-C (R 11 ) 2- , -C (R 11 ) 2 -NH-O-, -S-NH-C ( R 11 ) 2- , -C (R 11 ) 2 -NH-S-, -NH-N = CH-, -CH = N-NH-, -NH-NH-C (R 11 ) 2- , -C (R 11 ) 2 -NH-NH, -N = N-NH- or -NH A group of -N = N-, wherein R 11 can form hydrogen or (C 1 -C 6 ) alkyl;

상기 화학식에서, m은 0, 1, 2, 3 또는 4이고;Wherein m is 0, 1, 2, 3 or 4;

각각의 Rc 기는 동일하거나 상이할 수 있으며, 수소, 할로게노, 트리플루오로메틸, 시아노, 이소시아노, 니트로, 히드록시, 머캅토, 아미노, 포르밀, 카르복시, 카르바모일, (C1-C6)알킬, (C2-C8)알케닐, (C2-C8)알키닐, (C1-C6)알콕시, (C2-C6)알케닐옥시, (C2-C6)알키닐옥시, (C1-C6)알킬티오, (C1-C6)알킬설피닐, (C1-C6)알킬설포닐, (C1-C6)알킬아미노, 디-[(C1-C6)알킬]아미노, (C1-C6)알콕시카르보닐, N-(C1-C6)알킬카르바모일, N,N-디-[(C1-C6)알킬]카르바모일, (C2-C6)알카노일, (C2-C6)알카노일옥시, (C2-C6)알카노일아미노, N-(C1-C6)알킬-(C2-C6)알카노일아미노, (C3-C6)알케노일아미노, N-(C1-C6)알킬-(C3-C6)알케노일아미노, (C3-C6)알키노일아미노, N-(C1-C6)알킬-(C3-C6)알키노일아미노, N-(C1-C6)알킬설파모일, N,N-디-[(C1-C6)알킬]설파모일, (C1-C6)알칸설포닐아미노 및 N-(C1-C6)알킬-(C1-C6)알칸설포닐아미노, 아릴, 아릴 -(C1-C6)알킬, (C3-C7)싸이클로알킬, (C3-C7)싸이클로알킬-(C1-C6)알킬, (C3-C7)싸이클로알케닐, (C3-C7)싸이클로알케닐-(C1-C6)알킬, 헤테로아릴, 헤테로아릴-(C1-C6)알킬, 헤테로싸이클릴 또는 헤테로싸이클릴-(C1-C6)알킬임]의 기에서 선택된다.Each R c group can be the same or different and is hydrogen, halogeno, trifluoromethyl, cyano, isocyano, nitro, hydroxy, mercapto, amino, formyl, carboxy, carbamoyl, (C 1 -C 6 ) alkyl, (C 2 -C 8 ) alkenyl, (C 2 -C 8 ) alkynyl, (C 1 -C 6 ) alkoxy, (C 2 -C 6 ) alkenyloxy, (C 2 -C 6) alkynyloxy, (C 1 -C 6) alkylthio, (C 1 -C 6) alkylsulfinyl, (C 1 -C 6) alkylsulfonyl, (C 1 -C 6) alkylamino, di - [(C 1 -C 6) alkyl] amino, (C 1 -C 6) alkoxycarbonyl, N- (C 1 -C 6) alkyl-carbamoyl, N, N- di - [(C 1 - C 6 ) alkyl] carbamoyl, (C 2 -C 6 ) alkanoyl, (C 2 -C 6 ) alkanoyloxy, (C 2 -C 6 ) alkanoylamino, N- (C 1 -C 6 ) Alkyl- (C 2 -C 6 ) alkanoylamino, (C 3 -C 6 ) alkenoylamino, N- (C 1 -C 6 ) alkyl- (C 3 -C 6 ) alkenoylamino, (C 3- C 6 ) alkynoylamino, N- (C 1 -C 6 ) alkyl- (C 3 -C 6 ) alkynoylamino, N- (C 1 -C 6 ) alkylsulfamoyl, N, N- di- [(C 1- C 6 ) alkyl] sulfamoyl, (C 1 -C 6 ) alkanesulfonylamino and N- (C 1 -C 6 ) alkyl- (C 1 -C 6 ) alkanesulfonylamino, aryl, aryl-(C 1 -C 6 ) alkyl, (C 3 -C 7 ) cycloalkyl, (C 3 -C 7 ) cycloalkyl- (C 1 -C 6 ) alkyl, (C 3 -C 7 ) cycloalkenyl, (C 3- C 7 ) cycloalkenyl- (C 1 -C 6 ) alkyl, heteroaryl, heteroaryl- (C 1 -C 6 ) alkyl, heterocyclyl or heterocyclyl- (C 1 -C 6 ) alkyl] Is selected from the group.

여기서 Rc 치환체내에서의 임의의 (C2-C6)알킬렌 기에서 인접 탄소 원자는 O, S, SO, SO2 , N(R12), CO, CH(OR12), CON(R12), N(R12)CO, SO2N(R12), N(R12)SO2 , CH=CH 및 C≡C에서 선택된 기의 삽입에 의해서 분리될 수 있고, 여기서 R12는 수소 또는 (C1-C6)알킬이고, Wherein adjacent carbon atoms in any (C 2 -C 6 ) alkylene group in the R c substituent are O, S, SO, SO 2 , N (R 12 ), CO, CH (OR 12 ), CON (R 12 ), N (R 12 ) CO, SO 2 N (R 12 ), N (R 12 ) SO 2 , CH = CH and C≡C can be separated by insertion of a group, wherein R 12 is hydrogen Or (C 1 -C 6 ) alkyl,

여기서 Rc 치환체내에서의 임의의 CH2=CH- 또는 HC≡C- 기는 말단 CH2= 또는 HC≡위치에서 할로게노, 카르복시, 카르바모일, (C1-C6)알콕시카르보닐, N-(C1-C6)알킬카르바모일, N,N-디-[(C1-C6)알킬]카르바모일, 아미노-(C1-C6)알킬, (C1-C6)알킬아미노-(C1-C6)알킬 및 디-[(C1-C6)알킬]아미노-(C1-C6)알킬에서 선택되거나 또는 화학식 Q5-X6-[여기서, X6는 직접 결합이거나, CO 및 N(R13)CO에서 선택되고, 여기서 R13는 수소 또는 (C1-C6)알킬이고, Q5는 아릴, 아릴-(C1-C6)알킬, 헤테로아릴, 헤테로아릴-(C1-C6)알킬, 헤테로싸이클릴 또는 헤테로싸이클릴-(C1-C6)알킬임]의 기에서 선택 된 치환체를 포함할 수 있고,Wherein any CH 2 ═CH— or HC≡C— group in the R c substituent is halogeno, carboxy, carbamoyl, (C 1 -C 6 ) alkoxycarbonyl, N at the terminal CH 2 = or HC≡ position - (C 1 -C 6 ) alkylcarbamoyl, N, N- di-[(C 1 -C 6 ) alkyl] carbamoyl, amino- (C 1 -C 6 ) alkyl, (C 1 -C 6 ) Alkylamino- (C 1 -C 6 ) alkyl and di-[(C 1 -C 6 ) alkyl] amino- (C 1 -C 6 ) alkyl or is selected from the formula Q 5 -X 6- [where X 6 is a direct bond or is selected from CO and N (R 13 ) CO, wherein R 13 is hydrogen or (C 1 -C 6 ) alkyl, Q 5 is aryl, aryl- (C 1 -C 6 ) alkyl, Heteroaryl, heteroaryl- (C 1 -C 6 ) alkyl, heterocyclyl or heterocyclyl- (C 1 -C 6 ) alkyl], and

여기서 Rc 치환체내에서의 임의의 CH2 또는 CH3기는 각각의 CH2 또는 CH3기에서 1 이상의 할로게노 또는 (C1-C6)알킬 치환체, 또는 히드록시, 시아노, 아미노, 카르복시, 카르바모일, (C1-C6)알콕시, (C1-C6)알킬티오, (C1-C6)알킬설피닐, (C1-C6)알킬설포닐, (C1-C6)알킬아미노, 디-[(C1-C6)알킬]아미노, (C1-C6)알콕시카르보닐, N-(C1-C6)알킬카르바모일, N,N-디-[(C1-C6)알킬]카르바모일, (C2-C6)알카노일, (C2-C6)알카노일옥시, (C2-C6)알카노일아미노, N-(C1-C6)알킬-(C2-C6)알카노일아미노, N-(C1-C6)알킬설파모일, N,N-디-[(C1-C6)알킬]설파모일, (C1-C6)알칸설포닐아미노 및 N-(C1-C6)알킬-(C1-C6)알칸설포닐아미노에서 선택된 치환체 또는, 화학식 -X7-Q6 [여기서, X7는 직접 결합이거나, O, S, SO, SO2, N(R14), CO, CH(OR14), CON(R14), N(R14)CO, SO2N(R14), N(R14)SO2, C(R14)2O, C(R14)2S 및 N(R14)C(R14)2에서 선택되고, 여기서 R14은 수소 또는 (C1-C6)알킬이고, Q6는 아릴, 아릴-(C1-C6)알킬, (C3-C7)싸이클로알킬, (C3-C7)싸이클로알킬-(C1-C6)알킬, (C3-C7)싸이클로알케닐, (C3-C7)싸이클로알케닐-(C1-C6)알킬, 헤테로아릴, 헤테로아릴-(C1-C6)알킬, 헤테로싸이클릴 또는 헤테로싸이 클릴-(C1-C6)알킬임]의 기에서 선택되는 치환체를 포함할 수 있으며,Wherein any CH 2 or CH 3 group in the R c substituent is at least one halogeno or (C 1 -C 6 ) alkyl substituent at each CH 2 or CH 3 group, or hydroxy, cyano, amino, carboxy, Carbamoyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) alkylthio, (C 1 -C 6 ) alkylsulfinyl, (C 1 -C 6 ) alkylsulfonyl, (C 1 -C 6 ) alkylamino, di-[(C 1 -C 6 ) alkyl] amino, (C 1 -C 6 ) alkoxycarbonyl, N- (C 1 -C 6 ) alkylcarbamoyl, N, N- di- [(C 1 -C 6) alkyl] carbamoyl, (C 2 -C 6) alkanoyl, (C 2 -C 6) alkanoyloxy, (C 2 -C 6) alkanoylamino, N- (C 1- C 6 ) alkyl- (C 2 -C 6 ) alkanoylamino, N- (C 1 -C 6 ) alkylsulfamoyl, N, N- di-[(C 1 -C 6 ) alkyl] sulfamoyl, (C 1 -C 6) alkane sulfonylamino N- and (C 1 -C 6) alkyl, - (C 6 -C 1) alkane sulfonyl substituent selected from amino, or the formula -X 7 -Q 6 [where, X 7 is a direct bond or O, S, SO, SO 2 , N (R 14 ), CO, CH (OR 14 ), CON (R 14 ), N (R 14 ) CO, SO 2 N (R 14 ), N (R 14 ) SO 2 , C (R 14 ) 2 O, C (R 14 ) 2 S and N (R 14 ) C (R 14 ) 2 , Wherein R 14 is hydrogen or (C 1 -C 6 ) alkyl, Q 6 is aryl, aryl- (C 1 -C 6 ) alkyl, (C 3 -C 7 ) cycloalkyl, (C 3 -C 7 ) cyclo alkyl, - (C 1 -C 6) alkyl, (C 3 -C 7) cyclo-alkenyl, (C 3 -C 7) cyclo alkenyl, - (C 1 -C 6) alkyl, heteroaryl, heteroaryl - (C 1 -C 6 ) alkyl, heterocyclyl or heterocyclyl- (C 1 -C 6 ) alkyl], and

여기서, Rc 기내에서의 임의의 아릴, 헤테로아릴 또는 헤테로싸이클릴기는 1, 2 또는 3개의 치환체를 포함할 수 있고, 이 치환체는 동일하거나 상이할 수 있으며, 수소, 할로게노, 트리플루오로메틸, 시아노, 니트로, 히드록시, 아미노, 카르복시, 카르바모일, (C1-C6)알킬, (C2-C8)알케닐, (C2-C8)알키닐, (C1-C6)알콕시, (C2-C6)알케닐옥시, (C2-C6)알키닐옥시, (C1-C6)알킬티오, (C1-C6)알킬설피닐, (C1-C6)알킬설포닐, (C1-C6)알킬아미노, 디-[(C1-C6)알킬]아미노, (C1-C6)알콕시카르보닐, N-(C1-C6)알킬카르바모일, N,N-디-[(C1-C6)알킬]카르바모일, (C2-C6)알카노일, (C2-C6)알카노일옥시, (C2-C6)알카노일아미노, N-(C1-C6)알킬-(C2-C6)알카노일아미노, (C3-C6)알케노일아미노, N-(C1-C6)알킬-(C3-C6)알케노일아미노, (C3-C6)알키노일아미노, N-(C1-C6)알킬-(C3-C6)알키노일아미노, N-(C1-C6)알킬설파모일, N,N-디-[(C1-C6)알킬]설파모일, (C1-C6)알칸설포닐아미노 및 N-(C1-C6)알킬-(C1-C6)알칸설포닐아미노에서 선택되거나 화학식 -X8-R15 [여기서, X8은 직접 결합이거나, O 및 N(R16)에서 선택되고, 여기서 R16는 수소 또는 (C1-C6)알킬이고, R15은 할로게노-(C1-C6)알킬, 히드록시-(C1-C6)알킬, (C1-C6)알콕시-(C1-C6)알킬, 시아노-(C1-C6)알킬, 아미노-(C1-C6)알킬, (C1-C6)알킬아미노-(C1-C6)알킬 또는 디-[(C1-C6)알킬]아미노-(C1-C6)알킬 임]의 기에서 선택되거나 또는 화학식 -X9-Q7 [여기서, X9은 직접 결합이거나 O, CO 및 N(R17)에서 선택되고, R17은 수소 또는 (C1-C6)알킬이고, Q7은 1 또는 2개의 치환체를 지닐 수 있는, 아릴, 아릴-(C1-C6)알킬, 헤테로아릴, 헤테로아릴-(C1-C6)알킬, 헤테로싸이클릴 또는 헤테로싸이클릴-(C1-C6)알킬이고, 이 치환체는 동일하거나 상이할 수 있으며, 할로게노, (C1-C6)알킬 및 (C1-C6)알콕시에서 선택되고, Q7 내에서의 임의의 헤테로싸이클릴기는 1 또는 2개의 옥소 또는 티옥소 치환체를 포함할 수 있음]의 기에서 선택되고, Wherein any aryl, heteroaryl, or heterocyclyl group in the R c group may comprise 1, 2 or 3 substituents, which substituents may be the same or different and are hydrogen, halogeno, trifluoromethyl , Cyano, nitro, hydroxy, amino, carboxy, carbamoyl, (C 1 -C 6 ) alkyl, (C 2 -C 8 ) alkenyl, (C 2 -C 8 ) alkynyl, (C 1- C 6 ) alkoxy, (C 2 -C 6 ) alkenyloxy, (C 2 -C 6 ) alkynyloxy, (C 1 -C 6 ) alkylthio, (C 1 -C 6 ) alkylsulfinyl, (C 1- C 6 ) alkylsulfonyl, (C 1 -C 6 ) alkylamino, di-[(C 1 -C 6 ) alkyl] amino, (C 1 -C 6 ) alkoxycarbonyl, N- (C 1- C 6 ) alkylcarbamoyl, N, N- di-[(C 1 -C 6 ) alkyl] carbamoyl, (C 2 -C 6 ) alkanoyl, (C 2 -C 6 ) alkanoyloxy, ( C 2 -C 6 ) alkanoylamino, N- (C 1 -C 6 ) alkyl- (C 2 -C 6 ) alkanoylamino, (C 3 -C 6 ) alkenoylamino, N- (C 1 -C 6) alkyl, - (C 3 -C 6) alkenyl alkanoyl amino, (C 3 -C 6) Al Keno ilah No, N- (C 1 -C 6) alkyl, - (C 3 -C 6) Al Keno-ylamino, N- (C 1 -C 6) alkyl sulfamoyl, N, N- di - [(C 1 -C 6 ) alkyl] sulfamoyl, (C 1 -C 6 ) alkanesulfonylamino and N- (C 1 -C 6 ) alkyl- (C 1 -C 6 ) alkanesulfonylamino or is selected from the formula -X 8 -R 15 wherein X 8 is a direct bond or is selected from O and N (R 16 ), wherein R 16 is hydrogen or (C 1 -C 6 ) alkyl and R 15 is halogeno- (C 1 -C 6 ) Alkyl, hydroxy- (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy- (C 1 -C 6 ) alkyl, cyano- (C 1 -C 6 ) alkyl, amino- (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkylamino- (C 1 -C 6 ) alkyl or di-[(C 1 -C 6 ) alkyl] amino- (C 1 -C 6 ) alkyl] Is selected from the group or of the formula -X 9 -Q 7 wherein X 9 is a direct bond or is selected from O, CO and N (R 17 ), R 17 is hydrogen or (C 1 -C 6 ) alkyl, Q 7 is aryl, aryl- (C 1 -C 6 ) alkyl, heteroaryl, heteroa, which may bear 1 or 2 substituents Aryl- (C 1 -C 6 ) alkyl, heterocyclyl or heterocyclyl- (C 1 -C 6 ) alkyl, which substituents may be the same or different, halogeno, (C 1 -C 6 ) alkyl And (C 1 -C 6 ) alkoxy, and any heterocyclyl group in Q 7 may include 1 or 2 oxo or thioxo substituents, and

여기서 Rc 상의 치환체내에서 헤테로싸이클릴기는 1 또는 2개의 옥소 또는 티옥소 치환체를 포함할 수 있으며,Wherein the heterocyclyl group in the substituent on R c may comprise one or two oxo or thioxo substituents,

Rc 기내에서의 임의의 아릴, 헤테로아릴 또는 헤테로싸이클릴기의 동일하거나 상이한 치환기는 서로 결합하여 화학식 CH=CH-CH=CH-, -N=CH-CH=CH-, -CH=N-CH=CH-, -CH=CH-N=CH-, CH=CH-CH=N-, -N=CH-N=CH-, -CH=N-CH=N-, -N=CH-CH=N-, -N=N-CH=CH-, -CH=CH-N=N-, -CH=CH-O-, -O-CH=CH-, -CH=CH-S-, -S-CH=CH-, -C(R18)2-C(R18)2-O-, -O-C(R18)2-C(R18)2-, -C(R18)2-C(R18)2-S-, -S-C(R18)2-C(R18)2-, -O-C(R18)2-O-, -O-C(R18)2-C(R18)2-O-, -S-C(R18)2-S-, -S-C(R18)2-C(R18)2-S-, -CH=CH-NH-, -NH-CH=CH-, -C(R18)2-C(R18)2-NH-, -NH-C(R18)2-C(R18)2-, -N=CH-NH-, -NH-CH=N-, -NH-C(R18)2-NH-, -O-CH=N-, -N=CH-O-, -S-CH=N-, -N=CH-S-, -O-C(R18)2-NH-, -NH-C(R18)2-O-, -S-C(R18)2-NH-, -NH-C(R18)2-S-, -O-N=CH-, -CH=N-O-, -S-N=CH-, -CH=N-S-, -O-NH-C(R18)2-, -C(R18)2-NH-O-, -S-NH-C(R18)2-, -C(R18)2-NH-S-, -NH-N=CH-, -CH=N-NH-, -NH-NH-C(R18)2-, -C(R18)2-NH-NH, -N=N-NH- 또는 -NH-N=N-의 기 [여기서, R18은 수소 또는 (C1-C6)알킬]를 형성할 수 있다.The same or different substituents of any aryl, heteroaryl, or heterocyclyl group in the R c group are bonded to each other to form the formula CH = CH-CH = CH-, -N = CH-CH = CH-, -CH = N-CH = CH-, -CH = CH-N = CH-, CH = CH-CH = N-, -N = CH-N = CH-, -CH = N-CH = N-, -N = CH-CH = N-, -N = N-CH = CH-, -CH = CH-N = N-, -CH = CH-O-, -O-CH = CH-, -CH = CH-S-, -S- CH = CH-, -C (R 18 ) 2 -C (R 18 ) 2 -O-, -OC (R 18 ) 2 -C (R 18 ) 2- , -C (R 18 ) 2 -C (R 18 ) 2 -S-, -SC (R 18 ) 2 -C (R 18 ) 2- , -OC (R 18 ) 2 -O-, -OC (R 18 ) 2 -C (R 18 ) 2 -O -, -SC (R 18 ) 2 -S-, -SC (R 18 ) 2 -C (R 18 ) 2 -S-, -CH = CH-NH-, -NH-CH = CH-, -C ( R 18 ) 2 -C (R 18 ) 2 -NH-, -NH-C (R 18 ) 2 -C (R 18 ) 2- , -N = CH-NH-, -NH-CH = N-,- NH-C (R 18 ) 2 -NH-, -O-CH = N-, -N = CH-O-, -S-CH = N-, -N = CH-S-, -OC (R 18 ) 2 -NH-, -NH-C (R 18 ) 2 -O-, -SC (R 18 ) 2 -NH-, -NH-C (R 18 ) 2 -S-, -ON = CH-, -CH = NO-, -SN = CH-, -CH = NS-, -O-NH-C (R 18 ) 2- , -C (R 18 ) 2 -NH-O-, -S-NH-C (R 18 ) 2- , -C (R 18 ) 2 -NH-S-, -NH-N = CH-, -CH = N-NH-, -NH-NH-C (R 18 ) 2- , -C ( R 18) 2 -NH-NH, -N = N-NH- or -NH-N = N- of It may form a [where, R 18 is hydrogen or (C 1 -C 6) alkyl].

상기 화학식 1로 표시되는 퀴나졸린 화합물 중에서도 바람직하기로는 다음 화학식 1-1로 표시되는 화합물이다.Among the quinazoline compounds represented by Chemical Formula 1, preferably, the compounds are represented by the following Chemical Formula 1-1.

[화학식 1-1][Formula 1-1]

Figure 112005078193254-PAT00002
Figure 112005078193254-PAT00002

상기 화학식 1-1에서, In Chemical Formula 1-1,

X는 직접 결합이거나, O, S, SO, SO2 또는 NR5에서 선택되고, R5는 수소, (C1-C6)알킬, 아릴, 아릴-(C1-C6)알킬, (C3-C7)싸이클로알킬, (C3-C7)싸이클로알킬-(C1-C6)알킬, 헤테로아릴, 헤테로아릴-(C1-C6)알킬, 헤테로싸이클릴 또는 헤테로싸이클릴-(C1-C6)알킬의 기이며;X is a direct bond or is selected from O, S, SO, SO 2 or NR 5 , R 5 is hydrogen, (C 1 -C 6 ) alkyl, aryl, aryl- (C 1 -C 6 ) alkyl, (C 3 -C 7 ) cycloalkyl, (C 3 -C 7 ) cycloalkyl- (C 1 -C 6 ) alkyl, heteroaryl, heteroaryl- (C 1 -C 6 ) alkyl, heterocyclyl or heterocyclyl- A group of (C 1 -C 6 ) alkyl;

R1은 수소, (C1-C8)알킬, 할로게노-(C1-C6)알킬, 히드록시-(C1-C6)알킬, (C1-C6)알콕시-(C1-C6)알킬, 아미노-(C1-C6)알킬, (C1-C6)알킬아미노-(C1-C6)알킬, 디-[(C1-C6)알킬]아미노-(C1-C6)알킬 및 (C1-C6)알킬설피닐 중에서 선택된 치환체이거나, 또는 화학식 -X1-Q1 [여기서, X1는 직접 결합이거나, O, S 또는 NR5]에서 선택되고, Q1은 R5와 동일하거나 상이한 치환기에서 선택될 수 있으며,R 1 is hydrogen, (C 1 -C 8 ) alkyl, halogeno- (C 1 -C 6 ) alkyl, hydroxy- (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy- (C 1 -C 6 ) alkyl, amino- (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkylamino- (C 1 -C 6 ) alkyl, di-[(C 1 -C 6 ) alkyl] amino- (C 1 -C 6) alkyl and (C 1 -C 6), or a substituent selected from alkyl sulfinyl, or the formula -X 1 -Q 1 [wherein, X 1 is either a direct bond, O, S or NR 5] from Q 1 may be selected from the same or different substituents as R 5 ,

그리고, 여기서 R1 기내에서의 (C2-C6)알킬렌 기에서 인접 탄소 원자는 O, S 및 N(R5)에서 선택된 기의 삽입에 의해서 분리될 수 있고,And wherein adjacent carbon atoms in the (C 2 -C 6) alkylene group of R 1 in flight may be separated by insertion of a group selected from O, S and N (R 5),

여기서 R1 기내에서의 임의의 CH2 또는 CH3기는 각각의 CH2 또는 CH3기에서 1 이상의 할로게노, (C1-C6)알킬 치환체, 히드록시, 아미노, (C1-C6)알콕시 (C1-C6)알킬티오, (C1-C6)알킬설피닐, (C1-C6)알킬아미노 및 디-[(C1-C6)알킬]아미노에서 선택된 치환체를 포함할 수 있고,Wherein any CH 2 or CH 3 group in the R 1 group is at least one halogeno, (C 1 -C 6 ) alkyl substituent, hydroxy, amino, (C 1 -C 6 ) at each CH 2 or CH 3 group Substituents selected from alkoxy (C 1 -C 6 ) alkylthio, (C 1 -C 6 ) alkylsulfinyl, (C 1 -C 6 ) alkylamino and di-[(C 1 -C 6 ) alkyl] amino Can do it,

여기서 R1상의 치환체내에서의 임의의 아릴, 헤테로아릴 또는 헤테로싸이클릴기는 0 내지 3개의 치환체를 포함할 수 있고, 이 치환체는 동일하거나 상이할 수 있으며, 할로게노, 히드록시, 아미노, (C1-C6)알킬, 아릴, 아릴-(C1-C6)알킬, 헤테로아릴, 헤테로아릴-(C1-C6)알킬, 헤테로싸이클릴 또는 헤테로싸이클릴-(C1-C6)알킬, (C1-C6)알콕시, (C1-C6)알킬티오 및 (C1-C6)알킬설피닐 중에서 선택된 치환체를 포함할 수 있고,Wherein any aryl, heteroaryl or heterocyclyl group in the substituent on R 1 may comprise 0 to 3 substituents, which substituents may be the same or different and include halogeno, hydroxy, amino, (C 1 -C 6 ) alkyl, aryl, aryl- (C 1 -C 6 ) alkyl, heteroaryl, heteroaryl- (C 1 -C 6 ) alkyl, heterocyclyl or heterocyclyl- (C 1 -C 6 ) May include a substituent selected from alkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) alkylthio and (C 1 -C 6 ) alkylsulfinyl,

그리고, 여기서 R1 상의 치환체내에서 헤테로싸이클릴기는 1 또는 2개의 옥소 또는 티옥소 치환체를 포함할 수 있으며;And wherein the heterocyclyl group in the substituent on R 1 may comprise one or two oxo or thioxo substituents;

R2은 수소, (C1-C18)알킬, (C2-C8)알케닐, 할로게노-(C1-C8)알킬, 히드록시-(C1-C8)알킬, (C1-C8)알콕시-(C1-C8)알킬, 아미노-(C1-C8)알킬, (C1-C8)알킬아미노-(C1-C8)알킬, 디-[(C1-C8)알킬]아미노-(C1-C8)알킬, (C1-C8)알킬설피닐, 아릴, 아릴-(C1-C8)알킬, (C3-C7)싸이클로알킬, (C3-C7)싸이클로알킬-(C1-C8)알킬, 헤테로아릴, 헤테로아릴-(C1-C8)알킬, 헤테로싸이클릴 및 헤테로싸이클릴-(C1-C8)알킬 중의 치환기에서 선택될 수 있으며,R 2 is hydrogen, (C 1 -C 18 ) alkyl, (C 2 -C 8 ) alkenyl, halogeno- (C 1 -C 8 ) alkyl, hydroxy- (C 1 -C 8 ) alkyl, (C 1 -C 8 ) alkoxy- (C 1 -C 8 ) alkyl, amino- (C 1 -C 8 ) alkyl, (C 1 -C 8 ) alkylamino- (C 1 -C 8 ) alkyl, di-[( C 1 -C 8 ) alkyl] amino- (C 1 -C 8 ) alkyl, (C 1 -C 8 ) alkylsulfinyl, aryl, aryl- (C 1 -C 8 ) alkyl, (C 3 -C 7 ) Cycloalkyl, (C 3 -C 7 ) cycloalkyl- (C 1 -C 8 ) alkyl, heteroaryl, heteroaryl- (C 1 -C 8 ) alkyl, heterocyclyl and heterocyclyl- (C 1 -C 8 ) may be selected from substituents in alkyl,

그리고, 여기서 R2 기내에서의 (C2-C6)알킬렌 기에서 인접 탄소 원자는 O, S, N(R5), CO, CH(OR5), CON(R5), N(R5)CO, SO2N(R5), N(R5)SO2 및 CH=CH에서 선택된 기 의 삽입에 의해서 분리될 수 있고,And wherein adjacent carbon atoms in the (C 2 -C 6 ) alkylene group in the R 2 group are O, S, N (R 5 ), CO, CH (OR 5 ), CON (R 5 ), N (R 5 ) can be separated by insertion of a group selected from CO, SO 2 N (R 5 ), N (R 5 ) SO 2 and CH = CH,

여기서 R2 기내에서의 임의의 CH2 또는 CH3기는 각각의 CH2 또는 CH3기에서 1 이상의 할로게노, (C1-C6)알킬 치환체, 히드록시, 시아노, 아미노, 카르복시, 카르바모일, (C1-C6)알콕시 (C1-C6)알킬티오 및 (C1-C6)알킬설피닐, (C1-C6)알킬아미노, 디-[(C1-C6)알킬]아미노, (C1-C6)알콕시카르보닐, N-(C1-C6)알킬카르바모일, N,N-디-[(C1-C6)알킬]카르바모일, 아릴, 아릴-(C1-C6)알킬, (C3-C7)싸이클로 알킬, (C3-C7)싸이클로알킬-(C1-C6)알킬, 헤테로아릴, 헤테로아릴-(C1-C6)알킬, 헤테로싸이클릴 및 헤테로싸이클릴-(C1-C6)알킬기 중에서 선택된 치환체를 포함할 수 있고,Wherein any CH 2 or CH 3 group in the R 2 group is at least one halogeno, (C 1 -C 6 ) alkyl substituent, hydroxy, cyano, amino, carboxy, carba at each CH 2 or CH 3 group Moyl, (C 1 -C 6 ) alkoxy (C 1 -C 6 ) alkylthio and (C 1 -C 6 ) alkylsulfinyl, (C 1 -C 6 ) alkylamino, di-[(C 1 -C 6 ) Alkyl] amino, (C 1 -C 6 ) alkoxycarbonyl, N- (C 1 -C 6 ) alkylcarbamoyl, N, N -di-[(C 1 -C 6 ) alkyl] carbamoyl, Aryl, aryl- (C 1 -C 6 ) alkyl, (C 3 -C 7 ) cycloalkyl, (C 3 -C 7 ) cycloalkyl- (C 1 -C 6 ) alkyl, heteroaryl, heteroaryl- (C It may include a substituent selected from 1 -C 6 ) alkyl, heterocyclyl and heterocyclyl- (C 1 -C 6 ) alkyl group,

여기서 R2상의 치환체내에서의 임의의 아릴, 헤테로아릴 또는 헤테로싸이클릴기는 0 내지 3개의 치환체를 포함할 수 있고, 이 치환체는 동일하거나 상이할 수 있으며, 할로게노, 트리플루오로메틸, 시아노, 니트로, 히드록시, 아미노, 카르복시, 카르바모일, (C1-C6)알킬, 아릴, 아릴-(C1-C6)알킬, 헤테로아릴, 헤테로아릴-(C1-C6)알킬, 헤테로싸이클릴 또는 헤테로싸이클릴-(C1-C6)알킬, (C2-C8)알케닐, (C2-C8)알키닐, (C1-C6)알콕시, (C1-C6)알킬티오, (C1-C6)알킬설피닐, (C1-C6)알킬아미노, 디-[(C1-C6)알킬]아미노, (C1-C6)알콕시카르보닐, N-(C1-C6)알킬카르바모일 및 N,N-디-[(C1-C6)알킬]카르바모일에서 선택된 치환체를 포함할 수 있고,Wherein any aryl, heteroaryl, or heterocyclyl group in a substituent on R 2 may comprise 0 to 3 substituents, which substituents may be the same or different and include halogeno, trifluoromethyl, cyano , Nitro, hydroxy, amino, carboxy, carbamoyl, (C 1 -C 6 ) alkyl, aryl, aryl- (C 1 -C 6 ) alkyl, heteroaryl, heteroaryl- (C 1 -C 6 ) alkyl , Heterocyclyl or heterocyclyl- (C 1 -C 6 ) alkyl, (C 2 -C 8 ) alkenyl, (C 2 -C 8 ) alkynyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) alkylthio, (C 1 -C 6 ) alkylsulfinyl, (C 1 -C 6 ) alkylamino, di-[(C 1 -C 6 ) alkyl] amino, (C 1 -C 6 ) alkoxy Carbonyl, N- (C 1 -C 6 ) alkylcarbamoyl and N, N -di-[(C 1 -C 6 ) alkyl] carbamoyl;

그리고, 여기서 R2 상의 치환체내에서 헤테로싸이클릴기는 1 또는 2개의 옥소 또는 티옥소 치환체를 포함할 수 있으며,And wherein the heterocyclyl group in the substituent on R 2 may comprise one or two oxo or thioxo substituents,

그리고 R2기내에서의 임의의 아릴, 헤테로아릴 또는 헤테로싸이클릴기의 동일하거나 상이한 치환기는 서로 결합하여 화학식 CH=CH-CH=CH-, -N=CH-CH=CH-, -CH=N-CH=CH-, -CH=CH-N=CH-, CH=CH-CH=N-, -N=CH-N=CH-, -CH=N-CH=N-, -N=CH-CH=N-, -CH=CH-O-, -O-CH=CH-, -CH=CH-S-, -S-CH=CH-, -C(R6)2-C(R6)2-O-, -O-C(R6)2-C(R6)2-, -C(R6)2-C(R6)2-S-, -S-C(R6)2-C(R6)2-, -O-C(R6)2-O-, -O-C(R6)2-C(R6)2-O-, -S-C(R6)2-S-, -S-C(R6)2-C(R6)2-S-, -CH=CH-NH-, -NH-CH=CH-, -C(R6)2-C(R6)2-NH-, -NH-C(R6)2-C(R6)2-, -N=CH-NH-, -NH-CH=N-, -NH-C(R6)2-NH-, -O-CH=N-, -N=CH-O-, -S-CH=N-, -N=CH-S-, -O-C(R6)2-NH-, -NH-C(R6)2-O-, -S-C(R6)2-NH-, -NH-C(R6)2-S-, -N=N-NH- 또는 -NH-N=N-의 기 [여기서, R6는 수소 또는 (C1-C3)알킬기]를 형성할 수 있고; And the same or different substituents of any aryl, heteroaryl, or heterocyclyl group in the R 2 group are bonded to each other to form the formula CH = CH-CH = CH-, -N = CH-CH = CH-, -CH = N- CH = CH-, -CH = CH-N = CH-, CH = CH-CH = N-, -N = CH-N = CH-, -CH = N-CH = N-, -N = CH-CH = N-, -CH = CH-O-, -O-CH = CH-, -CH = CH-S-, -S-CH = CH-, -C (R 6 ) 2 -C (R 6 ) 2 -O-, -OC (R 6 ) 2 -C (R 6 ) 2- , -C (R 6 ) 2 -C (R 6 ) 2 -S-, -SC (R 6 ) 2 -C (R 6 ) 2- , -OC (R 6 ) 2 -O-, -OC (R 6 ) 2 -C (R 6 ) 2 -O-, -SC (R 6 ) 2 -S-, -SC (R 6 ) 2 -C (R 6 ) 2 -S-, -CH = CH-NH-, -NH-CH = CH-, -C (R 6 ) 2 -C (R 6 ) 2 -NH-, -NH-C (R 6 ) 2 -C (R 6 ) 2- , -N = CH-NH-, -NH-CH = N-, -NH-C (R 6 ) 2 -NH-, -O-CH = N- , -N = CH-O-, -S-CH = N-, -N = CH-S-, -OC (R 6 ) 2 -NH-, -NH-C (R 6 ) 2 -O-,- Group of SC (R 6 ) 2 -NH-, -NH-C (R 6 ) 2 -S-, -N = N-NH- or -NH-N = N-, wherein R 6 is hydrogen or (C 1 -C 3 ) alkyl group];

R3 및 R4는 각각 동일하거나 상이할 수 있으며, 수소, 할로게노, 트리플루오로메틸, 시아노, 니트로, 히드록시, 머캅토, 아미노, 포르밀, 카르복시, 카르바모일,(C1-C6)알킬, (C2-C8)알케닐, (C2-C6)알콕시, (C1-C6)알킬티오, (C1-C6)알킬설피닐, (C1-C6)알킬아미노, 디-[(C1-C6)알킬]아미노, (C1-C6)알콕시카르보닐, N-(C1-C6)알킬카르바모일, N,N-디-[(C1-C6)알킬]카르바모일, 아릴, 아릴-(C1-C6)알킬, (C3-C7)싸이클로알킬, (C3-C7)싸이클로알킬-(C1-C6)알킬, 헤테로아릴, 헤테로아릴-(C1-C6)알킬, 헤테로싸이클릴 또는 헤테로싸이클릴-(C1-C6)알킬기에서 선택될 수 있고, R 3 and R 4 may be the same or different, respectively, hydrogen, halogeno, trifluoromethyl, cyano, nitro, hydroxy, mercapto, amino, formyl, carboxy, carbamoyl, (C 1- C 6 ) alkyl, (C 2 -C 8 ) alkenyl, (C 2 -C 6 ) alkoxy, (C 1 -C 6 ) alkylthio, (C 1 -C 6 ) alkylsulfinyl, (C 1 -C 6 ) alkylamino, di-[(C 1 -C 6 ) alkyl] amino, (C 1 -C 6 ) alkoxycarbonyl, N- (C 1 -C 6 ) alkylcarbamoyl, N, N -di- [(C 1 -C 6) alkyl] carbamoyl, aryl, - (C 1 -C 6) alkyl, (C 3 -C 7) cyclo-alkyl, (C 3 -C 7) cyclo-alkyl - (C 1 May be selected from a -C 6 ) alkyl, heteroaryl, heteroaryl- (C 1 -C 6 ) alkyl, heterocyclyl or heterocyclyl- (C 1 -C 6 ) alkyl group,

여기서 R3 및 R4 치환체 내에서의 임의의 CH2 또는 CH3기는 각각의 CH2 또는 CH3기에서 1 이상의 할로게노, 히드록시, 아미노, 카르복시, 카르바모일, (C1-C6)알콕시, (C1-C6)알킬티오, (C1-C6)알킬설피닐, (C1-C6)알킬아미노, 디-[(C1-C6)알킬]아미노, (C1-C6)알콕시카르보닐, N-(C1-C6)알킬카르바모일, N,N-디-[(C1-C6)알킬]카르바모일, 아릴, 아릴-(C1-C6)알킬, (C3-C7)싸이클로알킬, (C3-C7)싸이클로알킬-(C1-C6)알킬, 헤테로아릴, 헤테로아릴-(C1-C6)알킬, 헤테로싸이클릴 및 헤테로싸이클릴-(C1-C6)알킬기 중에서 선택되는 치환체를 포함할 수 있으며,Wherein any CH 2 or CH 3 group in the R 3 and R 4 substituents is at least one halogeno, hydroxy, amino, carboxy, carbamoyl, (C 1 -C 6 ) group at each CH 2 or CH 3 group Alkoxy, (C 1 -C 6 ) alkylthio, (C 1 -C 6 ) alkylsulfinyl, (C 1 -C 6 ) alkylamino, di-[(C 1 -C 6 ) alkyl] amino, (C 1 -C 6 ) alkoxycarbonyl, N- (C 1 -C 6 ) alkylcarbamoyl, N, N -di-[(C 1 -C 6 ) alkyl] carbamoyl, aryl, aryl- (C 1- C 6 ) alkyl, (C 3 -C 7 ) cycloalkyl, (C 3 -C 7 ) cycloalkyl- (C 1 -C 6 ) alkyl, heteroaryl, heteroaryl- (C 1 -C 6 ) alkyl, hetero May include a substituent selected from a cyclyl and a heterocyclyl- (C 1 -C 6 ) alkyl group,

여기서 R3 및 R4 기내에서의 임의의 아릴, 헤테로아릴 또는 헤테로싸이클릴기는 1, 2 또는 3개의 치환체를 포함할 수 있고, 이 치환체는 동일하거나 상이할 수 있으며 할로게노, 트리플루오로메텔, 니트로, 히드록시, 아미노, (C1-C6)알콕시, (C1-C6)알킬티오, (C1-C6)알킬아미노, 디-[(C1-C6)알킬]아미노, (C1-C6)알콕시카르보닐, N-(C1-C6)알킬카르바모일 및 N,N-디-[(C1-C6)알킬]카르바모일기에서 선택되는 치 환체를 포함할 수 있으며,Wherein any aryl, heteroaryl or heterocyclyl group in the R 3 and R 4 groups may comprise 1, 2 or 3 substituents, which substituents may be the same or different and may be halogeno, trifluoromethel, Nitro, hydroxy, amino, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) alkylthio, (C 1 -C 6 ) alkylamino, di-[(C 1 -C 6 ) alkyl] amino, A substituent selected from (C 1 -C 6 ) alkoxycarbonyl, N- (C 1 -C 6 ) alkylcarbamoyl and N, N -di-[(C 1 -C 6 ) alkyl] carbamoyl groups Can include,

여기서 R3 및 R4 상의 치환체내에서 헤테로싸이클릴기는 1 또는 2개의 옥소 또는 티옥소 치환체를 포함할 수 있다.Wherein the heterocyclyl group in the substituents on R 3 and R 4 may comprise one or two oxo or thioxo substituents.

상기 화학식 1-1로 표시되는 퀴나졸린 화합물에 있어, 보다 바람직하게는 다음과 같다 :In the quinazoline compound represented by Formula 1-1, more preferably:

상기 X는 O, S 또는 NR5이고; R1은 수소원자, C1-C6알킬기, C1-C4할로알킬기, C1-C6알킬하이드록시기, C1-C6알킬설파닐기, 페닐기, 페닐 C1-C8알킬기, 피리딘기, 퓨란기, 티오펜기, C3-C7싸이클로알킬기, 피롤리딘기, 피페리딘기, 몰포린기, 또는 N-(C1-C6)알킬 피페라진기이고; R2는 C1-C18알킬기, C2-C8할로알킬기, C3-C7싸이클로알킬기, (C3-C7)싸이클로알킬 C1-C8알킬기, C2-C8알케닐기, (C3-C7)싸이클로알케닐 C1-C8알킬기, (C1-C8)알킬 C1-C8알콕시알킬기, C1-C8의 하이드록시알킬기, 하이드록시-(C1-C8)알킬-(C1-C8)알콕시알킬기, 페닐기, 페닐 C1-C8알킬기, 디-페닐 C1-C8알킬기, 페닐 C1-C8알킬하이드록시기, 페닐 C1-C8알케닐기, 피페리딘 C1-C8알킬기, N-[페닐-(C1-C6)알킬] 피페리딘기, N-(C1-C6)알킬 피페리딘 C1-C8알킬기, 피롤리딘온 N-(C1-C8)알킬기, 나프탈렌 C1-C8알킬기, 몰포린 C1-C8알킬기, 피페라진 C1-C8알킬기, N-(C1-C6)알 킬피페라진 C1-C8알킬기, 피리딘 C1-C8알킬기, 피롤리딘 C1-C8알킬기, N-(C1-C6)알킬피롤리딘 C1-C8알킬기, 티오펜 C1-C8알킬기 또는 벤조디옥솔 C1-C8알킬기; R3, 및 R4는 각각 수소원자, 니트로기, 또는 C1-C8알콕시기이고; R5는 수소원자, C1-C4알킬기 또는 C1-C8의 하이드록시알킬기이고; 그리고, 상기 C3-C7싸이클로알킬, 페닐, 피페리딘, 나프탈렌, 몰포린, 피리딘, 피롤리딘, 피롤리딘온, 피페라진, 티오펜, 및 벤조디옥솔 중에서 선택된 치환체는 C1-C8알킬기, 할로겐원자, 하이드록시, C1-C8알콕시기, 니트로기, 및 트리플루오로메틸기 중에서 선택된 치환기가 1 내지 3개 치환된 화합물의 경우이다.X is O, S or NR 5 ; R 1 is a hydrogen atom, a C 1 -C 6 alkyl group, a C 1 -C 4 haloalkyl group, a C 1 -C 6 alkylhydroxy group, a C 1 -C 6 alkylsulfanyl group, a phenyl group, a phenyl C 1 -C 8 alkyl group, A pyridine group, a furan group, a thiophene group, a C 3 -C 7 cycloalkyl group, a pyrrolidine group, a piperidine group, a morpholine group, or an N- (C 1 -C 6 ) alkyl piperazine group; R 2 is a C 1 -C 18 alkyl group, a C 2 -C 8 haloalkyl group, a C 3 -C 7 cycloalkyl group, a (C 3 -C 7 ) cycloalkyl C 1 -C 8 alkyl group, a C 2 -C 8 alkenyl group, (C 3 -C 7 ) cycloalkenyl C 1 -C 8 alkyl group, (C 1 -C 8 ) alkyl C 1 -C 8 alkoxyalkyl group, C 1 -C 8 hydroxyalkyl group, hydroxy- (C 1- C 8 ) alkyl- (C 1 -C 8 ) alkoxyalkyl group, phenyl group, phenyl C 1 -C 8 alkyl group, di-phenyl C 1 -C 8 alkyl group, phenyl C 1 -C 8 alkylhydroxy group, phenyl C 1- C 8 alkenyl group, piperidine C 1 -C 8 alkyl group, N- [phenyl- (C 1 -C 6 ) alkyl] piperidine group, N- (C 1 -C 6 ) alkyl piperidine C 1 -C 8 alkyl group, pyrrolidinone N- (C 1 -C 8 ) alkyl group, naphthalene C 1 -C 8 alkyl group, morpholine C 1 -C 8 alkyl group, piperazine C 1 -C 8 alkyl group, N- (C 1 -C 6 ) Al-Kilpiperazine C 1 -C 8 alkyl group, pyridine C 1 -C 8 alkyl group, pyrrolidine C 1 -C 8 alkyl group, N- (C 1 -C 6 ) alkylpyrrolidine C 1 -C 8 alkyl group , Thiophene C 1 -C 8 alkyl group or benzodioxol C 1- C 8 alkyl group; R 3 , and R 4 are each a hydrogen atom, a nitro group, or a C 1 -C 8 alkoxy group; R 5 is a hydrogen atom, a C 1 -C 4 alkyl group or a C 1 -C 8 hydroxyalkyl group; And the substituent selected from C 3 -C 7 cycloalkyl, phenyl, piperidine, naphthalene, morpholine, pyridine, pyrrolidine, pyrrolidinone, piperazine, thiophene, and benzodioxol is C 1 -C 8 is a compound in which 1 to 3 substituents are selected from an alkyl group, a halogen atom, hydroxy, a C 1 -C 8 alkoxy group, a nitro group, and a trifluoromethyl group.

상기 화학식 1-1로 표시되는 화합물을 구체적으로 예시하면 다음 표 1과 같다:Specific examples of the compound represented by Formula 1-1 are shown in Table 1 below:

Figure 112005078193254-PAT00003
Figure 112005078193254-PAT00003
화합물 번호Compound number XX R1 R 1 R2 R 2 R3 R 3 R4 R 4 1One NHNH 페닐Phenyl 2-(2-히드록시-에톡시)-에틸2- (2-hydroxy-ethoxy) -ethyl HH HH 22 NHNH 트리클로로메틸Trichloromethyl 이소프로필Isopropyl HH HH 33 NHNH 트리클로로메틸Trichloromethyl 싸이클로프로필Cyclopropyl HH HH 44 NHNH 트리클로로메틸Trichloromethyl 2-피페리딘-1-일-에틸2-piperidin-1-yl-ethyl HH HH 55 NHNH 트리클로로메틸Trichloromethyl 1-페닐-에틸1-phenyl-ethyl HH HH 66 NHNH 트리클로로메틸Trichloromethyl 4-페닐-부틸4-phenyl-butyl HH HH 77 NHNH 트리클로로메틸Trichloromethyl n-프로필 n- profile HH HH 88 NHNH 에틸설파닐Ethylsulfanyl 이소프로필Isopropyl HH HH 99 NHNH 에틸설파닐Ethylsulfanyl 3-플루오로-벤질3-fluoro-benzyl HH HH 1010 NHNH 에틸설파닐Ethylsulfanyl 2-(3-플루오로-페닐)-에틸2- (3-Fluoro-phenyl) -ethyl HH HH 1111 NHNH 에틸설파닐Ethylsulfanyl 2-몰포린-4-일-에틸2-morpholin-4-yl-ethyl HH HH 1212 NHNH 에틸설파닐Ethylsulfanyl 2-(3-트리플루오로메틸-페닐)-에틸2- (3-Trifluoromethyl-phenyl) -ethyl HH HH 1313 NHNH HH 페닐Phenyl 니트로Nitro HH 1414 NHNH HH 나프탈렌-1-일메틸Naphthalen-1-ylmethyl 에톡시Ethoxy 에톡시Ethoxy 1515 NHNH HH 3-몰포린-4-일-프로필3-morpholin-4-yl-propyl 에톡시Ethoxy 에톡시Ethoxy 1616 NHNH HH 알릴Allyl 에톡시Ethoxy 에톡시Ethoxy 1717 NHNH HH 2-피리딘-2-일-에틸2-pyridin-2-yl-ethyl 에톡시Ethoxy 에톡시Ethoxy 1818 NHNH HH 4-클로로-벤질4-chloro-benzyl 에톡시Ethoxy 에톡시Ethoxy 1919 NHNH 에틸설파닐Ethylsulfanyl n-부틸 n- butyl HH HH 2020 NHNH 에틸설파닐Ethylsulfanyl sec-부틸 sec- butyl HH HH 2121 NHNH 에틸설파닐Ethylsulfanyl 이소부틸Isobutyl HH HH 2222 NHNH 에틸설파닐Ethylsulfanyl 벤질benzyl HH HH 2323 NHNH 에틸설파닐Ethylsulfanyl 1-페닐-에틸1-phenyl-ethyl HH HH 2424 NHNH 에틸설파닐Ethylsulfanyl 3-메톡시-벤질3-methoxy-benzyl HH HH 2525 NHNH 에틸설파닐Ethylsulfanyl 4-메톡시-벤질4-methoxy-benzyl HH HH 2626 NHNH 에틸설파닐Ethylsulfanyl 3-트리플루오로메틸3-trifluoromethyl HH HH 2727 NHNH 에틸설파닐Ethylsulfanyl 싸이클로헥실Cyclohexyl HH HH 2828 NHNH 에틸설파닐Ethylsulfanyl 싸이클로펜틸Cyclopentyl HH HH 2929 NHNH 에틸설파닐Ethylsulfanyl 펜에틸Phenethyl HH HH 3030 NHNH 에틸설파닐Ethylsulfanyl 4-페닐-부틸4-phenyl-butyl HH HH

3131 NHNH 에틸설파닐Ethylsulfanyl n-프로필 n- profile HH HH 3232 NHNH 에틸설파닐Ethylsulfanyl 3-페닐-프로필3-phenyl-propyl HH HH 3333 NHNH 에틸설파닐Ethylsulfanyl 3-이소프로폭시-프로필3-isopropoxy-propyl HH HH 3434 NHNH 에틸설파닐Ethylsulfanyl 2-메톡시-에틸2-methoxy-ethyl HH HH 3535 NHNH 에틸설파닐Ethylsulfanyl 나프탈렌-1-일메틸Naphthalen-1-ylmethyl HH HH 3636 NHNH 에틸설파닐Ethylsulfanyl 3-몰포린-4-일-프로필3-morpholin-4-yl-propyl HH HH 3737 NHNH 에틸설파닐Ethylsulfanyl 벤조[1,3]디옥솔-5-일메틸Benzo [1,3] dioxol-5-ylmethyl HH HH 3838 NHNH 에틸설파닐Ethylsulfanyl 3,5-디메톡시-벤질3,5-dimethoxy-benzyl HH HH 3939 NHNH 에틸설파닐Ethylsulfanyl 2-플루오로-벤질2-fluoro-benzyl HH HH 4040 NHNH 에틸설파닐Ethylsulfanyl 1-메톡시메틸-프로필1-methoxymethyl-propyl HH HH 4141 NHNH 에틸설파닐Ethylsulfanyl 1-벤질-피페리딘-4-일1-benzyl-piperidin-4-yl HH HH 4242 NHNH 에틸설파닐Ethylsulfanyl 알릴Allyl HH HH 4343 NHNH 에틸설파닐Ethylsulfanyl n-헥사데실 n -hexadecyl HH HH 4444 NHNH 에틸설파닐Ethylsulfanyl 2-피페리딘-1-일-에틸2-piperidin-1-yl-ethyl HH HH 4545 NHNH 에틸설파닐Ethylsulfanyl 2-피롤리딘-1-일-에틸2-pyrrolidin-1-yl-ethyl HH HH 4646 NHNH 에틸설파닐Ethylsulfanyl 2-피리딘-2-일-에틸2-pyridin-2-yl-ethyl HH HH 4747 NHNH 에틸설파닐Ethylsulfanyl 2-에탄올2-ethanol HH HH 4848 NHNH 에틸설파닐Ethylsulfanyl 3-(2-메틸-피페리딘-1-일)-프로필3- (2-Methyl-piperidin-1-yl) -propyl HH HH 4949 NHNH 에틸설파닐Ethylsulfanyl 2-클로로-6-플루오로-벤질2-chloro-6-fluoro-benzyl HH HH 5050 NHNH 에틸설파닐Ethylsulfanyl 2-(2-히드록시-에톡시)-에틸2- (2-hydroxy-ethoxy) -ethyl HH HH 5151 NHNH 페닐Phenyl 싸이클로헥실Cyclohexyl HH HH 5252 NHNH 페닐Phenyl 4-페닐-부틸4-phenyl-butyl HH HH 5353 NHNH 페닐Phenyl 5-페닐-펜틸5-phenyl-pentyl HH HH 5454 NHNH 페닐Phenyl 4-메틸-벤질4-methyl-benzyl HH HH 5555 NHNH 페닐Phenyl 이소부틸Isobutyl HH HH 5656 NHNH 페닐Phenyl n-부틸 n- butyl HH HH 5757 NHNH 페닐Phenyl 나프탈렌-1-일메틸Naphthalen-1-ylmethyl HH HH 5858 NHNH 페닐Phenyl 피리딘-2-일메틸Pyridin-2-ylmethyl HH HH 5959 NHNH 페닐Phenyl 티오펜-2-일메틸Thiophen-2-ylmethyl HH HH 6060 NHNH 페닐Phenyl 이소프로필Isopropyl HH HH 6161 NHNH 페닐Phenyl n-프로필 n- profile HH HH 6262 NHNH 페닐Phenyl 3-이소프로폭시-프로필3-isopropoxy-propyl HH HH 6363 NHNH 페닐Phenyl 3-플루오로-벤질3-fluoro-benzyl HH HH 6464 NHNH 페닐Phenyl 2-(3-트리플루오로메틸-페닐)-에틸2- (3-Trifluoromethyl-phenyl) -ethyl HH HH 6565 NHNH 페닐Phenyl 벤조[1,3]디옥솔-5-일메틸Benzo [1,3] dioxol-5-ylmethyl HH HH 6666 NHNH 페닐Phenyl 3-트리플루오로메틸-벤질3-trifluoromethyl-benzyl HH HH 6767 NHNH 페닐Phenyl 2-메톡시-에틸2-methoxy-ethyl HH HH 6868 NHNH 페닐Phenyl 펜에틸Phenethyl HH HH 6969 NHNH 페닐Phenyl 페닐Phenyl HH HH 7070 NHNH 페닐Phenyl 4-메톡시-페닐4-methoxy-phenyl HH HH 7171 NHNH 페닐Phenyl o-톨릴 o- tolyl HH HH 7272 NHNH 페닐Phenyl 4-이소프로필-페닐4-isopropyl-phenyl HH HH 7373 NHNH 페닐Phenyl 2,4-디메틸-페닐2,4-dimethyl-phenyl HH HH 7474 NHNH 페닐Phenyl 4-n-운데실-페닐4- n- undecyl-phenyl HH HH 7575 NHNH 페닐Phenyl 4-에틸-페닐4-ethyl-phenyl HH HH 7676 NHNH 페닐Phenyl 4-플루오로-페닐4-fluoro-phenyl HH HH 7777 NHNH 페닐Phenyl 2-메톡시-페닐2-methoxy-phenyl HH HH 7878 NHNH 페닐Phenyl 2,4,6-트리메틸-페닐2,4,6-trimethyl-phenyl HH HH 7979 NHNH 페닐Phenyl 4-n-부틸-페닐4- n- butyl-phenyl HH HH 8080 NHNH 페닐Phenyl 2-페녹시-페닐2-phenoxy-phenyl HH HH

8181 NHNH 페닐Phenyl 3-페녹시-페닐3-phenoxy-phenyl HH HH 8282 NHNH 페닐Phenyl 4-페녹시-페닐4-phenoxy-phenyl HH HH 8383 NHNH 페닐Phenyl 3-브로모-페닐3-bromo-phenyl HH HH 8484 NHNH 페닐Phenyl 2-메톡시-5-페놀2-methoxy-5-phenol HH HH 8585 NHNH 페닐Phenyl 5-히드록시-펜탄-1-일5-hydroxy-pentan-1-yl HH HH 8686 NHNH 페닐Phenyl 벤질benzyl HH HH 8787 NHNH 페닐Phenyl 1-페닐-에틸1-phenyl-ethyl HH HH 8888 NHNH 페닐Phenyl 4-클로로-벤질4-chloro-benzyl HH HH 8989 NHNH 페닐Phenyl 3,4-디클로로-벤질3,4-dichloro-benzyl HH HH 9090 NHNH 페닐Phenyl 3-메톡시-벤질3-methoxy-benzyl HH HH 9191 NHNH 페닐Phenyl 2-메톡시-벤질2-methoxy-benzyl HH HH 9292 NHNH 페닐Phenyl 3,5-디메톡시-벤질3,5-dimethoxy-benzyl HH HH 9393 NHNH 페닐Phenyl 2,3-디메톡시-벤질2,3-dimethoxy-benzyl HH HH 9494 NHNH 페닐Phenyl 2-플루오로-벤질2-fluoro-benzyl HH HH 9595 NHNH 페닐Phenyl 싸이클로펜틸Cyclopentyl HH HH 9696 NHNH 페닐Phenyl sec-부틸 sec- butyl HH HH 9797 NHNH 페닐Phenyl 알릴Allyl HH HH 9898 NHNH 페닐Phenyl 2-트리플루오로메틸-벤질2-trifluoromethyl-benzyl HH HH 9999 NHNH 페닐Phenyl n-헥사데실n-hexadecyl HH HH 100100 NHNH 페닐Phenyl 2-피롤리딘-1-일-에틸2-pyrrolidin-1-yl-ethyl HH HH 101101 NHNH 페닐Phenyl 2-피페리딘-1-일-에틸2-piperidin-1-yl-ethyl HH HH 102102 NHNH 페닐Phenyl 2-피리딘-2-일-에틸2-pyridin-2-yl-ethyl HH HH 103103 NHNH 페닐Phenyl 2-(3-플루오로-페닐)-에틸2- (3-Fluoro-phenyl) -ethyl HH HH 104104 NHNH 페닐Phenyl 1-메톡시메틸-프로필1-methoxymethyl-propyl HH HH 105105 NHNH 페닐Phenyl 1-벤질-피페리딘-4-일1-benzyl-piperidin-4-yl HH HH 106106 NHNH 페닐Phenyl 2-몰포린-4-일-에틸2-morpholin-4-yl-ethyl HH HH 107107 NHNH 페닐Phenyl 2-(3,4-디메톡시-페닐)-에틸2- (3,4-Dimethoxy-phenyl) -ethyl HH HH 108108 NHNH 페닐Phenyl 2,4-디클로로-벤질2,4-dichloro-benzyl HH HH 109109 NHNH 페닐Phenyl 2-클로로-벤질2-chloro-benzyl HH HH 110110 NHNH 페닐Phenyl 싸이클로프로필Cyclopropyl HH HH 111111 NHNH 페닐Phenyl 피리딘-3-일메틸Pyridin-3-ylmethyl HH HH 112112 NHNH 페닐Phenyl 1-히드록시-프로판-2-일1-hydroxy-propan-2-yl HH HH 113113 NHNH 페닐Phenyl (4-히드록시-3-메톡시-페닐)-메틸(4-hydroxy-3-methoxy-phenyl) -methyl HH HH 114114 NHNH 페닐Phenyl 2-플루오로-에틸2-fluoro-ethyl HH HH 115115 NHNH 페닐Phenyl 2,3-디클로로-벤질2,3-dichloro-benzyl HH HH 116116 NHNH 페닐Phenyl 3-니트로-벤질3-nitro-benzyl HH HH 117117 NHNH 페닐Phenyl 1-에틸-피롤리딘-2-일메틸1-ethyl-pyrrolidin-2-ylmethyl HH HH 118118 NHNH 페닐Phenyl 3,4-디메톡시-벤질3,4-dimethoxy-benzyl HH HH 119119 NHNH 페닐Phenyl 2-p-톨릴-에틸2- p -tolyl-ethyl HH HH 120120 NHNH 페닐Phenyl 2-(3-메톡시-페닐)-에틸2- (3-methoxy-phenyl) -ethyl HH HH 121121 NHNH 페닐Phenyl 1-에틸-프로필1-ethyl-propyl HH HH 122122 NHNH 페닐Phenyl 2-(2,5-디메톡시-페닐)-에틸2- (2,5-dimethoxy-phenyl) -ethyl HH HH 123123 NHNH 페닐Phenyl 2-(4-클로로-페닐)-에틸2- (4-Chloro-phenyl) -ethyl HH HH 124124 NHNH 페닐Phenyl 2-(4-메톡시-페닐)-에틸2- (4-methoxy-phenyl) -ethyl HH HH 125125 NHNH 페닐Phenyl 1,3-디메틸-부틸1,3-dimethyl-butyl HH HH 126126 NHNH 페닐Phenyl 2-(3-클로로-페닐)-에틸2- (3-Chloro-phenyl) -ethyl HH HH 127127 NHNH 페닐Phenyl 2-(2,4-디클로로-페닐)-에틸2- (2,4-Dichloro-phenyl) -ethyl HH HH 128128 NHNH 페닐Phenyl 2-(3,4-디플루오로-페닐)-에틸2- (3,4-Difluoro-phenyl) -ethyl HH HH 129129 NHNH 페닐Phenyl 3,4,5-트리메톡시-벤질3,4,5-trimethoxy-benzyl HH HH 130130 NHNH 페닐Phenyl 3-메틸-부틸3-methyl-butyl HH HH

131131 NHNH 페닐Phenyl 2-싸이클로헥스-1-에닐-에틸2-cyclohex-1-enyl-ethyl HH HH 132132 NHNH 페닐Phenyl 싸이클로헥실메틸Cyclohexylmethyl HH HH 133133 NHNH 페닐Phenyl 2,2-디페닐-에틸2,2-diphenyl-ethyl HH HH 134134 NHNH 페닐Phenyl 2,4-디플루오로-벤질2,4-difluoro-benzyl HH HH 135135 NHNH 페닐Phenyl 2,5-디플루오로-벤질2,5-difluoro-benzyl HH HH 136136 NHNH 페닐Phenyl 3,3-디페닐-프로필3,3-diphenyl-propyl HH HH 137137 NHNH 페닐Phenyl 2-(4-브로모-페닐)-에틸2- (4-Bromo-phenyl) -ethyl HH HH 138138 NMeNMe 페닐Phenyl n-부틸 n -butyl HH HH 139139 NHNH 페닐Phenyl 4-트리플루오로메틸-벤질4-trifluoromethyl-benzyl HH HH 140140 NHNH 페닐Phenyl 2-(2-플루오로-페닐)-에틸2- (2-Fluoro-phenyl) -ethyl HH HH 141141 NHNH 페닐Phenyl 피리딘-4-일메틸Pyridin-4-ylmethyl HH HH 142142 NHNH 페닐Phenyl 피리딘-2-일메틸Pyridin-2-ylmethyl HH HH 143143 NHNH 페닐Phenyl 2,3-디메틸-싸이클로헥실2,3-dimethyl-cyclohexyl HH HH 144144 NHNH 페닐Phenyl 2,4-디메톡시-벤질2,4-dimethoxy-benzyl HH HH 145145 NHNH 페닐Phenyl 3-클로로-벤질3-chloro-benzyl HH HH 146146 NHNH 페닐Phenyl 2-히드록시-2-페닐-에틸2-hydroxy-2-phenyl-ethyl HH HH 147147 NHNH 페닐Phenyl 2,5-디메톡시-벤질2,5-dimethoxy-benzyl HH HH 148148 NHNH 페닐Phenyl 4-브로모-벤질4-bromo-benzyl HH HH 149149 NHNH 페닐Phenyl 2-(3,4-디클로로-페닐)-에틸2- (3,4-Dichloro-phenyl) -ethyl HH HH 150150 NHNH 페닐Phenyl 3-(2-옥소-피롤리딘-1-일)-프로판-1-일3- (2-oxo-pyrrolidin-1-yl) -propan-1-yl HH HH 151151 NHNH 페닐Phenyl 2-(2-클로로-페닐)-에틸2- (2-Chloro-phenyl) -ethyl HH HH 152152 NHNH 페닐Phenyl 2-(2-히드록시-페닐)-에틸2- (2-hydroxy-phenyl) -ethyl HH HH 153153 NHNH 페닐Phenyl 3-브로모-벤질3-bromo-benzyl HH HH 154154 NHNH 페닐Phenyl 2,6-디메톡시-벤질2,6-dimethoxy-benzyl HH HH 155155 NHNH 페닐Phenyl 2-브로모-벤질2-bromo-benzyl HH HH 156156 NHNH 페닐Phenyl 3-몰포린-4-일-프로필3-morpholin-4-yl-propyl HH HH 157157 N-n-BuN- n -Bu 페닐Phenyl 2-히드록시-에틸2-hydroxy-ethyl HH HH 158158 NHNH 페닐Phenyl 2-(4-메틸-피페라진-1-일)-에틸2- (4-Methyl-piperazin-1-yl) -ethyl HH HH 159159 NMeNMe 페닐Phenyl 싸이클로펜틸Cyclopentyl HH HH 160160 NHNH 페닐Phenyl 2-피페라진-1-일-에틸2-piperazin-1-yl-ethyl HH HH 161161 NHNH 페닐Phenyl O-(4-니트로-벤질)-히드록실 O- (4-nitro-benzyl) -hydroxyl HH HH 162162 NHNH 페닐Phenyl 4-클로로-페닐4-chloro-phenyl HH HH 163163 NHNH 메틸methyl 벤질benzyl HH HH 164164 NHNH 메틸methyl 3-메톡시-벤질3-methoxy-benzyl HH HH 165165 NHNH 메틸methyl 4-메톡시-벤질4-methoxy-benzyl HH HH 166166 NHNH 메틸methyl 3-트리플루오로메틸-벤질3-trifluoromethyl-benzyl HH HH 167167 NHNH 메틸methyl 펜에틸Phenethyl HH HH 168168 NHNH 메틸methyl 4-페닐-부틸4-phenyl-butyl HH HH 169169 NHNH 메틸methyl 나프탈렌-1-일메틸Naphthalen-1-ylmethyl HH HH 170170 NHNH 메틸methyl 벤조[1,3]디옥솔-5-일메틸Benzo [1,3] dioxol-5-ylmethyl HH HH 171171 NHNH 메틸methyl 3-플루오로-벤질3-fluoro-benzyl HH HH 172172 NHNH 메틸methyl 2-(3-플루오로-페닐)-에틸2- (3-Fluoro-phenyl) -ethyl HH HH 173173 NHNH 메틸methyl 2-(2-히드록시-에톡시)-에틸2- (2-hydroxy-ethoxy) -ethyl HH HH 174174 NHNH 메틸methyl 2-히드록시-에틸2-hydroxy-ethyl HH HH 175175 NHNH 이소프로필Isopropyl 벤질benzyl HH HH 176176 NHNH 이소프로필Isopropyl 3-메톡시-벤질3-methoxy-benzyl HH HH 177177 NHNH 이소프로필Isopropyl 4-메톡시-벤질4-methoxy-benzyl HH HH 178178 NHNH 이소프로필Isopropyl 3-트리플루오로메틸-벤질3-trifluoromethyl-benzyl HH HH 179179 NHNH 이소프로필Isopropyl 펜에틸Phenethyl HH HH 180180 NHNH 이소프로필Isopropyl 4-페닐-부틸4-phenyl-butyl HH HH

181181 NHNH 이소프로필Isopropyl 나프탈렌-1-일메틸Naphthalen-1-ylmethyl HH HH 182182 NHNH 이소프로필Isopropyl 벤조[1,3]디옥솔-5-일메틸Benzo [1,3] dioxol-5-ylmethyl HH HH 183183 NHNH 이소프로필Isopropyl 3-플루오로-벤질3-fluoro-benzyl HH HH 184184 NHNH 이소프로필Isopropyl 2-(3-플루오로-페닐)-에틸2- (3-Fluoro-phenyl) -ethyl HH HH 185185 NHNH 이소프로필Isopropyl 2-(2-히드록시-에톡시)-에틸2- (2-hydroxy-ethoxy) -ethyl HH HH 186186 NHNH 이소프로필Isopropyl 2-히드록시-에틸2-hydroxy-ethyl HH HH 187187 NHNH tert-부틸 tert -butyl 벤질benzyl HH HH 188188 NHNH tert-부틸 tert -butyl 3-메톡시-벤질3-methoxy-benzyl HH HH 189189 NHNH tert-부틸 tert -butyl 4-메톡시-벤질4-methoxy-benzyl HH HH 190190 NHNH tert-부틸 tert -butyl 3-트리플루오로메틸-벤질3-trifluoromethyl-benzyl HH HH 191191 NHNH tert-부틸 tert -butyl 펜에틸Phenethyl HH HH 192192 NHNH tert-부틸 tert -butyl 4-페닐-부틸4-phenyl-butyl HH HH 193193 NHNH tert-부틸 tert -butyl 나프탈렌-1-일메틸Naphthalen-1-ylmethyl HH HH 194194 NHNH tert-부틸 tert -butyl 벤조[1,3]디옥솔-5-일메틸Benzo [1,3] dioxol-5-ylmethyl HH HH 195195 NHNH tert-부틸 tert -butyl 3-플루오로-벤질3-fluoro-benzyl HH HH 196196 NHNH tert-부틸 tert -butyl 2-(3-플루오로-페닐)-에틸2- (3-Fluoro-phenyl) -ethyl HH HH 197197 NHNH tert-부틸 tert -butyl 2-(2-히드록시-에톡시)-에틸2- (2-hydroxy-ethoxy) -ethyl HH HH 198198 NHNH tert-부틸 tert -butyl 2-히드록시-에틸2-hydroxy-ethyl HH HH 199199 NHNH 싸이클로헥실Cyclohexyl 벤질benzyl HH HH 200200 NHNH 싸이클로헥실Cyclohexyl 3-메톡시-벤질3-methoxy-benzyl HH HH 201201 NHNH 싸이클로헥실Cyclohexyl 4-메톡시-벤질4-methoxy-benzyl HH HH 202202 NHNH 싸이클로헥실Cyclohexyl 3-트리플루오로메틸-벤질3-trifluoromethyl-benzyl HH HH 203203 NHNH 싸이클로헥실Cyclohexyl 펜에틸Phenethyl HH HH 204204 NHNH 싸이클로헥실Cyclohexyl 4-페닐-부틸4-phenyl-butyl HH HH 205205 NHNH 싸이클로헥실Cyclohexyl 나프탈렌-1-일메틸Naphthalen-1-ylmethyl HH HH 206206 NHNH 싸이클로헥실Cyclohexyl 벤조[1,3]디옥솔-5-일메틸Benzo [1,3] dioxol-5-ylmethyl HH HH 207207 NHNH 싸이클로헥실Cyclohexyl 3-플루오로-벤질3-fluoro-benzyl HH HH 208208 NHNH 싸이클로헥실Cyclohexyl 2-(3-플루오로-페닐)-에틸2- (3-Fluoro-phenyl) -ethyl HH HH 209209 NHNH 싸이클로헥실Cyclohexyl 2-(2-히드록시-에톡시)-에틸2- (2-hydroxy-ethoxy) -ethyl HH HH 210210 NHNH 싸이클로헥실Cyclohexyl 2-히드록시-에틸2-hydroxy-ethyl HH HH 211211 NHNH 벤질benzyl 벤질benzyl HH HH 212212 NHNH 벤질benzyl 3-메톡시-벤질3-methoxy-benzyl HH HH 213213 NHNH 벤질benzyl 4-메톡시-벤질4-methoxy-benzyl HH HH 214214 NHNH 벤질benzyl 3-트리플루오로메틸-벤질3-trifluoromethyl-benzyl HH HH 215215 NHNH 벤질benzyl 펜에틸Phenethyl HH HH 216216 NHNH 벤질benzyl 4-페닐-부틸4-phenyl-butyl HH HH 217217 NHNH 벤질benzyl 나프탈렌-1-일메틸Naphthalen-1-ylmethyl HH HH 218218 NHNH 벤질benzyl 벤조[1,3]디옥솔-5-일메틸Benzo [1,3] dioxol-5-ylmethyl HH HH 219219 NHNH 벤질benzyl 3-플루오로-벤질3-fluoro-benzyl HH HH 220220 NHNH 벤질benzyl 2-(3-플루오로-페닐)-에틸2- (3-Fluoro-phenyl) -ethyl HH HH 221221 NHNH 벤질benzyl 2-(2-히드록시-에톡시)-에틸2- (2-hydroxy-ethoxy) -ethyl HH HH 222222 NHNH 벤질benzyl 2-히드록시-에틸2-hydroxy-ethyl HH HH 223223 NHNH 피리딘-2-일Pyridin-2-yl 벤질benzyl HH HH 224224 NHNH 피리딘-2-일Pyridin-2-yl 3-메톡시-벤질3-methoxy-benzyl HH HH 225225 NHNH 피리딘-2-일Pyridin-2-yl 4-메톡시-벤질4-methoxy-benzyl HH HH 226226 NHNH 피리딘-2-일Pyridin-2-yl 3-트리플루오로메틸-벤질3-trifluoromethyl-benzyl HH HH 227227 NHNH 피리딘-2-일Pyridin-2-yl 펜에틸Phenethyl HH HH 228228 NHNH 피리딘-2-일Pyridin-2-yl 4-페닐-부틸4-phenyl-butyl HH HH 229229 NHNH 피리딘-2-일Pyridin-2-yl 나프탈렌-1-일메틸Naphthalen-1-ylmethyl HH HH 230230 NHNH 피리딘-2-일Pyridin-2-yl 벤조[1,3]디옥솔-5-일메틸Benzo [1,3] dioxol-5-ylmethyl HH HH

231231 NHNH 피리딘-2-일Pyridin-2-yl 3-플루오로-벤질3-fluoro-benzyl HH HH 232232 NHNH 피리딘-2-일Pyridin-2-yl 2-(3-플루오로-페닐)-에틸2- (3-Fluoro-phenyl) -ethyl HH HH 233233 NHNH 피리딘-2-일Pyridin-2-yl 2-(2-히드록시-에톡시)-에틸2- (2-hydroxy-ethoxy) -ethyl HH HH 234234 NHNH 피리딘-2-일Pyridin-2-yl 2-히드록시-에틸2-hydroxy-ethyl HH HH 235235 NHNH 피리딘-3-일Pyridin-3-yl 벤질benzyl HH HH 236236 NHNH 피리딘-3-일Pyridin-3-yl 3-메톡시-벤질3-methoxy-benzyl HH HH 237237 NHNH 피리딘-3-일Pyridin-3-yl 4-메톡시-벤질4-methoxy-benzyl HH HH 238238 NHNH 피리딘-3-일Pyridin-3-yl 3-트리플루오로메틸-벤질3-trifluoromethyl-benzyl HH HH 239239 NHNH 피리딘-3-일Pyridin-3-yl 펜에틸Phenethyl HH HH 240240 NHNH 피리딘-3-일Pyridin-3-yl 4-페닐-부틸4-phenyl-butyl HH HH 241241 NHNH 피리딘-3-일Pyridin-3-yl 나프탈렌-1-일메틸Naphthalen-1-ylmethyl HH HH 242242 NHNH 피리딘-3-일Pyridin-3-yl 벤조[1,3]디옥솔-5-일메틸Benzo [1,3] dioxol-5-ylmethyl HH HH 243243 NHNH 피리딘-3-일Pyridin-3-yl 3-플루오로-벤질3-fluoro-benzyl HH HH 244244 NHNH 피리딘-3-일Pyridin-3-yl 2-(3-플루오로-페닐)-에틸2- (3-Fluoro-phenyl) -ethyl HH HH 245245 NHNH 피리딘-3-일Pyridin-3-yl 2-(2-히드록시-에톡시)-에틸2- (2-hydroxy-ethoxy) -ethyl HH HH 246246 NHNH 피리딘-3-일Pyridin-3-yl 2-히드록시-에틸2-hydroxy-ethyl HH HH 247247 NHNH 피리딘-4-일Pyridin-4-yl 벤질benzyl HH HH 248248 NHNH 피리딘-4-일Pyridin-4-yl 3-메톡시-벤질3-methoxy-benzyl HH HH 249249 NHNH 피리딘-4-일Pyridin-4-yl 4-메톡시-벤질4-methoxy-benzyl HH HH 250250 NHNH 피리딘-4-일Pyridin-4-yl 3-트리플루오로메틸-벤질3-trifluoromethyl-benzyl HH HH 251251 NHNH 피리딘-4-일Pyridin-4-yl 펜에틸Phenethyl HH HH 252252 NHNH 피리딘-4-일Pyridin-4-yl 4-페닐-부틸4-phenyl-butyl HH HH 253253 NHNH 피리딘-4-일Pyridin-4-yl 나프탈렌-1-일메틸Naphthalen-1-ylmethyl HH HH 254254 NHNH 피리딘-4-일Pyridin-4-yl 벤조[1,3]디옥솔-5-일메틸Benzo [1,3] dioxol-5-ylmethyl HH HH 255255 NHNH 피리딘-4-일Pyridin-4-yl 3-플루오로-벤질3-fluoro-benzyl HH HH 256256 NHNH 피리딘-4-일Pyridin-4-yl 2-(3-플루오로-페닐)-에틸2- (3-Fluoro-phenyl) -ethyl HH HH 257257 NHNH 피리딘-4-일Pyridin-4-yl 2-(2-히드록시-에톡시)-에틸2- (2-hydroxy-ethoxy) -ethyl HH HH 258258 NHNH 피리딘-4-일Pyridin-4-yl 2-히드록시-에틸2-hydroxy-ethyl HH HH 259259 NHNH 4-클로로-페닐4-chloro-phenyl 벤질benzyl HH HH 260260 NHNH 4-클로로-페닐4-chloro-phenyl 3-메톡시-벤질3-methoxy-benzyl HH HH 261261 NHNH 4-클로로-페닐4-chloro-phenyl 4-메톡시-벤질4-methoxy-benzyl HH HH 262262 NHNH 4-클로로-페닐4-chloro-phenyl 3-트리플루오로메틸-벤질3-trifluoromethyl-benzyl HH HH 263263 NHNH 4-클로로-페닐4-chloro-phenyl 펜에틸Phenethyl HH HH 264264 NHNH 4-클로로-페닐4-chloro-phenyl 4-페닐-부틸4-phenyl-butyl HH HH 265265 NHNH 4-클로로-페닐4-chloro-phenyl 나프탈렌-1-일메틸Naphthalen-1-ylmethyl HH HH 266266 NHNH 4-클로로-페닐4-chloro-phenyl 벤조[1,3]디옥솔-5-일메틸Benzo [1,3] dioxol-5-ylmethyl HH HH 267267 NHNH 4-클로로-페닐4-chloro-phenyl 3-플루오로-벤질3-fluoro-benzyl HH HH 268268 NHNH 4-클로로-페닐4-chloro-phenyl 2-(3-플루오로-페닐)-에틸2- (3-Fluoro-phenyl) -ethyl HH HH 269269 NHNH 4-클로로-페닐4-chloro-phenyl 2-(2-히드록시-에톡시)-에틸2- (2-hydroxy-ethoxy) -ethyl HH HH 270270 NHNH 4-클로로-페닐4-chloro-phenyl 2-히드록시-에틸2-hydroxy-ethyl HH HH

271271 NHNH 이소프로필Isopropyl 2,4-디메톡시-벤질2,4-dimethoxy-benzyl HH HH 272272 NHNH 벤질benzyl 2,4-디메톡시-벤질2,4-dimethoxy-benzyl HH HH 273273 OO 페닐Phenyl 2,4-디메톡시-벤질2,4-dimethoxy-benzyl HH HH 274274 SS 페닐Phenyl 2,4-디메톡시-벤질2,4-dimethoxy-benzyl HH HH 275275 NHNH 피롤리딘-1-일Pyrrolidin-1-yl 2-메톡시-벤질2-methoxy-benzyl HH HH 276276 NHNH 피페리딘-1-일Piperidin-1-yl 2-메톡시-벤질2-methoxy-benzyl HH HH 277277 NHNH 몰포린-4-일Morpholin-4-yl 2-메톡시-벤질2-methoxy-benzyl HH HH 278278 NHNH 4-메틸-피페라진-1-일4-methyl-piperazin-1-yl 2-메톡시-벤질2-methoxy-benzyl HH HH 279279 NHNH 피롤리딘-1-일Pyrrolidin-1-yl 3-메톡시-벤질3-methoxy-benzyl HH HH 280280 NHNH 피페리딘-1-일Piperidin-1-yl 3-메톡시-벤질3-methoxy-benzyl HH HH 281281 NHNH 몰포린-4-일Morpholin-4-yl 3-메톡시-벤질3-methoxy-benzyl HH HH 282282 NHNH 4-메틸-피페라진-1-일4-methyl-piperazin-1-yl 3-메톡시-벤질3-methoxy-benzyl HH HH 283283 NHNH 피롤리딘-1-일Pyrrolidin-1-yl 4-메톡시-벤질4-methoxy-benzyl HH HH 284284 NHNH 피페리딘-1-일Piperidin-1-yl 4-메톡시-벤질4-methoxy-benzyl HH HH 285285 NHNH 몰포린-4-일Morpholin-4-yl 4-메톡시-벤질4-methoxy-benzyl HH HH 286286 NHNH 4-메틸-피페라진-1-일4-methyl-piperazin-1-yl 4-메톡시-벤질4-methoxy-benzyl HH HH 287287 NHNH 피롤리딘-1-일Pyrrolidin-1-yl 2,3-디메톡시-벤질2,3-dimethoxy-benzyl HH HH 288288 NHNH 피페리딘-1-일Piperidin-1-yl 2,3-디메톡시-벤질2,3-dimethoxy-benzyl HH HH 289289 NHNH 몰포린-4-일Morpholin-4-yl 2,3-디메톡시-벤질2,3-dimethoxy-benzyl HH HH 290290 NHNH 4-메틸-피페라진-1-일4-methyl-piperazin-1-yl 2,3-디메톡시-벤질2,3-dimethoxy-benzyl HH HH 291291 NHNH 피롤리딘-1-일Pyrrolidin-1-yl 2,4-디메톡시-벤질2,4-dimethoxy-benzyl HH HH 292292 NHNH 피페리딘-1-일Piperidin-1-yl 2,4-디메톡시-벤질2,4-dimethoxy-benzyl HH HH 293293 NHNH 몰포린-4-일Morpholin-4-yl 2,4-디메톡시-벤질2,4-dimethoxy-benzyl HH HH 294294 NHNH 4-메틸-피페라진-1-일4-methyl-piperazin-1-yl 2,4-디메톡시-벤질2,4-dimethoxy-benzyl HH HH 295295 NHNH 피롤리딘-1-일Pyrrolidin-1-yl 2,5-디메톡시-벤질2,5-dimethoxy-benzyl HH HH 296296 NHNH 피페리딘-1-일Piperidin-1-yl 2,5-디메톡시-벤질2,5-dimethoxy-benzyl HH HH 297297 NHNH 몰포린-4-일Morpholin-4-yl 2,5-디메톡시-벤질2,5-dimethoxy-benzyl HH HH 298298 NHNH 4-메틸-피페라진-1-일4-methyl-piperazin-1-yl 2,5-디메톡시-벤질2,5-dimethoxy-benzyl HH HH 299299 NHNH 피롤리딘-1-일Pyrrolidin-1-yl 3,4-디메톡시-벤질3,4-dimethoxy-benzyl HH HH 300300 NHNH 피페리딘-1-일Piperidin-1-yl 3,4-디메톡시-벤질3,4-dimethoxy-benzyl HH HH 301301 NHNH 몰포린-4-일Morpholin-4-yl 3,4-디메톡시-벤질3,4-dimethoxy-benzyl HH HH 302302 NHNH 4-메틸-피페라진-1-일4-methyl-piperazin-1-yl 3,4-디메톡시-벤질3,4-dimethoxy-benzyl HH HH 303303 NHNH 피롤리딘-1-일Pyrrolidin-1-yl 3,5-디메톡시-벤질3,5-dimethoxy-benzyl HH HH 304304 NHNH 피페리딘-1-일Piperidin-1-yl 3,5-디메톡시-벤질3,5-dimethoxy-benzyl HH HH 305305 NHNH 몰포린-4-일Morpholin-4-yl 3,5-디메톡시-벤질3,5-dimethoxy-benzyl HH HH 306306 NHNH 4-메틸-피페라진-1-일4-methyl-piperazin-1-yl 3,5-디메톡시-벤질3,5-dimethoxy-benzyl HH HH 307307 NHNH 피롤리딘-1-일Pyrrolidin-1-yl 벤조[1,3]디옥솔-5-일메틸Benzo [1,3] dioxol-5-ylmethyl HH HH 308308 NHNH 피페리딘-1-일Piperidin-1-yl 벤조[1,3]디옥솔-5-일메틸Benzo [1,3] dioxol-5-ylmethyl HH HH 309309 NHNH 몰포린-4-일Morpholin-4-yl 벤조[1,3]디옥솔-5-일메틸Benzo [1,3] dioxol-5-ylmethyl HH HH 310310 NHNH 4-메틸-피페라진-1-일4-methyl-piperazin-1-yl 벤조[1,3]디옥솔-5-일메틸Benzo [1,3] dioxol-5-ylmethyl HH HH 311311 NHNH 피롤리딘-1-일Pyrrolidin-1-yl 3,4,5-트리메톡시-벤질3,4,5-trimethoxy-benzyl HH HH 312312 NHNH 피페리딘-1-일Piperidin-1-yl 3,4,5-트리메톡시-벤질3,4,5-trimethoxy-benzyl HH HH 313313 NHNH 몰포린-4-일Morpholin-4-yl 3,4,5-트리메톡시-벤질3,4,5-trimethoxy-benzyl HH HH 314314 NHNH 4-메틸-피페라진-1-일4-methyl-piperazin-1-yl 3,4,5-트리메톡시-벤질3,4,5-trimethoxy-benzyl HH HH 315315 NHNH 피롤리딘-1-일Pyrrolidin-1-yl 2,4,6-트리메톡시-벤질2,4,6-trimethoxy-benzyl HH HH 316316 NHNH 피페리딘-1-일Piperidin-1-yl 2,4,6-트리메톡시-벤질2,4,6-trimethoxy-benzyl HH HH 317317 NHNH 몰포린-4-일Morpholin-4-yl 2,4,6-트리메톡시-벤질2,4,6-trimethoxy-benzyl HH HH 318318 NHNH 4-메틸-피페라진-1-일4-methyl-piperazin-1-yl 2,4,6-트리메톡시-벤질2,4,6-trimethoxy-benzyl HH HH 319319 NHNH 에톡시Ethoxy 2,4-디메톡시-벤질2,4-dimethoxy-benzyl HH HH 320320 NHNH 에톡시Ethoxy 벤조[1,3]디옥솔-5-일메틸Benzo [1,3] dioxol-5-ylmethyl HH HH

321321 NHNH 이소프로필Isopropyl 2-메톡시-벤질2-methoxy-benzyl HH HH 322322 NHNH 이소프로필Isopropyl 2,3-디메톡시-벤질2,3-dimethoxy-benzyl HH HH 323323 NHNH 이소프로필Isopropyl 3,5-디메톡시-벤질3,5-dimethoxy-benzyl HH HH 324324 NHNH 이소프로필Isopropyl 3,4-디메톡시-벤질3,4-dimethoxy-benzyl HH HH 325325 NHNH 이소프로필Isopropyl 3,4,5-트리메톡시-벤질3,4,5-trimethoxy-benzyl HH HH 326326 NHNH 이소프로필Isopropyl 2,5-디메톡시-벤질2,5-dimethoxy-benzyl HH HH 327327 NHNH 이소프로필Isopropyl 2,4,6-트리메톡시-벤질2,4,6-trimethoxy-benzyl HH HH 328328 NHNH 벤질benzyl 2-메톡시-벤질2-methoxy-benzyl HH HH 329329 NHNH 벤질benzyl 2,3-디메톡시-벤질2,3-dimethoxy-benzyl HH HH 330330 NHNH 벤질benzyl 3,5-디메톡시-벤질3,5-dimethoxy-benzyl HH HH 331331 NHNH 벤질benzyl 3,4-디메톡시-벤질3,4-dimethoxy-benzyl HH HH 332332 NHNH 벤질benzyl 3,4,5-트리메톡시-벤질3,4,5-trimethoxy-benzyl HH HH 333333 NHNH 벤질benzyl 2,4-디메톡시-벤질2,4-dimethoxy-benzyl HH HH 334334 NHNH 벤질benzyl 2,5-디메톡시-벤질2,5-dimethoxy-benzyl HH HH 335335 NHNH 벤질benzyl 2,4,6-트리메톡시-벤질2,4,6-trimethoxy-benzyl HH HH 336336 NHNH 페닐Phenyl 3,4,5-트리메톡시-벤질3,4,5-trimethoxy-benzyl HH HH 337337 NHNH 페닐Phenyl 2,4,6-트리메톡시-벤질2,4,6-trimethoxy-benzyl HH HH 338338 NHNH 퓨란-2-일Furan-2-yl 2-메톡시-벤질2-methoxy-benzyl HH HH 339339 NHNH 퓨란-2-일Furan-2-yl 3-메톡시-벤질3-methoxy-benzyl HH HH 340340 NHNH 퓨란-2-일Furan-2-yl 4-메톡시-벤질4-methoxy-benzyl HH HH 341341 NHNH 퓨란-2-일Furan-2-yl 벤조[1,3]디옥솔-5-일메틸Benzo [1,3] dioxol-5-ylmethyl HH HH 342342 NHNH 퓨란-2-일Furan-2-yl 2,3-디메톡시-벤질2,3-dimethoxy-benzyl HH HH 343343 NHNH 퓨란-2-일Furan-2-yl 3,5-디메톡시-벤질3,5-dimethoxy-benzyl HH HH 344344 NHNH 퓨란-2-일Furan-2-yl 3,4-디메톡시-벤질3,4-dimethoxy-benzyl HH HH 345345 NHNH 퓨란-2-일Furan-2-yl 3,4,5-트리메톡시-벤질3,4,5-trimethoxy-benzyl HH HH 346346 NHNH 퓨란-2-일Furan-2-yl 2,4-디메톡시-벤질2,4-dimethoxy-benzyl HH HH 347347 NHNH 퓨란-2-일Furan-2-yl 2,5-디메톡시-벤질2,5-dimethoxy-benzyl HH HH 348348 NHNH 퓨란-2-일Furan-2-yl 2,4,6-트리메톡시-벤질2,4,6-trimethoxy-benzyl HH HH 349349 NHNH 티오펜-2-일Thiophen-2-yl 2-메톡시-벤질2-methoxy-benzyl HH HH 350350 NHNH 티오펜-2-일Thiophen-2-yl 3-메톡시-벤질3-methoxy-benzyl HH HH 351351 NHNH 티오펜-2-일Thiophen-2-yl 4-메톡시-벤질4-methoxy-benzyl HH HH 352352 NHNH 티오펜-2-일Thiophen-2-yl 벤조[1,3]디옥솔-5-일메틸Benzo [1,3] dioxol-5-ylmethyl HH HH 353353 NHNH 티오펜-2-일Thiophen-2-yl 2,3-디메톡시-벤질2,3-dimethoxy-benzyl HH HH 354354 NHNH 티오펜-2-일Thiophen-2-yl 3,5-디메톡시-벤질3,5-dimethoxy-benzyl HH HH 355355 NHNH 티오펜-2-일Thiophen-2-yl 3,4-디메톡시-벤질3,4-dimethoxy-benzyl HH HH 356356 NHNH 티오펜-2-일Thiophen-2-yl 3,4,5-트리메톡시-벤질3,4,5-trimethoxy-benzyl HH HH 357357 NHNH 티오펜-2-일Thiophen-2-yl 2,4-디메톡시-벤질2,4-dimethoxy-benzyl HH HH 358358 NHNH 티오펜-2-일Thiophen-2-yl 2,5-디메톡시-벤질2,5-dimethoxy-benzyl HH HH 359359 NHNH 티오펜-2-일Thiophen-2-yl 2,4,6-트리메톡시-벤질2,4,6-trimethoxy-benzyl HH HH 360360 NHNH 메톡시-페닐-메틸Methoxy-phenyl-methyl 2-메톡시-벤질2-methoxy-benzyl HH HH 361361 NHNH 메톡시-페닐-메틸Methoxy-phenyl-methyl 3-메톡시-벤질3-methoxy-benzyl HH HH 362362 NHNH 메톡시-페닐-메틸Methoxy-phenyl-methyl 4-메톡시-벤질4-methoxy-benzyl HH HH 363363 NHNH 메톡시-페닐-메틸Methoxy-phenyl-methyl 벤조[1,3]디옥솔-5-일메틸Benzo [1,3] dioxol-5-ylmethyl HH HH 364364 NHNH 메톡시-페닐-메틸Methoxy-phenyl-methyl 2,3-디메톡시-벤질2,3-dimethoxy-benzyl HH HH 365365 NHNH 메톡시-페닐-메틸Methoxy-phenyl-methyl 3,5-디메톡시-벤질3,5-dimethoxy-benzyl HH HH 366366 NHNH 메톡시-페닐-메틸Methoxy-phenyl-methyl 3,4-디메톡시-벤질3,4-dimethoxy-benzyl HH HH 367367 NHNH 메톡시-페닐-메틸Methoxy-phenyl-methyl 3,4,5-트리메톡시-벤질3,4,5-trimethoxy-benzyl HH HH 368368 NHNH 메톡시-페닐-메틸Methoxy-phenyl-methyl 2,4-디메톡시-벤질2,4-dimethoxy-benzyl HH HH 369369 NHNH 메톡시-페닐-메틸Methoxy-phenyl-methyl 2,5-디메톡시-벤질2,5-dimethoxy-benzyl HH HH 370370 NHNH 메톡시-페닐-메틸Methoxy-phenyl-methyl 2,4,6-트리메톡시-벤질2,4,6-trimethoxy-benzyl HH HH

371371 NHNH 1-페닐에틸1-phenylethyl 2-메톡시-벤질2-methoxy-benzyl HH HH 372372 NHNH 1-페닐에틸1-phenylethyl 3-메톡시-벤질3-methoxy-benzyl HH HH 373373 NHNH 1-페닐에틸1-phenylethyl 4-메톡시-벤질4-methoxy-benzyl HH HH 374374 NHNH 1-페닐에틸1-phenylethyl 벤조[1,3]디옥솔-5-일메틸Benzo [1,3] dioxol-5-ylmethyl HH HH 375375 NHNH 1-페닐에틸1-phenylethyl 2,3-디메톡시-벤질2,3-dimethoxy-benzyl HH HH 376376 NHNH 1-페닐에틸1-phenylethyl 3,5-디메톡시-벤질3,5-dimethoxy-benzyl HH HH 377377 NHNH 1-페닐에틸1-phenylethyl 3,4-디메톡시-벤질3,4-dimethoxy-benzyl HH HH 378378 NHNH 1-페닐에틸1-phenylethyl 3,4,5-트리메톡시-벤질3,4,5-trimethoxy-benzyl HH HH 379379 NHNH 1-페닐에틸1-phenylethyl 2,4-디메톡시-벤질2,4-dimethoxy-benzyl HH HH 380380 NHNH 1-페닐에틸1-phenylethyl 2,5-디메톡시-벤질2,5-dimethoxy-benzyl HH HH 381381 NHNH 1-페닐에틸1-phenylethyl 2,4,6-트리메톡시-벤질2,4,6-trimethoxy-benzyl HH HH 382382 NHNH 싸이클로프로필Cyclopropyl 2-메톡시-벤질2-methoxy-benzyl HH HH 383383 NHNH 싸이클로프로필Cyclopropyl 3-메톡시-벤질3-methoxy-benzyl HH HH 384384 NHNH 싸이클로프로필Cyclopropyl 4-메톡시-벤질4-methoxy-benzyl HH HH 385385 NHNH 싸이클로프로필Cyclopropyl 벤조[1,3]디옥솔-5-일메틸Benzo [1,3] dioxol-5-ylmethyl HH HH 386386 NHNH 싸이클로프로필Cyclopropyl 2,3-디메톡시-벤질2,3-dimethoxy-benzyl HH HH 387387 NHNH 싸이클로프로필Cyclopropyl 3,5-디메톡시-벤질3,5-dimethoxy-benzyl HH HH 388388 NHNH 싸이클로프로필Cyclopropyl 3,4-디메톡시-벤질3,4-dimethoxy-benzyl HH HH 389389 NHNH 싸이클로프로필Cyclopropyl 3,4,5-트리메톡시-벤질3,4,5-trimethoxy-benzyl HH HH 390390 NHNH 싸이클로프로필Cyclopropyl 2,4-디메톡시-벤질2,4-dimethoxy-benzyl HH HH 391391 NHNH 싸이클로프로필Cyclopropyl 2,5-디메톡시-벤질2,5-dimethoxy-benzyl HH HH 392392 NHNH 싸이클로프로필Cyclopropyl 2,4,6-트리메톡시-벤질2,4,6-trimethoxy-benzyl HH HH 393393 NHNH n-프로필 n -propyl 2-메톡시-벤질2-methoxy-benzyl HH HH 394394 NHNH n-프로필 n -propyl 3-메톡시-벤질3-methoxy-benzyl HH HH 395395 NHNH n-프로필 n -propyl 4-메톡시-벤질4-methoxy-benzyl HH HH 396396 NHNH n-프로필 n -propyl 벤조[1,3]디옥솔-5-일메틸Benzo [1,3] dioxol-5-ylmethyl HH HH 397397 NHNH n-프로필 n -propyl 2,3-디메톡시-벤질2,3-dimethoxy-benzyl HH HH 398398 NHNH n-프로필 n -propyl 3,5-디메톡시-벤질3,5-dimethoxy-benzyl HH HH 399399 NHNH n-프로필 n -propyl 3,4-디메톡시-벤질3,4-dimethoxy-benzyl HH HH 400400 NHNH n-프로필 n -propyl 3,4,5-트리메톡시-벤질3,4,5-trimethoxy-benzyl HH HH 401401 NHNH n-프로필 n -profile 2,4-디메톡시-벤질2,4-dimethoxy-benzyl HH HH 402402 NHNH n-프로필 n -propyl 2,5-디메톡시-벤질2,5-dimethoxy-benzyl HH HH 403403 NHNH n-프로필 n -propyl 2,4,6-트리메톡시-벤질2,4,6-trimethoxy-benzyl HH HH 404404 NHNH HH 2-메톡시-벤질2-methoxy-benzyl HH HH 405405 NHNH HH 3-메톡시-벤질3-methoxy-benzyl HH HH 406406 NHNH HH 4-메톡시-벤질4-methoxy-benzyl HH HH 407407 NHNH HH 벤조[1,3]디옥솔-5-일메틸Benzo [1,3] dioxol-5-ylmethyl HH HH 408408 NHNH HH 2,3-디메톡시-벤질2,3-dimethoxy-benzyl HH HH 409409 NHNH HH 3,5-디메톡시-벤질3,5-dimethoxy-benzyl HH HH 410410 NHNH HH 3,4-디메톡시-벤질3,4-dimethoxy-benzyl HH HH 411411 NHNH HH 3,4,5-트리메톡시-벤질3,4,5-trimethoxy-benzyl HH HH 412412 NHNH HH 2,4-디메톡시-벤질2,4-dimethoxy-benzyl HH HH 413413 NHNH HH 2,5-디메톡시-벤질2,5-dimethoxy-benzyl HH HH 414414 NHNH HH 2,4,6-트리메톡시-벤질2,4,6-trimethoxy-benzyl HH HH 415415 OO 이소프로필Isopropyl 벤질benzyl HH HH 416416 SS 이소프로필Isopropyl 벤질benzyl HH HH

본 발명에 따른 상기 화학식 1로 표시되는 화합물은 약제학적으로 허용가능한 염을 형성할 수도 있는 바, 예를 들면 염산염, 황산염, 인산염, 이인산염, 브롬화수소염 및 질산염과 같은 무기산과의 염, 또는 말레이트, 말레에이트, 푸마레이트, 타르트레이트, 숙시네이트, 시트레이트, 아세테이트, 락테이트, 메탄술포네이트, p-톨루엔술포네이트, 팔미테이트, 살리실레이트 및 스테아레이트와 같은 유기산과의 염을 포함한다.The compound represented by Chemical Formula 1 according to the present invention may form a pharmaceutically acceptable salt, for example, salts with inorganic acids such as hydrochloride, sulfate, phosphate, diphosphate, hydrogen bromide and nitrate, or Salts with organic acids such as maleate, maleate, fumarate, tartrate, succinate, citrate, acetate, lactate, methanesulfonate, p- toluenesulfonate, palmitate, salicylate and stearate do.

본 발명의 화합물의 일부는 수성 및 유기 용매와 같은 용매로부터 결정화되거나 또는 재결정화될 수 있다. 그러한 경우, 용매화물이 형성될 수 있다. 동결건조와 같은 방법으로 제조 가능한 다양한 양의 물 함유 화합물 이외에 수화물을 비롯한 화학 양론적 용매화물도 본 발명의 범위에 속한다.Some of the compounds of the present invention may be crystallized or recrystallized from solvents such as aqueous and organic solvents. In such cases, solvates may be formed. In addition to various amounts of water-containing compounds that can be prepared by methods such as lyophilization, stoichiometric solvates, including hydrates, are also within the scope of the present invention.

상기 화학식 1로 표시되는 화합물은 거울상 이성질체, 입체 이성질체 또는 토토머일 수도 있다. 상이한 이성질체는 통상의 방법에 의해 분리되거나 또는 분해될 수 있거나, 또는 임의의 소정 이성질체는 통상의 합성법에 의해 또는 입체특이적 또는 비대칭적 합성에 의해 수득할 수 있다.The compound represented by Formula 1 may be an enantiomer, stereoisomer or tautomer. Different isomers can be separated or resolved by conventional methods, or any given isomer can be obtained by conventional synthesis or by stereospecific or asymmetric synthesis.

또한, 본 발명은 상기 화학식 1로 표시되는 화합물의 방사성 유도체를 포함하며, 이들 방사성 화합물은 생체연구 분야에 유용하다.In addition, the present invention includes a radioactive derivative of the compound represented by the formula (1), these radioactive compounds are useful in the field of biological research.

한편, 본 발명은 상기 화학식 1로 표시되는 퀴나졸린 유도체와 약제학적으로 허용 가능한 이들의 염의 제조과정을 포함한다.On the other hand, the present invention includes a process for preparing a quinazoline derivative represented by the formula (1) and pharmaceutically acceptable salts thereof.

또한, 본 발명은 상기 화학식 1-1로 표시되는 화합물의 제조방법을 포함하는 바, 다음 반응식 1에 나타낸 바와 같이 다음 화학식 2로 표시되는 4-클로로-2-치환-퀴나졸린 유도체와 다음 화학식 3으로 표시되는 화합물과의 치환 반응하여 합성할 수 있다.In addition, the present invention includes a method for preparing a compound represented by Chemical Formula 1-1, as shown in the following Scheme 1, 4-chloro-2-substituted-quinazoline derivative represented by the following Chemical Formula 2 and the following Chemical Formula 3 Substitution reaction with the compound represented by is synthesize | combined.

Figure 112005078193254-PAT00004
Figure 112005078193254-PAT00004

상기 반응식 1에서, R1, R2, R3, R4 및 X는 각각 상기 화학식 1에서 정의한 바와 같다.In Reaction Scheme 1, R 1 , R 2 , R 3, R 4 and X are as defined in Formula 1, respectively.

상기 반응식 1에 따른 치환반응은 염기와 유기극성용매를 사용하는 조건에서 수행한다. 이때, 염기는 피리딘 또는 알킬아민류를 포함하는 유기염기, 또는 알칼리금속 및 토금속염을 포함하는 무기염기를 사용할 수 있다.The substitution reaction according to Scheme 1 is carried out under conditions using a base and an organic polar solvent. In this case, an organic base including pyridine or alkylamines, or an inorganic base including an alkali metal and a earth metal salt may be used.

본 발명에 따른 상기 화학식 1-1로 표시되는 화합물의 다른 제조방법으로는, 다음 반응식 2에 나타낸 바와 같이 다음 화학식 4로 표시되는 2-클로로-4-치환-퀴나졸린 유도체와 다음 화학식 5로 표시되는 화합물과의 치환 반응하여 합성할 수 있다.As another method for preparing the compound represented by Chemical Formula 1-1 according to the present invention, a 2-chloro-4-substituted-quinazolin derivative represented by the following Chemical Formula 4 and the following Chemical Formula 5 may be represented as shown in the following Scheme 2. It can synthesize | combine by substitution reaction with the compound to become.

Figure 112005078193254-PAT00005
Figure 112005078193254-PAT00005

상기 반응식 2에서, R1, R2, R3, R4 및 X는 각각 상기 화학식 1에서 정의한 바와 같다.In Scheme 2, R 1 , R 2 , R 3, R 4 and X are as defined in Formula 1, respectively.

상기 반응식 2에 따른 치환반응은 염기와 유기극성용매를 사용하는 조건에서 수행한다. 염기는 피리딘 또는 알킬아민류를 포함하는 유기염기, 또는 알칼리금속 및 토금속염을 포함하는 무기염기를 사용할 수 있다.The substitution reaction according to Scheme 2 is carried out under conditions using a base and an organic polar solvent. The base may be an organic base containing pyridine or alkylamines, or an inorganic base including alkali metal and earth metal salts.

본 발명에 따른 상기 화학식 1-1로 표시되는 화합물의 또 다른 제조방법으로는, 다음 반응식 3에 나타낸 바와 같이 다음 화학식 6으로 표시되는 2-메틸-3H-퀴나졸린-4-온의 4번 위치가 X로 치환된 유도체와 다음 화학식 7로 표시되는 화합물과의 치환 반응하여 합성할 수 있다.As another method for preparing a compound represented by Chemical Formula 1-1 according to the present invention, No. 4 of 2-methyl- 3H -quinazolin-4-one represented by Chemical Formula 6 as shown in the following Scheme 3 It may be synthesized by substitution reaction of a derivative having a position substituted with X with a compound represented by the following Chemical Formula 7.

Figure 112005078193254-PAT00006
Figure 112005078193254-PAT00006

상기 반응식 3에서, R1, R2, R3, R4 및 X는 각각 상기 화학식 1에서 정의한 바와 같고, Y는 Cl, Br, I, OMs 및 OTs 중에서 선택된 이탈기이다.In Reaction Scheme 3, R 1 , R 2 , R 3, R 4 and X are as defined in Formula 1, respectively, and Y is a leaving group selected from Cl, Br, I, OMs and OTs.

상기 반응식 3에 따른 치환반응은 염기와 유기극성용매를 사용하는 조건에서 수행한다. 염기는 피리딘 또는 알킬아민류를 포함하는 유기염기, 또는 알칼리금속 및 토금속염을 포함하는 무기염기를 사용할 수 있다.The substitution reaction according to Scheme 3 is carried out under conditions using a base and an organic polar solvent. The base may be an organic base containing pyridine or alkylamines, or an inorganic base including alkali metal and earth metal salts.

한편, 상기 반응식 1에 따른 치환반응에서 사용된 원료물질로서 상기 화학식 2 및 3으로 표시되는 화합물은 각각 공지화합물로서, 유기합성 분야에서는 잘 알려진 공지합성법에 의거하여 제조 사용할 수 있다. On the other hand, the compounds represented by the formula (2) and 3 as the raw material used in the substitution reaction according to Scheme 1 are known compounds, respectively, can be produced and used according to well-known synthesis method well known in the field of organic synthesis.

상기 화학식 2로 표시되는 화합물에 있어, R1=에틸설파닐기인 퀴나졸린 유도체는 다음 반응식 4에 따른 제조방법에 의해 합성할 수 있다.In the compound represented by Formula 2, the quinazoline derivative wherein R 1 = ethylsulfanyl group can be synthesized by the preparation method according to the following Scheme 4.

Figure 112005078193254-PAT00007
Figure 112005078193254-PAT00007

상기 반응식 4에서, R3, 및 R4는 각각 상기 화학식 1에서 정의한 바와 같다.In Scheme 4, R 3, and R 4 are as defined in Formula 1, respectively.

상기 반응식 4에 의하면, 먼저 2-머캅토-3H-퀴나졸린-4-온을 소듐에톡사이드(NaOEt) 및 에틸아이오다이드(EtI)와 함께 실온 내지 용매의 환류온도 범위에서 교반 반응하여, C-2 위치에 에틸설파닐기를 도입한다. 그런 다음, 상기에서 제조한 2-에틸설파닐-3H-퀴나졸린-4-온은 -20 내지 10 ℃ 온도에서 티오닐 클로라이드(SOCl2)를 가한 후, N,N-디메틸포름아마이드 촉매 존재 하에서 환류반응시켜, C-4 위치의 케톤기를 클로로(Cl)로 전환한다.According to Scheme 4, first, 2-mercapto-3 H -quinazolin-4-one is stirred with sodium ethoxide (NaOEt) and ethyl iodide (EtI) at room temperature to the reflux temperature of the solvent. , An ethylsulfanyl group is introduced at the C-2 position. Then, 2-ethylsulfanyl-3H-quinazolin-4-one prepared above was added with thionyl chloride (SOCl 2 ) at a temperature of −20 to 10 ° C., and then in the presence of N, N- dimethylformamide catalyst. By refluxing, the ketone group at the C-4 position is converted into chloro (Cl).

또한, 상기 화학식 2로 표시되는 화합물에 있어, R1=수소, 알킬 또는 아릴 유도체는 다음 반응식 5에 따른 제조방법에 의해 합성할 수 있다.In addition, in the compound represented by Formula 2, R 1 = hydrogen, alkyl or aryl derivatives can be synthesized by the preparation method according to the following Scheme 5.

Figure 112005078193254-PAT00008
Figure 112005078193254-PAT00008

상기 반응식 5에서, R3, 및 R4는 각각 상기 화학식 1에서 정의한 바와 같다.In Scheme 5, R 3 and R 4 are as defined in Formula 1, respectively.

상기 반응식 5에 의하면, 먼저 이미데이트 화합물을 안트라닐릭 엑시드 및 소듐메톡사이드(NaOMe)와 함께 실온 내지 용매의 환류온도 범위에서 교반 반응하 여, 원하는 치환체 R1을 포함하는 3H-퀴나졸린-4-온을 제조한다. 그런 다음, 포스포러스 옥시클로라이드와 디에틸아닐린을 첨가하고 실온 내지 용매의 환류온도 범위에서 교반 반응하여, C-4 위치의 케톤기를 클로로(Cl)로 전환한다.According to Scheme 5, first, the imidate compound is stirred with anthranilic acid and sodium methoxide (NaOMe) at room temperature to the reflux temperature of the solvent, and 3H -quinazolin-4 including the desired substituent R 1 is obtained. Prepare the on-ion. Then, phosphorus oxychloride and diethylaniline are added and stirred at room temperature to the reflux temperature of the solvent to convert the ketone group at the C-4 position to chloro (Cl).

또한, 상기 화학식 2로 표시되는 화합물에 있어, R1=수소, 알킬 또는 아릴 유도체는 상기 반응식 4와 함께 다음 반응식 6에 따른 제조방법에 의해 합성할 수 있다.In addition, in the compound represented by Chemical Formula 2, R 1 = hydrogen, alkyl or aryl derivative may be synthesized by the preparation method according to the following Scheme 6 together with the above Scheme 4.

Figure 112005078193254-PAT00009
Figure 112005078193254-PAT00009

상기 반응식 6에서, R1, R3, 및 R4는 각각 상기 화학식 1에서 정의한 바와 같다.In Scheme 6, R 1 , R 3, and R 4 are each as defined in Chemical Formula 1.

상기 반응식 6에 의하면, 먼저 아실 할라이드를 안트라닐 아미드와 반응시킨 후 NaOH 존재 하에서 환류 반응하여, 원하는 치환체 R1을 포함하는 3H-퀴나졸린-4-온을 제조한다. 그런 다음, 포스포러스 옥시클로라이드와 디에틸아닐린을 첨가하고 실온 내지 용매의 환류온도 범위에서 교반 반응하여, C-4 위치의 케톤기를 클로로(Cl)로 전환한다.According to Scheme 6, the acyl halide is first reacted with anthranyl amide and then refluxed in the presence of NaOH to prepare 3H -quinazolin-4-one including the desired substituent R 1 . Then, phosphorus oxychloride and diethylaniline are added and stirred at room temperature to the reflux temperature of the solvent to convert the ketone group at the C-4 position to chloro (Cl).

또한, 상기 반응식 2에 따른 치환반응에서 원료 물질로 사용된 상기 화학식 4 및 5로 표시되는 화합물은 각각 공지화합물로서, 유기합성 분야에서는 잘 알려진 공지합성법에 의거하여 제조 사용할 수 있다. 예컨대 상기 화학식 4로 표시되 는 화합물은 다음 반응식 7에 따른 제조방법에 의해 합성할 수 있다.In addition, the compounds represented by Chemical Formulas 4 and 5 used as raw materials in the substitution reaction according to Scheme 2 are known compounds, respectively, and may be manufactured and used according to well-known synthesis methods well known in the field of organic synthesis. For example, the compound represented by Chemical Formula 4 may be synthesized by a manufacturing method according to the following Scheme 7.

Figure 112005078193254-PAT00010
Figure 112005078193254-PAT00010

상기 반응식 7에서, R2, R3, R4, 및 X는 각각 상기 화학식 1에서 정의한 바와 같다.In Scheme 7, R 2 , R 3 , R 4 , and X are as defined in Chemical Formula 1, respectively.

상기 반응식 7에 따른 치환반응은 상기 화학식 3의 화합물을 유기용매겸 반응물질로서 과량 사용하거나 반응물로서 화학양론적으로 사용하고 별도의 유기용매를 사용할 수 있으며, 필요에 따라 염기를 사용하는 조건에서 반응을 수행할 수도 있다. 이때, 염기는 피리딘 또는 알킬아민류를 포함하는 유기염기, 또는 알칼리금속 및 토금속염을 포함하는 무기염기를 사용할 수 있다.Substitution reaction according to Scheme 7 may be used in excess of the compound of formula 3 as an organic solvent and reactant or stoichiometrically used as a reactant and using a separate organic solvent, reaction under conditions using a base if necessary You can also do In this case, an organic base including pyridine or alkylamines, or an inorganic base including an alkali metal and a earth metal salt may be used.

이상의 제조방법으로부터 합성한 중간체 화합물 및 최종 목적 화합물은 크로마토그래피와 재결정화와 같은 통상적인 방법에 의하여 분리 및 정제될 수 있다.Intermediate compounds and final target compounds synthesized from the above preparation methods can be separated and purified by conventional methods such as chromatography and recrystallization.

본 발명에 따른 화합물들은 적당한 방법, 예를 들면 경구, 구강내, 혀밑, 직장내, 질내, 비강내, 국소 또는 비경구(정맥내, 해면체내, 근육내, 피하 및 관내를 포함)의 방법으로 투여될 수 있다.The compounds according to the invention can be prepared by any suitable method, for example, by oral, oral, sublingual, rectal, vaginal, intranasal, topical or parenteral (including intravenous, cavernous, intramuscular, subcutaneous and intraluminal) methods. May be administered.

상술한 바 있는 당뇨 및 비만의 치료 또는 예방을 목적으로 상기 화학식 1로 표시되는 화합물을 경구, 구강내 또는 혀밑 투여하는 경우, 투여량은 평균 몸무게가 70 ㎏인 성인환자를 기준으로할 때 일반적으로 0.1 ∼ 400 ㎎/일이다. 따라서, 일반 성인환자의 경우 약제학적으로 허용 가능한 부형제 또는 담체를 사용하여 유효 화합물이 0.05 ∼ 200 ㎎ 함유되도록 정제 또는 캡슐로 제형화하여 하루에 한 번 또는 여러 회에 걸쳐서, 1회의 투여량 또는 여러 번의 투여량으로 복용된다.In the case of oral, oral or sublingual administration of the compound represented by Formula 1 for the purpose of treating or preventing diabetes and obesity as described above, the dosage is generally based on an adult patient having an average weight of 70 kg. 0.1-400 mg / day. Thus, in general adult patients, a single dose or several doses, once or several times a day, may be formulated into tablets or capsules containing pharmaceutically acceptable excipients or carriers to contain 0.05-200 mg of the active compound. Is taken in one dose.

비경구 투여를 위한 제형에 있어서는, 유효 화합물은 0.01 ∼ 100 ㎎의 양으로 투여되는데, 실제적으로 의사는 각각의 환자에 대하여 환자의 나이, 몸무게 및 환자의 특성에 따라 가장 적당한 투여량을 결정한다. 상기한 투여량은 평균적인 경우를 예시한 것으로서 개인적인 차이에 따라 그 투여량이 높거나 낮을 수 있으며, 이러한 것은 본 발명의 범주에 속하는 것이다.In formulations for parenteral administration, the effective compound is administered in an amount of 0.01 to 100 mg, in practice the physician determines the most appropriate dosage for each patient depending on the age, weight and characteristics of the patient. The above dosages exemplify the average case and may be high or low depending on individual differences, which is within the scope of the present invention.

사람에게 적용함에 있어서, 상기 화학식 1로 표시되는 화합물은 단독으로 투여될 수 있으나, 일반적으로 투여방식과 표준 약제학적 관행(standard phamaceutical practice)을 고려하여 선택된 약제학적 담체와 혼합되어 투여될 수 있다. 예를 들면, 상기 화합물은 전분 또는 락토오즈를 함유하는 정제 형태로, 또는 단독 또는 부형제를 함유하는 캡슐 또는 포낭(ovules) 형태로, 또는 맛을 내거나 색을 띄게 하는 화학 약품을 함유하는 엘릭시르 또는 현탁제 형태로 경구, 구강내 또는 혀밑 투여될 수 있다.In human application, the compound represented by Formula 1 may be administered alone, but may be generally administered in admixture with a pharmaceutical carrier selected in consideration of the mode of administration and standard phamaceutical practice. For example, the compounds may be in the form of tablets containing starch or lactose, in the form of capsules or ovules containing alone or excipients, or elixirs or suspensions containing chemicals that flavor or color. Oral, oral or sublingual.

이러한 액체 제제는 현탁제(예를 들면, 메틸셀룰로오즈, 위텝솔(witepsol)과 같은 반합성 글리세라이드 또는 행인유(apricot kernel oil)와 PEG-6 에스테르의 혼합물 또는 PEG-8과 카프릴릭/카프릭 글리세라이드의 혼합물과 같은 글리세라이드 혼합물)와 같은 약제학적으로 허용 가능한 첨가제와 함께 제조된다. 또한, 비경구적으로 예를 들면, 정맥내, 해면체내, 근육내, 피하 및 관내를 통하여 주사될 수 있다. 또한, 비경구 투여를 위해서는 상기 화합물을 무균의 수용액 형태로 서 사용하는 것이 가장 바람직하며, 이때 상기 용액은 혈액과의 등장성을 갖기 위하여 다른 물질들(예를 들면 염(salt) 또는 만니톨, 글루코오스와 같은 단당류)를 함유할 수도 있다.Such liquid preparations may be suspending agents (e.g., semisynthetic glycerides such as methylcellulose, witepsol or mixtures of apricot kernel oil and PEG-6 esters or PEG-8 and caprylic / capric Pharmaceutically acceptable additives such as glyceride mixtures such as mixtures of glycerides). It can also be injected parenterally, for example, intravenously, intracavernosally, intramuscularly, subcutaneously and intratracheally. In addition, for parenteral administration, it is most preferable to use the compound in the form of a sterile aqueous solution, in which the solution has other substances (e.g. salt or mannitol, glucose) to have isotonicity with blood. Monosaccharides).

따라서, 본 발명은 상기 화학식 1로 표시되는 화합물 또는 약제학적으로 허용 가능한 이들의 염을 유효성분으로 하고, 여기에 약제학적으로 허용 가능한 희석제 또는 부형제가 함유되어 있는 약제학적 조성물을 포함한다. Therefore, the present invention includes a pharmaceutical composition containing a compound represented by the formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient, and containing a pharmaceutically acceptable diluent or excipient.

본 발명은 의약품의 용도로서 상기 화학식 1로 표시되는 화합물 또는 약제학적으로 허용 가능한 이들의 염 또는 약제학적으로 허용 가능한 이들의 프로드럭을 유효성분으로 함유하는 약제학적 조성물을 제공한다.The present invention provides a pharmaceutical composition containing a compound represented by the formula (1) or a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable prodrug thereof as an active ingredient as a use of a pharmaceutical.

이와 같은 본 발명은 다음의 실시예 및 시험예를 통하여 보다 구체적으로 설명하겠는 바, 본 발명이 이에 한정되는 것은 아니다.Such the present invention will be described in more detail through the following examples and test examples, but the present invention is not limited thereto.

다음의 실시예 1 내지 3은 X=NH 및 R1=에틸설파닐기인 화합물 합성을 위한 일구현예이다. Examples 1 to 3 below are one embodiment for synthesizing compounds wherein X = NH and R 1 = ethylsulfanyl group.

Figure 112005078193254-PAT00011
Figure 112005078193254-PAT00011

실시예 1. 2-에틸설파닐-3H-퀴나졸린-4-온 (화학식 B)의 합성Example 1 Synthesis of 2-ethylsulfanyl-3H-quinazolin-4-one (Formula B)

2-머캅토-3H-퀴나졸린-4-온(화학식 A; 3 g, 16.83 mmol)을 에탄올 100 mL에 녹인 후 NaOEt(1.5 eq, 9.4 mL, 25.25 mmol)와 EtI(1.5 eq, 2.02 mL, 25.25 mmol)를 실온에서 첨가하였다. 첨가된 혼합물을 3시간 환류하여 출발물질이 사라지면 감압 증류하여 에탄올을 제거하였다. 혼합물에 에틸 아세테이트를 첨가하고 물로 씻어준 후 무수 황산마그네슘으로 수분을 제거하였다. 유기용매를 감압 증류 한 후 혼합물을 관 크로마토그래피(실리카겔; 230∼400 mesh)를 이용하여 수율 80%의 목적 화합물(2.78 g)을 얻었다.  2-mercapto-3H-quinazolin-4-one (Formula A; 3 g, 16.83 mmol) was dissolved in 100 mL of ethanol, followed by NaOEt (1.5 eq, 9.4 mL, 25.25 mmol) and EtI (1.5 eq, 2.02 mL, 25.25 mmol) was added at room temperature. The mixture was refluxed for 3 hours to remove starting material and distilled under reduced pressure to remove ethanol. Ethyl acetate was added to the mixture, and the mixture was washed with water and then dried with anhydrous magnesium sulfate. After distillation of the organic solvent under reduced pressure, the mixture was subjected to column chromatography (silica gel; 230 to 400 mesh) to obtain a target compound (2.78 g) having a yield of 80%.

1H NMR (CDCl3, 300 MHz) δ 8.27 (d, J=7.8 Hz, 1H), 7.73 (t, J=7.5 Hz, 1H), 7.71 (d, J=7.8 Hz, 1H), 7.41 (t, J=7.5, 1H), 3.34 (q, J=14.4 Hz, 2H), 1.49 (t, J=7.35 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.27 (d, J = 7.8 Hz, 1H), 7.73 (t, J = 7.5 Hz, 1H), 7.71 (d, J = 7.8 Hz, 1H), 7.41 (t , J = 7.5, 1H), 3.34 (q, J = 14.4 Hz, 2H), 1.49 (t, J = 7.35 Hz, 3H)

실시예 2. 4-클로로-2-에틸설파닐-퀴나졸린 (화학식 2a)의 합성Example 2. Synthesis of 4-chloro-2-ethylsulfanyl-quinazolin (Formula 2a)

2-에틸설파닐-3H-퀴나졸린-4-온(화학식 B; 1.5 g, 7.27 mmol)에 티오닐 클로라이드 50 mL를 0 ℃에서 천천히 가하였다. N,N-디메틸포름아마이드를 2∼3방울 넣고 3∼4시간 환류하여 출발물질이 사라지면 감압 증류하여 티오닐 클로라이드를 제거하였다. 잔여 티오닐 클로라이드는 탄산나트륨 포화수용액을 이용하여 씻어 주었다. 혼합물을 에틸 아세테이트로 추출하고 유기층을 소금물으로 씻어준 후 무수 황산마그네슘으로 수분을 제거하였다. 유기용매를 감압 증류한 후 혼합물을 관 크로마토그래피(실리카겔; 230∼400 mesh)를 이용하여 수율 79%의 목적 화합물(1.29 g)을 얻었다.50 mL of thionyl chloride was slowly added to 2-ethylsulfanyl-3H-quinazolin-4-one (Formula B; 1.5 g, 7.27 mmol) at 0 ° C. 2-3 drops of N, N- dimethylformamide was added to the mixture, and the mixture was refluxed for 3 to 4 hours. When the starting material disappeared, distillation under reduced pressure was carried out to remove thionyl chloride. The remaining thionyl chloride was washed with a saturated aqueous sodium carbonate solution. The mixture was extracted with ethyl acetate, and the organic layer was washed with brine, and then dried over anhydrous magnesium sulfate. After distilling the organic solvent under reduced pressure, the mixture was subjected to column chromatography (silica gel; 230 to 400 mesh) to obtain a target compound (1.29 g) having a yield of 79%.

1H NMR (CDCl3, 300 MHz) δ 8.02 (d, J=7.8 Hz, 1H), 7.85 (m, 2H), 7.56 (t, J=7.5 Hz, 1H), 3.29 (q, J=14.4 Hz, 2H), 1.49 (t, J=7.35 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.02 (d, J = 7.8 Hz, 1H), 7.85 (m, 2H), 7.56 (t, J = 7.5 Hz, 1H), 3.29 (q, J = 14.4 Hz , 2H), 1.49 (t, J = 7.35 Hz, 3H)

실시예 3. 4-치환된아민-2-에틸설파닐-퀴나졸린 (화학식 1a)의 합성Example 3. Synthesis of 4-substituted Amine-2-ethylsulfanyl-quinazolin (Formula 1a)

THF 40 mL에 4-클로로-2-에틸설파닐-퀴나졸린(1.0 g, 4.45 mmol)을 녹인 후 트리에틸아민(TEA; 3 eq, 1.86 mL, 13.35 mmol)과 아민 화합물(1.5 eq)을 넣고 실온에서 밤새 교반 하였다. 출발물질이 사라지면 감압 증류하여 THF를 제거하였다. 감압 증류한 혼합물을 관 크로마토그래피(실리카겔; 230∼400 mesh)를 이용하여 수율 90%의 목적 화합물을 얻었다. Dissolve 4-chloro-2-ethylsulfanyl-quinazolin (1.0 g, 4.45 mmol) in 40 mL of THF, add triethylamine (TEA; 3 eq, 1.86 mL, 13.35 mmol) and amine compound (1.5 eq). Stir overnight at room temperature. When the starting material disappeared, the mixture was distilled under reduced pressure to remove THF. The target compound of 90% yield was obtained using the column distillation under reduced pressure using the column chromatography (silica gel; 230-400 mesh).

다음의 실시예 4는 X=NH 및 R1=페닐기인 화합물 합성을 위한 일구현예이다. Example 4 below is an embodiment for synthesizing compounds wherein X = NH and R 1 = phenyl.

Figure 112005078193254-PAT00012
Figure 112005078193254-PAT00012

실시예 4. 4-치환된아민-2-페닐-퀴나졸린 (화학식 1b)의 합성Example 4. Synthesis of 4-Substituted Amine-2-phenyl-Quinazoline (Formula 1b)

THF 30 mL에 4-클로로-2-페닐-퀴나졸린(화학식 2b; 0.5 g, 2.08 mmol)을 녹인 후 TEA(5 eq, 1.45 mL, 10.38 mmol)와 아민(1.5 eq)를 넣고 실온에서 밤새 교반하였다. 출발물질이 사라지면 감압 증류하여 THF를 제거하였다. 감압 증류한 혼합물을 관 크로마토그래피(실리카겔; 230∼400 mesh)를 이용하여 수율 90%의 목적 화합물을 얻었다. Dissolve 4-chloro-2-phenyl-quinazoline (Formula 2b; 0.5 g, 2.08 mmol) in 30 mL of THF, add TEA (5 eq, 1.45 mL, 10.38 mmol) and amine (1.5 eq) and stir overnight at room temperature It was. When the starting material disappeared, the mixture was distilled under reduced pressure to remove THF. The target compound of 90% yield was obtained using the column distillation under reduced pressure using the column chromatography (silica gel; 230-400 mesh).

다음의 실시예 5 내지 7은 X=NH 및 R1=수소, 알킬 또는 아릴기인 화합물 합성을 위한 일구현예이다.Examples 5-7 which follow are one embodiment for the synthesis of compounds wherein X = NH and R 1 = hydrogen, alkyl or aryl groups.

Figure 112005078193254-PAT00013
Figure 112005078193254-PAT00013

실시예 5. 2-치환된-3H-퀴나졸린-4-온 (화학식 E)의 합성Example 5. Synthesis of 2-substituted-3 H -quinazolin-4-one (Formula E)

R1을 포함하는 이미데이트 화합물(화학식 C; 50 mmol)의 염산염을 메탄올 100 mL에 녹인 후 NaOMe(1.2 eq, 60 mmol)와 안트라닐릭 엑시드(화학식 D, 1.0 eq, 50 mmol)를 0 ℃에서 천천히 가하였다. 첨가된 혼합물을 환류 온도까지 천천히 온도를 올린 후 밤새 환류하였다. TLC로 출발물질이 완전히 사라지는 것을 확인한 후 온도를 0 ℃로 냉각하였다. 혼합물에 물(100 mL)를 가한 후 생성된 결정을 여과 후 건조하여 수율 70%의 목적 화합물(35 mmol)을 얻었다.Hydrochloride of an imidate compound containing R 1 (Formula C; 50 mmol) was dissolved in 100 mL of methanol, followed by NaOMe (1.2 eq, 60 mmol) and anthranilic acid (Formula D, 1.0 eq, 50 mmol) at 0 ° C. Slowly added. The added mixture was slowly raised to reflux and then refluxed overnight. After confirming that the starting material disappeared completely by TLC, the temperature was cooled to 0 ° C. Water (100 mL) was added to the mixture, and the resulting crystals were filtered and dried to afford the desired compound (35 mmol) with a yield of 70%.

실시예 6. 4-클로로-2-치환된-퀴나졸린 (화학식 2c)의 합성Example 6. Synthesis of 4-chloro-2-substituted-quinazolin (Formula 2c)

2-치환된-3H-퀴나졸린-4-온(화학식 E; 35 mmol)을 톨루엔 100 mL에 녹인 후 N,N-디에틸아닐린(1.5 eq, 52.5 mmol)과 포스포러스 옥시클로라이드(1.0 eq, 35 mmol)를 첨가하였다. 혼합물을 80 ℃에서 3시간 교반하여 출발물질이 사라지면 0 ℃로 냉각하였다. 혼합물을 1N-NaOH과 1N-HCl로 씻어준 후 무수 황산나트륨으로 수분을 제거하였다. 유기용매를 감압 증류한 후 혼합물을 관 크로마토그래피(실리카겔; 230∼400 mesh)를 이용하여 수율 98%의 목적 화합물 (34 mmol)을 얻었다.2-substituted-3 H -quinazolin-4-one (Formula E; 35 mmol) was dissolved in 100 mL of toluene , followed by N, N -diethylaniline (1.5 eq, 52.5 mmol) and phosphorus oxychloride (1.0 eq). , 35 mmol) was added. The mixture was stirred at 80 ° C. for 3 hours and cooled to 0 ° C. when the starting material disappeared. The mixture was washed with 1 N -NaOH and 1 N -HCl was dried over anhydrous sodium sulfate. After distilling off the organic solvent under reduced pressure, the mixture was purified by column chromatography (silica gel; 230 to 400 mesh) to obtain a target compound (34 mmol) having a yield of 98%.

실시예 7. R2-(2-(R1-치환된)-퀴나졸린-4-일)-아민 (화학식 1c)의 합성Example 7. R 2 - synthesis of the amine (Formula 1c) - (2- (1 R-substituted) - quinazolin-4-yl)

4-클로로-2-치환된-퀴나졸린(화학식 2c; 10 mmol)을 THF 30mL에 녹인 후 트리에틸아민 (2 eq, 20 mmol)과 아민 화합물(1.5 eq, 15 mmol)을 넣고 실온에서 밤새 교반하였다. 출발물질이 사라지면 감압 증류하여 THF를 제거하였다. 클로로포름을 첨가한 후 탄산나트륨 포화수용액, 소금물로 씻어준 후 무수 황산나트륨으로 수분을 제거하였다. 유기용매를 감압 증류로 제거한 후 혼합물을 관 크로마토그래피(실리카겔; 230∼400 mesh)를 이용하여 수율 95%의 목적 화합물(9.5 mmol)을 얻었다.Dissolve 4-chloro-2-substituted-quinazoline (Formula 2c; 10 mmol) in 30 mL of THF, add triethylamine (2 eq, 20 mmol) and amine compound (1.5 eq, 15 mmol) and stir overnight at room temperature It was. When the starting material disappeared, the mixture was distilled under reduced pressure to remove THF. After adding chloroform, washed with saturated aqueous sodium carbonate solution and brine, and then water was removed with anhydrous sodium sulfate. After distilling off the organic solvent under reduced pressure, the mixture was purified by column chromatography (silica gel; 230 to 400 mesh) to obtain a target compound (9.5 mmol) with a yield of 95%.

다음의 실시예 8 내지 9는 R1=H, 알킬 또는 아릴기인 화합물 합성을 위한 일구현예이다.Examples 8 to 9 below are one embodiment for synthesizing compounds wherein R 1 = H, alkyl or aryl groups.

Figure 112005078193254-PAT00014
Figure 112005078193254-PAT00014

실시예 8. 2-(치환된-카르보닐-아미노)-벤즈아미드 (화학식 H)의 합성Example 8. Synthesis of 2- (substituted-carbonyl-amino) -benzamide (Formula H)

R1을 포함하는 아실 클로라이드(화학식 F; 50 mmol), 안트라닐아미드(1.0 eq, 화학식 G, 50 mmol)과 트리에틸아민(1.5 eq, 75 mmol)을 THF에 녹인 후 실온에서 밤새 교반하였다. 출발물질이 사라지면 감압 증류하여 THF를 제거하였다. 클로로포름을 첨가한 후 1N-NaOH와 소금물로 씻어준 후 황산나트륨으로 수분을 제거하였다. 유기용매를 감압증류한 후 디에틸에테르로 결정화하여 수율 95%의 목적화합물(48 mmol)을 얻었다.Acyl chloride containing R 1 (Formula F; 50 mmol), anthranylamide (1.0 eq, Formula G, 50 mmol), and triethylamine (1.5 eq, 75 mmol) were dissolved in THF, followed by stirring at room temperature overnight. When the starting material disappeared, the mixture was distilled under reduced pressure to remove THF. After adding chloroform and washed with 1N-NaOH and brine, water was removed with sodium sulfate. The organic solvent was distilled under reduced pressure and crystallized with diethyl ether to obtain the title compound (48 mmol) with a yield of 95%.

실시예 9. 2-치환된-3H-퀴나졸린-4-온 (화학식 E)의 합성Example 9. Synthesis of 2-substituted-3 H -quinazolin-4-one (Formula E)

2-(치환된-카르보닐-아미노)-벤즈아미드(화학식 H; 45 mmol)를 2.5N-NaOH 60 mL에 녹인후 1시간 환류하였다. 출발물질이 사라지면 0 ℃로 냉각한 후 3N-HCl로 중화하였다. 생성된 결정을 여과를 통하여 취한 후 건조하여 수율 95%의 목적 화합물(43 mmol)을 얻었다. 얻은 목적화합물(화학식 E)은 상기 실시예 6과 7의 방법을 통하여 X=NH 및 R1=H, 알킬 또는 아릴기인 화합물 합성에 이용할 수 있다.2- (substituted-carbonyl-amino) -benzamide (Formula H; 45 mmol) was dissolved in 60 mL of 2.5 N- NaOH and refluxed for 1 hour. When the starting material disappeared, it was cooled to 0 ℃ and neutralized with 3 N -HCl. The resulting crystals were collected through filtration and dried to give the title compound (43 mmol) with a yield of 95%. The obtained target compound (Formula E) can be used for the synthesis of compounds in which X = NH and R 1 = H, alkyl or aryl groups through the methods of Examples 6 and 7.

다음의 실시예 10 내지 11은 X=NH 및 R1=아민인 화합물 합성을 위한 일구현예이다.Examples 10 to 11 which follow are one embodiment for the synthesis of compounds wherein X = NH and R 1 = amine.

Figure 112005078193254-PAT00015
Figure 112005078193254-PAT00015

실시예 10. (2-클로로-퀴나졸린-4-일)-치환된-아민 (화학식 4a)의 합성Example 10. Synthesis of (2-chloro-quinazolin-4-yl) -substituted-amine (Formula 4a)

THF 30 mL에 2,4-디클로로-퀴나졸린(화학식 J; 10 mmol)을 녹인 후 트리에틸아민(1.2 eq, 12 mmol)과 R2로 치환된 아민화합물(화학식 I, 1.05 eq, 10.5 mmol)을 넣고 실온에서 3시간 교반하였다. 출발물질이 사라지면 감압 증류하여 유기용매를 제거하였다. 에틸아세테이트를 첨가한 후 탄산나트륨 포화수용액, 소금물로 씻어준 후 무수황산나트륨으로 수분을 제거하였다. 유기용매는 감압 증류하여 제거한 후 혼합물을 디에틸 에테르로 결정화하여 수율 100%의 목적화합물(10 mmol)을 얻었다.Amine compound substituted with triethylamine (1.2 eq, 12 mmol) and R 2 after dissolving 2,4-dichloro-quinazolin (Formula J; 10 mmol) in 30 mL of THF (Formula I, 1.05 eq, 10.5 mmol) Was added and stirred at room temperature for 3 hours. When the starting material disappeared, the organic solvent was removed by distillation under reduced pressure. Ethyl acetate was added, washed with saturated aqueous sodium carbonate solution and brine, and then dried with anhydrous sodium sulfate. The organic solvent was distilled off under reduced pressure, and the mixture was crystallized with diethyl ether to obtain a target compound (10 mmol) with a yield of 100%.

실시예 11. (2-(R5-치환된 아민)-퀴나졸린-4-일)-R1-치환된-아민 (1d)의 합성Example 11.Synthesis of (2- (R 5 -substituted amine) -quinazolin-4-yl) -R 1 -substituted-amine (1d)

(2-클로로-퀴나졸린-4-일)-치환된-아민(화학식 4a; 1.5 mmol)과 R5로 치환된 아민(3 eq, 4.5 mmol)을 에탄올 15 mL에 녹인 후 밤새 환류교반 하였다. TLC로 출발물질이 완전히 사라진 것을 확인한 후 유기용매를 감압 증류로 제거하였다. 혼합물에 에틸 아세테이트를 첨가한 후 탄산나트륨 포화수용액과 소금물로 씻어준 후 무수 황산나트륨으로 수분을 제거하였다. 유기용매를 감압 증류로 제거한 후 혼합물을 관 크로마토그래피(실리카겔; 230∼400 mesh)를 이용하여 수율 95%의 목적 화합물(1.4 mmol)을 얻었다.(2-Chloro-quinazolin-4-yl) -substituted-amine (Formula 4a; 1.5 mmol) and R 5 substituted amine (3 eq, 4.5 mmol) were dissolved in 15 mL of ethanol and stirred under reflux overnight. After confirming that the starting material disappeared completely by TLC, the organic solvent was removed by distillation under reduced pressure. Ethyl acetate was added to the mixture, followed by washing with saturated aqueous sodium carbonate solution and brine, followed by anhydrous sodium sulfate. After distilling off the organic solvent under reduced pressure, the mixture was purified by column chromatography (silica gel; 230 to 400 mesh) to obtain a target compound (1.4 mmol) having a yield of 95%.

다음의 실시예 12는 X=NH 및 R1=알콕시인 화합물 합성을 위한 일구현예이다.Example 12 below is an embodiment for the synthesis of compounds wherein X = NH and R 1 = alkoxy.

Figure 112005078193254-PAT00016
Figure 112005078193254-PAT00016

실시예 12. (2-(R5-치환된 알콕시)-퀴나졸린-4-일)-R1-치환된-아민 (1d)의 합성Example 12.Synthesis of (2- (R 5 -substituted alkoxy) -quinazolin-4-yl) -R 1 -substituted-amine (1d)

(2-클로로-퀴나졸린-4-일)-치환된-아민(화학식 4a; 1.5 mmol)을 에탄올 15 mL에 녹인 후 NaOEt(2 eq, 3.0mmol)을 0 ℃에서 첨가하였다. 첨가된 혼합물을 실온에서 3시간 교반하여 출발물질이 사라지면 감압증류하여 에탄올을 제거하였다. 혼합물에 에틸 아세테이트를 첨가하고 물로 씻어준 후 황산나트륨으로 수분을 제거하였다. 유기용매를 감압 증류한 후 혼합물을 관 크로마토그래피(실리카겔; 230∼400 mesh)를 이용하여 수율 85%의 목적 화합물(1.3 mmol)을 얻었다.(2-Chloro-quinazolin-4-yl) -substituted-amine (Formula 4a; 1.5 mmol) was dissolved in 15 mL of ethanol, and NaOEt (2 eq, 3.0 mmol) was added at 0 ° C. The added mixture was stirred at room temperature for 3 hours, after which the starting material disappeared and distilled under reduced pressure to remove ethanol. Ethyl acetate was added to the mixture, washed with water, and water was removed with sodium sulfate. After distilling the organic solvent under reduced pressure, the mixture was purified by column chromatography (silica gel; 230 to 400 mesh) to obtain a target compound (1.3 mmol) having a yield of 85%.

다음의 실시예 13 내지 14는 X=S인 화합물 합성을 위한 일구현예이다.Examples 13-14 below are one embodiment for synthesizing compounds where X = S.

Figure 112005078193254-PAT00017
Figure 112005078193254-PAT00017

실시예 13. 2-치환된-3H-퀴나졸린-4-티온 (화학식 6a)의 합성Example 13. Synthesis of 2-substituted-3 H -quinazolin-4-thione (Formula 6a)

톨루엔 9 mL에 2-치환된-3H-퀴나졸린-4-온(화학식 E; 3 mmol)과 Lawesson's 시약(0.5 eq, 1.5 mmol)을 녹인 후 1시간 환류교반 하였다. 출발물질이 사라지면 유기용매를 감압 증류한 후 혼합물을 관 크로마토그래피(실리카겔; 230∼400 mesh)를 이용하여 수율 95%의 목적 화합물(2.9 mmol)을 얻었다.2-substituted- 3H -quinazolin-4-one (Formula E; 3 mmol) and Lawesson's reagent (0.5 eq, 1.5 mmol) were dissolved in 9 mL of toluene and stirred under reflux for 1 hour. When the starting material disappeared, the organic solvent was distilled off under reduced pressure, and the mixture was subjected to column chromatography (silica gel; 230 to 400 mesh) to give a yield of 95% of the title compound (2.9 mmol).

실시예 14. 2-(R1-치환된)-4-(R2-설파닐)-퀴나졸린 (화학식 1f)의 합성Example 14 Synthesis of 2- (R 1 -Substituted) -4- (R 2 -sulfanyl) -quinazolin (Formula 1f)

2-치환된-3H-퀴나졸린-4-티온(화학식 6a, 2 mmol)과 탄산칼륨(1.5 eq, 3 mmol)을 N,N-디메틸포름아마이드 8 mL에 녹인 후 R2-치환된 브롬화합물(1.2 eq, 2.4 mmol)을 실온에서 첨가하였다. 1시간 교반하여 출발물질이 사라지면 혼합물을 에틸 아세테이트로 묽힌 후 물과 소금물로 씻어준 후 무수 황산나트륨으로 수분을 제거하였다. 유기용매를 감압 증류한 후 혼합물을 관 크로마토그래피(실리카겔; 230∼400 mesh)를 이용하여 수율 95%의 목적 화합물(1.9 mmol)을 얻었다.2-substituted- 3H -quinazolin-4-thione (Formula 6a, 2 mmol) and potassium carbonate (1.5 eq, 3 mmol) were dissolved in 8 mL of N, N -dimethylformamide and then R 2 -substituted bromine Compound (1.2 eq, 2.4 mmol) was added at room temperature. When the starting material disappeared by stirring for 1 hour, the mixture was diluted with ethyl acetate, washed with water and brine, and then water was removed with anhydrous sodium sulfate. After distilling the organic solvent under reduced pressure, the mixture was subjected to column chromatography (silica gel; 230 to 400 mesh) to obtain a target compound (1.9 mmol) having a yield of 95%.

다음의 실시예 15는 X=O인 화합물 합성을 위한 일구현예이다.Example 15 below is an embodiment for the synthesis of compounds wherein X═O.

Figure 112005078193254-PAT00018
Figure 112005078193254-PAT00018

실시예 15. 2-(R1-치환된)-4-(R2-치환된-옥시)-퀴나졸린 (화학식 1g)의 합성.Example 15. Synthesis of 2- (R 1 -substituted) -4- (R 2 -substituted-oxy) -quinazolin (Formula 1 g).

2-치환된-3H-퀴나졸린-4-온(화학식 E; 3 mmol)과 탄산칼륨(1.0 eq, 3 mmol)을 N,N-디메틸포름아마이드 9 mL에 녹인 후 R2-치환된 브롬화합물(1.5 eq, 4.5 mmol)을 실온에서 첨가하였다. 밤새 실온에서 교반하여 출발물질이 사라지면 혼합물을 에틸 아세테이트로 묽힌 후 물과 소금물로 씻어준 후 무수 황산나트륨으로 수분을 제거하였다. 유기용매를 감압 증류한 후 혼합물을 관 크로마토그래피(실리카겔; 230∼400 mesh)를 이용하여 수율 45%의 목적 화합물(1.4 mmol)을 얻었다.Dissolved 2- H -quinazolin-4-one (Formula E; 3 mmol) and potassium carbonate (1.0 eq, 3 mmol) in 9 mL of N, N -dimethylformamide followed by R 2 -substituted bromine Compound (1.5 eq, 4.5 mmol) was added at room temperature. After stirring at room temperature overnight, the starting material disappeared, the mixture was diluted with ethyl acetate, washed with water and brine, and then dried with anhydrous sodium sulfate. After distilling the organic solvent under reduced pressure, the mixture was purified by column chromatography (silica gel; 230 to 400 mesh) to obtain a target compound (1.4 mmol) having a yield of 45%.

다음의 실시예 16은 X=O인 화합물 합성을 위한 일구현예이다.Example 16 below is an embodiment for the synthesis of compounds wherein X═O.

Figure 112005078193254-PAT00019
Figure 112005078193254-PAT00019

실시예 16. 2-(R1-치환된)-4-(R2-치환된-옥시)-퀴나졸린 (화학식 1g)의 합성.Example 16 Synthesis of 2- (R 1 -substituted) -4- (R 2 -substituted-oxy) -quinazolin (Formula 1 g).

R2-치환된 알콜 화합물(1.2 eq, 24 mmol)과 소듐 히드리드(1.2 eq, 24 mmol)의 N,N-디메틸포름아마이드 60 mL 용액을 0 ℃에서 만든 후 4-클로로-2-치환된-퀴나졸린(화학식 2c; 20 mmol)을 첨가하였다. 밤새 실온에서 교반한 후 혼합물을 에틸 아세테이트로 묽힌 후 물과 소금물로 씻어준 후 무수 황산나트륨으로 수분을 제거하였다. 유기용매를 감압 증류한 후 혼합물을 관 크로마토그래피(실리카겔; 230∼400 mesh)를 이용하여 수율 46%의 목적 화합물(9.2 mmol)을 얻었다.A 60 mL solution of N, N -dimethylformamide of R 2 -substituted alcohol compound (1.2 eq, 24 mmol) and sodium hydride (1.2 eq, 24 mmol) was made at 0 ° C. and then 4-chloro-2-substituted. -Quinazoline (Formula 2c; 20 mmol) was added. After stirring overnight at room temperature, the mixture was diluted with ethyl acetate, washed with water and brine, and then dried with anhydrous sodium sulfate. After distilling off the organic solvent under reduced pressure, the mixture was purified by column chromatography (silica gel; 230 to 400 mesh) to obtain a target compound (9.2 mmol) having a yield of 46%.

당 분야에서 종사해온 전문가라면 상기 실시예 1 내지 4에 예시된 제조방법에 의거하여 본 발명에 따른 상기 화학식 1로 표시되는 화합물을 쉽게 합성할 수 있다. 본 발명에서 합성한 몇몇 화합물을 예시하면 다음과 같다.Those skilled in the art can easily synthesize the compound represented by Chemical Formula 1 according to the present invention based on the preparation methods illustrated in Examples 1 to 4. Some compounds synthesized in the present invention are as follows.

화합물번호 1. 2-[2-(2-페닐-퀴나졸린-4-일아미노)-에톡시]-에탄올Compound No. 1. 2- [2- (2-phenyl-quinazolin-4-ylamino) -ethoxy] -ethanol

1H NMR(CDCl3, 300 MHz) δ 8.56(m, 2H), 7.91(d, J=8.1 Hz, 1H), 7.70(m, 2H), 7.50(m, 3H), 7.37(t, J=7.5 Hz, 1H), 6.40(m, 1H), 4.00(m, 2H), 3.82(m, 4H), 3.64(m, 2H), 2.83(br s, 1H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.56 (m, 2H), 7.91 (d, J = 8.1 Hz, 1H), 7.70 (m, 2H), 7.50 (m, 3H), 7.37 (t, J = 7.5 Hz, 1H), 6.40 (m, 1H), 4.00 (m, 2H), 3.82 (m, 4H), 3.64 (m, 2H), 2.83 (br s, 1H)

화합물번호 2. 이소프로필-(2-트리클로로메틸-퀴나졸린-4-일)-아민Compound No. 2. Isopropyl- (2-trichloromethyl-quinazolin-4-yl) -amine

화합물번호 3. 싸이클로프로필-(2-트리클로로메틸-퀴나졸린-4-일)-아민Compound No. 3. Cyclopropyl- (2-trichloromethyl-quinazolin-4-yl) -amine

화합물번호 4. (2-피페리딘-1-일-에틸)-(2-트리클로로메틸-퀴나졸린-4-일)-아민Compound No. 4. (2-Piperidin-1-yl-ethyl)-(2-trichloromethyl-quinazolin-4-yl) -amine

화합물번호 5. (1-페닐-에틸)-(2-트리클로로메틸-퀴나졸린-4-일)-아민Compound No. 5. (1-phenyl-ethyl)-(2-trichloromethyl-quinazolin-4-yl) -amine

화합물번호 6. (4-페닐-부틸)-(2-트리클로로메틸-퀴나졸린-4-일)-아민Compound No. 6. (4-phenyl-butyl)-(2-trichloromethyl-quinazolin-4-yl) -amine

화합물번호 7. 프로필-(2-트리클로로메틸-퀴나졸린-4-일)-아민Compound No. 7. Propyl- (2-trichloromethyl-quinazolin-4-yl) -amine

화합물번호 8. (2-에틸설파닐-퀴나졸린-4-일)-이소프로필-아민Compound No. 8. (2-Ethylsulfanyl-quinazolin-4-yl) -isopropyl-amine

화합물번호 9. (2-에틸설파닐-퀴나졸린-4-일)-(3-플루오로-벤질)-아민Compound No. 9. (2-ethylsulfanyl-quinazolin-4-yl)-(3-fluoro-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.68(m, 3H), 7.30(m, 2H), 7.15(d, J=7.5 Hz, 1H), 7.05(d, J=7.5 Hz, 1H), 6.95(t, J=7.5 Hz, 1H), 6.24(s, 1H), 4.85(d, J=5.4 Hz, 2H), 3.15(q, J=14.4 Hz, 2H), 1.37(t, J=7.35 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.68 (m, 3H), 7.30 (m, 2H), 7.15 (d, J = 7.5 Hz, 1H), 7.05 (d, J = 7.5 Hz, 1H), 6.95 (t, J = 7.5 Hz, 1H), 6.24 (s, 1H), 4.85 (d, J = 5.4 Hz, 2H), 3.15 (q, J = 14.4 Hz, 2H), 1.37 (t, J = 7.35 Hz , 3H)

화합물번호 10. (2-에틸설파닐-퀴나졸린-4-일)-[2-(3-플루오로-페닐)-에틸]-아민Compound No. 10. (2-ethylsulfanyl-quinazolin-4-yl)-[2- (3-fluoro-phenyl) -ethyl] -amine

화합물번호 11. (2-에틸설파닐-퀴나졸린-4-일)-(2-몰포린-4-일-에틸)-아민Compound No. 11. (2-Ethylsulfanyl-quinazolin-4-yl)-(2-morpholin-4-yl-ethyl) -amine

화합물번호 12. (2-에틸설파닐-퀴나졸린-4-일)-[2-(3-트리플루오로메틸-페닐)에틸]-아민Compound No. 12. (2-ethylsulfanyl-quinazolin-4-yl)-[2- (3-trifluoromethyl-phenyl) ethyl] -amine

화합물번호 13. (6-니트로-퀴나졸린-4-일)-페닐-아민Compound No. 13. (6-Nitro-quinazolin-4-yl) -phenyl-amine

화합물번호 14. (6,7-디에톡시-퀴나졸린-4-일)-나프탈렌-1-일메틸-아민Compound No. 14. (6,7-Diethoxy-quinazolin-4-yl) -naphthalen-1-ylmethyl-amine

화합물번호 15. (6,7-디에톡시-퀴나졸린-4-일)-(3-몰포린-4-일-프로필)-아민Compound No. 15. (6,7-Diethoxy-quinazolin-4-yl)-(3-morpholin-4-yl-propyl) -amine

화합물번호 16. 알릴-(6,7-디에톡시-퀴나졸린-4-일)-아민Compound No. 16. Allyl- (6,7-diethoxy-quinazolin-4-yl) -amine

화합물번호 17. (6,7-디에톡시-퀴나졸린-4-일)-(2-피리딘-2-일-에틸)-아민Compound No. 17. (6,7-Diethoxy-quinazolin-4-yl)-(2-pyridin-2-yl-ethyl) -amine

화합물번호 18. (4-클로로-벤질)-(6,7-디에톡시-퀴나졸린-4-일)-아민Compound No. 18. (4-Chloro-benzyl)-(6,7-diethoxy-quinazolin-4-yl) -amine

화합물번호 19. 부틸-(2-에틸설파닐-퀴나졸린-4-일)-아민Compound No. 19. Butyl- (2-ethylsulfanyl-quinazolin-4-yl) -amine

화합물번호 20. sec-부틸-(2-에틸설파닐-퀴나졸린-4-일)-아민Compound No. 20. sec- Butyl- (2-ethylsulfanyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.86(d, J=7.5 Hz, 1H), 7.61(m, 2H), 7.30(d, J=7.5 Hz, 1H), 6.57(s, 1H), 4.42(m, 1H), 3.23(q, J=14.4 Hz, 2H), 1.74(m, 2H), 1.47-1.22(m, 6H), 1.00(t, J=7.35 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.86 (d, J = 7.5 Hz, 1H), 7.61 (m, 2H), 7.30 (d, J = 7.5 Hz, 1H), 6.57 (s, 1H), 4.42 (m, 1H), 3.23 (q, J = 14.4 Hz, 2H), 1.74 (m, 2H), 1.47-1.22 (m, 6H), 1.00 (t, J = 7.35 Hz, 3H)

화합물번호 21. (2-에틸설파닐-퀴나졸린-4-일)-이소부틸-아민Compound No. 21. (2-Ethylsulfanyl-quinazolin-4-yl) -isobutyl-amine

화합물번호 22. 벤질-(2-에틸설파닐-퀴나졸린-4-일)-아민Compound No. 22. Benzyl- (2-ethylsulfanyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.65(m, 3H), 7.34(m, 6H), 6.01(s, 1H), 4.86(d, J=5.4 Hz, 2H), 3.65(q, J=14.4 Hz, 2H), 1.40(t, J=7.35 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.65 (m, 3H), 7.34 (m, 6H), 6.01 (s, 1H), 4.86 (d, J = 5.4 Hz, 2H), 3.65 (q, J = 14.4 Hz, 2H), 1.40 (t, J = 7.35 Hz, 3H)

화합물번호 23. (2-에틸설파닐-퀴나졸린-4-일)-(1-페닐-에틸)-아민Compound No. 23. (2-Ethylsulfanyl-quinazolin-4-yl)-(1-phenyl-ethyl) -amine

화합물번호 24. (2-에틸설파닐-퀴나졸린-4-일)-(3-메톡시-벤질)-아민Compound No. 24. (2-Ethylsulfanyl-quinazolin-4-yl)-(3-methoxy-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.66(m, 3H), 7.29(m, 2H), 6.95(m, 2H), 6.88(m, 1H), 6.02(s, 1H), 4.82(d, J=5.5 Hz, 2H), 3.80(s, 3H), 3.20(q, J=14.4 Hz, 2H), 1.40(t, J=7.35 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.66 (m, 3H), 7.29 (m, 2H), 6.95 (m, 2H), 6.88 (m, 1H), 6.02 (s, 1H), 4.82 (d, J = 5.5 Hz, 2H), 3.80 (s, 3H), 3.20 (q, J = 14.4 Hz, 2H), 1.40 (t, J = 7.35 Hz, 3H)

화합물번호 25. (2-에틸설파닐-퀴나졸린-4-일)-(4-메톡시-벤질)-아민Compound No. 25. (2-Ethylsulfanyl-quinazolin-4-yl)-(4-methoxy-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.62(m, 3H), 7.33(m, 3H), 6.90(d, J=8.4 Hz, 2H), 4,78(d, J=5.7 Hz, 2H), 3.81(s, 3H), 3.23(q, J=14.4 Hz, 2H), 1.43(t, J=7.36 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.62 (m, 3H), 7.33 (m, 3H), 6.90 (d, J = 8.4 Hz, 2H), 4,78 (d, J = 5.7 Hz, 2H) , 3.81 (s, 3H), 3.23 (q, J = 14.4 Hz, 2H), 1.43 (t, J = 7.36 Hz, 3H)

화합물번호 26. (2-에틸설파닐-퀴나졸린-4-일)-(3-트리플루오로메틸-벤질)-아민Compound No. 26. (2-Ethylsulfanyl-quinazolin-4-yl)-(3-trifluoromethyl-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.92(d, J=8.3 Hz, 1H), 7.63(m, 4H), 7.55(m, 2H), 7.46(m, 2H), 7.33(m, 1H), 4.94(d, J=5.4 Hz, 2H), 3.12(q, J=14.4 Hz, 2H), 1.30(t, J=7.35 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.92 (d, J = 8.3 Hz, 1H), 7.63 (m, 4H), 7.55 (m, 2H), 7.46 (m, 2H), 7.33 (m, 1H) , 4.94 (d, J = 5.4 Hz, 2H), 3.12 (q, J = 14.4 Hz, 2H), 1.30 (t, J = 7.35 Hz, 3H)

화합물번호 27. 싸이클로헥실-(2-에틸설파닐-퀴나졸린-4-일)-아민Compound No. 27. Cyclohexyl- (2-ethylsulfanyl-quinazolin-4-yl) -amine

화합물번호 28. 싸이클로펜틸-(2-에틸설파닐-퀴나졸린-4-일)-아민Compound No. 28. Cyclopentyl- (2-ethylsulfanyl-quinazolin-4-yl) -amine

화합물번호 29. (2-에틸설파닐-퀴나졸린-4-일)-펜에틸-아민Compound No. 29. (2-Ethylsulfanyl-quinazolin-4-yl) -phenethyl-amine

1H NMR(CDCl3, 300 MHz) δ 7.66(m, 2H), 7.45(d, J=8.2 Hz, 1H), 7.33(m, 6H), 5.84(br s, 1H), 3.91(q, J=12.6 Hz, 2H), 3.26(q, J=14.4 Hz, 2H), 3.03(t, J=6.9 Hz, 2H), 1.47(t, J=7.36 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.66 (m, 2H), 7.45 (d, J = 8.2 Hz, 1H), 7.33 (m, 6H), 5.84 (br s, 1H), 3.91 (q, J = 12.6 Hz, 2H), 3.26 (q, J = 14.4 Hz, 2H), 3.03 (t, J = 6.9 Hz, 2H), 1.47 (t, J = 7.36 Hz, 3H)

화합물번호 30. (2-에틸설파닐-퀴나졸린-4-일)-(4-페닐-부틸)-아민Compound No. 30. (2-Ethylsulfanyl-quinazolin-4-yl)-(4-phenyl-butyl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.61(m, 3H), 7.30(m, 3H), 7.20(m, 3H), 5.74(br s, 1H), 3.68(m, 2H), 3.23(q, J=14.4 Hz, 2H), 2.69(m, 2H), 1.76(m, 4H), 1.44(t, J=7.36 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.61 (m, 3H), 7.30 (m, 3H), 7.20 (m, 3H), 5.74 (br s, 1H), 3.68 (m, 2H), 3.23 (q , J = 14.4 Hz, 2H), 2.69 (m, 2H), 1.76 (m, 4H), 1.44 (t, J = 7.36 Hz, 3H)

화합물번호 31. (2-에틸설파닐-퀴나졸린-4-일)-프로필-아민Compound number 31. (2-ethylsulfanyl-quinazolin-4-yl) -propyl-amine

화합물번호 32. (2-에틸설파닐-퀴나졸린4-일)-(3-페닐-프로필)-아민Compound 32. (2-ethylsulfanyl-quinazolin4-yl)-(3-phenyl-propyl) -amine

화합물번호 33. (2-에틸설파닐-퀴나졸린-4-일)-(3-이소프로폭시프로필)-아민Compound 33. (2-Ethylsulfanyl-quinazolin-4-yl)-(3-isopropoxypropyl) -amine

화합물번호 34. (2-에틸설파닐-퀴나졸린-4-일)-(2-메톡시-에틸)-아민Compound number 34. (2-ethylsulfanyl-quinazolin-4-yl)-(2-methoxy-ethyl) -amine

화합물번호 35. (2-에틸설파닐-퀴나졸린-4-일)-나프탈렌-1-일메틸-아민Compound No. 35. (2-Ethylsulfanyl-quinazolin-4-yl) -naphthalen-1-ylmethyl-amine

1H NMR(CDCl3, 300 MHz) δ 8.11(m, 1H), 7.90(m, 2H), 7.65(m, 2H), 7.53(m, 5H), 7.24(m, 1H), 5.92(br s, 1H), 5.27(d, J=4.5 Hz, 2H), 3.26(q, J=14.4 Hz, 2H), 1.22(t, J=7.4 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.11 (m, 1H), 7.90 (m, 2H), 7.65 (m, 2H), 7.53 (m, 5H), 7.24 (m, 1H), 5.92 (br s , 1H), 5.27 (d, J = 4.5 Hz, 2H), 3.26 (q, J = 14.4 Hz, 2H), 1.22 (t, J = 7.4 Hz, 3H)

화합물번호 36. (2-에틸설파닐-퀴나졸린-4-일)-(3-몰포린-4-일-프로필)-아민Compound No. 36. (2-Ethylsulfanyl-quinazolin-4-yl)-(3-morpholin-4-yl-propyl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.93(m, 1H), 7.70(m, 3H), 7.31(m, 1H), 3.78(m, 6H), 3.22(q, J=14.4 Hz, 2H), 2.59(m, 6H), 1.87(m, 2H), 1.43(t, J=7.41 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.93 (m, 1H), 7.70 (m, 3H), 7.31 (m, 1H), 3.78 (m, 6H), 3.22 (q, J = 14.4 Hz, 2H) , 2.59 (m, 6H), 1.87 (m, 2H), 1.43 (t, J = 7.41 Hz, 3H)

화합물번호 37. 벤조[1,3]디옥솔-5-일메틸-(2-에틸설파닐-퀴나졸린-4-일)-아민Compound No. 37.Benzo [1,3] dioxol-5-ylmethyl- (2-ethylsulfanyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.66(m, 3H), 7.31(m, 1H), 6.80(m, 3H), 5.97(s, 2H), 5.90(br s, 1H), 4.76(d, J=5.1 Hz, 2H), 3.23(q, J=14.4 Hz, 2H), 1.44(t, J=7.36 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.66 (m, 3H), 7.31 (m, 1H), 6.80 (m, 3H), 5.97 (s, 2H), 5.90 (br s, 1H), 4.76 (d , J = 5.1 Hz, 2H), 3.23 (q, J = 14.4 Hz, 2H), 1.44 (t, J = 7.36 Hz, 3H)

화합물번호 38. (3,5-디메톡시-벤질)-(2-에틸설파닐-퀴나졸린-4-일)-아민Compound No. 38. (3,5-Dimethoxy-benzyl)-(2-ethylsulfanyl-quinazolin-4-yl) -amine

화합물번호 39. (2-에틸설파닐-퀴나졸린-4-일)-(2-플루오로-벤질)-아민Compound No. 39. (2-Ethylsulfanyl-quinazolin-4-yl)-(2-fluoro-benzyl) -amine

화합물번호 40. (2-에틸설파닐-퀴나졸린-4-일)-(1-메톡시메틸-프로필)-아민Compound No. 40. (2-Ethylsulfanyl-quinazolin-4-yl)-(1-methoxymethyl-propyl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.65(m, 3H), 7.32(m, 1H), 5.96(d, J=7.5 Hz, 1H), 4.48(d, J=3.6 Hz, 1H), 3.60(m, 2H), 3.41(s, 3H), 3.20(q, J=14.4 Hz, 2H), 1.75(m, 2H), 1.44(t, J=7.4 Hz, 3H), 1.01(t, J=7.35 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.65 (m, 3H), 7.32 (m, 1H), 5.96 (d, J = 7.5 Hz, 1H), 4.48 (d, J = 3.6 Hz, 1H), 3.60 (m, 2H), 3.41 (s, 3H), 3.20 (q, J = 14.4 Hz, 2H), 1.75 (m, 2H), 1.44 (t, J = 7.4 Hz, 3H), 1.01 (t, J = 7.35 Hz, 3H)

화합물번호 41. (1-벤질-피페리딘-4-일)-(2-에틸설파닐-퀴나졸린-4-일)-아민Compound number 41. (1-benzyl-piperidin-4-yl)-(2-ethylsulfanyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.60(m, 3H), 7.34(m, 6H), 5.54(d, J=6.9 Hz, 1H), 4.26(m, 1H), 3.50(m, 2H), 3.22(q, J=14.4 Hz, 2H), 2.90(m, 2H), 2.17(m, 4H), 1.65(m, 2H), 1.22(t, J=7.35 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.60 (m, 3H), 7.34 (m, 6H), 5.54 (d, J = 6.9 Hz, 1H), 4.26 (m, 1H), 3.50 (m, 2H) , 3.22 (q, J = 14.4 Hz, 2H), 2.90 (m, 2H), 2.17 (m, 4H), 1.65 (m, 2H), 1.22 (t, J = 7.35 Hz, 3H)

화합물번호 42. 알릴-(2-에틸설파닐-퀴나졸린-4-일)-아민Compound number 42. Allyl- (2-ethylsulfanyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.66(m, 3H), 7.33(m ,1H), 6.03(m, 1H), 5.79(br s ,1H), 5.29(m, 2H), 4.31(t, J=5.55 Hz, 2H), 3.23(q, J=14.5 Hz, 2H), 1.44(t, J=7.35 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.66 (m, 3H), 7.33 (m, 1H), 6.03 (m, 1H), 5.79 (br s, 1H), 5.29 (m, 2H), 4.31 (t , J = 5.55 Hz, 2H), 3.23 (q, J = 14.5 Hz, 2H), 1.44 (t, J = 7.35 Hz, 3H)

화합물번호 43. (2-에틸설파닐-퀴나졸린-4-일)-헥사데실-아민Compound number 43. (2-ethylsulfanyl-quinazolin-4-yl) -hexadecyl-amine

화합물번호 44. (2-에틸설파닐-퀴나졸린-4-일)-(2-피페리딘-1-일-에틸)-아민Compound No. 44. (2-Ethylsulfanyl-quinazolin-4-yl)-(2-piperidin-1-yl-ethyl) -amine

화합물번호 45. (2-에틸설파닐-퀴나졸린-4-일)-(2-피롤리딘-1-일-에틸)-아민Compound No. 45. (2-ethylsulfanyl-quinazolin-4-yl)-(2-pyrrolidin-1-yl-ethyl) -amine

화합물번호 46. (2-에틸설파닐-퀴나졸린-4-일)-(2-피리딘-2-일-에틸)-아민Compound No. 46. (2-Ethylsulfanyl-quinazolin-4-yl)-(2-pyridin-2-yl-ethyl) -amine

화합물번호 47. 2-(2-에틸설파닐-퀴나졸린-4-일아미노)-에탄올Compound No. 47. 2- (2-Ethylsulfanyl-quinazolin-4-ylamino) -ethanol

1H NMR(DMSO-d6, 300 MHz) δ 8.33(m, 1H), 8.14(d, J=8.2 Hz, 1H), 7.67(t, J=7.5 Hz, 1H), 7.48(d, J=8.1 Hz, 1H), 7.36(t, J=7.6 Hz, 1H), 4.81(br s, 1H), 3.60(m, 4H), 3.13(q, J=14.4 Hz, 2H), 1.32(t, J=7.35 Hz, 3H) 1 H NMR (DMSO-d 6 , 300 MHz) δ 8.33 (m, 1H), 8.14 (d, J = 8.2 Hz, 1H), 7.67 (t, J = 7.5 Hz, 1H), 7.48 (d, J = 8.1 Hz, 1H), 7.36 (t, J = 7.6 Hz, 1H), 4.81 (br s, 1H), 3.60 (m, 4H), 3.13 (q, J = 14.4 Hz, 2H), 1.32 (t, J = 7.35 Hz, 3H)

화합물번호 48. (2-에틸설파닐-퀴나졸린-4-일)-[3-(2-메틸-피페리딘-1-일)-프로필]-아민Compound No. 48. (2-Ethylsulfanyl-quinazolin-4-yl)-[3- (2-methyl-piperidin-1-yl) -propyl] -amine

화합물번호 49. (2-클로로-6-플루오로-벤질)-(2-에틸설파닐-퀴나졸린-4-일)-아민Compound No. 49. (2-Chloro-6-fluoro-benzyl)-(2-ethylsulfanyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.64(m, 3H), 7.25(m, 3H), 7.05(m, 1H), 6.00(br s, 1H), 5.06(d, J=5.6 Hz, 2H), 3.28(q, J=14.4 Hz, 2H), 1.46(t, J=7.35 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.64 (m, 3H), 7.25 (m, 3H), 7.05 (m, 1H), 6.00 (br s, 1H), 5.06 (d, J = 5.6 Hz, 2H ), 3.28 (q, J = 14.4 Hz, 2H), 1.46 (t, J = 7.35 Hz, 3H)

화합물번호 50. 2-[2-(2-에틸설파닐-퀴나졸린-4-일아미노)-에톡시]-에탄올Compound number 50. 2- [2- (2-ethylsulfanyl-quinazolin-4-ylamino) -ethoxy] -ethanol

1H NMR(CDCl3, 300 MHz) δ 7.60(m, 3H), 7.27(m, 1H), 6.50(br s, 1H), 3.85(m, 4H), 3.78(m, 2H), 3.65(m, 2H), 3.20(q, J=14.4 Hz, 2H), 1.42(t, J=7.35 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.60 (m, 3H), 7.27 (m, 1H), 6.50 (br s, 1H), 3.85 (m, 4H), 3.78 (m, 2H), 3.65 (m , 2H), 3.20 (q, J = 14.4 Hz, 2H), 1.42 (t, J = 7.35 Hz, 3H)

화합물번호 51. 싸이클로헥실-(2-페닐-퀴나졸린-4-일)-아민Compound No. 51. Cyclohexyl- (2-phenyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.58(m, 4H), 7.93(m, 1H), 7.72(m, 2H), 7.50(m, 4H), 5.58(d, J=7.2 Hz, 1H), 4.43(m, 1H), 2.27(m, 2H), 1.85(m, 3H), 1.54(m, 2H), 1.34(m, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.58 (m, 4H), 7.93 (m, 1H), 7.72 (m, 2H), 7.50 (m, 4H), 5.58 (d, J = 7.2 Hz, 1H) , 4.43 (m, 1H), 2.27 (m, 2H), 1.85 (m, 3H), 1.54 (m, 2H), 1.34 (m, 3H)

화합물번호 52. (4-페닐-부틸)-(2-페닐-퀴나졸린-4-일)-아민Compound 52. (4-phenyl-butyl)-(2-phenyl-quinazolin-4-yl) -amine

화합물번호 53. (5-페닐-펜틸)-(2-페닐-퀴나졸린-4-일)-아민Compound 53. (5-phenyl-pentyl)-(2-phenyl-quinazolin-4-yl) -amine

화합물번호 54. (4-메틸-벤질)-(2-페닐-퀴나졸린-4-일)-아민Compound number 54. (4-Methyl-benzyl)-(2-phenyl-quinazolin-4-yl) -amine

화합물번호 55. 이소부틸-(2-페닐-퀴나졸린-4-일)-아민Compound number 55. Isobutyl- (2-phenyl-quinazolin-4-yl) -amine

화합물번호 56. 부틸-(2-페닐-퀴나졸린-4-일)-아민Compound No. 56. Butyl- (2-phenyl-quinazolin-4-yl) -amine

화합물번호 57. 나프탈렌-1-일메틸-(2-페닐-퀴나졸린-4-일)-아민Compound No. 57. Naphthalen-1-ylmethyl- (2-phenyl-quinazolin-4-yl) -amine

화합물번호 58. (2-페닐-퀴나졸린-4-일)-피리딘-2-일메틸-아민Compound 58. (2-phenyl-quinazolin-4-yl) -pyridin-2-ylmethyl-amine

1H NMR(CDCl3, 300 MHz) δ 8.61(m, 3H), 7.91(t, J=8.2 Hz, 1H), 7.72(t, J=8.2 Hz, 1H), 7.52(m, 6H), 7.28(m, 1H), 5.07(d, J=4.5 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.61 (m, 3H), 7.91 (t, J = 8.2 Hz, 1H), 7.72 (t, J = 8.2 Hz, 1H), 7.52 (m, 6H), 7.28 (m, 1H), 5.07 (d, J = 4.5 Hz, 2H)

화합물번호 59. (1-페닐-퀴나졸린-4-일)-티오펜-2-일메틸-아민Compound 59. (1-phenyl-quinazolin-4-yl) -thiophen-2-ylmethyl-amine

1H NMR(CDCl3, 300 MHz) δ 8.66(m, 2H), 7.96(d, J=8.1 Hz, 1H), 7.69(m, 2H), 7.53(m, 3H), 7.41(m, 1H), 7.24(t, J=7.4 Hz, 1H), 7.13(t, J=7.4 Hz, 1H), 7.00(t, J=7.36 Hz, 1H), 6.09(d, J=5.1 Hz, 1H), 5.17(d, J=5.4 Hz, 2H), 1 H NMR (CDCl 3 , 300 MHz) δ 8.66 (m, 2H), 7.96 (d, J = 8.1 Hz, 1H), 7.69 (m, 2H), 7.53 (m, 3H), 7.41 (m, 1H) , 7.24 (t, J = 7.4 Hz, 1H), 7.13 (t, J = 7.4 Hz, 1H), 7.00 (t, J = 7.36 Hz, 1H), 6.09 (d, J = 5.1 Hz, 1H), 5.17 (d, J = 5.4 Hz, 2H),

화합물번호 60. 이소프로필-(2-페닐-퀴나졸린-4-일)-아민Compound No. 60. Isopropyl- (2-phenyl-quinazolin-4-yl) -amine

화합물번호 61. (2-페닐-퀴나졸린-4-일)-프로필-아민Compound No. 61. (2-phenyl-quinazolin-4-yl) -propyl-amine

1H NMR(CDCl3, 300 MHz) δ 8.60(m, 1H), 7.94(d, J=8.2 Hz, 1H), 7.70(m, 2H), 7.41(m, 4H), 5.78(t, J=5.4 Hz, 1H), 3.76(q, J=13.2 Hz, 2H), 1.80(q, J=14.4 Hz, 2H), 1.08(t, J=8.4 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.60 (m, 1H), 7.94 (d, J = 8.2 Hz, 1H), 7.70 (m, 2H), 7.41 (m, 4H), 5.78 (t, J = 5.4 Hz, 1H), 3.76 (q, J = 13.2 Hz, 2H), 1.80 (q, J = 14.4 Hz, 2H), 1.08 (t, J = 8.4 Hz, 3H)

화합물번호 62. (3-이소프로폭시프로필)-(2-페닐-퀴나졸린-4-일)-아민Compound No. 62. (3-Isopropoxypropyl)-(2-phenyl-quinazolin-4-yl) -amine

화합물번호 63. (3-플루오로-벤질)-(2-페닐-퀴나졸린-4-일)-아민Compound No. 63. (3-Fluoro-benzyl)-(2-phenyl-quinazolin-4-yl) -amine

화합물번호 64. (2-페닐-퀴나졸린-4-일)-[2-(3-트리플루오로메틸-페닐)-에틸]-아민Compound No. 64. (2-phenyl-quinazolin-4-yl)-[2- (3-trifluoromethyl-phenyl) -ethyl] -amine

1H NMR(CDCl3, 300 MHz) δ 8.64(m, 2H), 7.95(d, J=8.3 Hz, 1H), 7.74(t, J=7.4 Hz, 1H), 7.50(m, 4H), 7.40(t, J=6.6 Hz, 1H), 7.30(m, 1H), 7.03(m, 3H), 5.85(t, J=5.4 Hz, 1H), 4.03(q, J=13.2 Hz, 2H), 3.10(t, J=7.9 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.64 (m, 2H), 7.95 (d, J = 8.3 Hz, 1H), 7.74 (t, J = 7.4 Hz, 1H), 7.50 (m, 4H), 7.40 (t, J = 6.6 Hz, 1H), 7.30 (m, 1H), 7.03 (m, 3H), 5.85 (t, J = 5.4 Hz, 1H), 4.03 (q, J = 13.2 Hz, 2H), 3.10 (t, J = 7.9 Hz, 2H)

화합물번호 65. 벤조[1,3]디옥솔-5-일메틸-(2-페닐-퀴나졸린-4-일)-아민Compound number 65. Benzo [1,3] dioxol-5-ylmethyl- (2-phenyl-quinazolin-4-yl) -amine

화합물번호 66. (2-페닐-퀴나졸린-4-일)-(3-트리플루오로메틸-벤질)-아민Compound No. 66. (2-phenyl-quinazolin-4-yl)-(3-trifluoromethyl-benzyl) -amine

화합물번호 67. (2-메톡시-에틸)-(2-페닐-퀴나졸린-4-일)-아민Compound number 67. (2-methoxy-ethyl)-(2-phenyl-quinazolin-4-yl) -amine

화합물번호 68. 펜에틸-(2-페닐-퀴나졸린-4-일)-아민Compound number 68. Phenethyl- (2-phenyl-quinazolin-4-yl) -amine

화합물번호 69. 페닐-(2-페닐-퀴나졸린-4-일)-아민Compound number 69. Phenyl- (2-phenyl-quinazolin-4-yl) -amine

1H NMR(DMSO, 300 MHz) δ 11.56(br s, 1H), 8.92(d, J=8.2 Hz, 1H), 8.35(m, 3H), 8.09(t, J=7.4 Hz, 1H), 7.83(m, 3H), 7.60(m, 5H), 7.38(d, J=8.4 Hz, 1H) 1 H NMR (DMSO, 300 MHz) δ 11.56 (br s, 1H), 8.92 (d, J = 8.2 Hz, 1H), 8.35 (m, 3H), 8.09 (t, J = 7.4 Hz, 1H), 7.83 (m, 3H), 7.60 (m, 5H), 7.38 (d, J = 8.4 Hz, 1H)

화합물번호 70. (4-메톡시-페닐)-(2-페닐-퀴나졸린-4-일)-아민Compound No. 70. (4-methoxy-phenyl)-(2-phenyl-quinazolin-4-yl) -amine

화합물번호 71. (2-페닐-퀴나졸린-4-일)-o-톨릴-아민Compound number 71. (2-phenyl-quinazolin-4-yl) -o- tolyl-amine

화합물번호 72. (4-이소프로필-페닐)-(2-페닐-퀴나졸린-4-일)-아민Compound number 72. (4-Isopropyl-phenyl)-(2-phenyl-quinazolin-4-yl) -amine

1H NMR(DMSO, 300 MHz) δ 11.45(br s, 1H), 8.90(d, J=8.2 Hz, 1H), 8.35(m, 3H), 8.08(t, J=7.4 Hz, 1H), 7.80(m, 3H), 7.68(m, 3H), 7.41(d, J=8.4 Hz, 1H) 1 H NMR (DMSO, 300 MHz) δ 11.45 (br s, 1H), 8.90 (d, J = 8.2 Hz, 1H), 8.35 (m, 3H), 8.08 (t, J = 7.4 Hz, 1H), 7.80 (m, 3H), 7.68 (m, 3H), 7.41 (d, J = 8.4 Hz, 1H)

화합물번호 73. (2,4-디메틸-페닐)-(2-페닐-퀴나졸린-4-일)-아민Compound No. 73. (2,4-Dimethyl-phenyl)-(2-phenyl-quinazolin-4-yl) -amine

1H NMR(DMSO, 300 MHz) δ 11.41(br s, 1H), 8.82(d, J=8.2 Hz, 1H), 8.33(d, J=8.2 Hz, 1H), 8.18(m, 3H), 7.83(t, J=7.4 Hz, 1H), 7.65(m, 3H), 7.38(d, J=8.1 Hz, 1H), 7.19(m, 3H), 2.37(s, 3H), 2.27(s, 3H) 1 H NMR (DMSO, 300 MHz) δ 11.41 (br s, 1H), 8.82 (d, J = 8.2 Hz, 1H), 8.33 (d, J = 8.2 Hz, 1H), 8.18 (m, 3H), 7.83 (t, J = 7.4 Hz, 1H), 7.65 (m, 3H), 7.38 (d, J = 8.1 Hz, 1H), 7.19 (m, 3H), 2.37 (s, 3H), 2.27 (s, 3H)

화합물번호 74. (2-페닐-퀴나졸린-4-일)-(4-운데실-페닐)-아민Compound number 74. (2-phenyl-quinazolin-4-yl)-(4-undecyl-phenyl) -amine

화합물번호 75. (4-에틸-페닐)-(2-페닐-퀴나졸린-4-일)-아민Compound number 75. (4-Ethyl-phenyl)-(2-phenyl-quinazolin-4-yl) -amine

화합물번호 76. (4-플루오로-페닐)-(2-페닐-퀴나졸린-4-일)-아민Compound number 76. (4-Fluoro-phenyl)-(2-phenyl-quinazolin-4-yl) -amine

1H NMR(DMSO, 300 MHz) δ 11.42(br s, 1H), 8.90(d, J=8.2 Hz, 1H), 8.34(m, 3H), 8.09(t, J=7.4 Hz, 1H), 7.86(m, 3H), 7.68(m, 3H), 7.40(m, 2H) 1 H NMR (DMSO, 300 MHz) δ 11.42 (br s, 1H), 8.90 (d, J = 8.2 Hz, 1H), 8.34 (m, 3H), 8.09 (t, J = 7.4 Hz, 1H), 7.86 (m, 3H), 7.68 (m, 3H), 7.40 (m, 2H)

화합물번호 77. (2-메톡시-페닐)-(2-페닐-퀴나졸린-4-일)-아민Compound No. 77. (2-Methoxy-phenyl)-(2-phenyl-quinazolin-4-yl) -amine

화합물번호 78. (2-페닐-퀴나졸린-4-일)-(2,4,6-트리메틸-페닐)-아민Compound number 78. (2-phenyl-quinazolin-4-yl)-(2,4,6-trimethyl-phenyl) -amine

1H NMR(DMSO, 300 MHz) δ 11.39(br s, 1H), 8.83(d, J=8.2 Hz, 1H), 8.27(t, J=7.4 Hz, 1H), 8.11(m, 3H), 7.85(t, J=7.5 Hz, 1H), 7.67(t, J=7.5 Hz, 1H), 7.60(m, 2H), 7.07(s, 2H), 2.33(s, 3H), 2.18(s, 6H) 1 H NMR (DMSO, 300 MHz) δ 11.39 (br s, 1H), 8.83 (d, J = 8.2 Hz, 1H), 8.27 (t, J = 7.4 Hz, 1H), 8.11 (m, 3H), 7.85 (t, J = 7.5 Hz, 1H), 7.67 (t, J = 7.5 Hz, 1H), 7.60 (m, 2H), 7.07 (s, 2H), 2.33 (s, 3H), 2.18 (s, 6H)

화합물번호 79. (4-부틸-페닐)-(2-페닐-퀴나졸린-4-일)-아민Compound number 79. (4-butyl-phenyl)-(2-phenyl-quinazolin-4-yl) -amine

화합물번호 80. (2-페녹시-페닐)-(2-페닐-퀴나졸린-4-일)-아민Compound No. 80. (2-Phenoxy-phenyl)-(2-phenyl-quinazolin-4-yl) -amine

1H NMR(DMSO, 300 MHz) δ 11.62(br s, 1H), 8.69(d, J=8.2 Hz, 1H), 8.28(m, 3H), 8.09(t, J=7.5 Hz, 1H), 7.79(t, J=7.5 Hz, 1H), 7.68(m, 3H), 7.34(d, J=7.8 Hz, 1H), 7.16(d, J=7.8 Hz, 1H), 7.12(m, 3H), 6.90(m, 3H) 1 H NMR (DMSO, 300 MHz) δ 11.62 (br s, 1H), 8.69 (d, J = 8.2 Hz, 1H), 8.28 (m, 3H), 8.09 (t, J = 7.5 Hz, 1H), 7.79 (t, J = 7.5 Hz, 1H), 7.68 (m, 3H), 7.34 (d, J = 7.8 Hz, 1H), 7.16 (d, J = 7.8 Hz, 1H), 7.12 (m, 3H), 6.90 (m, 3 H)

화합물번호 81. (3-페녹시-페닐)-(2-페닐-퀴나졸린-4-일)-아민Compound No. 81. (3-phenoxy-phenyl)-(2-phenyl-quinazolin-4-yl) -amine

화합물번호 82. (4-페녹시-페닐)-(2-페닐-퀴나졸린-4-일)-아민Compound number 82. (4-Penoxy-phenyl)-(2-phenyl-quinazolin-4-yl) -amine

화합물번호 83. (3-브로모-페닐)-(2-페닐-퀴나졸린-4-일)-아민Compound number 83. (3-Bromo-phenyl)-(2-phenyl-quinazolin-4-yl) -amine

화합물번호 84. 2-메톡시-5-(2-페닐-퀴나졸린-4-일아미노)페놀Compound number 84. 2-methoxy-5- (2-phenyl-quinazolin-4-ylamino) phenol

1H NMR(DMSO, 300 MHz) δ 11.29(br s, 1H), 9.45(br s, 1H), 8.82(d, J=8.2 Hz, 1H), 8.36(m, 2H), 8.25(d, J=8.1 Hz, 1H), 8.06(t, J=7.4 Hz, 1H), 7.79(t, J=7.4 Hz, 1H), 7.64(m, 3H), 7.33(s, 1H), 7.25(d, J=8.7 Hz, 1H), 7.05(d, J=8.7 Hz, 1H), 3.83(s, 3H) 1 H NMR (DMSO, 300 MHz) δ 11.29 (br s, 1H), 9.45 (br s, 1H), 8.82 (d, J = 8.2 Hz, 1H), 8.36 (m, 2H), 8.25 (d, J = 8.1 Hz, 1H), 8.06 (t, J = 7.4 Hz, 1H), 7.79 (t, J = 7.4 Hz, 1H), 7.64 (m, 3H), 7.33 (s, 1H), 7.25 (d, J = 8.7 Hz, 1H), 7.05 (d, J = 8.7 Hz, 1H), 3.83 (s, 3H)

화합물번호 85. 5-(2-페닐-퀴나졸린-4-일아미노)-펜탄-1-올Compound number 85. 5- (2-phenyl-quinazolin-4-ylamino) -pentan-1-ol

화합물번호 86. 벤질-(2-페닐-퀴나졸린-4-일)-아민Compound number 86. Benzyl- (2-phenyl-quinazolin-4-yl) -amine

화합물번호 87. (1-페닐-에틸)-(2-페닐-퀴나졸린-4-일)-아민Compound number 87. (1-phenyl-ethyl)-(2-phenyl-quinazolin-4-yl) -amine

화합물번호 88. (4-클로로-벤질)-(2-페닐-퀴나졸린-4-일)-아민Compound No. 88. (4-Chloro-benzyl)-(2-phenyl-quinazolin-4-yl) -amine

화합물번호 89. (3,4-디클로로-벤질)-(2-페닐-퀴나졸린-4-일)-아민Compound number 89. (3,4-Dichloro-benzyl)-(2-phenyl-quinazolin-4-yl) -amine

화합물번호 90. (3-메톡시-벤질)-(2-페닐-퀴나졸린-4-일)-아민Compound 90. (3-methoxy-benzyl)-(2-phenyl-quinazolin-4-yl) -amine

화합물번호 91. (2-메톡시-벤질)-(2-페닐-퀴나졸린-4-일)-아민Compound number 91. (2-methoxy-benzyl)-(2-phenyl-quinazolin-4-yl) -amine

화합물번호 92. (3,5-디메톡시-벤질)-(2-페닐-퀴나졸린-4-일)-아민Compound 92. (3,5-Dimethoxy-benzyl)-(2-phenyl-quinazolin-4-yl) -amine

화합물번호 93. (2,3-디메톡시-벤질)-(2-페닐-퀴나졸린-4-일)-아민Compound 93. (2,3-Dimethoxy-benzyl)-(2-phenyl-quinazolin-4-yl) -amine

화합물번호 94. (2-플루오로-벤질)-(2-페닐-퀴나졸린-4-일)-아민Compound 94. (2-Fluoro-benzyl)-(2-phenyl-quinazolin-4-yl) -amine

화합물번호 95. 싸이클로펜틸-(2-페닐-퀴나졸린-4-일)-아민Compound number 95. Cyclopentyl- (2-phenyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.61(m, 2H), 7.93(d, J=8.1 Hz, 1H), 7.72(m, 2H), 7.50(m, 4H), 5.67(d, J=6.3 Hz, 1H), 4.80(q, J=13.5 Hz, 1H), 2.31(m, 2H), 1.80(m, 4H), 1.65(m, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.61 (m, 2H), 7.93 (d, J = 8.1 Hz, 1H), 7.72 (m, 2H), 7.50 (m, 4H), 5.67 (d, J = 6.3 Hz, 1H), 4.80 (q, J = 13.5 Hz, 1H), 2.31 (m, 2H), 1.80 (m, 4H), 1.65 (m, 2H)

화합물번호 96. sec-부틸-(2-페닐-퀴나졸린-4-일)-아민Compound No. 96. sec- butyl- (2-phenyl-quinazolin-4-yl) -amine

화합물번호 97. 알릴-(2-페닐-퀴나졸린-4-일)-아민Compound number 97. Allyl- (2-phenyl-quinazolin-4-yl) -amine

화합물번호 98. (2-페닐-퀴나졸린-4-일)-(2-트리플루오로메틸-벤질)-아민Compound 98. (2-phenyl-quinazolin-4-yl)-(2-trifluoromethyl-benzyl) -amine

화합물번호 99. 헥사데실-(2-페닐-퀴나졸린-4-일)-아민Compound No. 99. Hexadecyl- (2-phenyl-quinazolin-4-yl) -amine

화합물번호 100. (2-페닐-퀴나졸린-4-일)-(2-피롤리딘-1-일-에틸)-아민Compound No. 100. (2-phenyl-quinazolin-4-yl)-(2-pyrrolidin-1-yl-ethyl) -amine

화합물번호 101. (2-페닐-퀴나졸린-4-일)-(2-피페리딘-1-일-에틸)-아민Compound 101. (2-phenyl-quinazolin-4-yl)-(2-piperidin-1-yl-ethyl) -amine

화합물번호 102. (2-페닐-퀴나졸린-4-일)-(2-피리딘-2-일-에틸)-아민Compound number 102. (2-phenyl-quinazolin-4-yl)-(2-pyridin-2-yl-ethyl) -amine

화합물번호 103. [2-(3-플루오로-페닐)-에틸]-(2-페닐-퀴나졸린-4-일)-아민Compound 103. [2- (3-Fluoro-phenyl) -ethyl]-(2-phenyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.59(dd, J 1 =7.8 Hz, J 2 =1.8 Hz, 2H), 7.93(d, J=8.1 Hz, 1H), 7.72(t, J=7.5 Hz, 1H), 7.47(m, 7H), 6.99(m, 3H), 5.76(br s, 1H), 4.06(m, 2H), 3.12(t, J=7.2 Hz, 2H) 1 H NMR (CDCl 3, 300 MHz) δ 8.59 (dd, J 1 = 7.8 Hz, J 2 = 1.8 Hz, 2H), 7.93 (d, J = 8.1 Hz, 1H), 7.72 (t, J = 7.5 Hz , 1H), 7.47 (m, 7H), 6.99 (m, 3H), 5.76 (br s, 1H), 4.06 (m, 2H), 3.12 (t, J = 7.2 Hz, 2H)

화합물번호 104. (1-메톡시메틸-프로필)-(2-페닐-퀴나졸린-4-일)-아민Compound number 104. (1-methoxymethyl-propyl)-(2-phenyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.56(t, J=3.8 Hz, 2H), 7.96(d J=8.3 Hz, 1H), 7.72(m, 2H), 7.49-7.39(m, 5H), 6.06(d J=7.2 Hz, 1H), 4.72(t J=3.8 Hz, 1H), 3.65(m, 2H), 3.43(s, 1H), 1.84(m, 2H), 1.06(t, J=7.4 Hz, 3H) 1 H NMR (CDCl 3, 300 MHz) δ 8.56 (t, J = 3.8 Hz, 2H), 7.96 (d J = 8.3 Hz, 1H), 7.72 (m, 2H), 7.49-7.39 (m, 5H), 6.06 (d J = 7.2 Hz, 1H), 4.72 (t J = 3.8 Hz, 1H), 3.65 (m, 2H), 3.43 (s, 1H), 1.84 (m, 2H), 1.06 (t, J = 7.4 Hz, 3H)

화합물번호 105. (1-벤질-피페리딘-4-일)-(2-페닐-퀴나졸린-4-일)-아민Compound number 105. (1-benzyl-piperidin-4-yl)-(2-phenyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.54(t J=6.7 Hz, 2H), 7.92(d, J=8.3 Hz, 1H), 7.69(m, 2H), 7.50-2.27(m, 8H), 5.59(d J=7.1 Hz, 1H), 4.46(m, 1H), 3.61(s, 2H), 2.95(m, 2H), 2.68(s, 1H), 2.30(m, 4H), 1.70(m, 2H) 1 H NMR (CDCl 3, 300 MHz) δ 8.54 (t J = 6.7 Hz, 2H), 7.92 (d, J = 8.3 Hz, 1H), 7.69 (m, 2H), 7.50-2.27 (m, 8H), 5.59 (d J = 7.1 Hz, 1H), 4.46 (m, 1H), 3.61 (s, 2H), 2.95 (m, 2H), 2.68 (s, 1H), 2.30 (m, 4H), 1.70 (m, 2H)

화합물번호 106.(2-몰포린-4-일-에틸)-(2-페닐-퀴나졸린-4-일)-아민Compound number 106. (2-Morpholin-4-yl-ethyl)-(2-phenyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.56(t J=6.2 Hz, 2H), 7.92(d, J=8.5 Hz, 2H), 7.71(m, 2H), 7.49-7.26(m, 4H), 6.56 (s, 1H), 3.86-3.74(m. 6H), 2.73(t, J=5.9 Hz 2H), 3.76(m, 4H) 1 H NMR (CDCl 3, 300 MHz) δ 8.56 (t J = 6.2 Hz, 2H), 7.92 (d, J = 8.5 Hz, 2H), 7.71 (m, 2H), 7.49-7.26 (m, 4H), 6.56 (s, 1H), 3.86-3.74 (m. 6H), 2.73 (t, J = 5.9 Hz 2H), 3.76 (m, 4H)

화합물번호 107. [2-(3,4-디메톡시-페닐)-에틸]-(2-페닐-퀴나졸린-4-일)-아민Compound number 107. [2- (3,4-Dimethoxy-phenyl) -ethyl]-(2-phenyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.60(t J=5.2 Hz, 2H), 7.93(d J=8.3 Hz, 1H), 7.69(t J=7.5 Hz, 1H), 7.57(t J=8.1 Hz, 1H), 7.50(m, 3H), 7.36(t J=3.6 Hz, 1H), 6.84(m, 3H), 5.96(s, 1H), 4.12(m, 2H), 3.87(s, 3H), 3.81(s, 3H), 3.03(t, J=6.7 Hz, 2H) 1 H NMR (CDCl 3, 300 MHz) δ 8.60 (t J = 5.2 Hz, 2H), 7.93 (d J = 8.3 Hz, 1H), 7.69 (t J = 7.5 Hz, 1H), 7.57 (t J = 8.1 Hz, 1H), 7.50 (m, 3H), 7.36 (t J = 3.6 Hz, 1H), 6.84 (m, 3H), 5.96 (s, 1H), 4.12 (m, 2H), 3.87 (s, 3H) , 3.81 (s, 3H), 3.03 (t, J = 6.7 Hz, 2H)

화합물번호 108. (2,4-디클로로-벤질)-(2-페닐-퀴나졸린-4-일)-아민Compound 108. (2,4-Dichloro-benzyl)-(2-phenyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.53(m, 2H), 7.93(d, J=8.1 Hz, 1H), 7.74(t, J=7.7Hz, 2H), 7.47(m, 6H), 7.17(dd, J 1 =8.4 Hz, J 2 =2.0Hz, 1H), 6.17(br, 1H), 5.06(d, J=6.0 Hz, 2H) 1 H NMR (CDCl 3, 300 MHz) δ 8.53 (m, 2H), 7.93 (d, J = 8.1 Hz, 1H), 7.74 (t, J = 7.7 Hz, 2H), 7.47 (m, 6H), 7.17 (dd, J 1 = 8.4 Hz, J 2 = 2.0 Hz, 1H), 6.17 (br, 1H), 5.06 (d, J = 6.0 Hz, 2H)

화합물번호 109. (2-클로로-벤질)-(2-페닐-퀴나졸린-4-일)-아민Compound 109. (2-Chloro-benzyl)-(2-phenyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.56(t, J=3.3 Hz, 2H), 7.95(d J=8.6 Hz, 1H), 7.71(m, 2H), 7.55-7.37(m, 6H), 7.21(t, J=3.6 Hz, 2H), 6.31(s, 1H), 5.09(d, J=5.8 Hz, 2H) 1 H NMR (CDCl 3, 300 MHz) δ 8.56 (t, J = 3.3 Hz, 2H), 7.95 (d J = 8.6 Hz, 1H), 7.71 (m, 2H), 7.55-7.37 (m, 6H), 7.21 (t, J = 3.6 Hz, 2H), 6.31 (s, 1H), 5.09 (d, J = 5.8 Hz, 2H)

화합물번호 110. 싸이클로프로필-(2-페닐-퀴나졸린-4-일)-아민Compound No. 110. Cyclopropyl- (2-phenyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.63(d, J=7.3 Hz, 2H), 7.93(d, J=8.3 Hz, 2H), 7.70(m, 2H), 7.49(m, 3H), 7.37(t, J=7.5 Hz, 1H), 6.03(s, 1H), 3.17(m, 1H), 0.97(m, 2H), 0.73(m, 2H) 1 H NMR (CDCl 3, 300 MHz) δ 8.63 (d, J = 7.3 Hz, 2H), 7.93 (d, J = 8.3 Hz, 2H), 7.70 (m, 2H), 7.49 (m, 3H), 7.37 (t, J = 7.5 Hz, 1H), 6.03 (s, 1H), 3.17 (m, 1H), 0.97 (m, 2H), 0.73 (m, 2H)

화합물번호 111. (2-페닐-퀴나졸린-4-일)-피리딘-3-일메틸-아민Compound number 111. (2-phenyl-quinazolin-4-yl) -pyridin-3-ylmethyl-amine

1H NMR(CDCl3, 300 MHz) δ 8.73(m, 1H), 8.51(m, 3H), 8.04(d J=8.2 Hz, 1H,), 7.94(d, J=8.2 Hz, 1H), 7.85(d, J=7.1 Hz, 1H), 7.67(t, J=7.7 Hz, 1H), 7.47(m, 3H), 7.37(m, 1H), 7.26(m, 2H), 5.03(d, J=5.1 Hz, 2H) 1 H NMR (CDCl 3, 300 MHz) δ 8.73 (m, 1H), 8.51 (m, 3H), 8.04 (d J = 8.2 Hz, 1H,), 7.94 (d, J = 8.2 Hz, 1H), 7.85 (d, J = 7.1 Hz, 1H), 7.67 (t, J = 7.7 Hz, 1H), 7.47 (m, 3H), 7.37 (m, 1H), 7.26 (m, 2H), 5.03 (d, J = 5.1 Hz, 2H)

화합물번호 112. 2-(2-페닐-퀴나졸린-4-일아미노)-프로판-1-올Compound number 112. 2- (2-phenyl-quinazolin-4-ylamino) -propan-1-ol

1H NMR(CDCl3, 300 MHz) δ 8.49(m, 2H), 7.93(t, J=7.8 Hz, 2H), 7.58(m, 5H), 7.34(t, J=7.6 Hz, 1H), 7.71(t, J=7.7 Hz, 1H), 3.91(m, 2H), 1.45(m, 4H) 1 H NMR (CDCl 3, 300 MHz) δ 8.49 (m, 2H), 7.93 (t, J = 7.8 Hz, 2H), 7.58 (m, 5H), 7.34 (t, J = 7.6 Hz, 1H), 7.71 (t, J = 7.7 Hz, 1H), 3.91 (m, 2H), 1.45 (m, 4H)

화합물번호 113. 2-메톡시-4-[(2-페닐-퀴나졸린-4-일아미노)-메틸]-페놀Compound number 113. 2-methoxy-4-[(2-phenyl-quinazolin-4-ylamino) -methyl] -phenol

1H NMR(MeOD, 300 MHz) δ 8.35(d, J=2.2 Hz, 2H), 8.02(m, 1H), 7.80(m,2H), 7.45(m, 4H), 7.07(s, 1H), 6.89(t, J=8.0 Hz, 1H), 6.75(t, J=8.0 Hz, 1H), 4.85(s, 2H), 3.72(s, 3H) 1 H NMR (MeOD , 300 MHz) δ 8.35 (d, J = 2.2 Hz, 2H), 8.02 (m, 1H), 7.80 (m, 2H), 7.45 (m, 4H), 7.07 (s, 1H), 6.89 (t, J = 8.0 Hz, 1H), 6.75 (t, J = 8.0 Hz, 1H), 4.85 (s, 2H), 3.72 (s, 3H)

화합물번호 114. (2-플루오로-에틸)-(2-페닐-퀴나졸린-4-일)-아민Compound number 114. (2-Fluoro-ethyl)-(2-phenyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.53(m, 2H), 7.93(d, J=8.4 Hz, 1H), 7.74(t, J=7.5Hz, 2H), 7.50(m, 4H), 6.03(br s, 1H), 4.86(t, J=4.8Hz, 1H), 4.70(t, J=5.1Hz, 1H), 4.20(q, J=5.1Hz, 1H), 4.10(q, J=5.1Hz, 1H) 1 H NMR (CDCl 3, 300 MHz) δ 8.53 (m, 2H), 7.93 (d, J = 8.4 Hz, 1H), 7.74 (t, J = 7.5 Hz, 2H), 7.50 (m, 4H), 6.03 (br s, 1H), 4.86 (t, J = 4.8 Hz, 1H), 4.70 (t, J = 5.1 Hz, 1H), 4.20 (q, J = 5.1 Hz, 1H), 4.10 (q, J = 5.1 Hz, 1H)

화합물번호 115. (2,3-디클로로-벤질)-(2-페닐-퀴나졸린-4-일)-아민Compound number 115. (2,3-Dichloro-benzyl)-(2-phenyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.52(t, J=3.7 Hz, 2H), 7.92(d, J=8.5 Hz, 1H), 7.72(t, J=6.6 Hz, 2H), 7.42(m, 6H), 7.08(t, J=7.8 Hz, 1H), 6.24(s, 1H), 5.09(d, J=5.9 Hz, 2H) 1 H NMR (CDCl 3, 300 MHz) δ 8.52 (t, J = 3.7 Hz, 2H), 7.92 (d, J = 8.5 Hz, 1H), 7.72 (t, J = 6.6 Hz, 2H), 7.42 (m) , 6H), 7.08 (t, J = 7.8 Hz, 1H), 6.24 (s, 1H), 5.09 (d, J = 5.9 Hz, 2H)

화합물번호 116. (3-니트로-벤질)-(2-페닐-퀴나졸린-4-일)-아민Compound No. 116. (3-Nitro-benzyl)-(2-phenyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.46(m, 2H), 8.19(m, 1H), 8.03(d, J=7.5 Hz, 1H), 7.91(d, J=7.9 Hz, 1H), 7.82(d, J=7.7 Hz, 1H), 7.70(d, J=6.0 Hz, 1H), 7.42(m, 5H), 6.54(s, 1H), 4.96(d, J=4.4 Hz, 2H) 1 H NMR (CDCl 3, 300 MHz) δ 8.46 (m, 2H), 8.19 (m, 1H), 8.03 (d, J = 7.5 Hz, 1H), 7.91 (d, J = 7.9 Hz, 1H), 7.82 (d, J = 7.7 Hz, 1H), 7.70 (d, J = 6.0 Hz, 1H), 7.42 (m, 5H), 6.54 (s, 1H), 4.96 (d, J = 4.4 Hz, 2H)

화합물번호 117. (1-에틸-피롤리딘-2-일메틸)-(2-페닐-퀴나졸린-4-일)-아민Compound 117. (1-Ethyl-pyrrolidin-2-ylmethyl)-(2-phenyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.47(d, J=5.6 Hz, 2H), 8.10(d, J=8.1 Hz, 1H), 7.94(s, 1H), 7.84(d, J=8.3 Hz, 1H), 7.68(t, J=7.6 Hz, 1H), 7.42(m, 4H), 5.97(s, 1H), 4.08(m, 2H), 3.58(m, 2H), 3.01(t, J=4.7 Hz, 1H), 2.67(m, 2H), 2.09-1.91(m, 4H), 1.19(m, 3H) 1 H NMR (CDCl 3, 300 MHz) δ 8.47 (d, J = 5.6 Hz, 2H), 8.10 (d, J = 8.1 Hz, 1H), 7.94 (s, 1H), 7.84 (d, J = 8.3 Hz , 1H), 7.68 (t, J = 7.6 Hz, 1H), 7.42 (m, 4H), 5.97 (s, 1H), 4.08 (m, 2H), 3.58 (m, 2H), 3.01 (t, J = 4.7 Hz, 1H), 2.67 (m, 2H), 2.09-1.91 (m, 4H), 1.19 (m, 3H)

화합물번호 118. (3,4-디메톡시-벤질)-(2-페닐-퀴나졸린-4-일)-아민Compound 118. (3,4-Dimethoxy-benzyl)-(2-phenyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.59(t, J=3.8 Hz, 2H), 7.93(d, J=8.1 Hz, 1H), 7.71(m, 2H), 7.45(m, 3H), 7.36(t, J=7.6 Hz, 1H), 7.04(s, 1H), 6.97(d, J=8.4 Hz, 1H), 6.80(t, J=4.1 Hz, 1H), 6.21(s, 1H), 4.90(d, J=5.2 Hz, 2H), 3.87(s, 3H), 3.78(s, 3H) 1 H NMR (CDCl 3, 300 MHz) δ 8.59 (t, J = 3.8 Hz, 2H), 7.93 (d, J = 8.1 Hz, 1H), 7.71 (m, 2H), 7.45 (m, 3H), 7.36 (t, J = 7.6 Hz, 1H), 7.04 (s, 1H), 6.97 (d, J = 8.4 Hz, 1H), 6.80 (t, J = 4.1 Hz, 1H), 6.21 (s, 1H), 4.90 (d, J = 5.2 Hz, 2H), 3.87 (s, 3H), 3.78 (s, 3H)

화합물번호 119. (2-페닐-퀴나졸린-4-일)-(2-p-톨릴-에틸)-아민Compound 119. (2-phenyl-quinazolin-4-yl)-(2- p -tolyl-ethyl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.59(t, J=3.3 Hz, 2H), 7.93(d, J=8.4 Hz, 1H), 7.69(t, J=7.6 Hz, 1H), 7.55(m, 4H), 7.36(t, J=7.5 Hz, 1H), 7.16(m, 4H), 5.91(s, 1H), 4.01(m, 2H), 3.05(t, J=6.9 Hz, 2H), 2.43(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.59 (t, J = 3.3 Hz, 2H), 7.93 (d, J = 8.4 Hz, 1H), 7.69 (t, J = 7.6 Hz, 1H), 7.55 (m , 4H), 7.36 (t, J = 7.5 Hz, 1H), 7.16 (m, 4H), 5.91 (s, 1H), 4.01 (m, 2H), 3.05 (t, J = 6.9 Hz, 2H), 2.43 (s, 3H)

화합물번호 120. [2-(3-메톡시-페닐)-에틸]-(2-페닐-퀴나졸린-4-일)-아민Compound number 120. [2- (3-Methoxy-phenyl) -ethyl]-(2-phenyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.61(t, J=3.8 Hz, 2H), 7.93(d, J=8.3 H, 1Hz), 7.70(m, 1H), 7.49(m, 4H), 7.30(m, 2H), 6.85(m, 3H), 5.90(s, 1H), 4.02(m, 2H), 3.76(s, 3H), 3.05(t, J=6.9 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.61 (t, J = 3.8 Hz, 2H), 7.93 (d, J = 8.3 H, 1 Hz), 7.70 (m, 1H), 7.49 (m, 4H), 7.30 (m, 2H), 6.85 (m, 3H), 5.90 (s, 1H), 4.02 (m, 2H), 3.76 (s, 3H), 3.05 (t, J = 6.9 Hz, 2H)

화합물번호 121. (1-에틸-프로필)-(2-페닐-퀴나졸린-4-일)-아민Compound 121. (1-ethyl-propyl)-(2-phenyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.55(t, J=3.5 Hz, 2H), 7.95(d, J=8.2 Hz, 1H), 7.69(m, 2H), 7.46(m, 4H), 5.59(s, 1H), 4.53(d, J=6.7 Hz, 1H), 1.85-1.62(m, 4H), 1.00(m, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.55 (t, J = 3.5 Hz, 2H), 7.95 (d, J = 8.2 Hz, 1H), 7.69 (m, 2H), 7.46 (m, 4H), 5.59 (s, 1H), 4.53 (d, J = 6.7 Hz, 1H), 1.85-1.62 (m, 4H), 1.00 (m, 6H)

화합물번호 122. [2-(2,5-디메톡시-페닐)-에틸]-(2-페닐-퀴나졸린-4-일)-아민Compound No. 122. [2- (2,5-Dimethoxy-phenyl) -ethyl]-(2-phenyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.59(t, J=3.2 Hz, 2H), 7.91(d, J=8.4 Hz, 1H), 7.67(t, J=7.6 Hz, 1H), 7.59(d, J=8.1 Hz, 1H), 7.47(m, 3H), 7.36(t, J=7.5 Hz, 1H), 6.80(m, 3H), 6.39(s, 1H), 3.98(m, 2H), 3.86(s, 3H), 3.71(s, 3H), 3.08(t, J=6.5 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.59 (t, J = 3.2 Hz, 2H), 7.91 (d, J = 8.4 Hz, 1H), 7.67 (t, J = 7.6 Hz, 1H), 7.59 (d , J = 8.1 Hz, 1H), 7.47 (m, 3H), 7.36 (t, J = 7.5 Hz, 1H), 6.80 (m, 3H), 6.39 (s, 1H), 3.98 (m, 2H), 3.86 (s, 3H), 3.71 (s, 3H), 3.08 (t, J = 6.5 Hz, 2H)

화합물번호 123. [2-(4-클로로-페닐)-에틸]-(2-페닐-퀴나졸린-4-일)-아민Compound 123. [2- (4-Chloro-phenyl) -ethyl]-(2-phenyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.57(t, J=3.6 Hz, 2H), 7.91(m, 1H), 7.69(m, 1H), 7.53(m, 4H), 7.38(d, J=6.9 Hz, 1H), 7.25(m, 2H), 7.18(m, 2H), 5.76(s, 1H), 4.00(m, 2H), 3.05(m, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.57 (t, J = 3.6 Hz, 2H), 7.91 (m, 1H), 7.69 (m, 1H), 7.53 (m, 4H), 7.38 (d, J = 6.9 Hz, 1H), 7.25 (m, 2H), 7.18 (m, 2H), 5.76 (s, 1H), 4.00 (m, 2H), 3.05 (m, 2H)

화합물번호 124. [2-(4-메톡시-페닐)-에틸]-(2-페닐-퀴나졸린-4-일)-아민Compound 124. [2- (4-methoxy-phenyl) -ethyl]-(2-phenyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.60(t, J=3.2 Hz, 2H), 7.93(d, J=8.3 Hz, 1H), 7.69(t, J=7.6 Hz, 1H), 7.50(m, 4H), 7.35(t, J=7.5 Hz, 1H), 7.20(d, J=8.3 Hz, 2H), 6.87(d, J=8.3 Hz, 2H), 5.85(s, 1H), 4.00(m, 2H), 3.79(s, 3H), 3.02(t, J=6.9 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.60 (t, J = 3.2 Hz, 2H), 7.93 (d, J = 8.3 Hz, 1H), 7.69 (t, J = 7.6 Hz, 1H), 7.50 (m , 4H), 7.35 (t, J = 7.5 Hz, 1H), 7.20 (d, J = 8.3 Hz, 2H), 6.87 (d, J = 8.3 Hz, 2H), 5.85 (s, 1H), 4.00 (m , 2H), 3.79 (s, 3H), 3.02 (t, J = 6.9 Hz, 2H)

화합물번호 125. (1,3-디메틸-부틸)-(2-페닐-퀴나졸린-4-일)-아민Compound No. 125. (1,3-Dimethyl-butyl)-(2-phenyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.58(t, J=3.8 Hz, 2H), 7.93(d, J=8.5 Hz, 1H), 7.69(m, 2H), 7.48-7.24(m, 4H), 5.52(d, J=6.9 Hz, 1H), 4.80(t, J=6.86 Hz, 1H), 1.78-1.63(m, 2H), 1.46(t, J=6.7 Hz, 1H), 1.39(m, 3H), 0.97(m, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.58 (t, J = 3.8 Hz, 2H), 7.93 (d, J = 8.5 Hz, 1H), 7.69 (m, 2H), 7.48-7.24 (m, 4H) , 5.52 (d, J = 6.9 Hz, 1H), 4.80 (t, J = 6.86 Hz, 1H), 1.78-1.63 (m, 2H), 1.46 (t, J = 6.7 Hz, 1H), 1.39 (m, 3H), 0.97 (m, 6H)

화합물번호 126. [2-(3-클로로-페닐)-에틸]-(2-페닐-퀴나졸린-4-일)-아민Compound 126. [2- (3-Chloro-phenyl) -ethyl]-(2-phenyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.59(t, J=3.3 Hz, 2H), 7.93(d, J=8.3 Hz, 1H), 7.69(m, 1H), 7.58(m, 1H), 7.49(m, 3H), 7.38(m, 1H), 7.24(m, 1H), 7.12(m, 2H), 7.11(m, 1H), 5.92(s, 1H), 3.95(m, 2H), 3.02(t, J= 7.1 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.59 (t, J = 3.3 Hz, 2H), 7.93 (d, J = 8.3 Hz, 1H), 7.69 (m, 1H), 7.58 (m, 1H), 7.49 (m, 3H), 7.38 (m, 1H), 7.24 (m, 1H), 7.12 (m, 2H), 7.11 (m, 1H), 5.92 (s, 1H), 3.95 (m, 2H), 3.02 ( t, J = 7.1 Hz, 2H)

화합물번호 127. [2-(2,4-디클로로-페닐)-에틸]-(2-페닐-퀴나졸린-4-일)-아민Compound 127. [2- (2,4-Dichloro-phenyl) -ethyl]-(2-phenyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.57(t, J=3.6 Hz, 2H), 7.92(d, J=8.2 Hz, 1H), 7.70(m, 1H), 7.59(d, J=8.1 Hz, 1H), 7.47(m, 2H), 7.37(m, 2H), 7.18(m, 2H), 5.81(s, 1H), 4.04(m, 2H), 3.23(, J=6.8 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.57 (t, J = 3.6 Hz, 2H), 7.92 (d, J = 8.2 Hz, 1H), 7.70 (m, 1H), 7.59 (d, J = 8.1 Hz , 1H), 7.47 (m, 2H), 7.37 (m, 2H), 7.18 (m, 2H), 5.81 (s, 1H), 4.04 (m, 2H), 3.23 (, J = 6.8 Hz, 2H)

화합물번호 128. [2-(3,4-디플루오로-페닐)-에틸]-(2-페닐-퀴나졸린-4-일)-아민Compound No. 128. [2- (3,4-Difluoro-phenyl) -ethyl]-(2-phenyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.50(t, J=4.0 Hz, 2H), 7.93(d, J=8.6 Hz, 1H), 7.72(m, 2H), 7.41(m, 4H), 7.22(t, J=8.8 Hz, 1H), 7.07(m, 2H), 6.11(s, 1H), 4.91(d, J=5.5 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.50 (t, J = 4.0 Hz, 2H), 7.93 (d, J = 8.6 Hz, 1H), 7.72 (m, 2H), 7.41 (m, 4H), 7.22 (t, J = 8.8 Hz, 1H), 7.07 (m, 2H), 6.11 (s, 1H), 4.91 (d, J = 5.5 Hz, 2H)

화합물번호 129. (2-페닐-퀴나졸린-4-일)-(3,4,5-트리메톡시-벤질)-아민Compound number 129. (2-phenyl-quinazolin-4-yl)-(3,4,5-trimethoxy-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.58(t, J=3.5 Hz, 2H), 7.96(d, J=8.4 Hz, 2H), 7.78(d, J=8.3 Hz, 1H), 7.67(t, J=7.6 Hz, 1H), 7.47(m, 3H), 7.36(t, J=7.6 Hz, 1H), 6.73(s, 2H), 6.43(s, 1H), 4.91(d, J=5.2 Hz, 2H), 3.86(d, J=6.6 Hz, 2H), 3.82(m, 9H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.58 (t, J = 3.5 Hz, 2H), 7.96 (d, J = 8.4 Hz, 2H), 7.78 (d, J = 8.3 Hz, 1H), 7.67 (t , J = 7.6 Hz, 1H), 7.47 (m, 3H), 7.36 (t, J = 7.6 Hz, 1H), 6.73 (s, 2H), 6.43 (s, 1H), 4.91 (d, J = 5.2 Hz , 2H), 3.86 (d, J = 6.6 Hz, 2H), 3.82 (m, 9H)

화합물번호 130. (3-메틸-부틸)-(2-페닐-퀴나졸린-4-일)-아민Compound No. 130. (3-Methyl-butyl)-(2-phenyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.57(t, J=3.4 Hz, 2H), 7.92(d, J=8.3 Hz, 1H), 7.68(m, 2H), 7.46(m, 3H), 7.37(t, J=7.5 Hz, 1H), 5.76(s, 1H), 3.80(m, 2H), 1.76(m, 1H), 1.65(m, 2H), 0.99(m, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.57 (t, J = 3.4 Hz, 2H), 7.92 (d, J = 8.3 Hz, 1H), 7.68 (m, 2H), 7.46 (m, 3H), 7.37 (t, J = 7.5 Hz, 1H), 5.76 (s, 1H), 3.80 (m, 2H), 1.76 (m, 1H), 1.65 (m, 2H), 0.99 (m, 6H)

화합물번호 131. (2-싸이클로hex-1-enyl-에틸)-(2-페닐-퀴나졸린-4-일)-아민Compound 131. (2-Cyclohex-1-enyl-ethyl)-(2-phenyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.57(t, J=3.4 Hz, 2H), 7.92(d, J=8.3 Hz, 1H), 7.69(t, J=7.7 Hz, 1H), 7.61(d, J=8.1 Hz, 1H), 7.49(m, 3H), 7.38(t, J=7.4 Hz, 1H), 5.82(s, 1H), 5.61(1H), 3.83(m, 2H), 2.39(t, J=6.6 Hz, 2H), 2.03(m, 4H), 1.62(m, 4H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.57 (t, J = 3.4 Hz, 2H), 7.92 (d, J = 8.3 Hz, 1H), 7.69 (t, J = 7.7 Hz, 1H), 7.61 (d , J = 8.1 Hz, 1H), 7.49 (m, 3H), 7.38 (t, J = 7.4 Hz, 1H), 5.82 (s, 1H), 5.61 (1H), 3.83 (m, 2H), 2.39 (t , J = 6.6 Hz, 2H), 2.03 (m, 4H), 1.62 (m, 4H)

화합물번호 132. 싸이클로헥실메틸-(2-페닐-퀴나졸린-4-일)-아민Compound No. 132. Cyclohexylmethyl- (2-phenyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.56(t, J=3.1 Hz, 2H), 7.92(d, J=8.7 Hz, 1H), 7.69(t, J=6.1 Hz, 2H), 7.49(m, 4H), 5.85(s, 1H), 3.64(t, J=6.1 Hz, 2H), 1.88-1.70(m, 6H), 1.29-1.05(m, 5H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.56 (t, J = 3.1 Hz, 2H), 7.92 (d, J = 8.7 Hz, 1H), 7.69 (t, J = 6.1 Hz, 2H), 7.49 (m , 4H), 5.85 (s, 1H), 3.64 (t, J = 6.1 Hz, 2H), 1.88-1.70 (m, 6H), 1.29-1.05 (m, 5H)

화합물번호 133. (2,2-디페닐-에틸)-(2-페닐-퀴나졸린-4-일)-아민Compound 133. (2,2-Diphenyl-ethyl)-(2-phenyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.63(t, J=3.8 Hz, 2H), 7.93(d, J=8.4 Hz, 1H), 7.67(t, J=7.5 Hz, 1H), 7.51(m, 3H), 7.29(m, 12H), 5.73(s, 1H), 4.56(t, J=7.7 Hz, 1H), 4.42(t, J=6.5 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.63 (t, J = 3.8 Hz, 2H), 7.93 (d, J = 8.4 Hz, 1H), 7.67 (t, J = 7.5 Hz, 1H), 7.51 (m , 3H), 7.29 (m, 12H), 5.73 (s, 1H), 4.56 (t, J = 7.7 Hz, 1H), 4.42 (t, J = 6.5 Hz, 2H)

화합물번호 134. (2,4-디플루오로-벤질)-(2-페닐-퀴나졸린-4-일)-아민Compound number 134. (2,4-Difluoro-benzyl)-(2-phenyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.55(t, J=3.9 Hz, 2H), 7.93(d, J=8.4 Hz, 1H), 7.71(m, 2H), 7.49(m, 5H), 6.80(m, 2H), 6.24(s, 1H), 5.00(d, J=5.6 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.55 (t, J = 3.9 Hz, 2H), 7.93 (d, J = 8.4 Hz, 1H), 7.71 (m, 2H), 7.49 (m, 5H), 6.80 (m, 2H), 6.24 (s, 1H), 5.00 (d, J = 5.6 Hz, 2H)

화합물번호 135. (2,5-디플루오로-벤질)-(2-페닐-퀴나졸린-4-일)-아민Compound number 135. (2,5-Difluoro-benzyl)-(2-phenyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.52(t, J=3.6 Hz, 2H), 7.93(d, J=8.4 Hz, 1H), 7.72(t, J=7.9 Hz, 2H), 7.41(m, 4H), 7.18(m, 1H), 7.00(m, 1H), 6.92(t, J=3.9 Hz, 1H), 6.20(s, 1H), 5.00(d, J=5.6 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.52 (t, J = 3.6 Hz, 2H), 7.93 (d, J = 8.4 Hz, 1H), 7.72 (t, J = 7.9 Hz, 2H), 7.41 (m , 4H), 7.18 (m, 1H), 7.00 (m, 1H), 6.92 (t, J = 3.9 Hz, 1H), 6.20 (s, 1H), 5.00 (d, J = 5.6 Hz, 2H)

화합물번호 136. (3,3-디페닐-프로필)-(2-페닐-퀴나졸린-4-일)-아민Compound 136. (3,3-Diphenyl-propyl)-(2-phenyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.51(m, 2H), 7.92(d, J=8.4 Hz, 1H), 7.67(m, 1H), 7.43(m, 3H), 7.34-7.20(m, 12H), 5.73(s, 1H), 4.09(t, J=7.7 Hz, 1H), 2.53(m, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.51 (m, 2H), 7.92 (d, J = 8.4 Hz, 1H), 7.67 (m, 1H), 7.43 (m, 3H), 7.34-7.20 (m, 12H), 5.73 (s, 1H), 4.09 (t, J = 7.7 Hz, 1H), 2.53 (m, 2H)

화합물번호 137. [2-(4-브로모-페닐)-에틸]-(2-페닐-퀴나졸린-4-일)-아민Compound number 137. [2- (4-Bromo-phenyl) -ethyl]-(2-phenyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.57(t, 2.8 Hz, 2H), 7.92(d, J=8.4 Hz, 1H), 7.71(m, 1H), 7.50(m, 7H), 7.20(m, 2H), 5.75(s, 1H), 3.98(m, 2H), 3.04(t, J=6.7 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.57 (t, 2.8 Hz, 2H), 7.92 (d, J = 8.4 Hz, 1H), 7.71 (m, 1H), 7.50 (m, 7H), 7.20 (m , 2H), 5.75 (s, 1H), 3.98 (m, 2H), 3.04 (t, J = 6.7 Hz, 2H)

화합물번호 138. 부틸-메틸-(2-페닐-퀴나졸린-4-일)-아민Compound number 138. Butyl-methyl- (2-phenyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.55(dd, J 1 =7.5 Hz, J 2 =1.5 Hz, 2H), 7.99-7.91(m, 2H), 7.67(m, 1H), 7.46(m, 3H), 7.34(m, 1H), 3.80(t, J=7.8 Hz, 2H), 3.41(s, 3H), 1.86(m, 2H), 1.43(m, 2H), 1.00(t, 3H, J=7.5 Hz) 1 H NMR (CDCl 3 , 300 MHz) δ 8.55 (dd, J 1 = 7.5 Hz, J 2 = 1.5 Hz, 2H), 7.99-7.91 (m, 2H), 7.67 (m, 1H), 7.46 (m, 3H), 7.34 (m, 1H), 3.80 (t, J = 7.8 Hz, 2H), 3.41 (s, 3H), 1.86 (m, 2H), 1.43 (m, 2H), 1.00 (t, 3H, J) = 7.5 Hz)

화합물번호 139. (2-페닐-퀴나졸린-4-일)-(4-트리플루오로메틸-벤질)-아민Compound 139. (2-phenyl-quinazolin-4-yl)-(4-trifluoromethyl-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.50(m, 2H), 7.96(d, J=8.1 Hz, 1H), 7.75(m, 2H), 7.59(m, 4H), 7.46(m, 4H), 6.06(br, 1H), 5.07(d, J=6.0 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.50 (m, 2H), 7.96 (d, J = 8.1 Hz, 1H), 7.75 (m, 2H), 7.59 (m, 4H), 7.46 (m, 4H) , 6.06 (br, 1 H), 5.07 (d, J = 6.0 Hz, 2 H)

화합물번호 140. [2-(2-플루오로-페닐)-에틸]-(2-페닐-퀴나졸린-4-일)-아민Compound number 140. [2- (2-Fluoro-phenyl) -ethyl]-(2-phenyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.60(t, J=3.5 Hz, 2H), 7.93(d, J=8.3 Hz, 1H), 7.69(, J=7.6 Hzt, 1H), 7.60(d, J=8.1 Hz, 1H), 7.49(m, 3H), 7.36(t, J=7.5 Hz, 1H), 7.24(t, J=7.2 Hz, 2H), 7.06(t, J=9.0 Hz, 2H), 4.00(m, 2H), 3.14(t, J=6.7 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.60 (t, J = 3.5 Hz, 2H), 7.93 (d, J = 8.3 Hz, 1H), 7.69 (, J = 7.6 Hzt, 1H), 7.60 (d, J = 8.1 Hz, 1H), 7.49 (m, 3H), 7.36 (t, J = 7.5 Hz, 1H), 7.24 (t, J = 7.2 Hz, 2H), 7.06 (t, J = 9.0 Hz, 2H) , 4.00 (m, 2H), 3.14 (t, J = 6.7 Hz, 2H)

화합물번호 141. (2-페닐-퀴나졸린-4-일)-피리딘-4-일메틸-아민Compound number 141. (2-phenyl-quinazolin-4-yl) -pyridin-4-ylmethyl-amine

1H NMR(CDCl3, 300 MHz) δ 8.51(m, 2H), 8.42(t, J=3.4 Hz, 2H), 8.00(d, J=8.4 Hz, 1H), 7.89(d, J=8.1 Hz, 1H), 7.71(t, J=7.6 Hz, 1H), 7.43(m, 4H), 7.31(m, 2H), 4.99(d, J=5.5 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.51 (m, 2H), 8.42 (t, J = 3.4 Hz, 2H), 8.00 (d, J = 8.4 Hz, 1H), 7.89 (d, J = 8.1 Hz , 1H), 7.71 (t, J = 7.6 Hz, 1H), 7.43 (m, 4H), 7.31 (m, 2H), 4.99 (d, J = 5.5 Hz, 2H)

화합물번호 142. (2-페닐-퀴나졸린-4-일)-피리딘-2-일메틸-아민Compound 142. (2-phenyl-quinazolin-4-yl) -pyridin-2-ylmethyl-amine

1H NMR(CDCl3, 300 MHz) δ 8.60(m, 2H), 7.91(m, 2H), 7.69(m, 3H), 7.43(m, 5H), 7.25(m, 1H), 5.00(d, J=4.3 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.60 (m, 2H), 7.91 (m, 2H), 7.69 (m, 3H), 7.43 (m, 5H), 7.25 (m, 1H), 5.00 (d, J = 4.3 Hz, 2H)

화합물번호 143. (2,3-디메틸-싸이클로헥실)-(2-페닐-퀴나졸린-4-일)-아민Compound 143. (2,3-Dimethyl-cyclohexyl)-(2-phenyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.53(t, J=3.5 Hz, 2H), 7.92 (d, J=8.3 Hz, 1H), 7.69(m, 2H), 7.41(m, 4H), 5.76(m, 1H), 4.56(m, 1H), 1.94-1.46(m, 7H), 1.00(m, 5H), 0.86(d, J=7.1 Hz, 1H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.53 (t, J = 3.5 Hz, 2H), 7.92 (d, J = 8.3 Hz, 1H), 7.69 (m, 2H), 7.41 (m, 4H), 5.76 (m, 1H), 4.56 (m, 1H), 1.94-1.46 (m, 7H), 1.00 (m, 5H), 0.86 (d, J = 7.1 Hz, 1H)

화합물번호 144. (2,4-디메톡시-벤질)-(2-페닐-퀴나졸린-4-일)-아민Compound 144. (2,4-Dimethoxy-benzyl)-(2-phenyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.60(m, 2H), 7.90(d, J=8.4 Hz, 1H), 7.72-7.63(m, 2H), 7.48(m, 3H), 7.38(m, 2H), 6.51(d, 1H, J=2.1 Hz), 6.45(dd, J 1 =8.1 Hz, J 2 =2.4 Hz, 1H), 6.16(br, 1H), 4.94(d, J=5.4 Hz, 2H), 3.90(s, 3H), 3.79(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.60 (m, 2H), 7.90 (d, J = 8.4 Hz, 1H), 7.72-7.63 (m, 2H), 7.48 (m, 3H), 7.38 (m, 2H), 6.51 (d, 1H, J = 2.1 Hz), 6.45 (dd, J 1 = 8.1 Hz, J 2 = 2.4 Hz, 1H), 6.16 (br, 1H), 4.94 (d, J = 5.4 Hz, 2H), 3.90 (s, 3H), 3.79 (s, 3H)

화합물번호 145. (3-클로로-벤질)-(2-페닐-퀴나졸린-4-일)-아민Compound 145. (3-Chloro-benzyl)-(2-phenyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.51(m, 2H), 7.92(d, J=8.8 Hz, 1H), 7.71(m, 2H), 7.45(m, 5H), 7.27(m, 3H), 5.13(s, 1H), 4.92(d, J=5.5 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.51 (m, 2H), 7.92 (d, J = 8.8 Hz, 1H), 7.71 (m, 2H), 7.45 (m, 5H), 7.27 (m, 3H) , 5.13 (s, 1 H), 4.92 (d, J = 5.5 Hz, 2 H)

화합물번호 146. 1-페닐-2-(2-페닐-퀴나졸린-4-일아미노)-에탄올Compound No. 146. 1-phenyl-2- (2-phenyl-quinazolin-4-ylamino) -ethanol

1H NMR(DMSO-d6, 300 MHz) δ 8.49(m, 2H), 8.25(dH, J=8.3 Hz, 1), 7.74(m, 2H), 7.50-7.31(m, 7H), 7.23(t, J=7.1 Hz, 1H), 5.62(d, J=4.3 Hz, 1H), 5.05(m, 1H), 4.01-3.90(m, 2H), 3.57(m, 1H), 3.28(m, 2H) 1 H NMR (DMSO-d 6 , 300 MHz) δ 8.49 (m, 2H), 8.25 (dH, J = 8.3 Hz, 1), 7.74 (m, 2H), 7.50-7.31 (m, 7H), 7.23 ( t, J = 7.1 Hz, 1H), 5.62 (d, J = 4.3 Hz, 1H), 5.05 (m, 1H), 4.01-3.90 (m, 2H), 3.57 (m, 1H), 3.28 (m, 2H )

화합물번호 147. (2,5-디메톡시-벤질)-(2-페닐-퀴나졸린-4-일)-아민Compound 147. (2,5-Dimethoxy-benzyl)-(2-phenyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.60(dd, J 1 =8.1 Hz, J 2 =2.1 Hz, 2H), 7.91(d, J=8.4 Hz, 1H), 7.67(m, 2H), 7.52-7.36(m, 4H), 7.10(d, J=3.0 Hz, 1H), 6.85(d, J=9.0 Hz, 1H), 6.78(dd, J 1 =9.0 Hz, J 2 =3.0 Hz, 1H), 6.272(br, 1H), 4.99(d, J=6.0 Hz, 2H), 3.89(s, 3H), 3.71(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.60 (dd, J 1 = 8.1 Hz, J 2 = 2.1 Hz, 2H), 7.91 (d, J = 8.4 Hz, 1H), 7.67 (m, 2H), 7.52 -7.36 (m, 4H), 7.10 (d, J = 3.0 Hz, 1H), 6.85 (d, J = 9.0 Hz, 1H), 6.78 (dd, J 1 = 9.0 Hz, J 2 = 3.0 Hz, 1H) , 6.272 (br, 1H), 4.99 (d, J = 6.0 Hz, 2H), 3.89 (s, 3H), 3.71 (s, 3H)

화합물번호 148. (4-브로모-벤질)-(2-페닐-퀴나졸린-4-일)-아민Compound 148. (4-Bromo-benzyl)-(2-phenyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.54(t, J=3.6 Hz, 2H), 7.92(d, J=8.3 Hz, 1H), 7.71(t, J=6.6 Hz, 1H), 7.44(m, 6H), 7.26(t, J=7.0 Hz, 2H), 6.09(s, 1H), 4.91(d, J=5.5 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.54 (t, J = 3.6 Hz, 2H), 7.92 (d, J = 8.3 Hz, 1H), 7.71 (t, J = 6.6 Hz, 1H), 7.44 (m , 6H), 7.26 (t, J = 7.0 Hz, 2H), 6.09 (s, 1H), 4.91 (d, J = 5.5 Hz, 2H)

화합물번호 149. [2-(3,4-디클로로-페닐)-에틸]-(2-페닐-퀴나졸린-4-일)-아민Compound 149. [2- (3,4-Dichloro-phenyl) -ethyl]-(2-phenyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.57(m, 2H), 7.94(d, J=8.4 Hz, 1H), 7.74(m, 1H), 7.59(d, J=7.8 Hz, 1H), 7.55-7.37(m, 6H), 7.10(dd, J 1 =8.4 Hz, J 2 =1.8 Hz, 1H), 5.75(br, 1H), 4.03(q, J=7.2 Hz, 2H), 3.08(t, J=7.2 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.57 (m, 2H), 7.94 (d, J = 8.4 Hz, 1H), 7.74 (m, 1H), 7.59 (d, J = 7.8 Hz, 1H), 7.55 -7.37 (m, 6H), 7.10 (dd, J 1 = 8.4 Hz, J 2 = 1.8 Hz, 1H), 5.75 (br, 1H), 4.03 (q, J = 7.2 Hz, 2H), 3.08 (t, J = 7.2 Hz, 2H)

화합물번호 150. 1-[3-(2-페닐-퀴나졸린-4-일아미노)-프로필]-피롤리딘-2-온Compound number 150. 1- [3- (2-phenyl-quinazolin-4-ylamino) -propyl] -pyrrolidin-2-one

1H NMR(CDCl3, 300 MHz) δ 8.55(m, 2H), 8.00(d, J=8.1 Hz, 1H), 7.89(d, J=8.6 Hz, 1H), 7.69(d, J=7.3 Hz, 1H), 7.59(s, 1H), 7.44(m, 4H), 3.76(m, 2H), 3.41(m, 4H), 2.45(t, J=8.1 Hz, 2H), 2.06(m, 2H), 1.87(m, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.55 (m, 2H), 8.00 (d, J = 8.1 Hz, 1H), 7.89 (d, J = 8.6 Hz, 1H), 7.69 (d, J = 7.3 Hz , 1H), 7.59 (s, 1H), 7.44 (m, 4H), 3.76 (m, 2H), 3.41 (m, 4H), 2.45 (t, J = 8.1 Hz, 2H), 2.06 (m, 2H) , 1.87 (m, 2 H)

화합물번호 151. [2-(2-클로로-페닐)-에틸]-(2-페닐-퀴나졸린-4-일)-아민Compound 151. [2- (2-Chloro-phenyl) -ethyl]-(2-phenyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.59(m, 2H), 7.92(d, J=8.4 Hz, 1H), 7.71(d, J=7.3 Hz, 1H), 7.63(d, J=8.1 Hz, 1H), 7.48(m, 3H), 7.37(t, J=7.2 Hz, 2H), 7.25(t, J=3.5 Hz, 1H), 7.17(t, J=4.5 Hz, 2H), 5.99(s, 1H), 4.05(m, 2H), 3.24(t, J=6.9 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.59 (m, 2H), 7.92 (d, J = 8.4 Hz, 1H), 7.71 (d, J = 7.3 Hz, 1H), 7.63 (d, J = 8.1 Hz , 1H), 7.48 (m, 3H), 7.37 (t, J = 7.2 Hz, 2H), 7.25 (t, J = 3.5 Hz, 1H), 7.17 (t, J = 4.5 Hz, 2H), 5.99 (s , 1H), 4.05 (m, 2H), 3.24 (t, J = 6.9 Hz, 2H)

화합물번호 152. 2-[2-(2-페닐-퀴나졸린-4-일아미노)-에틸]-페놀Compound 152. 2- [2- (2-phenyl-quinazolin-4-ylamino) -ethyl] -phenol

1H NMR(DMSO-d6, 300 MHz) δ 9.18(s, 1H), 8.46(m, 3H), 8.19(d, J=8.1 Hz, 1H), 7.73(m, 2H),7.47(m, 4H), 7.07(d, J=8.2 Hz, 2H), 6.66(d, J=8.2 Hz, 2H), 4.12(s, 1H), 3.77(m, 2H), 2,91(t, J=7.4 Hz, 2H) 1 H NMR (DMSO-d 6 , 300 MHz) δ 9.18 (s, 1H), 8.46 (m, 3H), 8.19 (d, J = 8.1 Hz, 1H), 7.73 (m, 2H), 7.47 (m, 4H), 7.07 (d, J = 8.2 Hz, 2H), 6.66 (d, J = 8.2 Hz, 2H), 4.12 (s, 1H), 3.77 (m, 2H), 2,91 (t, J = 7.4 Hz, 2H)

화합물번호 153. (3-브로모-벤질)-(2-페닐-퀴나졸린-4-일)-아민Compound 153. (3-Bromo-benzyl)-(2-phenyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.52(m, 2H), 7.92(d, J=8.5 Hz, 1H), 7.71(t, J=3.1 Hz, 2H), 7.56(s, 1H), 7.45(m, 6H), 7.14(m, 1H), 6.13(s, 1H), 4.91(d, J=5.3 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.52 (m, 2H), 7.92 (d, J = 8.5 Hz, 1H), 7.71 (t, J = 3.1 Hz, 2H), 7.56 (s, 1H), 7.45 (m, 6H), 7.14 (m, 1H), 6.13 (s, 1H), 4.91 (d, J = 5.3 Hz, 2H)

화합물번호 154. (2,6-디메톡시-벤질)-(2-페닐-퀴나졸린-4-일)-아민Compound 154. (2,6-Dimethoxy-benzyl)-(2-phenyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.70(m, 2H), 7.92(d, J=8.4 Hz, 1H), 7.84(m, 2H), 7.51(m, 3H), 7.46(m, 1H), 7.23(m, 1H), 6.58(d, J=8.4 Hz, 2H), 6.38(s, 1H), 5.13(d, J=5.3 Hz, 2H), 3.88(s, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.70 (m, 2H), 7.92 (d, J = 8.4 Hz, 1H), 7.84 (m, 2H), 7.51 (m, 3H), 7.46 (m, 1H) , 7.23 (m, 1H), 6.58 (d, J = 8.4 Hz, 2H), 6.38 (s, 1H), 5.13 (d, J = 5.3 Hz, 2H), 3.88 (s, 6H)

화합물번호 155. (2-브로모-벤질)-(2-페닐-퀴나졸린-4-일)-아민Compound 155. (2-Bromo-benzyl)-(2-phenyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.56(t, J=3.8 Hz, 2H), 7.92(d, J=8.4 Hz, 1H), 7.72(m, 2H), 7.50(m, 5H), 7.46(m, 1H), 7.24(m, 1H), 6.34(s, 1H), 5.06(d, J=5.8 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.56 (t, J = 3.8 Hz, 2H), 7.92 (d, J = 8.4 Hz, 1H), 7.72 (m, 2H), 7.50 (m, 5H), 7.46 (m, 1H), 7.24 (m, 1H), 6.34 (s, 1H), 5.06 (d, J = 5.8 Hz, 2H)

화합물번호 156. (3-몰포린-4-일-프로필)-(2-페닐-퀴나졸린-4-일)-아민Compound 156. (3-Morpholin-4-yl-propyl)-(2-phenyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.55(m, 2H), 7.89(d, J=8.3 Hz, 1H), 7.78(d, J=8.1 Hz, 1H), 7.68(m, 3H), 7.45(m, 3H), 3.81(m, 6H), 2.57(m, 7H), 1.89(m, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.55 (m, 2H), 7.89 (d, J = 8.3 Hz, 1H), 7.78 (d, J = 8.1 Hz, 1H), 7.68 (m, 3H), 7.45 (m, 3H), 3.81 (m, 6H), 2.57 (m, 7H), 1.89 (m, 2H)

화합물번호 157. 2-[부틸-(2-페닐-퀴나졸린-4-일)-아미노]-에탄올Compound 157. 2- [butyl- (2-phenyl-quinazolin-4-yl) -amino] -ethanol

1H NMR(CDCl3, 300 MHz) δ 8.53(m, 2H), 8.18-7.91(m,2H), 7.69(m, 1H), 7.45(m, 4H), 4.85(t, J=5.2 Hz, 1H), 4.01(s, 2H), 3.67(t, J=8.0 Hz, 1H), 3.21(t, J=5.2 Hz, 1H), 2.74(t, J=7.3 Hz, 1H), 1.95(m, 1H), 1.60(m, 1H), 1.03-0.87(m, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.53 (m, 2H), 8.18-7.91 (m, 2H), 7.69 (m, 1H), 7.45 (m, 4H), 4.85 (t, J = 5.2 Hz, 1H), 4.01 (s, 2H), 3.67 (t, J = 8.0 Hz, 1H), 3.21 (t, J = 5.2 Hz, 1H), 2.74 (t, J = 7.3 Hz, 1H), 1.95 (m, 1H), 1.60 (m, 1H), 1.03-0.87 (m, 3H)

화합물번호 158. [2-(4-메틸-피페라진-1-일)-에틸]-(2-페닐-퀴나졸린-4-일)-아민Compound 158. [2- (4-Methyl-piperazin-1-yl) -ethyl]-(2-phenyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.51(t, J=3.9 Hz, 2H), 8.03(s, 1H), 7.92(d, J=8.3 Hz, 1H), 7.84(d, J=8.8 Hz, 1H), 7.65(t, J=7.6 Hz, 1H), 7.39(m, 4H), 5.84(br s, 1H), 3.83(m, 2H), 2.98(m, 4H), 2.66(m, 10H), 2.33(s, 3H), 1.05(m, 2H), 1.29(m, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.51 (t, J = 3.9 Hz, 2H), 8.03 (s, 1H), 7.92 (d, J = 8.3 Hz, 1H), 7.84 (d, J = 8.8 Hz , 1H), 7.65 (t, J = 7.6 Hz, 1H), 7.39 (m, 4H), 5.84 (br s, 1H), 3.83 (m, 2H), 2.98 (m, 4H), 2.66 (m, 10H ), 2.33 (s, 3H), 1.05 (m, 2H), 1.29 (m, 6H)

화합물번호 159. 싸이클로펜틸-메틸-(2-페닐-퀴나졸린-4-일)-아민Compound 159. Cyclopentyl-methyl- (2-phenyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.84(m, 2H), 7.98(t, J=8.1 Hz, 2H), 7.68(t, J=7.7 Hz, 1H), 7.47(m, 3H), 7.35(t, J=7.6 Hz, 1H), 4.99(t, J=7.7 Hz, 1H), 3.26(s, 3H), 2.08(m, 2H), 1.71(m, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.84 (m, 2H), 7.98 (t, J = 8.1 Hz, 2H), 7.68 (t, J = 7.7 Hz, 1H), 7.47 (m, 3H), 7.35 (t, J = 7.6 Hz, 1H), 4.99 (t, J = 7.7 Hz, 1H), 3.26 (s, 3H), 2.08 (m, 2H), 1.71 (m, 6H)

화합물번호 160. (2-페닐-퀴나졸린-4-일)-(2-피페라진-1-일-에틸)-아민Compound No. 160. (2-phenyl-quinazolin-4-yl)-(2-piperazin-1-yl-ethyl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.54(m, 2H), 7.97(m, 2H), 7.74(m, 1H), 7.46(m, 4H), 4.08(m, 4H), 3.06(m, 4H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.54 (m, 2H), 7.97 (m, 2H), 7.74 (m, 1H), 7.46 (m, 4H), 4.08 (m, 4H), 3.06 (m, 4H)

화합물번호 161. O-(4-니트로-벤질)-N-(2-페닐-퀴나졸린-4-일)-히드록실아민Compound No. 161. O - (4- nitro-benzyl) -N- (2- phenyl-quinazolin-4-yl) hydroxylamine

1H NMR(CDCl3, 300 MHz) δ 8.21(m, 3H), 7.97(m, 2H), 7.88(d, J=7.9 Hz, 1H), 7.57(m, 8H), 7.28(m, 1H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.21 (m, 3H), 7.97 (m, 2H), 7.88 (d, J = 7.9 Hz, 1H), 7.57 (m, 8H), 7.28 (m, 1H)

화합물번호 162. (4-클로로-페닐)-(2-페닐-퀴나졸린-4-일)-아민Compound 162. (4-Chloro-phenyl)-(2-phenyl-quinazolin-4-yl) -amine

1H NMR(DMSO-d6, 300 MHz) δ 9.92(s, 1H), 8.53(d, J=8.3 Hz, 1H), 8.41(t, J=3.9 Hz, 2H), 7.98(d, J=8.8 Hz, 2H), 7.85(d, J=3.8 Hz, 2H), 7.62-7.48(m, 6H) 1 H NMR (DMSO-d 6 , 300 MHz) δ 9.92 (s, 1H), 8.53 (d, J = 8.3 Hz, 1H), 8.41 (t, J = 3.9 Hz, 2H), 7.98 (d, J = 8.8 Hz, 2H), 7.85 (d, J = 3.8 Hz, 2H), 7.62-7.48 (m, 6H)

화합물번호 163. 벤질-(2-메틸-퀴나졸린-4-일)-아민Compound number 163. Benzyl- (2-methyl-quinazolin-4-yl) -amine

1H NMR(DMSO-d6, 300 MHz) δ 9.69(s, 1H), 8.47(d, J=8.1 Hz, 1H), 8.20(t, J=7.2 Hz, 2H), 7.81(d, J=3.6 Hz, 2H), 7.55(t, J= 4.1 Hz, 1H), 7.46-7.23(m, 7H), 2.22(s, 3H) 1 H NMR (DMSO-d 6 , 300 MHz) δ 9.69 (s, 1H), 8.47 (d, J = 8.1 Hz, 1H), 8.20 (t, J = 7.2 Hz, 2H), 7.81 (d, J = 3.6 Hz, 2H), 7.55 (t, J = 4.1 Hz, 1H), 7.46-7.23 (m, 7H), 2.22 (s, 3H)

화합물번호 164. (3-메톡시-벤질)-(2-메틸-퀴나졸린-4-일)-아민Compound 164. (3-methoxy-benzyl)-(2-methyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.77-7.63(m, 3H), 7.35(t, J=7.6 Hz, 1H), 7.24(t, J=6.3 Hz, 1H), 6.96(m, 2H), 6.82(m, 1H), 6.32(s, 1H), 4.84(m, 2H), 3.74(s, 3H), 2.62(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.77-7.63 (m, 3H), 7.35 (t, J = 7.6 Hz, 1H), 7.24 (t, J = 6.3 Hz, 1H), 6.96 (m, 2H) , 6.82 (m, 1H), 6.32 (s, 1H), 4.84 (m, 2H), 3.74 (s, 3H), 2.62 (s, 3H)

화합물번호 165. (4-메톡시-벤질)-(2-메틸-퀴나졸린-4-일)-아민Compound 165. (4-Methoxy-benzyl)-(2-methyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.74(d, J=8.2 Hz, 1H), 7.67(m, 2H), 7.35(m, 3H), 6.86(d, J=8.6 Hz, 2H), 6.12(s, 1H), 4.77(d, J=4.0 Hz, 2H), 3.78(s, 3H), 2.64(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.74 (d, J = 8.2 Hz, 1H), 7.67 (m, 2H), 7.35 (m, 3H), 6.86 (d, J = 8.6 Hz, 2H), 6.12 (s, 1H), 4.77 (d, J = 4.0 Hz, 2H), 3.78 (s, 3H), 2.64 (s, 3H)

화합물번호 166. (2-메틸-퀴나졸린-4-일)-(3-트리플루오로메틸-벤질)-아민Compound 166. (2-Methyl-quinazolin-4-yl)-(3-trifluoromethyl-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.82(m, 2H), 7.64(m, 2H), 7.52(m, 1H), 7.35(m, 2H), 6.73(s, 1H), 4.93(s, 2H), 2.63(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.82 (m, 2H), 7.64 (m, 2H), 7.52 (m, 1H), 7.35 (m, 2H), 6.73 (s, 1H), 4.93 (s, 2H), 2.63 (s, 3H)

화합물번호 167. (2-메틸-퀴나졸린-4-일)-펜에틸-아민Compound 167. (2-Methyl-quinazolin-4-yl) -phenethyl-amine

1H NMR(CDCl3, 300 MHz) δ 7.77(d, J=8.3 Hz, 1H), 7.60(m, 2H), 7.33(m, 3H), 7.24(m, 3H), 6.12(br, 1H), 3.94(m, 2H), 3.01(t, J=6.9 Hz, 2H), 2.65(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.77 (d, J = 8.3 Hz, 1H), 7.60 (m, 2H), 7.33 (m, 3H), 7.24 (m, 3H), 6.12 (br, 1H) , 3.94 (m, 2H), 3.01 (t, J = 6.9 Hz, 2H), 2.65 (s, 3H)

화합물번호 168. (2-메틸-퀴나졸린-4-일)-(4-페닐-부틸)-아민Compound 168. (2-Methyl-quinazolin-4-yl)-(4-phenyl-butyl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.70(m, 3H), 7.36(t, J=7.5 Hz, 1H), 7.26(m, 2H), 7,17(m, 3H), 6.12(br, 1H), 3.69(d, J=5.3 Hz, 2H), 2.68(t, J=6.8 Hz, 2H), 2.62(s, 3H), 1.75(t, J=3.4 Hz, 4H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.70 (m, 3H), 7.36 (t, J = 7.5 Hz, 1H), 7.26 (m, 2H), 7,17 (m, 3H), 6.12 (br, 1H), 3.69 (d, J = 5.3 Hz, 2H), 2.68 (t, J = 6.8 Hz, 2H), 2.62 (s, 3H), 1.75 (t, J = 3.4 Hz, 4H)

화합물번호 169. (2-메틸-퀴나졸린-4-일)-나프탈렌-1-일메틸-아민Compound 169. (2-Methyl-quinazolin-4-yl) -naphthalen-1-ylmethyl-amine

1H NMR(CDCl3, 300 MHz) δ 8.07(m, 1H), 7.86(m, 3H), 7.64(t, J=7.4 Hz, 2H), 7.55-7.42(m, 4H), 7.24(m, 2H), 6.22(br s, 1H), 5.27(s, 2H), 2.70(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.07 (m, 1H), 7.86 (m, 3H), 7.64 (t, J = 7.4 Hz, 2H), 7.55-7.42 (m, 4H), 7.24 (m, 2H), 6.22 (br s, 1H), 5.27 (s, 2H), 2.70 (s, 3H)

화합물번호 170. 벤조[1,3]디옥솔-5-일메틸-(2-메틸-퀴나졸린-4-일)-아민Compound number 170. Benzo [1,3] dioxol-5-ylmethyl- (2-methyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.74(m, 3H), 7.35(t, J=7.5 Hz, 1H), 6.84(t, J=6.5 Hz, 2H), 6.74(d, J=7.8 Hz, 1H), 6.24(br, 1H), 5.92(s, 2H), 4.76(d, J=4.1 Hz, 2H), 2.65(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.74 (m, 3H), 7.35 (t, J = 7.5 Hz, 1H), 6.84 (t, J = 6.5 Hz, 2H), 6.74 (d, J = 7.8 Hz , 1H), 6.24 (br, 1H), 5.92 (s, 2H), 4.76 (d, J = 4.1 Hz, 2H), 2.65 (s, 3H)

화합물번호 171. (3-플루오로-벤질)-(2-메틸-퀴나졸린-4-일)-아민Compound 171. (3-Fluoro-benzyl)-(2-methyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.79(m, 2H), 7.66(t, J=7.7 Hz, 1H), 7.37(t, J=7.5 Hz, 1H), 7.26(t, J=3.9 Hz, 1H), 7.14(m, 2H), 6.96 (m, 1H), 6.51(s, 1H), 4.87(d, J=3.3 Hz, 2H), 2.63(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.79 (m, 2H), 7.66 (t, J = 7.7 Hz, 1H), 7.37 (t, J = 7.5 Hz, 1H), 7.26 (t, J = 3.9 Hz , 1H), 7.14 (m, 2H), 6.96 (m, 1H), 6.51 (s, 1H), 4.87 (d, J = 3.3 Hz, 2H), 2.63 (s, 3H)

화합물번호 172. [2-(3-플루오로-페닐)-에틸]-(2-메틸-퀴나졸린-4-일)-아민Compound 172. [2- (3-Fluoro-phenyl) -ethyl]-(2-methyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.78(d, J=8.5 Hz, 1H), 7.65(t, J=7.3 Hz, 2H), 7.35(t, J=7.8 Hz, 1H), 7.27(m, 1H), 6.94(m, 3H), 6.24(br, 1H), 3.93(m, 2H), 3.02(t, J=6.99 Hz, 2H), 2.65 (s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.78 (d, J = 8.5 Hz, 1H), 7.65 (t, J = 7.3 Hz, 2H), 7.35 (t, J = 7.8 Hz, 1H), 7.27 (m , 1H), 6.94 (m, 3H), 6.24 (br, 1H), 3.93 (m, 2H), 3.02 (t, J = 6.99 Hz, 2H), 2.65 (s, 3H)

화합물번호 173. 2-[2-(2-메틸-퀴나졸린-4-일아미노)-에톡시]-에탄올Compound 173. 2- [2- (2-Methyl-quinazolin-4-ylamino) -ethoxy] -ethanol

1H NMR(CDCl3, 300 MHz) δ 7.83(d, J=8.1 Hz, 1H), 7.72(d, J=10.7 Hz, 1H), 7.61(t, J=7.1 Hz, 1H), 7.30(t, J=6.5 Hz, 1H), 6.96(br, 1H), 3.82(m, 6H), 3.68(m, 2H), 2.60(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.83 (d, J = 8.1 Hz, 1H), 7.72 (d, J = 10.7 Hz, 1H), 7.61 (t, J = 7.1 Hz, 1H), 7.30 (t , J = 6.5 Hz, 1H), 6.96 (br, 1H), 3.82 (m, 6H), 3.68 (m, 2H), 2.60 (s, 3H)

화합물번호 174. 2-(2-메틸-퀴나졸린-4-일아미노)-에탄올Compound No. 174. 2- (2-Methyl-quinazolin-4-ylamino) -ethanol

1H NMR(CDCl3, 300 MHz) δ 8.27(d, J=8.2 Hz, 1H), 7.88(t, J=7.2 Hz, 1H), 7.79(t, J=7.5 Hz, 1H), 7.51(m, 1H), 3.93(m, 4H), 2.70(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.27 (d, J = 8.2 Hz, 1H), 7.88 (t, J = 7.2 Hz, 1H), 7.79 (t, J = 7.5 Hz, 1H), 7.51 (m , 1H), 3.93 (m, 4H), 2.70 (s, 3H)

화합물번호 175. 벤질-(2-이소프로필-퀴나졸린-4-일)-아민Compound number 175. Benzyl- (2-isopropyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.82(d, J=7.8 Hz, 1H), 7.71-7.63(m, 2H), 7.45-7.26(m, 6H), 5.88(br, 1H), 4.90(d, J=5.4 Hz, 2H), 3.12(m, 1H), 1.37(d, J=6.6 Hz, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.82 (d, J = 7.8 Hz, 1H), 7.71-7.63 (m, 2H), 7.45-7.26 (m, 6H), 5.88 (br, 1H), 4.90 ( d, J = 5.4 Hz, 2H), 3.12 (m, 1H), 1.37 (d, J = 6.6 Hz, 6H)

화합물번호 176. (2-이소프로필-퀴나졸린-4-일)-(3-메톡시-벤질)-아민Compound number 176. (2-Isopropyl-quinazolin-4-yl)-(3-methoxy-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.82(d, J=8.4 Hz, 1H), 7.75(m, 1H), 7.66(m, 1H), 7.38(t, J=7.9 Hz, 1H), 7.25(t, J=7.7 Hz, 1H), 7.00(m, 2H), 6.80(m, 1H), 4.88(d, J=5.0 Hz, 2H), 3.77(s, 3H), 3.13(m, 1H), 1.37(d, J=6.8 Hz, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.82 (d, J = 8.4 Hz, 1H), 7.75 (m, 1H), 7.66 (m, 1H), 7.38 (t, J = 7.9 Hz, 1H), 7.25 (t, J = 7.7 Hz, 1H), 7.00 (m, 2H), 6.80 (m, 1H), 4.88 (d, J = 5.0 Hz, 2H), 3.77 (s, 3H), 3.13 (m, 1H) , 1.37 (d, J = 6.8 Hz, 6H)

화합물번호 177. (2-이소프로필-퀴나졸린-4-일)-(4-메톡시-벤질)-아민Compound 177. (2-Isopropyl-quinazolin-4-yl)-(4-methoxy-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.82(d, J=8.1 Hz, 1H), 7.70-7.61(m, 2H), 7.35(m, 3H), 6.89(d, J=8.7 Hz, 2H), 5.86(br, 1H), 4.83(d, J=5.4 Hz, 2H), 3.81(s, 3H), 3.14(m, 1H), 1.38(d, J=6.6 Hz, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.82 (d, J = 8.1 Hz, 1H), 7.70-7.61 (m, 2H), 7.35 (m, 3H), 6.89 (d, J = 8.7 Hz, 2H) , 5.86 (br, 1H), 4.83 (d, J = 5.4 Hz, 2H), 3.81 (s, 3H), 3.14 (m, 1H), 1.38 (d, J = 6.6 Hz, 6H)

화합물번호 178. (2-이소프로필-퀴나졸린-4-일)-(3-트리플루오로메틸-벤질)-아민Compound 178. (2-Isopropyl-quinazolin-4-yl)-(3-trifluoromethyl-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.87(m, 2H), 7.66(m, 3H), 7.51(d, J=7.8 Hz, 1H), 7.39(m, 2H), 4.96(d, J=5.0 Hz, 2H), 3.17 (m, 1H), 1.33(d, J=6.8 Hz, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.87 (m, 2H), 7.66 (m, 3H), 7.51 (d, J = 7.8 Hz, 1H), 7.39 (m, 2H), 4.96 (d, J = 5.0 Hz, 2H), 3.17 (m, 1H), 1.33 (d, J = 6.8 Hz, 6H)

화합물번호 179. (2-이소프로필-퀴나졸린-4-일)-펜에틸-아민Compound number 179. (2-isopropyl-quinazolin-4-yl) -phenethyl-amine

1H NMR(CDCl3, 300 MHz) δ 7.82(d, J=8.1 Hz, 1H), 7.67(m, 1H), 7.55(d, J=7.8 Hz, 1H), 7.38-7.21(m, 6H), 5.84(br, 1H), 3.95(q, J=6.9 Hz, 2H), 3.16(m, 1H), 3.05(t, J=6.9 Hz, 2H), 1.40(d, J=6.9 Hz, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.82 (d, J = 8.1 Hz, 1H), 7.67 (m, 1H), 7.55 (d, J = 7.8 Hz, 1H), 7.38-7.21 (m, 6H) , 5.84 (br, 1H), 3.95 (q, J = 6.9 Hz, 2H), 3.16 (m, 1H), 3.05 (t, J = 6.9 Hz, 2H), 1.40 (d, J = 6.9 Hz, 6H)

화합물번호 180. (2-이소프로필-퀴나졸린-4-일)-(4-페닐-부틸)-아민Compound number 180. (2-isopropyl-quinazolin-4-yl)-(4-phenyl-butyl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.83(d, J=7.9 Hz, 1H), 7.75(d, J=7.7 Hz, 1H), 7.65(t, J=7.6 Hz, 1H), 7.35(t, J=7.6 Hz, 1H), 7.25(m, 6H), 3.73(d, J=5.5 Hz, 2H), 3.14(m, 1H), 2.68(d, J=6.5 Hz, 2H), 1.77(m, 4H), 1.36(d, J=6.8 Hz, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.83 (d, J = 7.9 Hz, 1H), 7.75 (d, J = 7.7 Hz, 1H), 7.65 (t, J = 7.6 Hz, 1H), 7.35 (t , J = 7.6 Hz, 1H), 7.25 (m, 6H), 3.73 (d, J = 5.5 Hz, 2H), 3.14 (m, 1H), 2.68 (d, J = 6.5 Hz, 2H), 1.77 (m , 4H), 1.36 (d, J = 6.8 Hz, 6H)

화합물번호 181. (2-이소프로필-퀴나졸린-4-일)-나프탈렌-1-일메틸-아민Compound number 181. (2-isopropyl-quinazolin-4-yl) -naphthalen-1-ylmethyl-amine

1H NMR(CDCl3, 300 MHz) δ 8.18(m, 1H), 7.93-7.81(m, 3H), 7.68-7.43(m, 6H), 7.30(m, 1H), 5.85(br, 1H), 5.35(d, J=5.1 Hz, 2H), 3.20(m, 1H), 1.44(d, J=6.6 Hz, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.18 (m, 1H), 7.93-7.81 (m, 3H), 7.68-7.43 (m, 6H), 7.30 (m, 1H), 5.85 (br, 1H), 5.35 (d, J = 5.1 Hz, 2H), 3.20 (m, 1H), 1.44 (d, J = 6.6 Hz, 6H)

화합물번호 182. 벤조[1,3]디옥솔-5-일메틸-(2-이소프로필-퀴나졸린-4-일)-아민Compound No. 182. Benzo [1,3] dioxol-5-ylmethyl- (2-isopropyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.81(d, J=7.8 Hz, 1H), 7.70-7.63(m, 2H), 7.66(m, 1H), 6.94-6.87(m, 2H), 6.78(d, 1H, J=7.8 Hz), 5.94(s, 2H), 5.90(br, 1H), 4.80(d, J=5.4 Hz, 2H), 3.13(m, 1H), 1.38(d, J=6.6 Hz, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.81 (d, J = 7.8 Hz, 1H), 7.70-7.63 (m, 2H), 7.66 (m, 1H), 6.94-6.87 (m, 2H), 6.78 ( d, 1H, J = 7.8 Hz, 5.94 (s, 2H), 5.90 (br, 1H), 4.80 (d, J = 5.4 Hz, 2H), 3.13 (m, 1H), 1.38 (d, J = 6.6 Hz, 6H)

화합물번호 183. (3-플루오로-벤질)-(2-이소프로필-퀴나졸린-4-일)-아민Compound 183. (3-Fluoro-benzyl)-(2-isopropyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.82(t, J=5.6 Hz, 1H), 7.67(t, J=7.7 Hz, 1H), 7.37(t, J=7.5 Hz, 1H), 7.28-7.12(m, 3H), 6.95(t, J=7.3 Hz, 1H), 6.34(br, 1H), 4.89(d, J=3.5 Hz, 2H), 3.14(m, 1H), 1.33(d, J=6.8 Hz, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.82 (t, J = 5.6 Hz, 1H), 7.67 (t, J = 7.7 Hz, 1H), 7.37 (t, J = 7.5 Hz, 1H), 7.28-7.12 (m, 3H), 6.95 (t, J = 7.3 Hz, 1H), 6.34 (br, 1H), 4.89 (d, J = 3.5 Hz, 2H), 3.14 (m, 1H), 1.33 (d, J = 6.8 Hz, 6H)

화합물번호 184. [2-(3-플루오로-페닐)-에틸]-(2-이소프로필-퀴나졸린-4-일)-아민Compound 184. [2- (3-Fluoro-phenyl) -ethyl]-(2-isopropyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.83(d, J=8.7 Hz, 1H), 7.66(t, J=7.2 Hz, 2H), 7.38-7.23(m, 2H), 6.89(m, 3H), 6.32(br, 1H), 3.94(m, 1H), 3.17(t, J=6.8 Hz, 1H), 3.06(m, 1H), 1.39(d, J=6.8 Hz, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.83 (d, J = 8.7 Hz, 1H), 7.66 (t, J = 7.2 Hz, 2H), 7.38-7.23 (m, 2H), 6.89 (m, 3H) , 6.32 (br, 1H), 3.94 (m, 1H), 3.17 (t, J = 6.8 Hz, 1H), 3.06 (m, 1H), 1.39 (d, J = 6.8 Hz, 6H)

화합물번호 185. 2-[2-(2-이소프로필-퀴나졸린-4-일아미노)-에톡시]-에탄올Compound 185. 2- [2- (2-isopropyl-quinazolin-4-ylamino) -ethoxy] -ethanol

1H NMR(MeOD, 300 MHz) δ 7.78(t, J=8.1 Hz, 2H), 7.61(t, J=7.6 Hz, 1H), 7.29(m, 1H), 6.78(br, 1H), 3.89(d, J=4.4 Hz, 2H), 3.80(m, 4H), 3.66(t, J=4.4 Hz, 2H), 3.11(m, 1H), 1.33(d, J=6.8 Hz, 6H) 1 H NMR (MeOD, 300 MHz) δ 7.78 (t, J = 8.1 Hz, 2H), 7.61 (t, J = 7.6 Hz, 1H), 7.29 (m, 1H), 6.78 (br, 1H), 3.89 ( d, J = 4.4 Hz, 2H), 3.80 (m, 4H), 3.66 (t, J = 4.4 Hz, 2H), 3.11 (m, 1H), 1.33 (d, J = 6.8 Hz, 6H)

화합물번호 186. 2-(2-이소프로필-퀴나졸린-4-일아미노)-에탄올Compound No.186. 2- (2-Isopropyl-quinazolin-4-ylamino) -ethanol

1H NMR(CDCl3+MeOD, 300 MHz) δ 7.85(d, J=8.2 Hz, 1H), 7.64(m, 2H), 7.31(m, 1H), 3.78(m, 4H), 3.02(m, 1H), 1.27(d, J=6.8 Hz, 6H) 1 H NMR (CDCl 3 + MeOD, 300 MHz) δ 7.85 (d, J = 8.2 Hz, 1H), 7.64 (m, 2H), 7.31 (m, 1H), 3.78 (m, 4H), 3.02 (m, 1H), 1.27 (d, J = 6.8 Hz, 6H)

화합물번호 187. 벤질-(2-tert-부틸-퀴나졸린-4-일)-아민Compound number 187. Benzyl- (2- tert -butyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.90(d, J=8.2 Hz, 1H), 7.12(d, J=5.3 Hz, 1H), 7.53(t, J=7.6 Hz, 1H), 7.36-7.25(m, 6H), 6.22(br, 1H), 4.90(d, J=5.3 Hz, 2H), 1.44(s, 9H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.90 (d, J = 8.2 Hz, 1H), 7.12 (d, J = 5.3 Hz, 1H), 7.53 (t, J = 7.6 Hz, 1H), 7.36-7.25 (m, 6H), 6.22 (br, 1H), 4.90 (d, J = 5.3 Hz, 2H), 1.44 (s, 9H)

화합물번호 188. (2-tert-부틸-퀴나졸린-4-일)-(3-메톡시-벤질)-아민Compound 188. (2- tert -Butyl-quinazolin-4-yl)-(3-methoxy-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.88(d, J=8.1 Hz, 1H), 7.66(m, 2H), 7.44-7.23(m, 3H, 6.99(d, J=8.0 Hz, 2H), 6.84(t, J=4.2 Hz, 1H), 6.16(br, 1H), 4.87(d, J=5.3 Hz, 2H), 3.78(s, 3H), 1.44(s, 9H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.88 (d, J = 8.1 Hz, 1H), 7.66 (m, 2H), 7.44-7.23 (m, 3H, 6.99 (d, J = 8.0 Hz, 2H), 6.84 (t, J = 4.2 Hz, 1H), 6.16 (br, 1H), 4.87 (d, J = 5.3 Hz, 2H), 3.78 (s, 3H), 1.44 (s, 9H)

화합물번호 189. (2-tert-부틸-퀴나졸린-4-일)-(4-메톡시-벤질)-아민Compound number 189. (2- tert -Butyl-quinazolin-4-yl)-(4-methoxy-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.86(m, 1H), 7.64(m, 2H), 7.32(m, 3H), 6.99(d, J=8.7 Hz, 1H), 6.86(d, J=5.6 Hz, 2H), 6.19(br, 1H), 4.82 (d, J=5.4 Hz, 2H), 3.80(s, 3H), 1.44(s, 9H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.86 (m, 1H), 7.64 (m, 2H), 7.32 (m, 3H), 6.99 (d, J = 8.7 Hz, 1H), 6.86 (d, J = 5.6 Hz, 2H), 6.19 (br, 1H), 4.82 (d, J = 5.4 Hz, 2H), 3.80 (s, 3H), 1.44 (s, 9H)

화합물번호 190. (2-tert-부틸-퀴나졸린-4-일)-(3-트리플루오로메틸-벤질)-아민Compound No. 190. (2- tert -Butyl-quinazolin-4-yl)-(3-trifluoromethyl-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.91(d, J=8.3 Hz, 1H), 7.79-7.61(m, 4H), 7.53(d, J=7.9 Hz, 1H), 7.46-7.34(m, 2H), 6.21(br, 1H), 4.95(d, J=5.3 Hz, 2H), 1.45(s, 9H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.91 (d, J = 8.3 Hz, 1H), 7.79-7.61 (m, 4H), 7.53 (d, J = 7.9 Hz, 1H), 7.46-7.34 (m, 2H), 6.21 (br, 1H), 4.95 (d, J = 5.3 Hz, 2H), 1.45 (s, 9H)

화합물번호 191. (2-tert-부틸-퀴나졸린-4-일)-펜에틸-아민Compound 191. (2- tert -Butyl-quinazolin-4-yl) -phenethyl-amine

1H NMR(CDCl3, 300 MHz) δ 7.85(d, J=8.4 Hz, 1H), 7.66(t, J=7.5 Hz, 1H), 7.53(d, J=7.8 Hz, 1H), 7.31(m, 6H), 5.72(br s, 1H), 3.93(q, J=6.9 Hz, 2H), 3.05(t, J=7.2 Hz, 2H), 1.48(s, 9H) 1 H NMR (CDCl 3, 300 MHz) δ 7.85 (d, J = 8.4 Hz, 1H), 7.66 (t, J = 7.5 Hz, 1H), 7.53 (d, J = 7.8 Hz, 1H), 7.31 (m , 6H), 5.72 (br s, 1H), 3.93 (q, J = 6.9 Hz, 2H), 3.05 (t, J = 7.2 Hz, 2H), 1.48 (s, 9H)

화합물번호 192. (2-tert-부틸-퀴나졸린-4-일)-(4-페닐-부틸)-아민Compound number 192. (2- tert -butyl-quinazolin-4-yl)-(4-phenyl-butyl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.87(d, J=8.3 Hz, 1H), 7.65(m, 2H), 7.37-7.25(m, 3H), 7.19(m, 3H), 5.98(br, 1H), 3.71(d, J=5.66 Hz, 2H), 2.68(d, J=6.5 Hz, 2H), 1.44(m, 4H), 1.44(s, 9H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.87 (d, J = 8.3 Hz, 1H), 7.65 (m, 2H), 7.37-7.25 (m, 3H), 7.19 (m, 3H), 5.98 (br, 1H), 3.71 (d, J = 5.66 Hz, 2H), 2.68 (d, J = 6.5 Hz, 2H), 1.44 (m, 4H), 1.44 (s, 9H)

화합물번호 193. (2-tert-부틸-퀴나졸린-4-일)-나프탈렌-1-일메틸-아민Compound number 193. (2- tert -butyl-quinazolin-4-yl) -naphthalen-1-ylmethyl-amine

1H NMR(CDCl3, 300 MHz) δ 8.20(d, J=9.4 Hz, 1H), 7.89(m, 3H), 7.61(m, 3H), 7.50(m, 3H), 6.10(br, 1H), 5.35(d, J=5.1 Hz, 2H), 1.52(s, 9H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.20 (d, J = 9.4 Hz, 1H), 7.89 (m, 3H), 7.61 (m, 3H), 7.50 (m, 3H), 6.10 (br, 1H) , 5.35 (d, J = 5.1 Hz, 2H), 1.52 (s, 9H)

화합물번호 194. 벤조[1,3]디옥솔-5-일메틸-(2-tert-부틸-퀴나졸린-4-일)-아민Compound 194.Benzo [1,3] dioxol-5-ylmethyl- (2- tert -butyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.89(d, J=8.3Hz, 1H), 7.66(m, 2H), 7.34(t, J=7.5 Hz, 1H), 6.91(m, 2H), 6.76(d, J=7.9 Hz, 1H), 6.21(br, 1H), 5.93(s, 2H), 4.80(d, J=6.2 Hz, 2H), 1.44(s, 9H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.89 (d, J = 8.3 Hz, 1H), 7.66 (m, 2H), 7.34 (t, J = 7.5 Hz, 1H), 6.91 (m, 2H), 6.76 (d, J = 7.9 Hz, 1H), 6.21 (br, 1H), 5.93 (s, 2H), 4.80 (d, J = 6.2 Hz, 2H), 1.44 (s, 9H)

화합물번호 195. (2-tert-부틸-퀴나졸린-4-일)-(3-플루오로-벤질)-아민Compound 195. (2- tert -Butyl-quinazolin-4-yl)-(3-fluoro-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.89(d, J=8.3 Hz, 1H), 7.69(m, 2H), 7.35(m, 1H), 7.28(m, 1H), 7.14(m, 2H), 6.94(d, J=5.4 Hz, 1H), 6.24(br, 1H), 4.99(d, J=6.2Hz, 2H), 1.45(s, 9H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.89 (d, J = 8.3 Hz, 1H), 7.69 (m, 2H), 7.35 (m, 1H), 7.28 (m, 1H), 7.14 (m, 2H) , 6.94 (d, J = 5.4 Hz, 1H), 6.24 (br, 1H), 4.99 (d, J = 6.2 Hz, 2H), 1.45 (s, 9H)

화합물번호 196. (2-tert-부틸-퀴나졸린-4-일)-[2-(3-플루오로-페닐)-에틸]-아민Compound number 196. (2- tert -Butyl-quinazolin-4-yl)-[2- (3-fluoro-phenyl) -ethyl] -amine

1H NMR(CDCl3, 300 MHz) δ 7.89(d, J=8.3 Hz, 1H), 7.68(m, 2H), 7.33(m, 1H), 7.25(m, 1H), 6.98(m, 2H), 6.01(br, 1H), 3.93(m, 2H), 3.06(t, J=2.6 Hz, 2H), 1.45(s, 9H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.89 (d, J = 8.3 Hz, 1H), 7.68 (m, 2H), 7.33 (m, 1H), 7.25 (m, 1H), 6.98 (m, 2H) , 6.01 (br, 1H), 3.93 (m, 2H), 3.06 (t, J = 2.6 Hz, 2H), 1.45 (s, 9H)

화합물번호 197. 2-[2-(2-tert-부틸-퀴나졸린-4-일아미노)-에톡시]-에탄올Compound 197. 2- [2- (2- tert -butyl-quinazolin-4-ylamino) -ethoxy] -ethanol

1H NMR(CDCl3, 300 MHz) δ 7.85(d, J=8.3 Hz, 1H), 7.71(d, J=8.2 Hz, 1H), 7.63(t, J=7.8 Hz, 1H), 7.33(t, J=7.5 Hz, 1H), 6.33(br, 1H), 3.90(d, J=4.1 Hz, 2H), 3.80(t, J=4.6 Hz, 4H), 3.65(t, J=4.6 Hz, 2H), 1.44(s, 9H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.85 (d, J = 8.3 Hz, 1H), 7.71 (d, J = 8.2 Hz, 1H), 7.63 (t, J = 7.8 Hz, 1H), 7.33 (t , J = 7.5 Hz, 1H), 6.33 (br, 1H), 3.90 (d, J = 4.1 Hz, 2H), 3.80 (t, J = 4.6 Hz, 4H), 3.65 (t, J = 4.6 Hz, 2H ), 1.44 (s, 9 H)

화합물번호 198. 2-(2-tert-부틸-퀴나졸린-4-일아미노)-에탄올Compound 198. 2- (2- tert -butyl-quinazolin-4-ylamino) -ethanol

1H NMR(CDCl3, 300 MHz) δ 7.83(d, J=8.0 Hz, 1H), 7.69(t, J=7.6 Hz, 2H), 7.38(t, J=7.6 Hz, 1H), 6.14(br, 1H), 4.59(s, 1H), 3.93-3.83(m, 4H), 1.44(s, 9H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.83 (d, J = 8.0 Hz, 1H), 7.69 (t, J = 7.6 Hz, 2H), 7.38 (t, J = 7.6 Hz, 1H), 6.14 (br) , 1H), 4.59 (s, 1H), 3.93-3.83 (m, 4H), 1.44 (s, 9H)

화합물번호 199. 벤질-(2-싸이클로헥실-퀴나졸린-4-일)-아민Compound number 199. Benzyl- (2-cyclohexyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.83(d, J=8.0 Hz, 1H), 7.68(m, 2H), 7.43(d, J=7.5 Hz, 2H), 7.31(m, 4H), 6.26(br, 1H), 4.90((d, J=5.2 Hz, 2H), 2.82(t, J=11.5 Hz, 1H), 1.97 (m, 2H), 1.73(m, 5H), 1.33(m, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.83 (d, J = 8.0 Hz, 1H), 7.68 (m, 2H), 7.43 (d, J = 7.5 Hz, 2H), 7.31 (m, 4H), 6.26 (br, 1H), 4.90 ((d, J = 5.2 Hz, 2H), 2.82 (t, J = 11.5 Hz, 1H), 1.97 (m, 2H), 1.73 (m, 5H), 1.33 (m, 3H )

화합물번호 200. (2-싸이클로헥실-퀴나졸린-4-일)-(3-메톡시-벤질)-아민Compound No. 200. (2-Cyclohexyl-quinazolin-4-yl)-(3-methoxy-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.84(d, J=8.3 Hz, 1H), 7.73(d, J=8.2 Hz, 1H), 7.65(t, J=7.3 Hz, 1H), 7.34(t, J=7.6 Hz, 1H), 7.26(t, J=7.8 Hz, 1H), 7.01(d, J=7.3 Hz, 2H), 6.84(t, J=4.5 Hz, 1H), 6.43(br, 1H), 4.88(d, J=6.8 Hz, 2H), 3.78(s, 3H), 2.84(m, 1H), 2.02(m, 2H), 1.85-1.66(m, 5H), 1.48-1.28(m, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.84 (d, J = 8.3 Hz, 1H), 7.73 (d, J = 8.2 Hz, 1H), 7.65 (t, J = 7.3 Hz, 1H), 7.34 (t , J = 7.6 Hz, 1H), 7.26 (t, J = 7.8 Hz, 1H), 7.01 (d, J = 7.3 Hz, 2H), 6.84 (t, J = 4.5 Hz, 1H), 6.43 (br, 1H ), 4.88 (d, J = 6.8 Hz, 2H), 3.78 (s, 3H), 2.84 (m, 1H), 2.02 (m, 2H), 1.85-1.66 (m, 5H), 1.48-1.28 (m, 3H)

화합물번호 201. (2-싸이클로헥실-퀴나졸린-4-일)-(4-메톡시-벤질)-아민Compound No. 201. (2-Cyclohexyl-quinazolin-4-yl)-(4-methoxy-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.84(d, J=8.3 Hz, 1H), 7.73(d, J=8.2 Hz, 1H), 7.64(t, J=7.4 Hz, 1H), 7.36(m, 3H), 6.87(d, J=8.5 Hz, 2H), 6.48n (br, 1H), 4.83(d, J=6.8 Hz, 2H), 3.80(s, 3H), 2.85(m, 1H), 2.02(m, 2H), 2.04-1.69(m, 5H), 1.49-1.25(m, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.84 (d, J = 8.3 Hz, 1H), 7.73 (d, J = 8.2 Hz, 1H), 7.64 (t, J = 7.4 Hz, 1H), 7.36 (m , 3H), 6.87 (d, J = 8.5 Hz, 2H), 6.48 n (br, 1H), 4.83 (d, J = 6.8 Hz, 2H), 3.80 (s, 3H), 2.85 (m, 1H), 2.02 (m, 2H), 2.04-1.69 (m, 5H), 1.49-1.25 (m, 3H)

화합물번호 202. (2-싸이클로헥실-퀴나졸린-4-일)-(3-트리플루오로메틸-벤질)-아민Compound 202. (2-Cyclohexyl-quinazolin-4-yl)-(3-trifluoromethyl-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.83(m, 2H), 7.78(m, 1H), 7.64(m, 2H), 7.53(m, 1H), 7.40(m, 2H), 6.67(br, 1H), 4.93(d, J=5.0 Hz, 2H), 2.80 (m, 1H), 1.90(m, 2H), 1.84-1.60(m, 5H), 1.45-1.25(m, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.83 (m, 2H), 7.78 (m, 1H), 7.64 (m, 2H), 7.53 (m, 1H), 7.40 (m, 2H), 6.67 (br, 1H), 4.93 (d, J = 5.0 Hz, 2H), 2.80 (m, 1H), 1.90 (m, 2H), 1.84-1.60 (m, 5H), 1.45-1.25 (m, 3H)

화합물번호 203. (2-싸이클로헥실-퀴나졸린-4-일)-펜에틸-아민Compound 203. (2-Cyclohexyl-quinazolin-4-yl) -phenethyl-amine

1H NMR(CDCl3, 300 MHz) δ 7.83(d, J=8.3 Hz, 1H), 7.65(m, 2H), 7.28(m, 6H), 6.06(br, 1H), 3.95(m, 2H), 3.05(t, J=7.0 Hz, 2H), 2.83(m, 1H), 2.04(m, 2H), 1.88-1.71(m, 5H), 1.50-1.35(m, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.83 (d, J = 8.3 Hz, 1H), 7.65 (m, 2H), 7.28 (m, 6H), 6.06 (br, 1H), 3.95 (m, 2H) , 3.05 (t, J = 7.0 Hz, 2H), 2.83 (m, 1H), 2.04 (m, 2H), 1.88-1.71 (m, 5H), 1.50-1.35 (m, 3H)

화합물번호 204. (2-싸이클로헥실-퀴나졸린-4-일)-(4-페닐-부틸)-아민Compound 204. (2-Cyclohexyl-quinazolin-4-yl)-(4-phenyl-butyl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.83(d, J=8.3 Hz, 1H), 7.69(m, 2H), 7.37-7.17(m, 7H), 6.12(br, 1H), 3.72(d, J=5.6 Hz, 2H), 2.78(t, J= 11.1 Hz, 1H), 2.70(t, J=6.7 Hz, 2H), 2.00(m, 2H), 1.86-1.68(m, 9H), 1.44-1.28(m, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.83 (d, J = 8.3 Hz, 1H), 7.69 (m, 2H), 7.37-7.17 (m, 7H), 6.12 (br, 1H), 3.72 (d, J = 5.6 Hz, 2H), 2.78 (t, J = 11.1 Hz, 1H), 2.70 (t, J = 6.7 Hz, 2H), 2.00 (m, 2H), 1.86-1.68 (m, 9H), 1.44- 1.28 (m, 3H)

화합물번호 205. (2-싸이클로헥실-퀴나졸린-4-일)-나프탈렌-1-일메틸-아민Compound 205. (2-Cyclohexyl-quinazolin-4-yl) -naphthalen-1-ylmethyl-amine

1H NMR(CDCl3, 300 MHz) δ 8.20 (d, J=9.4 Hz, 1H), 7.87(m, 3H), 7.62(m, 3H), 7.50(m, 3H), 7.30(m, 1H), 6.34(br, 1H), 5.35(d, J=4.9 Hz, 2H), 2.92(m, 1H), 2.08(m, 2H), 1.86-1.73(m, 5H), 1.47-1.25(m, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.20 (d, J = 9.4 Hz, 1H), 7.87 (m, 3H), 7.62 (m, 3H), 7.50 (m, 3H), 7.30 (m, 1H) , 6.34 (br, 1H), 5.35 (d, J = 4.9 Hz, 2H), 2.92 (m, 1H), 2.08 (m, 2H), 1.86-1.73 (m, 5H), 1.47-1.25 (m, 3H )

화합물번호 206. 벤조[1,3]디옥솔-5-일메틸-(2-싸이클로헥실-퀴나졸린-4-일)-아민Compound 206. Benzo [1,3] dioxol-5-ylmethyl- (2-cyclohexyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.83(d, J=8.4 Hz, 1H), 7.73(d, J=8.2 Hz, 1H), 7.65(t, J=7.5 Hz, 2H), 6.91 (m, 2H), 6.76(d, J=7.9 Hz, 1H), 6.34(br, 1H), 5.93(s, 2H), 4.80(d, J=5.2 Hz, 2H), 2.84(m, 1H), 2.00(m, 2H), 1.86-1.68(m, 5H), 1.48-1.25(m, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.83 (d, J = 8.4 Hz, 1H), 7.73 (d, J = 8.2 Hz, 1H), 7.65 (t, J = 7.5 Hz, 2H), 6.91 (m , 2H), 6.76 (d, J = 7.9 Hz, 1H), 6.34 (br, 1H), 5.93 (s, 2H), 4.80 (d, J = 5.2 Hz, 2H), 2.84 (m, 1H), 2.00 (m, 2H), 1.86-1.68 (m, 5H), 1.48-1.25 (m, 3H)

화합물번호 207. (2-싸이클로헥실-퀴나졸린-4-일)-(3-플루오로-벤질)-아민Compound 207. (2-Cyclohexyl-quinazolin-4-yl)-(3-fluoro-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.80(m, 1H), 7.66(t, J=7.6 Hz, 1H), 7.35(m, 1H), 7.27(m, 2H), 7.16(m, 2H), 6.95(d, J=8.4 Hz, 1H), 6.47(br, 1H), 4.90(d, J=5.2 Hz, 2H), 2.83(m, 1H), 1.99(m, 2H), 1.84-1.63(m, 5H), 1.46-1.25(m, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.80 (m, 1H), 7.66 (t, J = 7.6 Hz, 1H), 7.35 (m, 1H), 7.27 (m, 2H), 7.16 (m, 2H) , 6.95 (d, J = 8.4 Hz, 1H), 6.47 (br, 1H), 4.90 (d, J = 5.2 Hz, 2H), 2.83 (m, 1H), 1.99 (m, 2H), 1.84-1.63 ( m, 5H), 1.46-1.25 (m, 3H)

화합물번호 208. (2-싸이클로헥실-퀴나졸린-4-일)-[2-(3-플루오로-페닐)-에틸]-아민Compound 208. (2-Cyclohexyl-quinazolin-4-yl)-[2- (3-fluoro-phenyl) -ethyl] -amine

1H NMR(CDCl3, 300 MHz) δ 7.83(d, J=8.3 Hz, 1H), 7.65(t, J=7.7 Hz, 2H), 7.30(m, 2H), 6.99(m, 3H), 6.15(br, 1H), 3.94(m, 2H), 3.05(t, J=7.1 Hz, 2H), 2.83(m, 1H), 2.00(m, 2H), 1.88-1.69(m, 5H), 1.46-1.25(m, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.83 (d, J = 8.3 Hz, 1H), 7.65 (t, J = 7.7 Hz, 2H), 7.30 (m, 2H), 6.99 (m, 3H), 6.15 (br, 1H), 3.94 (m, 2H), 3.05 (t, J = 7.1 Hz, 2H), 2.83 (m, 1H), 2.00 (m, 2H), 1.88-1.69 (m, 5H), 1.46- 1.25 (m, 3H)

화합물번호 209. 2-[2-(2-싸이클로헥실-퀴나졸린-4-일아미노)-에톡시]-에탄올Compound 209. 2- [2- (2-cyclohexyl-quinazolin-4-ylamino) -ethoxy] -ethanol

1H NMR(CDCl3, 300 MHz) δ 7.75(m, 2H), 7.62(t, J=7.6 Hz, 1H), 7.31(t, J=7.5 Hz, 1H), 6.48(br, 1H), 3.90(m, 2H), 3.80(m, 4H), 3.36(m, 2H), 2.78(m, 1H), 1.90(m, 2H), 1.85-1.62(m, 5H), 1.47-1.27(m, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.75 (m, 2H), 7.62 (t, J = 7.6 Hz, 1H), 7.31 (t, J = 7.5 Hz, 1H), 6.48 (br, 1H), 3.90 (m, 2H), 3.80 (m, 4H), 3.36 (m, 2H), 2.78 (m, 1H), 1.90 (m, 2H), 1.85-1.62 (m, 5H), 1.47-1.27 (m, 3H )

화합물번호 210. 2-(2-싸이클로헥실-퀴나졸린-4-일아미노)-에탄올Compound No. 210. 2- (2-Cyclohexyl-quinazolin-4-ylamino) -ethanol

1H NMR(CDCl3, 300 MHz) δ 7.80(d, J=8.4 Hz, 1H), 7.69(m, 2H), 7.40(t, J=7.0 Hz, 1H), 6.20(br, 1H), 5.08(br, 1H), 3.93(m, 2H), 3.85(m, 2H), 2.77(m, 1H), 1.97(m, 2H), 1.86-1.66(m, 5H), 1.47-1.25(m, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.80 (d, J = 8.4 Hz, 1H), 7.69 (m, 2H), 7.40 (t, J = 7.0 Hz, 1H), 6.20 (br, 1H), 5.08 (br, 1H), 3.93 (m, 2H), 3.85 (m, 2H), 2.77 (m, 1H), 1.97 (m, 2H), 1.86-1.66 (m, 5H), 1.47-1.25 (m, 3H )

화합물번호 211. 벤질-(2-벤질-퀴나졸린-4-일)-아민Compound number 211. Benzyl- (2-benzyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.82(d, J=8.4 Hz, 1H), 7.71(m, 2H), 7.47(m, 2H), 7.29(m, 9H), 5.94(br, 1H), 4.82(d, J=5.5 Hz, 2H), 4.19(s, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.82 (d, J = 8.4 Hz, 1H), 7.71 (m, 2H), 7.47 (m, 2H), 7.29 (m, 9H), 5.94 (br, 1H) , 4.82 (d, J = 5.5 Hz, 2H), 4.19 (s, 2H)

화합물번호 212. (2-벤질-퀴나졸린-4-일)-(3-메톡시-벤질)-아민Compound number 212. (2-benzyl-quinazolin-4-yl)-(3-methoxy-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.82(d, J=8.1 Hz, 1H), 7.69(t, J=6.9 Hz, 1H), 7.60(d, J=8.1 Hz, 1H), 7.45(d, J=7.2 Hz, 2H), 7.37(t, J=7.2 Hz, 1H), 7.25(m, 4H), 6.85(m, 3H), 5.87(br, 1H), 4.80(d, J=5.4 Hz, 2H), 4.19(s, 2H), 3.76(s, 3H) 1 H NMR (CDCl 3, 300 MHz) δ 7.82 (d, J = 8.1 Hz, 1H), 7.69 (t, J = 6.9 Hz, 1H), 7.60 (d, J = 8.1 Hz, 1H), 7.45 (d , J = 7.2 Hz, 2H), 7.37 (t, J = 7.2 Hz, 1H), 7.25 (m, 4H), 6.85 (m, 3H), 5.87 (br, 1H), 4.80 (d, J = 5.4 Hz , 2H), 4.19 (s, 2H), 3.76 (s, 3H)

화합물번호 213. (2-벤질-퀴나졸린-4-일)-(4-메톡시-벤질)-아민Compound 213. (2-benzyl-quinazolin-4-yl)-(4-methoxy-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.81(d, J=8.4 Hz, 1H), 7.67(t, J=7.7 Hz, 1H), 7.59(d, J=8.1 Hz, 1H), 7.46(d, J=7.3 Hz, 2H), 7.35(t, J=7.6 Hz, 1H), 7.23(m, 5H), 6.83(d, J=8.5 Hz, 2H), 5.87(br, 1H), 4.74(d, J=5.3 Hz, 2H), 4.20(s, 2H), 3.80(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.81 (d, J = 8.4 Hz, 1H), 7.67 (t, J = 7.7 Hz, 1H), 7.59 (d, J = 8.1 Hz, 1H), 7.46 (d , J = 7.3 Hz, 2H), 7.35 (t, J = 7.6 Hz, 1H), 7.23 (m, 5H), 6.83 (d, J = 8.5 Hz, 2H), 5.87 (br, 1H), 4.74 (d , J = 5.3 Hz, 2H), 4.20 (s, 2H), 3.80 (s, 3H)

화합물번호 214. (2-벤질-퀴나졸린-4-일)-(3-트리플루오로메틸-벤질)-아민Compound number 214. (2-benzyl-quinazolin-4-yl)-(3-trifluoromethyl-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.80(m, 2H), 7.66(m, 2H), 7.49(m, 2H), 7.37(m, 4H), 7.20(m, 2H), 6.56(br, 1H), 4.86(d, J=6.3 Hz, 2H), 4.18(s, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.80 (m, 2H), 7.66 (m, 2H), 7.49 (m, 2H), 7.37 (m, 4H), 7.20 (m, 2H), 6.56 (br, 1H), 4.86 (d, J = 6.3 Hz, 2H), 4.18 (s, 2H)

화합물번호 215. (2-벤질-퀴나졸린-4-일)-펜에틸-아민Compound 215. (2-benzyl-quinazolin-4-yl) -phenethyl-amine

1H NMR(CDCl3, 300 MHz) δ 7.82(d, J=8.3 Hz, 1H), 7.61(m, 4H), 7.34-7.17(m, 6H), 6.12(br, 1H), 4.21(s, 2H), 3.88(m, 2H), 2.94(t, J=7.2 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.82 (d, J = 8.3 Hz, 1H), 7.61 (m, 4H), 7.34-7.17 (m, 6H), 6.12 (br, 1H), 4.21 (s, 2H), 3.88 (m, 2H), 2.94 (t, J = 7.2 Hz, 2H)

화합물번호 216. (2-벤질-퀴나졸린-4-일)-(4-페닐-부틸)-아민Compound number 216. (2-benzyl-quinazolin-4-yl)-(4-phenyl-butyl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.81(d, J = 8.3 Hz, 1H), 7.63(t, J = 7.8 Hz, 2H), 7.46(d, J = 7.3 Hz, 2H), 7.33(m, 5H), 7.24(m, 4H), 5.98(br, 1H), 4.18(s, 2H), 3.62(d, J = 5.7 Hz, 2H), 2.64(t, J = 5.1 Hz, 2H), 1.69(m, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.81 (d, J = 8.3 Hz, 1H), 7.63 (t, J = 7.8 Hz, 2H), 7.46 (d, J = 7.3 Hz, 2H), 7.33 (m , 5H), 7.24 (m, 4H), 5.98 (br, 1H), 4.18 (s, 2H), 3.62 (d, J = 5.7 Hz, 2H), 2.64 (t, J = 5.1 Hz, 2H), 1.69 (m, 2H)

화합물번호 217. (2-벤질-퀴나졸린-4-일)-나프탈렌-1-일메틸-아민Compound number 217. (2-benzyl-quinazolin-4-yl) -naphthalen-1-ylmethyl-amine

1H NMR(CDCl3, 300 MHz) δ 8.01(d, J=8.3 Hz, 1H), 7.85(m, 3H), 7.54(m, 2H), 7.52-7.39(m, 6H), 7.25(m, 4H), 6.32(br, 1H), 5.28(d, J=5.0 Hz, 2H), 4.25(s, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.01 (d, J = 8.3 Hz, 1H), 7.85 (m, 3H), 7.54 (m, 2H), 7.52-7.39 (m, 6H), 7.25 (m, 4H), 6.32 (br, 1H), 5.28 (d, J = 5.0 Hz, 2H), 4.25 (s, 2H)

화합물번호 218. 벤조[1,3]디옥솔-5-일메틸-(2-벤질-퀴나졸린-4-일)-아민Compound 218.Benzo [1,3] dioxol-5-ylmethyl- (2-benzyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.82(d, J=8.4 Hz, 1H), 7.68(m, 1H), 7.61(d, J=8.1 Hz, 1H), 7.46(d, J=7.2 Hz, 2H), 7.36(m, 1H), 7.25(m, 2H), 7.18(m, 1H), 6.81-6.71(m, 3H), 5.94(s, 2H), 5.89(br, 1H), 4.71(d, J=5.7 Hz, 2H), 4.20(s, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.82 (d, J = 8.4 Hz, 1H), 7.68 (m, 1H), 7.61 (d, J = 8.1 Hz, 1H), 7.46 (d, J = 7.2 Hz , 2H), 7.36 (m, 1H), 7.25 (m, 2H), 7.18 (m, 1H), 6.81-6.71 (m, 3H), 5.94 (s, 2H), 5.89 (br, 1H), 4.71 ( d, J = 5.7 Hz, 2H), 4.20 (s, 2H)

화합물번호 219. (2-벤질-퀴나졸린-4-일)-(3-플루오로-벤질)-아민Compound number 219. (2-benzyl-quinazolin-4-yl)-(3-fluoro-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.83(d, J=8.0 Hz, 1H), 7.69(t, J=7.3 Hz, 2H), 7.40(m, 3H), 7.23(m, 4H), 7.03(m, 3H), 6.15(br, 1H), 4.81(d, J=5.7 Hz, 2H), 4.18(s, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.83 (d, J = 8.0 Hz, 1H), 7.69 (t, J = 7.3 Hz, 2H), 7.40 (m, 3H), 7.23 (m, 4H), 7.03 (m, 3H), 6.15 (br, 1H), 4.81 (d, J = 5.7 Hz, 2H), 4.18 (s, 2H)

화합물번호 220. (2-벤질-퀴나졸린-4-일)-[2-(3-플루오로-페닐)-에틸]-아민Compound number 220. (2-benzyl-quinazolin-4-yl)-[2- (3-fluoro-phenyl) -ethyl] -amine

1H NMR(CDCl3, 300 MHz) δ 7.82(d, J=8.4 Hz, 1H), 7.68(d, J=7.5 Hz, 1H), 7.49(m, 3H), 7.34(m, 5H), 6.92(m, 3H), 5.69(br, 1H), 4.21(s, 2H), 3.84(q, J=6.6 Hz, 2H), 2.92(t, J=7.2 Hz, 2H) 1 H NMR (CDCl 3, 300 MHz) δ 7.82 (d, J = 8.4 Hz, 1H), 7.68 (d, J = 7.5 Hz, 1H), 7.49 (m, 3H), 7.34 (m, 5H), 6.92 (m, 3H), 5.69 (br, 1H), 4.21 (s, 2H), 3.84 (q, J = 6.6 Hz, 2H), 2.92 (t, J = 7.2 Hz, 2H)

화합물번호 221. 2-[2-(2-벤질-퀴나졸린-4-일아미노)-에톡시]-에탄올Compound number 221. 2- [2- (2-benzyl-quinazolin-4-ylamino) -ethoxy] -ethanol

1H NMR(CDCl3, 300 MHz) δ 7.80(d, J=8.4 Hz, 1H), 7.66(d, J=8.4 Hz, 2H), 7.45(d, J=7.2 Hz, 2H), 7.36(d, J=7.7 Hz, 1H), 7.28(m, 3H), 6.12(br, 1H), 4.17(s, 2H), 3.78(m, 6H), 3.59(t, J=4.5 Hz, 2H), 2.13(br s, 1H), 1 H NMR (CDCl 3, 300 MHz) δ 7.80 (d, J = 8.4 Hz, 1H), 7.66 (d, J = 8.4 Hz, 2H), 7.45 (d, J = 7.2 Hz, 2H), 7.36 (d , J = 7.7 Hz, 1H), 7.28 (m, 3H), 6.12 (br, 1H), 4.17 (s, 2H), 3.78 (m, 6H), 3.59 (t, J = 4.5 Hz, 2H), 2.13 (br s, 1H),

화합물번호 222. 2-(2-벤질-퀴나졸린-4-일아미노)-에탄올Compound 222. 2- (2-benzyl-quinazolin-4-ylamino) -ethanol

1H NMR(CDCl3, 300 MHz) δ 7.80(d, J=8.3 Hz, 1H), 7.67(m, 2H), 7.40(m, 3H), 7.23(m, 4H), 6.22(br, 1H), 4.15(s, 2H), 3.83(t, J=4.5 Hz, 2H), 3.76(m, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.80 (d, J = 8.3 Hz, 1H), 7.67 (m, 2H), 7.40 (m, 3H), 7.23 (m, 4H), 6.22 (br, 1H) , 4.15 (s, 2H), 3.83 (t, J = 4.5 Hz, 2H), 3.76 (m, 2H)

화합물번호 223. 벤질-(2-피리딘-2-일-퀴나졸린-4-일)-아민Compound number 223. Benzyl- (2-pyridin-2-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.80(d, J=3.9 Hz, 1H), 8.55(d, J=7.9 Hz, 1H), 8.08(d, J=8.4 Hz, 1H), 7.84(m, 2H), 7.71(t, J=7.7 Hz, 1H), 7.42(m, 3H), 7.34(m, 4H), 6.65(br, 1H), 4.99(s, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.80 (d, J = 3.9 Hz, 1H), 8.55 (d, J = 7.9 Hz, 1H), 8.08 (d, J = 8.4 Hz, 1H), 7.84 (m) , 2H), 7.71 (t, J = 7.7 Hz, 1H), 7.42 (m, 3H), 7.34 (m, 4H), 6.65 (br, 1H), 4.99 (s, 2H)

화합물번호 224. (3-메톡시-벤질)-(2-피리딘-2-일-퀴나졸린-4-일)-아민Compound number 224. (3-Methoxy-benzyl)-(2-pyridin-2-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.81(d, J=4.2 Hz, 1H), 8.56(d, J=7.8 Hz, 1H), 8.08(d, J=8.4 Hz, 1H), 7.92-7.72(m, 3H), 7.44(t, J=7.6 Hz, 1H), 7.36(t, J=6.1 Hz, 1H), 7.24(m, 2H), 7.02(m, 1H), 6.83(m,1H), 6.80(br, 1H), 4.97(s, 2H), 3.75(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.81 (d, J = 4.2 Hz, 1H), 8.56 (d, J = 7.8 Hz, 1H), 8.08 (d, J = 8.4 Hz, 1H), 7.92-7.72 (m, 3H), 7.44 (t, J = 7.6 Hz, 1H), 7.36 (t, J = 6.1 Hz, 1H), 7.24 (m, 2H), 7.02 (m, 1H), 6.83 (m, 1H) , 6.80 (br, 1 H), 4.97 (s, 2 H), 3.75 (s, 3 H)

화합물번호 225. (4-메톡시-벤질)-(2-피리딘-2-일-퀴나졸린-4-일)-아민Compound 225. (4-Methoxy-benzyl)-(2-pyridin-2-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.82(d, J=4.2 Hz, 1H), 8.59(d, J=7.9 Hz, 1H), 8.08(d, J=8.3 Hz, 1H), 7.84(m, 2H), 7.71(t, J=7.3 Hz, 1H), 7.43(m, 4H), 6.86(d, J=8.6 Hz, 2H), 6.61(br, 1H), 4.93(s, 2H), 3.78(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.82 (d, J = 4.2 Hz, 1H), 8.59 (d, J = 7.9 Hz, 1H), 8.08 (d, J = 8.3 Hz, 1H), 7.84 (m , 2H), 7.71 (t, J = 7.3 Hz, 1H), 7.43 (m, 4H), 6.86 (d, J = 8.6 Hz, 2H), 6.61 (br, 1H), 4.93 (s, 2H), 3.78 (s, 3H)

화합물번호 226. (2-피리딘-2-일-퀴나졸린-4-일)-(3-트리플루오로메틸-벤질)-아민Compound 226. (2-Pyridin-2-yl-quinazolin-4-yl)-(3-trifluoromethyl-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.78(d, J=4.4 Hz, 1H), 8.44(d, J=7.9 Hz, 1H), 8.04(m, 2H), 7.74(m, 1H), 7.65(m, 2H), 7.48(m, 1H), 7.44-7.34(m, 4H), 6.12(br, 1H), 5.03(s, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.78 (d, J = 4.4 Hz, 1H), 8.44 (d, J = 7.9 Hz, 1H), 8.04 (m, 2H), 7.74 (m, 1H), 7.65 (m, 2H), 7.48 (m, 1H), 7.44-7.34 (m, 4H), 6.12 (br, 1H), 5.03 (s, 2H)

화합물번호 227. 펜에틸-(2-피리딘-2-일-퀴나졸린-4-일)-아민Compound number 227. Phenethyl- (2-pyridin-2-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.84(d, J=4.0 Hz, 1H), 8.62(d, J=7.9 Hz, 1H), 8.08(d, J=8.3 Hz, 1H), 7.86(t, J=3.8 Hz, 1H), 7.73(m, 2H), 7.45-7.24(m, 7H), 6.54(br, 1H), 4.07(t, J=6.7 Hz, 2H), 3.10(t, J=7.1 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.84 (d, J = 4.0 Hz, 1H), 8.62 (d, J = 7.9 Hz, 1H), 8.08 (d, J = 8.3 Hz, 1H), 7.86 (t , J = 3.8 Hz, 1H), 7.73 (m, 2H), 7.45-7.24 (m, 7H), 6.54 (br, 1H), 4.07 (t, J = 6.7 Hz, 2H), 3.10 (t, J = 7.1 Hz, 2H)

화합물번호 228. (4-페닐-부틸)-(2-피리딘-2-일-퀴나졸린-4-일)-아민Compound number 228. (4-phenyl-butyl)-(2-pyridin-2-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.83(d, J=4.2 Hz, 1H), 8.55(d, J=7.9 Hz, 1H), 8.06(d, J=8.3 H, 1Hz), 7.84(m, 2H), 7.71(t, J=7.5 Hz, 1H), 7.44(t, J=7.5 Hz, 1H), 7.37(t, J=6.0 Hz, 1H), 7.28-7.16(m, 5H), 6.44(br, 1H), 3.83(m, 2H), 2.70(t, J=6.3 Hz, 2H), 1.81(m, 4H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.83 (d, J = 4.2 Hz, 1H), 8.55 (d, J = 7.9 Hz, 1H), 8.06 (d, J = 8.3 H, 1 Hz), 7.84 (m , 2H), 7.71 (t, J = 7.5 Hz, 1H), 7.44 (t, J = 7.5 Hz, 1H), 7.37 (t, J = 6.0 Hz, 1H), 7.28-7.16 (m, 5H), 6.44 (br, 1H), 3.83 (m, 2H), 2.70 (t, J = 6.3 Hz, 2H), 1.81 (m, 4H)

화합물번호 229. 나프탈렌-1-일메틸-(2-피리딘-2-일-퀴나졸린-4-일)-아민Compound number 229. Naphthalen-1-ylmethyl- (2-pyridin-2-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.83(d, J=4.0 Hz, 1H), 8.60(d, J=7.9 Hz, 1H), 8.10(d, J=8.3 Hz, 1H), 8.05(m, 1H), 7.83(m, 4H), 7,71(m, 1H), 7.63(m, 1H), 7.50-7.36(m, 5H), 6.78(br, 1H), 5.43(s, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.83 (d, J = 4.0 Hz, 1H), 8.60 (d, J = 7.9 Hz, 1H), 8.10 (d, J = 8.3 Hz, 1H), 8.05 (m , 1H), 7.83 (m, 4H), 7,71 (m, 1H), 7.63 (m, 1H), 7.50-7.36 (m, 5H), 6.78 (br, 1H), 5.43 (s, 2H)

화합물번호 230. 벤조[1,3]디옥솔-5-일메틸-(2-피리딘-2-일-퀴나졸린-4-일)-아민Compound number 230. Benzo [1,3] dioxol-5-ylmethyl- (2-pyridin-2-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.83(d, J=4.1 Hz, 1H), 8.58(d, J=8.0 Hz, 1H), 8.08(d, J=8.3 Hz, 1H), 7.84(m, 2H), 7.73(d, J=7.2 Hz, 1H), 7.45(m, 1H), 7.36(m, 1H), 6.90(m, 2H), 6.76(d, J=7.8 Hz, 1H), 6.61(br, 1H), 5.92(s, 2H), 4.90(s, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.83 (d, J = 4.1 Hz, 1H), 8.58 (d, J = 8.0 Hz, 1H), 8.08 (d, J = 8.3 Hz, 1H), 7.84 (m , 2H), 7.73 (d, J = 7.2 Hz, 1H), 7.45 (m, 1H), 7.36 (m, 1H), 6.90 (m, 2H), 6.76 (d, J = 7.8 Hz, 1H), 6.61 (br, 1H), 5.92 (s, 2H), 4.90 (s, 2H)

화합물번호 231. (3-플루오로-벤질)-(2-피리딘-2-일-퀴나졸린-4-일)-아민Compound number 231. (3-Fluoro-benzyl)-(2-pyridin-2-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.80(d, J=4.1 Hz, 1H), 8.49(d, J=8.1 Hz, 1H), 8.05(m, 2H), 7.83(m, 1H), 7.73(t, J=7.7 Hz, 1H), 7.47(m, 1H), 7.37(m, 1H), 7.28(m, 2H), 7.18(m, 1H), 6.94(m, 1H), 6.43(br, 1H), 5.00(s, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.80 (d, J = 4.1 Hz, 1H), 8.49 (d, J = 8.1 Hz, 1H), 8.05 (m, 2H), 7.83 (m, 1H), 7.73 (t, J = 7.7 Hz, 1H), 7.47 (m, 1H), 7.37 (m, 1H), 7.28 (m, 2H), 7.18 (m, 1H), 6.94 (m, 1H), 6.43 (br, 1H), 5.00 (s, 2H)

화합물번호 232. [2-(3-플루오로-페닐)-에틸]-(2-피리딘-2-일-퀴나졸린-4-일)-아민Compound number 232. [2- (3-Fluoro-phenyl) -ethyl]-(2-pyridin-2-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.83(d, J=4.1 Hz, 1H), 8.59(d, J=8.2 Hz, 1H), 8.07(d, J=8.3 Hz, 1H), 7.86(t, J=7.7 Hz, 1H), 7.73(m, 2H), 7.39(m, 2H), 7.25(m, 1H), 7.00(m, 3H), 6.45(br, 1H), 4.03(m, 2H), 3.08(t, J=6.6 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.83 (d, J = 4.1 Hz, 1H), 8.59 (d, J = 8.2 Hz, 1H), 8.07 (d, J = 8.3 Hz, 1H), 7.86 (t , J = 7.7 Hz, 1H), 7.73 (m, 2H), 7.39 (m, 2H), 7.25 (m, 1H), 7.00 (m, 3H), 6.45 (br, 1H), 4.03 (m, 2H) , 3.08 (t, J = 6.6 Hz, 2H)

화합물번호 233. 2-[2-(2-피리딘-2-일-퀴나졸린-4-일아미노)-에톡시]-에탄올Compound 233. 2- [2- (2-pyridin-2-yl-quinazolin-4-ylamino) -ethoxy] -ethanol

1H NMR(CDCl3, 300 MHz) δ 8.89(t, J=6.8 Hz, 2H), 8.46(d, J=8.0 Hz, 1H), 8.00(m, 2H), 7.58(d, J=7.5 Hz, 2H), 7.41(, J=7.2 Hzt, 1H), 6.63(br, 1H), 4.08(m, 4H), 8.83(m, 4H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.89 (t, J = 6.8 Hz, 2H), 8.46 (d, J = 8.0 Hz, 1H), 8.00 (m, 2H), 7.58 (d, J = 7.5 Hz , 2H), 7.41 (, J = 7.2 Hzt, 1H), 6.63 (br, 1H), 4.08 (m, 4H), 8.83 (m, 4H)

화합물번호 234. 2-(2-피리딘-2-일-퀴나졸린-4-일아미노)-에탄올Compound 234. 2- (2-Pyridin-2-yl-quinazolin-4-ylamino) -ethanol

1H NMR(CDCl3, 300 MHz) δ 8.80(d, J=4.6 Hz, 1H), 8.56(d, J=8.1 Hz, 1H), 8.01(d, J=8.3 Hz, 1H), 7.84(m, 2H), 7.74(t, J=7.7 Hz, 1H), 7.40(m, 1H), 7.36(m, 1H), 6.81(br, 1H), 3.97(m, 4H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.80 (d, J = 4.6 Hz, 1H), 8.56 (d, J = 8.1 Hz, 1H), 8.01 (d, J = 8.3 Hz, 1H), 7.84 (m , 2H), 7.74 (t, J = 7.7 Hz, 1H), 7.40 (m, 1H), 7.36 (m, 1H), 6.81 (br, 1H), 3.97 (m, 4H)

화합물번호 235. 벤질-(2-피리딘-3-일-퀴나졸린-4-일)-아민Compound number 235. Benzyl- (2-pyridin-3-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 9.72(s, 1H), 8.67(d, J=4.5 Hz, 1H), 8.54(m, 1H), 7.96(d, J=8.3 Hz, 1H), 7.79(m, 2H), 7.46-7.29(m, 6H), 6.52(br, 1H), 4.99(d, J=5.4 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 9.72 (s, 1H), 8.67 (d, J = 4.5 Hz, 1H), 8.54 (m, 1H), 7.96 (d, J = 8.3 Hz, 1H), 7.79 (m, 2H), 7.46-7.29 (m, 6H), 6.52 (br, 1H), 4.99 (d, J = 5.4 Hz, 2H)

화합물번호 236. (3-메톡시-벤질)-(2-피리딘-3-일-퀴나졸린-4-일)-아민Compound 236. (3-Methoxy-benzyl)-(2-pyridin-3-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 9.72(s, 1H), 8.86(d, J = 7.9 Hz, 1H), 8.68(d, J=3.8 Hz, 1H), 8.01(d, J=8.3 Hz, 1H), 7.85(d, J=8.1 Hz, 1H), 7.83(m, 1H), 7.43(m, 2H), 7.26(m, 1H), 7.01(t, J=5.9 Hz, 2H), 6.84(t, J=4.13 Hz, 1H), 6.68(br, 1H), 4.97(d, J=5.4 Hz, 2H), 3.77(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 9.72 (s, 1H), 8.86 (d, J = 7.9 Hz, 1H), 8.68 (d, J = 3.8 Hz, 1H), 8.01 (d, J = 8.3 Hz , 1H), 7.85 (d, J = 8.1 Hz, 1H), 7.83 (m, 1H), 7.43 (m, 2H), 7.26 (m, 1H), 7.01 (t, J = 5.9 Hz, 2H), 6.84 (t, J = 4.13 Hz, 1H), 6.68 (br, 1H), 4.97 (d, J = 5.4 Hz, 2H), 3.77 (s, 3H)

화합물번호 237. (4-메톡시-벤질)-(2-피리딘-3-일-퀴나졸린-4-일)-아민Compound 237. (4-Methoxy-benzyl)-(2-pyridin-3-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 9.74(s, 1H), 8.83(d, J=7.9 Hz, 1H), 8.66(d, J=3.6 Hz, 1H), 7.95(d, J=8.3 Hz, 1H), 7.75(m, 2H), 7.38(m, 4H), 6.87(d, J=8.8 Hz, 2H), 6.38(br, 1H), 4.90(d, J=5.4 Hz, 2H), 3.78(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 9.74 (s, 1H), 8.83 (d, J = 7.9 Hz, 1H), 8.66 (d, J = 3.6 Hz, 1H), 7.95 (d, J = 8.3 Hz , 1H), 7.75 (m, 2H), 7.38 (m, 4H), 6.87 (d, J = 8.8 Hz, 2H), 6.38 (br, 1H), 4.90 (d, J = 5.4 Hz, 2H), 3.78 (s, 3H)

화합물번호 238. (2-피리딘-3-일-퀴나졸린-4-일)-(3-트리플루오로메틸-벤질)-아민Compound 238. (2-Pyridin-3-yl-quinazolin-4-yl)-(3-trifluoromethyl-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 9.89(s, 1H), 8.74(m, 2H), 7.96(d, J=8.3 Hz, 1H), 7.78(m, 4H), 7.47(m, 4H), 6.39(br, 1H), 5.05(d, J=5.4 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 9.89 (s, 1H), 8.74 (m, 2H), 7.96 (d, J = 8.3 Hz, 1H), 7.78 (m, 4H), 7.47 (m, 4H) , 6.39 (br, 1 H), 5.05 (d, J = 5.4 Hz, 2 H)

화합물번호 239. 펜에틸-(2-피리딘-3-일-퀴나졸린-4-일)-아민Compound number 239. Phenethyl- (2-pyridin-3-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 9.77(s, 1H), 8.85(s, J=8.0 Hz, 1H), 7.95(d, J=8.5 Hz, 1H), 7.73(m, 1H), 7.41(m, 7H), 6.17(br, 1H), 4.05(m, 2H), 3.10(t, J=6.9 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 9.77 (s, 1H), 8.85 (s, J = 8.0 Hz, 1H), 7.95 (d, J = 8.5 Hz, 1H), 7.73 (m, 1H), 7.41 (m, 7H), 6.17 (br, 1H), 4.05 (m, 2H), 3.10 (t, J = 6.9 Hz, 2H)

화합물번호 240. (4-페닐-부틸)-(2-피리딘-3-일-퀴나졸린-4-일)-아민Compound number 240. (4-phenyl-butyl)-(2-pyridin-3-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 9.74(s, 1H), 8.82(d, J=8.0 Hz, 1H), 8.68(d, J=3.9 Hz, 1H), 7.95(d, J=8.1 Hz, 1H), 7.72(t, J=7.6 Hz, 2H), 7.41(m, 2H), 7.24(m, 5H), 6.12(br, 1H), 3.80(t, J=5.9 Hz, 2H), 2.71(t, J=6.7 Hz, 2H), 1.81(t, J=3.4 Hz, 4H) 1 H NMR (CDCl 3 , 300 MHz) δ 9.74 (s, 1H), 8.82 (d, J = 8.0 Hz, 1H), 8.68 (d, J = 3.9 Hz, 1H), 7.95 (d, J = 8.1 Hz , 1H), 7.72 (t, J = 7.6 Hz, 2H), 7.41 (m, 2H), 7.24 (m, 5H), 6.12 (br, 1H), 3.80 (t, J = 5.9 Hz, 2H), 2.71 (t, J = 6.7 Hz, 2H), 1.81 (t, J = 3.4 Hz, 4H)

화합물번호 241. 나프탈렌-1-일메틸-(2-피리딘-3-일-퀴나졸린-4-일)-아민Compound number 241. Naphthalen-1-ylmethyl- (2-pyridin-3-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz)) δ 9.82(s, 1H), 8.88(d, J=7.9 Hz, 1H), 8.69(m, 1H), 8.12(m, 1H), 7.92(m, 3H), 7.80(m, 1H), 7.61(m, 2H), 7.50(m, 5H), 6.05(br, 1H), 5.43(d, J=4.8 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 9.82 (s, 1H), 8.88 (d, J = 7.9 Hz, 1H), 8.69 (m, 1H), 8.12 (m, 1H), 7.92 (m, 3H ), 7.80 (m, 1H), 7.61 (m, 2H), 7.50 (m, 5H), 6.05 (br, 1H), 5.43 (d, J = 4.8 Hz, 2H)

화합물번호 242. 벤조[1,3]디옥솔-5-일메틸-(2-피리딘-3-일-퀴나졸린-4-일)-아민Compound 242. Benzo [1,3] dioxol-5-ylmethyl- (2-pyridin-3-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 9.72(s, 1H), 8.89(d, J=8.0 Hz, 1H), 8.69(d, J=4.5 Hz, 1H), 8.03(d, J=8.5 Hz, 1H), 7.86(d, J=8.1 Hz, 1H), 7.73(t, J=7.3 Hz, 1H), 7.43(t, J=6.5 Hz, 2H), 6.92(d, J=7.8 Hz, 2H), 7.77(d, J=7.7 Hz, 2H), 5.92(s, 2H), 4.90(d, J = 5.4 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 9.72 (s, 1H), 8.89 (d, J = 8.0 Hz, 1H), 8.69 (d, J = 4.5 Hz, 1H), 8.03 (d, J = 8.5 Hz , 1H), 7.86 (d, J = 8.1 Hz, 1H), 7.73 (t, J = 7.3 Hz, 1H), 7.43 (t, J = 6.5 Hz, 2H), 6.92 (d, J = 7.8 Hz, 2H ), 7.77 (d, J = 7.7 Hz, 2H), 5.92 (s, 2H), 4.90 (d, J = 5.4 Hz, 2H)

화합물번호 243. (3-플루오로-벤질)-(2-피리딘-3-일-퀴나졸린-4-일)-아민Compound number 243. (3-Fluoro-benzyl)-(2-pyridin-3-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 9.69(s, 1H), 8.81(d, J=8.0 Hz, 1H), 8.68(d, J=3.8 Hz, 1H), 8.00(d, J=8.3 Hz, 1H), 7.87(d, J=8.1 Hz, 1H), 7.75(m, 1H), 7.44(m, 2H), 7.29(m, 2H), 7.14(m, 1H), 6.96(m, 1H), 6.72(br, 1H), 5.00(d, J=5.6 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 9.69 (s, 1H), 8.81 (d, J = 8.0 Hz, 1H), 8.68 (d, J = 3.8 Hz, 1H), 8.00 (d, J = 8.3 Hz , 1H), 7.87 (d, J = 8.1 Hz, 1H), 7.75 (m, 1H), 7.44 (m, 2H), 7.29 (m, 2H), 7.14 (m, 1H), 6.96 (m, 1H) , 6.72 (br, 1 H), 5.00 (d, J = 5.6 Hz, 2H)

화합물번호 244. [2-(3-플루오로-페닐)-에틸]-(2-피리딘-3-일-퀴나졸린-4-일)-아민Compound 244. [2- (3-Fluoro-phenyl) -ethyl]-(2-pyridin-3-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 9.75(s, 1H), 8.86(d, J=8.0 Hz, 1H), 8.69(d, J=4. Hz, 1H), 7.97(d, J=8.4 Hz, 1H), 7.70(m, 2H), 7.43(m, 2H), 7.27(m, 2H), 6.99(m, 3H), 6.28(br, 1H), 4.05(m, 2H), 3.11(t, J=6.9 H, 2Hz) 1 H NMR (CDCl 3 , 300 MHz) δ 9.75 (s, 1H), 8.86 (d, J = 8.0 Hz, 1H), 8.69 (d, J = 4. Hz, 1H), 7.97 (d, J = 8.4 Hz, 1H), 7.70 (m, 2H), 7.43 (m, 2H), 7.27 (m, 2H), 6.99 (m, 3H), 6.28 (br, 1H), 4.05 (m, 2H), 3.11 (t , J = 6.9 H, 2 Hz)

화합물번호 245. 2-[2-(2-피리딘-3-일-퀴나졸린-4-일아미노)-에톡시]-에탄올Compound 245. 2- [2- (2-pyridin-3-yl-quinazolin-4-ylamino) -ethoxy] -ethanol

1H NMR(CDCl3, 300 MHz) δ 9.66(s, 1H), 8.73(d, J=7.2 Hz, 1H), 8.63(d, J=2.8 Hz, 1H), 7.86(d, J=8.3 H, 1Hz), 7.79(d, J=8.2 Hz, 1H), 7.65(m, 1H), 7.35(m, 2H), 6.81(br, 1H), 3.97(m, 2H), 3.83(m, 4H), 3.67(m, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 9.66 (s, 1H), 8.73 (d, J = 7.2 Hz, 1H), 8.63 (d, J = 2.8 Hz, 1H), 7.86 (d, J = 8.3 H , 1 Hz), 7.79 (d, J = 8.2 Hz, 1H), 7.65 (m, 1H), 7.35 (m, 2H), 6.81 (br, 1H), 3.97 (m, 2H), 3.83 (m, 4H) , 3.67 (m, 2 H)

화합물번호 246. 2-(2-피리딘-3-일-퀴나졸린-4-일아미노)-에탄올Compound 246. 2- (2-Pyridin-3-yl-quinazolin-4-ylamino) -ethanol

1H NMR(CDCl3, 300 MHz) δ 9.67(s, 1H), 8.76(d, J=8.03 Hz, 1H), 8.66(d, J=3.4 Hz, 1H), 7.94(t, J=7.7 Hz, 2H), 7.72(t, J=7.6 Hz, 1H), 7.42(m, 2H), 6.94(br, 1H), 4.00(m, 4H) 1 H NMR (CDCl 3 , 300 MHz) δ 9.67 (s, 1H), 8.76 (d, J = 8.03 Hz, 1H), 8.66 (d, J = 3.4 Hz, 1H), 7.94 (t, J = 7.7 Hz , 2H), 7.72 (t, J = 7.6 Hz, 1H), 7.42 (m, 2H), 6.94 (br, 1H), 4.00 (m, 4H)

화합물번호 247. 벤질-(2-피리딘-4-일-퀴나졸린-4-일)-아민Compound number 247. Benzyl- (2-pyridin-4-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.74(m, 2H),8.43(d, J=5.5 Hz, 2H), 7.98(d, J=8.3 Hz, 1H), 7.75(t, J=4.4 Hz, 2H), 7.48(m, 3H), 7.36(m, 3H), 6.21(br, 1H), 5.01(d, J=5.4 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.74 (m, 2H), 8.43 (d, J = 5.5 Hz, 2H), 7.98 (d, J = 8.3 Hz, 1H), 7.75 (t, J = 4.4 Hz , 2H), 7.48 (m, 3H), 7.36 (m, 3H), 6.21 (br, 1H), 5.01 (d, J = 5.4 Hz, 2H)

화합물번호 248. (3-메톡시-벤질)-(2-피리딘-4-일-퀴나졸린-4-일)-아민Compound 248. (3-Methoxy-benzyl)-(2-pyridin-4-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.73(d, J=5.0 Hz, 2H), 8.43(d, J=5.5 Hz, 2H), 9.98(d, J=8.2 Hz, 1H), 7.77(t, J=7.7 Hz, 2H), 7.49(d, J=7.2 Hz, 1H), 7.26(m, 2H), 6.84(m, 1H), 6.35(br, 1H), 4.98(d, J=5.3 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.73 (d, J = 5.0 Hz, 2H), 8.43 (d, J = 5.5 Hz, 2H), 9.98 (d, J = 8.2 Hz, 1H), 7.77 (t , J = 7.7 Hz, 2H), 7.49 (d, J = 7.2 Hz, 1H), 7.26 (m, 2H), 6.84 (m, 1H), 6.35 (br, 1H), 4.98 (d, J = 5.3 Hz , 2H)

화합물번호 249. (4-메톡시-벤질)-(2-피리딘-4-일-퀴나졸린-4-일)-아민Compound number 249. (4-Methoxy-benzyl)-(2-pyridin-4-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.74(d, J=5.5 Hz, 2H), 8.46(d, J=5.5 Hz, 2H), 7.98(d, J=8.2 Hz, 1H), 7.76(t, J=7.6 Hz, 2H), 7.47(t, J=7.6 Hz, 1H), 7.38(d, J=8.5 Hz, 2H), 6.90(d, J=8.5 Hz, 2H), 6.29(br, 1H), 4.93(d, J=5.4 Hz, 2H), 3.80(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.74 (d, J = 5.5 Hz, 2H), 8.46 (d, J = 5.5 Hz, 2H), 7.98 (d, J = 8.2 Hz, 1H), 7.76 (t , J = 7.6 Hz, 2H), 7.47 (t, J = 7.6 Hz, 1H), 7.38 (d, J = 8.5 Hz, 2H), 6.90 (d, J = 8.5 Hz, 2H), 6.29 (br, 1H) ), 4.93 (d, J = 5.4 Hz, 2H), 3.80 (s, 3H)

화합물번호 250. (2-피리딘-4-일-퀴나졸린-4-일)-(3-트리플루오로메틸-벤질)-아민Compound 250. (2-Pyridin-4-yl-quinazolin-4-yl)-(3-trifluoromethyl-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.72(m, 2H), 8.40(d, J=4.71 Hz, 2H), 8.02(d, J=8.3 Hz, 1H), 7.84(m, 2H), 7.75(m, 1H), 7.65(m, 1H), 7.52(m, 3H), 6.57(br, 1H), 5.02(d, J=5.3 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.72 (m, 2H), 8.40 (d, J = 4.71 Hz, 2H), 8.02 (d, J = 8.3 Hz, 1H), 7.84 (m, 2H), 7.75 (m, 1H), 7.65 (m, 1H), 7.52 (m, 3H), 6.57 (br, 1H), 5.02 (d, J = 5.3 Hz, 2H)

화합물번호 251. 펜에틸-(2-피리딘-4-일-퀴나졸린-4-일)-아민Compound 251.Phenethyl- (2-pyridin-4-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.74(d, J=5.5 Hz, 2H), 8.45(d, J=5.5 Hz, 2H), 7.96(d, J=8.3 Hz, 1H), 7.76(t, J=7.4 Hz, 1H), 7.67(dH, J=8.2 Hz, 1), 7.46(d, J=7.2 Hz, 1H), 7.33(m, 5H), 6.09(br, 1H), 4.06(m, 2H), 3.11(t, J=6.9 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.74 (d, J = 5.5 Hz, 2H), 8.45 (d, J = 5.5 Hz, 2H), 7.96 (d, J = 8.3 Hz, 1H), 7.76 (t , J = 7.4 Hz, 1H), 7.67 (dH, J = 8.2 Hz, 1), 7.46 (d, J = 7.2 Hz, 1H), 7.33 (m, 5H), 6.09 (br, 1H), 4.06 (m , 2H), 3.11 (t, J = 6.9 Hz, 2H)

화합물번호 252. (4-페닐-부틸)-(2-피리딘-4-일-퀴나졸린-4-일)-아민Compound 252. (4-phenyl-butyl)-(2-pyridin-4-yl-quinazolin-4-yl) -amine

1H NMR(300MHz, CDCl3, 300 MHz) δ 8.76(d, J=5.4 Hz, 2H), 8.42(d, J=5.5 Hz, 2H), 7.97(d, J=8.3 Hz, 1H), 7.75(t, J=7.5 Hz, 2H), 7.47(t, J=7.5 Hz, 1H), 7.25(m, 6H), 6.10(br, 1H), 3.82(d, J=5.6 Hz, 2H), 2.73(t, J=6.6 Hz, 2H), 1.84(m, 4H) 1 H NMR (300 MHz, CDCl 3, 300 MHz) δ 8.76 (d, J = 5.4 Hz, 2H), 8.42 (d, J = 5.5 Hz, 2H), 7.97 (d, J = 8.3 Hz, 1H), 7.75 ( t, J = 7.5 Hz, 2H), 7.47 (t, J = 7.5 Hz, 1H), 7.25 (m, 6H), 6.10 (br, 1H), 3.82 (d, J = 5.6 Hz, 2H), 2.73 ( t, J = 6.6 Hz, 2H), 1.84 (m, 4H)

화합물번호 253. 나프탈렌-1-일메틸-(2-피리딘-4-일-퀴나졸린-4-일)-아민Compound number 253. Naphthalen-1-ylmethyl- (2-pyridin-4-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.76(d, J=5.4 Hz, 2H), 8.46(d, J=5.3 Hz, 2H), 8.12(d, J=8.4 Hz, 1H), 7.95(m, 3H), 7.77(m, 1H), 7.62(t, J=5.8 Hz, 2H), 7.50(m, 4H), 5.99(br, 1H), 5.44(d, J=4.9 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.76 (d, J = 5.4 Hz, 2H), 8.46 (d, J = 5.3 Hz, 2H), 8.12 (d, J = 8.4 Hz, 1H), 7.95 (m) , 3H), 7.77 (m, 1H), 7.62 (t, J = 5.8 Hz, 2H), 7.50 (m, 4H), 5.99 (br, 1H), 5.44 (d, J = 4.9 Hz, 2H)

화합물번호 254. 벤조[1,3]디옥솔-5-일메틸-(2-피리딘-4-일-퀴나졸린-4-일)-아민Compound 254. Benzo [1,3] dioxol-5-ylmethyl- (2-pyridin-4-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.74(d, J=5.4 Hz, 2H), 8.40(d, J=6.06 Hz, 2H), 7.96(d, J=8.4 Hz, 1H), 7.76(m, 2H), 7.48(t, J=7.6 Hz, 1H), 6.92(d, J=7.97 Hz, 2H), 6.80(d, J=7.7 Hz, 1H), 6.07(br, 1H), 5.96(s, 2H), 4.91(d, J=5.3 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.74 (d, J = 5.4 Hz, 2H), 8.40 (d, J = 6.06 Hz, 2H), 7.96 (d, J = 8.4 Hz, 1H), 7.76 (m , 2H), 7.48 (t, J = 7.6 Hz, 1H), 6.92 (d, J = 7.97 Hz, 2H), 6.80 (d, J = 7.7 Hz, 1H), 6.07 (br, 1H), 5.96 (s , 2H), 4.91 (d, J = 5.3 Hz, 2H)

화합물번호 255. (3-플루오로-벤질)-(2-피리딘-4-일-퀴나졸린-4-일)-아민Compound 255. (3-Fluoro-benzyl)-(2-pyridin-4-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.74(d, J=5.4 Hz, 2H), 8.38(d, J=5.1 Hz, 2H), 7.98(d, J=8.4 H, 1Hz), 7.79(t, J=7.8 Hz, 2H), 7.51(t, J=3.9 Hz, 1H), 7.35(t, J=3.9 Hz, 1H), 7.25(m, 1H), 7.17(m, 1H), 7.01(m, 1H), 6.24(br, 1H), 5.01(d, J=5.5 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.74 (d, J = 5.4 Hz, 2H), 8.38 (d, J = 5.1 Hz, 2H), 7.98 (d, J = 8.4 H, 1 Hz), 7.79 (t , J = 7.8 Hz, 2H), 7.51 (t, J = 3.9 Hz, 1H), 7.35 (t, J = 3.9 Hz, 1H), 7.25 (m, 1H), 7.17 (m, 1H), 7.01 (m , 1H), 6.24 (br, 1H), 5.01 (d, J = 5.5 Hz, 2H)

화합물번호 256. [2-(3-플루오로-페닐)-에틸]-(2-피리딘-4-일-퀴나졸린-4-일)-아민Compound No. 256. [2- (3-Fluoro-phenyl) -ethyl]-(2-pyridin-4-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.76(d, J=5.5 Hz, 2H), 8.44(d, J=5.3 Hz, 2H), 7.98(d, J=8.4 Hz, 1H), 7.67(d, J=8.0 Hz, 1H), 7.48(d, J=7.3 Hz, 1H), 7.28(m, 1H), 7.03(m, 3H), 6.14(br, 1H), 4.05(m, 2H), 3.11(t, J=6.9 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.76 (d, J = 5.5 Hz, 2H), 8.44 (d, J = 5.3 Hz, 2H), 7.98 (d, J = 8.4 Hz, 1H), 7.67 (d , J = 8.0 Hz, 1H), 7.48 (d, J = 7.3 Hz, 1H), 7.28 (m, 1H), 7.03 (m, 3H), 6.14 (br, 1H), 4.05 (m, 2H), 3.11 (t, J = 6.9 Hz, 2H)

화합물번호 257. 2-[2-(2-피리딘-4-일-퀴나졸린-4-일아미노)-에톡시]-에탄올Compound number 257. 2- [2- (2-pyridin-4-yl-quinazolin-4-ylamino) -ethoxy] -ethanol

1H NMR(CDCl3, 300 MHz) δ 8.72(d, J=4.8 Hz, 2H), 8.36(d, J=5.8 Hz, 2H), 7.92(d, J=8.3 Hz, 1H), 7.83(d, J=8.2 Hz, 1H), 7.73(t, J=7.6 Hz, 1H), 7.45(t, J=7.6 Hz, 1H), 6.64(br, 1H), 4.02(m, 2H), 3.81(m, 4H), 3.69(m, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.72 (d, J = 4.8 Hz, 2H), 8.36 (d, J = 5.8 Hz, 2H), 7.92 (d, J = 8.3 Hz, 1H), 7.83 (d , J = 8.2 Hz, 1H), 7.73 (t, J = 7.6 Hz, 1H), 7.45 (t, J = 7.6 Hz, 1H), 6.64 (br, 1H), 4.02 (m, 2H), 3.81 (m) , 4H), 3.69 (m, 2H)

화합물번호 258. 2-(2-피리딘-4-일-퀴나졸린-4-일아미노)-에탄올Compound number 258. 2- (2-Pyridin-4-yl-quinazolin-4-ylamino) -ethanol

1H NMR(CDCl3, 300 MHz) δ 8.71(d, J=4.8 Hz, 2H), 8.35(d, J=5.5 Hz, 2H), 8.13(d, J=8.4 Hz, 1H), 7.90(d, J=8.2 Hz, 1H), 7.73(t, J=8.3 Hz, 1H), 7.47(t, J=7.6 Hz, 1H), 7.18(br, 1H), 3.99(m, 4H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.71 (d, J = 4.8 Hz, 2H), 8.35 (d, J = 5.5 Hz, 2H), 8.13 (d, J = 8.4 Hz, 1H), 7.90 (d , J = 8.2 Hz, 1H), 7.73 (t, J = 8.3 Hz, 1H), 7.47 (t, J = 7.6 Hz, 1H), 7.18 (br, 1H), 3.99 (m, 4H)

화합물번호 259. 벤질-[2-(4-클로로-페닐)-퀴나졸린-4-일]-아민Compound number 259. Benzyl- [2- (4-chloro-phenyl) -quinazolin-4-yl] -amine

1H NMR(CDCl3, 300 MHz) δ 8.52(d, J=8.6 Hz, 2H), 7.92(d, J=8.2 Hz, 1H), 7.71(m, 2H), 7.40(m, 8H), 5.97(br, 1H), 5.00(d, J=5.5 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.52 (d, J = 8.6 Hz, 2H), 7.92 (d, J = 8.2 Hz, 1H), 7.71 (m, 2H), 7.40 (m, 8H), 5.97 (br, 1H), 5.00 (d, J = 5.5 Hz, 2H)

화합물번호 260. [2-(4-클로로-페닐)-퀴나졸린-4-일]-(3-메톡시-벤질)-아민Compound 260. [2- (4-Chloro-phenyl) -quinazolin-4-yl]-(3-methoxy-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.52(d, J=8.5 Hz, 2H), 7.92(d, J=8.3 Hz, 1H), 7.72(m, 2H), 7.42(m, 3H), 7.28(m, 1H), 7.03(d, J=8.0 Hz, 2H), 6.87(t, J=4.2 Hz, 1H), 5.98(br, 1H), 4.98(d, J=5.5 Hz, 2H), 3.78(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.52 (d, J = 8.5 Hz, 2H), 7.92 (d, J = 8.3 Hz, 1H), 7.72 (m, 2H), 7.42 (m, 3H), 7.28 (m, 1H), 7.03 (d, J = 8.0 Hz, 2H), 6.87 (t, J = 4.2 Hz, 1H), 5.98 (br, 1H), 4.98 (d, J = 5.5 Hz, 2H), 3.78 (s, 3H)

화합물번호 261. [2-(4-클로로-페닐)-퀴나졸린-4-일]-(4-메톡시-벤질)-아민Compound number 261. [2- (4-Chloro-phenyl) -quinazolin-4-yl]-(4-methoxy-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.53(d, J=8.5 Hz, 2H), 7.96(d, J=8.55 Hz, 1H), 7.72(m, 2H), 7.38(m, 5H), 6.90(d, J=8.6 Hz, 2H), 4.92(d, J=5.3 Hz, 2H), 3.80(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.53 (d, J = 8.5 Hz, 2H), 7.96 (d, J = 8.55 Hz, 1H), 7.72 (m, 2H), 7.38 (m, 5H), 6.90 (d, J = 8.6 Hz, 2H), 4.92 (d, J = 5.3 Hz, 2H), 3.80 (s, 3H)

화합물번호 262. [2-(4-클로로-페닐)-퀴나졸린-4-일]-(3-트리플루오로메틸-벤질)-아민Compound 262. [2- (4-Chloro-phenyl) -quinazolin-4-yl]-(3-trifluoromethyl-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.45(d, J=8.6 Hz, 2H), 7.95(d,, J=8.5 Hz 1H), 7.75(m, 3H), 7.65(d, J=7.7 Hz, 1H), 7.56(d, J=7.7 Hz, 1H), 7.45(m, 4H), 6.12(br, 1H), 5.05(d, J=5.5 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.45 (d, J = 8.6 Hz, 2H), 7.95 (d, J = 8.5 Hz 1H), 7.75 (m, 3H), 7.65 (d, J = 7.7 Hz , 1H), 7.56 (d, J = 7.7 Hz, 1H), 7.45 (m, 4H), 6.12 (br, 1H), 5.05 (d, J = 5.5 Hz, 2H)

화합물번호 263. [2-(4-클로로-페닐)-퀴나졸린-4-일]-펜에틸-아민Compound 263. [2- (4-Chloro-phenyl) -quinazolin-4-yl] -phenethyl-amine

1H NMR(CDCl3, 300 MHz) δ 8.54(d, J=8.4 Hz, 2H), 7.94(d, J=8.5 Hz, 1H), 7.70(t, J=7.5 Hz, 1H), 7.60(d, J=8.1 Hz, 1H), 7.46(d, J=8.6 Hz, 2H), 7.35(m, 6H), 6.04(br, 1H), 4.05(m, 2H), 3.10(t, J=7.0 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.54 (d, J = 8.4 Hz, 2H), 7.94 (d, J = 8.5 Hz, 1H), 7.70 (t, J = 7.5 Hz, 1H), 7.60 (d , J = 8.1 Hz, 1H), 7.46 (d, J = 8.6 Hz, 2H), 7.35 (m, 6H), 6.04 (br, 1H), 4.05 (m, 2H), 3.10 (t, J = 7.0 Hz , 2H)

화합물번호 264. [2-(4-클로로-페닐)-퀴나졸린-4-일]-(4-페닐-부틸)-아민Compound number 264. [2- (4-Chloro-phenyl) -quinazolin-4-yl]-(4-phenyl-butyl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.50(d, J=8.5 Hz, 2H), 7.93(d, J=8.6 Hz, 1H), 7.70(m, 2H), 7.41(m, 3H), 7.25(m, 5H), 6.09(br, 1H), 3.80(d, J=5.5 Hz, 2H), 2.72(m, 2H), 1.82(m, 4H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.50 (d, J = 8.5 Hz, 2H), 7.93 (d, J = 8.6 Hz, 1H), 7.70 (m, 2H), 7.41 (m, 3H), 7.25 (m, 5H), 6.09 (br, 1H), 3.80 (d, J = 5.5 Hz, 2H), 2.72 (m, 2H), 1.82 (m, 4H)

화합물번호 265. [2-(4-클로로-페닐)-퀴나졸린-4-일]-나프탈렌-1-일메틸-아민Compound 265. [2- (4-Chloro-phenyl) -quinazolin-4-yl] -naphthalen-1-ylmethyl-amine

1H NMR(CDCl3, 300 MHz) δ 8.58(d, J=8.5 Hz, 2H), 8.17(m, 1H), 7.91(m, 3H), 7.63(m, 1H), 7.51(m, 7H), 7.36(m, 1H), 5.87(br, 1H), 5.42(d, J=4.8 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.58 (d, J = 8.5 Hz, 2H), 8.17 (m, 1H), 7.91 (m, 3H), 7.63 (m, 1H), 7.51 (m, 7H) , 7.36 (m, 1H), 5.87 (br, 1H), 5.42 (d, J = 4.8 Hz, 2H)

화합물번호 266. 벤조[1,3]디옥솔-5-일메틸-[2-(4-클로로-페닐)-퀴나졸린-4-일]-아민Compound No. 266. Benzo [1,3] dioxol-5-ylmethyl- [2- (4-chloro-phenyl) -quinazolin-4-yl] -amine

1H NMR(CDCl3, 300 MHz) δ 8.52(d, J=8.6 Hz, 2H), 7.92(d, J=8.3 Hz, 1H), 7.71(m, 2H), 7.43(m, 3H), 6.93(d, J=11.4 Hz, 2H), 6.80(d, J=10.2 Hz, 1H), 5.95(s, 2H), 5.94(br, 1H), 4.89(d, J=4.9 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.52 (d, J = 8.6 Hz, 2H), 7.92 (d, J = 8.3 Hz, 1H), 7.71 (m, 2H), 7.43 (m, 3H), 6.93 (d, J = 11.4 Hz, 2H), 6.80 (d, J = 10.2 Hz, 1H), 5.95 (s, 2H), 5.94 (br, 1H), 4.89 (d, J = 4.9 Hz, 2H)

화합물번호 267. [2-(4-클로로-페닐)-퀴나졸린-4-일]-(3-플루오로-벤질)-아민Compound number 267. [2- (4-Chloro-phenyl) -quinazolin-4-yl]-(3-fluoro-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.48(d, J=8.5 Hz, 2H), 7.92(d, J=8.5 Hz, 1H), 7.74(m, 2H, 7.77(m, 3H), 7.23(m, 3H), 7.00(m, 1H), 6.07(br, 1H), 4.98(d, J=5.5 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.48 (d, J = 8.5 Hz, 2H), 7.92 (d, J = 8.5 Hz, 1H), 7.74 (m, 2H, 7.77 (m, 3H), 7.23 ( m, 3H), 7.00 (m, 1H), 6.07 (br, 1H), 4.98 (d, J = 5.5 Hz, 2H)

화합물번호 268. [2-(4-클로로-페닐)-퀴나졸린-4-일]-[2-(3-플루오로-페닐)-에틸]-아민Compound 268. [2- (4-Chloro-phenyl) -quinazolin-4-yl]-[2- (3-fluoro-phenyl) -ethyl] -amine

1H NMR(CDCl3, 300 MHz) δ 8.52(d, J=8.6 Hz, 2H), 7.94(d, J=8.6 Hz, 1H), 7.72(d, J=7.2 Hz, 1H), 7.63(d, J=8.1 Hz, 1H), 7.43(m, 3H), 7.28(m, 1H), 7.02(m, 3H), 6.08(br, 1H), 4.03(m, 2H), 3.10(t, J=7.0 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.52 (d, J = 8.6 Hz, 2H), 7.94 (d, J = 8.6 Hz, 1H), 7.72 (d, J = 7.2 Hz, 1H), 7.63 (d , J = 8.1 Hz, 1H), 7.43 (m, 3H), 7.28 (m, 1H), 7.02 (m, 3H), 6.08 (br, 1H), 4.03 (m, 2H), 3.10 (t, J = 7.0 Hz, 2H)

화합물번호 269. 2-{2-[2-(4-클로로-페닐)-퀴나졸린-4-일아미노]-에톡시}-에탄올Compound number 269. 2- {2- [2- (4-Chloro-phenyl) -quinazolin-4-ylamino] -ethoxy} -ethanol

1H NMR(CDCl3, 300 MHz) δ 8.47(d, J=8.4 Hz, 2H), 7.90(d, J=8.3 Hz, 1H), 7.72(m, 2H), 7.41(m, 3H), 6.52(br, 1H), 4.00(m, 2H), 3.81(m, 4H), 3.67(m, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.47 (d, J = 8.4 Hz, 2H), 7.90 (d, J = 8.3 Hz, 1H), 7.72 (m, 2H), 7.41 (m, 3H), 6.52 (br, 1H), 4.00 (m, 2H), 3.81 (m, 4H), 3.67 (m, 2H)

화합물번호 270. 2-[2-(4-클로로-페닐)-퀴나졸린-4-일아미노]-에탄올Compound 270. 2- [2- (4-Chloro-phenyl) -quinazolin-4-ylamino] -ethanol

1H NMR(CDCl3, 300 MHz) δ 8.46(d, J=8.5 Hz, 2H), 7.90(d, J=8.4 Hz, 1H), 7.75(m, 2H), 7.46(m, 3H), 6.21(br, 1H), 3.00(m, 4H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.46 (d, J = 8.5 Hz, 2H), 7.90 (d, J = 8.4 Hz, 1H), 7.75 (m, 2H), 7.46 (m, 3H), 6.21 (br, 1H), 3.00 (m, 4H)

화합물번호 271. (2,4-디메톡시-벤질)-(2-이소프로필-퀴나졸린-4-일)-아민Compound 271. (2,4-Dimethoxy-benzyl)-(2-isopropyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.83(d, J=8.1 Hz, 1H), 7.68-7.60(m, 2H), 7.38-7.33(m, 2H), 6.50-6.42(m, 2H), 6.24(br, 1H), 4.83(d, J=5.7 Hz, 2H), 3.88(s, 3H), 3.80(s, 3H), 3.17(m, 1H), 1.40(d, J=6.9 Hz, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.83 (d, J = 8.1 Hz, 1H), 7.68-7.60 (m, 2H), 7.38-7.33 (m, 2H), 6.50-6.42 (m, 2H), 6.24 (br, 1H), 4.83 (d, J = 5.7 Hz, 2H), 3.88 (s, 3H), 3.80 (s, 3H), 3.17 (m, 1H), 1.40 (d, J = 6.9 Hz, 6H )

화합물번호 272. (2-벤질-퀴나졸린-4-일)-(2,4-디메톡시-벤질)-아민Compound number 272. (2-benzyl-quinazolin-4-yl)-(2,4-dimethoxy-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.77(d, J=8.4 Hz, 1H), 7.64(t, J=7.7Hz, 1H), 7.56(d, J=8.1 Hz, 1H), 7.48(d, J=6.9 Hz, 2H), 7.30(m, 4H), 7.09(d, J=8.4 Hz, 1H), 6.45(d, J=2.4Hz, 1H), 6.32(dd, J 1 =8.4 Hz, J 2 =2.4Hz, 1H), 6.17(br, 1H), 4.73(d, J=6.0 Hz, 2H), 4.20(s, 2H), 3.85(s, 3H), 3.78(s, 3H) 1 H NMR (CDCl 3, 300 MHz) δ 7.77 (d, J = 8.4 Hz, 1H), 7.64 (t, J = 7.7 Hz, 1H), 7.56 (d, J = 8.1 Hz, 1H), 7.48 (d , J = 6.9 Hz, 2H), 7.30 (m, 4H), 7.09 (d, J = 8.4 Hz, 1H), 6.45 (d, J = 2.4 Hz, 1H), 6.32 (dd, J 1 = 8.4 Hz, J 2 = 2.4 Hz, 1H), 6.17 (br, 1H), 4.73 (d, J = 6.0 Hz, 2H), 4.20 (s, 2H), 3.85 (s, 3H), 3.78 (s, 3H)

화합물번호 273. 4-(2,4-디메톡시-벤질옥시)-2-페닐-퀴나졸린Compound number 273. 4- (2,4-Dimethoxy-benzyloxy) -2-phenyl-quinazoline

1H NMR(CDCl3, 300 MHz) δ 8.63(m, 2H), 8.17(d, 1H, J=7.8 Hz), 7.98(d, J=8.1 Hz, 1H), 7.79(m, 1H), 7.53(m, 5H), 6.53(m, 2H), 5.75(s, 2H), 3.87(s, 3H), 3.83(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.63 (m, 2H), 8.17 (d, 1H, J = 7.8 Hz), 7.98 (d, J = 8.1 Hz, 1H), 7.79 (m, 1H), 7.53 (m, 5H), 6.53 (m, 2H), 5.75 (s, 2H), 3.87 (s, 3H), 3.83 (s, 3H)

화합물번호 274. 4-(2,4-디메톡시-벤질설파닐)-2-페닐-퀴나졸린Compound 274. 4- (2,4-Dimethoxy-benzylsulfanyl) -2-phenyl-quinazoline

1H NMR(CDCl3, 300 MHz) δ 8.68(dd, J 1 =7.5 Hz, J 2 =2.1Hz, 2H), 8.05(d, J=8.4Hz, 1H), 7.98(d, J=8.4 Hz, 1H), 7.80(t, J=7.5 Hz, 1H), 7.45(m, 5H), 6.50(d, J=2.4 Hz, 1H), 6.41(dd, J 1 =8.4 Hz, J 2 =2.3Hz, 1H), 4.80(s, 2H), 3.88(s, 3H), 3.78(s, 3H) 1 H NMR (CDCl 3, 300 MHz) δ 8.68 (dd, J 1 = 7.5 Hz, J 2 = 2.1 Hz, 2H), 8.05 (d, J = 8.4 Hz, 1H), 7.98 (d, J = 8.4 Hz , 1H), 7.80 (t, J = 7.5 Hz, 1H), 7.45 (m, 5H), 6.50 (d, J = 2.4 Hz, 1H), 6.41 (dd, J 1 = 8.4 Hz, J 2 = 2.3 Hz , 1H), 4.80 (s, 2H), 3.88 (s, 3H), 3.78 (s, 3H)

화합물번호 275. (2-메톡시-벤질)-(2-피롤리딘-1-일-퀴나졸린-4-일)-아민Compound 275. (2-Methoxy-benzyl)-(2-pyrrolidin-1-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.48-7.38(m, 4H), 7.26(m, 1H), 6.99(m, 1H), 6.92(m, 2H), 6.02(br, 1H), 4.82(d, J=5.7 Hz, 2H), 3.91(s, 3H), 3.70(t, J=6.6 Hz, 4H), 1.98(m, 4H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.48-7.38 (m, 4H), 7.26 (m, 1H), 6.99 (m, 1H), 6.92 (m, 2H), 6.02 (br, 1H), 4.82 ( d, J = 5.7 Hz, 2H), 3.91 (s, 3H), 3.70 (t, J = 6.6 Hz, 4H), 1.98 (m, 4H)

화합물번호 276. (2-메톡시-벤질)-(2-피페리딘-1-일-퀴나졸린-4-일)-아민Compound 276. (2-Methoxy-benzyl)-(2-piperidin-1-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.50-7.46(m, 4H), 7.30-7.26(m, 1H), 7.00(t, J=7.5 Hz, 1H), 6.92(m, 2H), 5.96(br, 1H), 4.80(d, J=5.4 Hz, 2H), 3.91(s, 7H), 1.62(m, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.50-7.46 (m, 4H), 7.30-7.26 (m, 1H), 7.00 (t, J = 7.5 Hz, 1H), 6.92 (m, 2H), 5.96 ( br, 1H), 4.80 (d, J = 5.4 Hz, 2H), 3.91 (s, 7H), 1.62 (m, 6H)

화합물번호 277. (2-메톡시-벤질)-(2-몰포린-4-일-퀴나졸린-4-일)-아민Compound number 277. (2-Methoxy-benzyl)-(2-morpholin-4-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.53-7.44(m, 3H), 7.36-7.26(m, 2H), 7.06(td, J 1 =6.6 Hz, J 2 =1.5 Hz, 1H), 6.93(m, 2H), 6.04(br, 1H), 4.80(d, J=5.7 Hz, 2H), 3.90(m, 7H), 3.79(m, 4H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.53-7.44 (m, 3H), 7.36-7.26 (m, 2H), 7.06 (td, J 1 = 6.6 Hz, J 2 = 1.5 Hz, 1H), 6.93 ( m, 2H), 6.04 (br, 1H), 4.80 (d, J = 5.7 Hz, 2H), 3.90 (m, 7H), 3.79 (m, 4H)

화합물번호 278. (2-메톡시-벤질)-[2-(4-메틸-피페라진-1-일)-퀴나졸린-4-일]-아민Compound number 278. (2-Methoxy-benzyl)-[2- (4-methyl-piperazin-1-yl) -quinazolin-4-yl] -amine

1H NMR(CDCl3, 300 MHz) δ 7.52-7.43(m, 3H), 7.36(d, J=7.5 Hz, 1H), 7.28(m, 1H), 7.04(t, J=8.1 Hz, 1H), 6.93(m, 2H), 6.01(br, 1H), 4.80(d, J=5.4 Hz, 2H), 3.97(t, J=4.8 Hz, 4H), 3.91(s, 3H), 2.50(t, J=4.8 Hz, 4H), 2.35(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.52-7.43 (m, 3H), 7.36 (d, J = 7.5 Hz, 1H), 7.28 (m, 1H), 7.04 (t, J = 8.1 Hz, 1H) , 6.93 (m, 2H), 6.01 (br, 1H), 4.80 (d, J = 5.4 Hz, 2H), 3.97 (t, J = 4.8 Hz, 4H), 3.91 (s, 3H), 2.50 (t, J = 4.8 Hz, 4H), 2.35 (s, 3H)

화합물번호 279. (3-메톡시-벤질)-(2-피롤리딘-1-일-퀴나졸린-4-일)-아민Compound number 279. (3-Methoxy-benzyl)-(2-pyrrolidin-1-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.50-7.44(m, 3H), 7.27(m, 1H), 7.03-6.96(m, 3H), 6.83(dd, J 1 =8.4 Hz, J 2 =2.4 Hz, 1H), 5.73(br, 1H), 4.80(d, J=5.1 Hz, 2H), 3.80(s, 3H), 3.67(t, J=6.6 Hz, 4H), 1.96(m, 4H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.50-7.44 (m, 3H), 7.27 (m, 1H), 7.03-6.96 (m, 3H), 6.83 (dd, J 1 = 8.4 Hz, J 2 = 2.4 Hz, 1H), 5.73 (br, 1H), 4.80 (d, J = 5.1 Hz, 2H), 3.80 (s, 3H), 3.67 (t, J = 6.6 Hz, 4H), 1.96 (m, 4H)

화합물번호 280. (3-메톡시-벤질)-(2-피페리딘-1-일-퀴나졸린-4-일)-아민Compound 280. (3-methoxy-benzyl)-(2-piperidin-1-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.52-7.43(m, 3H), 7.27(m, 1H), 7.04-6.96(m, 1H), 6.84(dd, J 1 =8.1 Hz, J 2 =2.1 Hz, 1H), 5.69(br, 1H), 4.77(d, J=5.4 Hz, 2H), 3.87(m, 4H), 3.80(s, 3H), 1.62(m, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.52-7.43 (m, 3H), 7.27 (m, 1H), 7.04-6.96 (m, 1H), 6.84 (dd, J 1 = 8.1 Hz, J 2 = 2.1 Hz, 1H), 5.69 (br, 1H), 4.77 (d, J = 5.4 Hz, 2H), 3.87 (m, 4H), 3.80 (s, 3H), 1.62 (m, 6H)

화합물번호 281. (3-메톡시-벤질)-(2-몰포린-4-일-퀴나졸린-4-일)-아민Compound number 281. (3-methoxy-benzyl)-(2-morpholin-4-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.57-7.47(m, 3H), 7.28(m, 1H), 7.08(t, J=7.8 Hz, 1H), 7.00-6.94(m, 2H), 6.85(dd, J 1 =8.4 Hz, J 2 =2.4 Hz, 1H), 5.76(br, 1H), 4.77(d, J=5.4 Hz, 2H), 3.89(m, 4H), 3.80-3.75(m, 7H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.57-7.47 (m, 3H), 7.28 (m, 1H), 7.08 (t, J = 7.8 Hz, 1H), 7.00-6.94 (m, 2H), 6.85 ( dd, J 1 = 8.4 Hz, J 2 = 2.4 Hz, 1H), 5.76 (br, 1H), 4.77 (d, J = 5.4 Hz, 2H), 3.89 (m, 4H), 3.80-3.75 (m, 7H )

화합물번호 282. (3-메톡시-벤질)-[2-(4-메틸-피페라진-1-일)-퀴나졸린-4-일]-아민Compound number 282. (3-Methoxy-benzyl)-[2- (4-methyl-piperazin-1-yl) -quinazolin-4-yl] -amine

1H NMR(CDCl3, 300 MHz) δ 7.54-7.45(m, 3H), 7.27(m, 1H), 7.05(m, 1H), 6.97(m, 2H), 6.84(dd, J 1 =8.4 Hz, J 2 =2.1 Hz, 1H), 5.74(br, 1H), 4.77(d, J=5.4 Hz, 2H), 3.93(t, J=4.8 Hz, 4H), 3.80(s, 3H), 2.47(t, J=4.8 Hz, 4H), 2.34(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.54-7.45 (m, 3H), 7.27 (m, 1H), 7.05 (m, 1H), 6.97 (m, 2H), 6.84 (dd, J 1 = 8.4 Hz , J 2 = 2.1 Hz, 1H), 5.74 (br, 1H), 4.77 (d, J = 5.4 Hz, 2H), 3.93 (t, J = 4.8 Hz, 4H), 3.80 (s, 3H), 2.47 ( t, J = 4.8 Hz, 4H), 2.34 (s, 3H)

화합물번호 283. (4-메톡시-벤질)-(2-피롤리딘-1-일-퀴나졸린-4-일)-아민Compound number 283. (4-Methoxy-benzyl)-(2-pyrrolidin-1-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.49(d, J=3.6 Hz, 2H), 7.44(d, J=8.1 Hz, 1H), 7.33(d, J=8.7 Hz, 2H), 6.99(m, 1H), 6.88(d, J=8.7 Hz, 2H), 5.68(br, 1H), 4.75(d, J=5.4 Hz, 2H), 3.81(s, 3H), 3.68(t, J=6.9 Hz, 4H), 1.96(m, 4H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.49 (d, J = 3.6 Hz, 2H), 7.44 (d, J = 8.1 Hz, 1H), 7.33 (d, J = 8.7 Hz, 2H), 6.99 (m , 1H), 6.88 (d, J = 8.7 Hz, 2H), 5.68 (br, 1H), 4.75 (d, J = 5.4 Hz, 2H), 3.81 (s, 3H), 3.68 (t, J = 6.9 Hz , 4H), 1.96 (m, 4H)

화합물번호 284. (4-메톡시-벤질)-(2-피페리딘-1-일-퀴나졸린-4-일)-아민Compound number 284. (4-Methoxy-benzyl)-(2-piperidin-1-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.51-7.41(m, 3H), 7.33(d, J=8.7 Hz, 2H), 7.00(m, 1H), 6.89(d, J=8.4 Hz, 2H), 5.62(br, 1H), 4.73(d, J=5.4 Hz, 2H), 3.88(m, 4H), 3.81(s, 3H), 1.27(m, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.51-7.41 (m, 3H), 7.33 (d, J = 8.7 Hz, 2H), 7.00 (m, 1H), 6.89 (d, J = 8.4 Hz, 2H) , 5.62 (br, 1H), 4.73 (d, J = 5.4 Hz, 2H), 3.88 (m, 4H), 3.81 (s, 3H), 1.27 (m, 6H)

화합물번호 285. (4-메톡시-벤질)-(2-몰포린-4-일-퀴나졸린-4-일)-아민Compound number 285. (4-Methoxy-benzyl)-(2-morpholin-4-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.53-7.44(m, 3H), 7.32(d, J=8.7 Hz, 2H), 7.06(m, 1H), 6.89(d, J=8.7 Hz, 2H), 5.69(br, 1H), 4.72(d, J=5.1 Hz, 2H), 3.88(m, 4H), 3.81(s, 3H), 3.77(m, 4H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.53-7.44 (m, 3H), 7.32 (d, J = 8.7 Hz, 2H), 7.06 (m, 1H), 6.89 (d, J = 8.7 Hz, 2H) , 5.69 (br, 1H), 4.72 (d, J = 5.1 Hz, 2H), 3.88 (m, 4H), 3.81 (s, 3H), 3.77 (m, 4H)

화합물번호 286. (4-메톡시-벤질)-[2-(4-메틸-피페라진-1-일)-퀴나졸린-4-일]-아민Compound No. 286. (4-methoxy-benzyl)-[2- (4-methyl-piperazin-1-yl) -quinazolin-4-yl] -amine

1H NMR(CDCl3, 300 MHz) δ 7.54-7.42(m, 3H), 7.33(d, J=8.7 Hz, 2H), 7.03(m, 1H), 6.89(d, J=8.7 Hz, 2H), 5.65(br, 1H), 4.73(d, J=5.4 Hz, 2H), 3.95(t, J=4.8 Hz, 4H), 3.81(s, 3H), 2.48(t, J=4.8 Hz, 4H), 2.34(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.54-7.42 (m, 3H), 7.33 (d, J = 8.7 Hz, 2H), 7.03 (m, 1H), 6.89 (d, J = 8.7 Hz, 2H) , 5.65 (br, 1H), 4.73 (d, J = 5.4 Hz, 2H), 3.95 (t, J = 4.8 Hz, 4H), 3.81 (s, 3H), 2.48 (t, J = 4.8 Hz, 4H) , 2.34 (s, 3H)

화합물번호 287. (2,3-디메톡시-벤질)-(2-피롤리딘-1-일-퀴나졸린-4-일)-아민Compound number 287. (2,3-dimethoxy-benzyl)-(2-pyrrolidin-1-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.47(m, 3H), 7.00(m, 3H), 6.88(dd, J 1 =5.4 Hz, J 2 =3.6 Hz, 1H), 6.01(br, 1H), 4.84(d, J=6.0 Hz, 2H), 3.92(s, 3H), 3.88(s, 3H), 3.69(t, 4H), 1.97(m, 4H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.47 (m, 3H), 7.00 (m, 3H), 6.88 (dd, J 1 = 5.4 Hz, J 2 = 3.6 Hz, 1H), 6.01 (br, 1H) , 4.84 (d, J = 6.0 Hz, 2H), 3.92 (s, 3H), 3.88 (s, 3H), 3.69 (t, 4H), 1.97 (m, 4H)

화합물번호 288. (2,3-디메톡시-벤질)-(2-피페리딘-1-일-퀴나졸린-4-일)-아민Compound number 288. (2,3-Dimethoxy-benzyl)-(2-piperidin-1-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.50-7.41(m, 3H), 7.00(m, 3H), 6.88(dd, J 1 =7.2 Hz, J 2 =2.7 Hz, 1H), 5.97(br, 1H), 4.82(d, J=5.7 Hz, 2H), 3.92(s, 3H), 3.88(s, 7H), 1.65(m, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.50-7.41 (m, 3H), 7.00 (m, 3H), 6.88 (dd, J 1 = 7.2 Hz, J 2 = 2.7 Hz, 1H), 5.97 (br, 1H), 4.82 (d, J = 5.7 Hz, 2H), 3.92 (s, 3H), 3.88 (s, 7H), 1.65 (m, 6H)

화합물번호 289. (2,3-디메톡시-벤질)-(2-몰포린-4-일-퀴나졸린-4-일)-아민Compound 289. (2,3-Dimethoxy-benzyl)-(2-morpholin-4-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.51-7.44(m, 3H), 7.08-6.94(m, 3H), 6.89(dd, J 1 =8.1 Hz, J 2 =1.5 Hz, 1H), 6.05(br, 1H), 4.81(d, J=5.7 Hz, 2H), 3.93-3.89(m, 10H), 3.79(t, J=4.8 Hz, 4H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.51-7.44 (m, 3H), 7.08-6.94 (m, 3H), 6.89 (dd, J 1 = 8.1 Hz, J 2 = 1.5 Hz, 1H), 6.05 ( br, 1H), 4.81 (d, J = 5.7 Hz, 2H), 3.93-3.89 (m, 10H), 3.79 (t, J = 4.8 Hz, 4H)

화합물번호 290. (2,3-디메톡시-벤질)-[2-(4-메틸-피페라진-1-일)-퀴나졸린-4-일]-아민Compound number 290. (2,3-Dimethoxy-benzyl)-[2- (4-methyl-piperazin-1-yl) -quinazolin-4-yl] -amine

1H NMR(CDCl3, 300 MHz) δ 7.49-7.44(m, 3H), 7.05-6.96(m, 3H), 6.89(dd, J 1 =7.5 Hz, J 2 =1.5 Hz, 1H), 6.00(br, 1H), 4.82(d, J=5.7 Hz, 2H), 3.96(t, J=4.8 Hz, 4H), 3.92(s, 3H), 3.89(s, 3H), 2.50(t, J=4.8 Hz, 4H), 2.35(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.49-7.44 (m, 3H), 7.05-6.96 (m, 3H), 6.89 (dd, J 1 = 7.5 Hz, J 2 = 1.5 Hz, 1H), 6.00 ( br, 1H), 4.82 (d, J = 5.7 Hz, 2H), 3.96 (t, J = 4.8 Hz, 4H), 3.92 (s, 3H), 3.89 (s, 3H), 2.50 (t, J = 4.8 Hz, 4H), 2.35 (s, 3H)

화합물번호 291. (2,4-디메톡시-벤질)-(2-피롤리딘-1-일-퀴나졸린-4-일)-아민Compound 291. (2,4-Dimethoxy-benzyl)-(2-pyrrolidin-1-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.46(d, J=3.9 Hz, 2H), 7.42(d, J=8.1 Hz, 1H), 7.31(d, J=8.4 Hz, 1H), 6.98(s, 1H), 6.49(d, J=2.4 Hz, 1H), 6.44(dd, J 1 =8.1 Hz, J 2 =2.4 Hz, 1H), 5.94(br, 1H), 4.74(d, J=6.0 Hz, 2H), 3.87(s, 3H), 3.80(s, 3H), 3.71(t, J=6.6 Hz, 4H), 1.98(m, 4H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.46 (d, J = 3.9 Hz, 2H), 7.42 (d, J = 8.1 Hz, 1H), 7.31 (d, J = 8.4 Hz, 1H), 6.98 (s , 1H), 6.49 (d, J = 2.4 Hz, 1H), 6.44 (dd, J 1 = 8.1 Hz, J 2 = 2.4 Hz, 1H), 5.94 (br, 1H), 4.74 (d, J = 6.0 Hz , 2H), 3.87 (s, 3H), 3.80 (s, 3H), 3.71 (t, J = 6.6 Hz, 4H), 1.98 (m, 4H)

화합물번호 292. (2,4-디메톡시-벤질)-(2-피페리딘-1-일-퀴나졸린-4-일)-아민Compound 292. (2,4-Dimethoxy-benzyl)-(2-piperidin-1-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.49-7.39(m, 3H), 7.27(m, 1H), 6.99(t, J=6.6 Hz, 1H), 6.49(d, J=2.4 Hz, 1H), 6.44(dd, J 1 =8.1 Hz, J 2 =2.1 Hz, 1H), 5.88(br, 1H), 4.72(d, J=5.4 Hz, 2H), 3.97(m, 4H), 3.87(s, 3H), 3.80(s, 3H), 1.66(m, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.49-7.39 (m, 3H), 7.27 (m, 1H), 6.99 (t, J = 6.6 Hz, 1H), 6.49 (d, J = 2.4 Hz, 1H) , 6.44 (dd, J 1 = 8.1 Hz, J 2 = 2.1 Hz, 1H), 5.88 (br, 1H), 4.72 (d, J = 5.4 Hz, 2H), 3.97 (m, 4H), 3.87 (s, 3H), 3.80 (s, 3H), 1.66 (m, 6H)

화합물번호 293. (2,4-디메톡시-벤질)-(2-몰포린-4-일-퀴나졸린-4-일)-아민Compound number 293. (2,4-Dimethoxy-benzyl)-(2-morpholin-4-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.53-7.43(m, 3H), 7.26(m, 2H), 7.05(m, 1H), 6.50(d, J=2.1 Hz, 1H), 6.45(dd, J 1 =8.1 Hz, J 2 =2.1 Hz, 1H), 5.94(br, 1H), 4.72(d, J=5.7 Hz, 2H), 3.94-3.78(m, 14H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.53-7.43 (m, 3H), 7.26 (m, 2H), 7.05 (m, 1H), 6.50 (d, J = 2.1 Hz, 1H), 6.45 (dd, J 1 = 8.1 Hz, J 2 = 2.1 Hz, 1H), 5.94 (br, 1H), 4.72 (d, J = 5.7 Hz, 2H), 3.94-3.78 (m, 14H)

화합물번호 294. (2,4-디메톡시-벤질)-[2-(4-메틸-피페라진-1-일)-퀴나졸린-4-일]-아민Compound number 294. (2,4-Dimethoxy-benzyl)-[2- (4-methyl-piperazin-1-yl) -quinazolin-4-yl] -amine

1H NMR(CDCl3, 300 MHz) δ 7.50(m, 2H), 7.43(d, 1H, J=8.1 Hz), 7.26(m, 1H), 7.06(m, 1H), 6.50(d, J=2.1 Hz, 1H), 6.45(dd, J 1 =8.1 Hz, J 2 =2.1 Hz, 1H), 6.00(br, 1H), 4.72(d, J=5.4 Hz, 2H), 4.01(m, 4H), 3.87(s, 3H), 3.81(s, 3H), 2.54(t, J=4.8 Hz, 4H), 2.37(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.50 (m, 2H), 7.43 (d, 1H, J = 8.1 Hz), 7.26 (m, 1H), 7.06 (m, 1H), 6.50 (d, J = 2.1 Hz, 1H), 6.45 (dd, J 1 = 8.1 Hz, J 2 = 2.1 Hz, 1H), 6.00 (br, 1H), 4.72 (d, J = 5.4 Hz, 2H), 4.01 (m, 4H) , 3.87 (s, 3H), 3.81 (s, 3H), 2.54 (t, J = 4.8 Hz, 4H), 2.37 (s, 3H)

화합물번호 295. (2,5-디메톡시-벤질)-(2-피롤리딘-1-일-퀴나졸린-4-일)-아민Compound 295. (2,5-Dimethoxy-benzyl)-(2-pyrrolidin-1-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.45(m, 3H), 6.99(m, 2H), 6.79(m, 2H), 6.02(br s, 1H), 4.79(d, J=5.7Hz, 2H), 3.86(s, 3H), 3.75(s, 3H), 3.71(br t, J=6.8Hz, 4H), 1.97(br t, J=6.8Hz, 4H) 1 H NMR (CDCl 3, 300 MHz) δ 7.45 (m, 3H), 6.99 (m, 2H), 6.79 (m, 2H), 6.02 (br s, 1H), 4.79 (d, J = 5.7 Hz, 2H ), 3.86 (s, 3H), 3.75 (s, 3H), 3.71 (br t, J = 6.8 Hz, 4H), 1.97 (br t, J = 6.8 Hz, 4H)

화합물번호 296. (2,5-디메톡시-벤질)-(2-피페리딘-1-일-퀴나졸린-4-일)-아민Compound No. 296. (2,5-Dimethoxy-benzyl)-(2-piperidin-1-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.44(m, 3H), 6.97(m, 2H), 6.79(m, 2H), 5.99(br s, 1H), 4.77(d, J=5.7Hz, 2H), 3.91(br s, 4H), 3.87(s, 3H), 3.75(s, 3H), 1.65(br s, 6H) 1 H NMR (CDCl 3, 300 MHz) δ 7.44 (m, 3H), 6.97 (m, 2H), 6.79 (m, 2H), 5.99 (br s, 1H), 4.77 (d, J = 5.7 Hz, 2H ), 3.91 (br s, 4H), 3.87 (s, 3H), 3.75 (s, 3H), 1.65 (br s, 6H)

화합물번호 297. (2,5-디메톡시-벤질)-(2-몰포린-4-일-퀴나졸린-4-일)-아민Compound No. 297. (2,5-Dimethoxy-benzyl)-(2-morpholin-4-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.48(m, 3H), 7.06(br t, J=7.5Hz, 1H), 6.94(d, J=2.7Hz, 1H), 6.80(m, 2H), 6.05(br s, 1H), 4.76(d, J=5.7Hz, 2H), 3.92(m, 4H), 3.90(s, 3H), 3.79(m, 4H), 3.75(s, 3H) 1 H NMR (CDCl 3, 300 MHz) δ 7.48 (m, 3H), 7.06 (br t, J = 7.5 Hz, 1H), 6.94 (d, J = 2.7 Hz, 1H), 6.80 (m, 2H), 6.05 (br s, 1H), 4.76 (d, J = 5.7 Hz, 2H), 3.92 (m, 4H), 3.90 (s, 3H), 3.79 (m, 4H), 3.75 (s, 3H)

화합물번호 298. (2,5-디메톡시-벤질)-[2-(4-메틸-피페라진-1-일)-퀴나졸린-4-일]-아민Compound number 298. (2,5-Dimethoxy-benzyl)-[2- (4-methyl-piperazin-1-yl) -quinazolin-4-yl] -amine

1H NMR(CDCl3, 300 MHz) δ 7.46(m, 3H), 7.06(br t, J=7.8Hz, 1H), 6.95(d, J=3.0Hz, 1H), 6.80(m, 2H), 6.02(br s, 1H), 4.77(d, J=5.7Hz, 2H), 3.97(br t, J=5.8Hz, 4H), 3.86(s, 3H), 3.75(s, 3H), 2.50(br t, J=5.8Hz, 4H), 2.35(s, 3H) 1 H NMR (CDCl 3, 300 MHz) δ 7.46 (m, 3H), 7.06 (br t, J = 7.8 Hz, 1H), 6.95 (d, J = 3.0 Hz, 1H), 6.80 (m, 2H), 6.02 (br s, 1H), 4.77 (d, J = 5.7 Hz, 2H), 3.97 (br t, J = 5.8 Hz, 4H), 3.86 (s, 3H), 3.75 (s, 3H), 2.50 (br t, J = 5.8 Hz, 4H), 2.35 (s, 3H)

화합물번호 299. (3,4-디메톡시-벤질)-(2-피롤리딘-1-일-퀴나졸린-4-일)-아민Compound 299. (3,4-Dimethoxy-benzyl)-(2-pyrrolidin-1-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.49(d, J=3.9Hz, 2H), 7.46(d, J=8.4Hz, 1H), 7.00(m, 3H), 6.84(m, 1H), 5.71(br s, 1H), 4.75(d, J=5.4Hz, 2H), 3.89(s, 3H), 3.86(s, 3H), 3.69(br t, J=6.6Hz, 4H), 1.97(br t, J=6.6Hz, 4H) 1 H NMR (CDCl 3, 300 MHz) δ 7.49 (d, J = 3.9 Hz, 2H), 7.46 (d, J = 8.4 Hz, 1H), 7.00 (m, 3H), 6.84 (m, 1H), 5.71 (br s, 1H), 4.75 (d, J = 5.4 Hz, 2H), 3.89 (s, 3H), 3.86 (s, 3H), 3.69 (br t, J = 6.6 Hz, 4H), 1.97 (br t , J = 6.6 Hz, 4H)

화합물번호 300. (3,4-디메톡시-벤질)-(2-피페리딘-1-일-퀴나졸린-4-일)-아민Compound No. 300. (3,4-Dimethoxy-benzyl)-(2-piperidin-1-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.45(m, 3H), 6.99(m, 3H), 6.85(d, J=8.4Hz, 1H) , 5.64(br s, 1H), 4.73(d, J=5.7Hz, 2H), 3.89(m, 10H), 1.65(m, 6H), 1 H NMR (CDCl 3, 300 MHz) δ 7.45 (m, 3H), 6.99 (m, 3H), 6.85 (d, J = 8.4 Hz, 1H), 5.64 (br s, 1H), 4.73 (d, J = 5.7 Hz, 2H), 3.89 (m, 10H), 1.65 (m, 6H),

화합물번호 301. (3,4-디메톡시-벤질)-(2-몰포린-4-일-퀴나졸린-4-일)-아민Compound 301. (3,4-Dimethoxy-benzyl)-(2-morpholin-4-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.52(m, 3H), 7.08(t, J=7.8Hz, 1H), 6.94(m, 2H), 6.85(d, J=8.4Hz, 1H), 5.71(br s, 1H), 4.72(d, J=4.8Hz, 2H), 3.91(m, 4H), 3.89(s, 3H), 3.86(s, 3H), 3.78(m, 4H) 1 H NMR (CDCl 3, 300 MHz) δ 7.52 (m, 3H), 7.08 (t, J = 7.8 Hz, 1H), 6.94 (m, 2H), 6.85 (d, J = 8.4 Hz, 1H), 5.71 (br s, 1H), 4.72 (d, J = 4.8 Hz, 2H), 3.91 (m, 4H), 3.89 (s, 3H), 3.86 (s, 3H), 3.78 (m, 4H)

화합물번호 302. (3,4-디메톡시-벤질)-[2-(4-메틸-피페라진-1-일)-퀴나졸린-4-일]-아민Compound number 302. (3,4-Dimethoxy-benzyl)-[2- (4-methyl-piperazin-1-yl) -quinazolin-4-yl] -amine

1H NMR(CDCl3, 300 MHz) δ 7.49(m, 3H), 7.05(t, J=7.8Hz, 1H), 6.95(m, 2H), 6.84(m, 1H), 5.66(br s, 1H), 4.73(d, J=5.4Hz, 2H), 3.96(br t, J=5.0Hz, 4H), 3.89(s, 3H), 3.86(s, 3H), 2.49(brvt, J=5.0Hz, 4H), 2.35(s, 3H) 1 H NMR (CDCl 3, 300 MHz) δ 7.49 (m, 3H), 7.05 (t, J = 7.8 Hz, 1H), 6.95 (m, 2H), 6.84 (m, 1H), 5.66 (br s, 1H ), 4.73 (d, J = 5.4 Hz, 2H), 3.96 (br t, J = 5.0 Hz, 4H), 3.89 (s, 3H), 3.86 (s, 3H), 2.49 (brvt, J = 5.0 Hz, 4H), 2.35 (s, 3H)

화합물번호 303. (3,5-디메톡시-벤질)-(2-피롤리딘-1-일-퀴나졸린-4-일)-아민Compound 303. (3,5-Dimethoxy-benzyl)-(2-pyrrolidin-1-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.50(m, 3H), 7.01(m, 1H), 6.56(d, J=1.8Hz, 2H), 6.39(br t, J=2.3Hz, 1H), 5.82(br s, 1H), 4.75(d, J=5.4Hz, 2H), 3.77(s, 6H), 3.67(br t, J=6.6 Hz, 4H), 1.95(br t, J=6.6 Hz, 4H) 1 H NMR (CDCl 3, 300 MHz) δ 7.50 (m, 3H), 7.01 (m, 1H), 6.56 (d, J = 1.8 Hz, 2H), 6.39 (br t, J = 2.3 Hz, 1H), 5.82 (br s, 1H), 4.75 (d, J = 5.4 Hz, 2H), 3.77 (s, 6H), 3.67 (br t, J = 6.6 Hz, 4H), 1.95 (br t, J = 6.6 Hz, 4H)

화합물번호 304. (3,5-디메톡시-벤질)-(2-피페리딘-1-일-퀴나졸린-4-일)-아민Compound number 304. (3,5-dimethoxy-benzyl)-(2-piperidin-1-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.46(m, 3H), 7.02(t, J=8.1Hz, 1H), 6.56(br d, J=2.4Hz, 2H), 6.40(br t, J=1.8Hz, 1H), 5.71(br s, 1H), 4.73(d J=5.4 Hz, 2H), 3.88(m, 4H), 3.78(s, 6H), 1.62(s, 6H) 1 H NMR (CDCl 3, 300 MHz) δ 7.46 (m, 3H), 7.02 (t, J = 8.1 Hz, 1H), 6.56 (br d, J = 2.4 Hz, 2H), 6.40 (br t, J = 1.8 Hz, 1H), 5.71 (br s, 1H), 4.73 (d J = 5.4 Hz, 2H), 3.88 (m, 4H), 3.78 (s, 6H), 1.62 (s, 6H)

화합물번호 305. (3,5-디메톡시-벤질)-(2-몰포린-4-일-퀴나졸린-4-일)-아민Compound 305. (3,5-Dimethoxy-benzyl)-(2-morpholin-4-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.52(m, 3H), 7.09(br t, J=7.8Hz, 1H), 6.55(br d, J=2.1Hz, 2H), 6.40(br t, J=2.1Hz, 1H), 5.75(br s, 1H), 4.73(d J=5.4 Hz, 2H), 3.91(m, 4H), 3.78(m, 10H) 1 H NMR (CDCl 3, 300 MHz) δ 7.52 (m, 3H), 7.09 (br t, J = 7.8 Hz, 1H), 6.55 (br d, J = 2.1 Hz, 2H), 6.40 (br t, J = 2.1 Hz, 1H), 5.75 (br s, 1H), 4.73 (d J = 5.4 Hz, 2H), 3.91 (m, 4H), 3.78 (m, 10H)

화합물번호 306. (3,5-디메톡시-벤질)-[2-(4-메틸-피페라진-1-일)-퀴나졸린-4-일]-아민Compound 306. (3,5-Dimethoxy-benzyl)-[2- (4-methyl-piperazin-1-yl) -quinazolin-4-yl] -amine

1H NMR(CDCl3, 300 MHz) δ 7.50(m, 3H), 7.06(t, J=7.8Hz, 1H), 6.56(d, J=2.4Hz, 2H), 6.40(br t, J=2.1Hz, 1H), 5.72(br s, 1H), 4.73(d J=5.4 Hz, 2H), 3.94(br t, J=4.2Hz, 4H), 3.78(s, 6H), 2.48(br t, J=5.0Hz, 4H), 2.34(s, 3H) 1 H NMR (CDCl 3, 300 MHz) δ 7.50 (m, 3H), 7.06 (t, J = 7.8 Hz, 1H), 6.56 (d, J = 2.4 Hz, 2H), 6.40 (br t, J = 2.1 Hz, 1H), 5.72 (br s, 1H), 4.73 (d J = 5.4 Hz, 2H), 3.94 (br t, J = 4.2 Hz, 4H), 3.78 (s, 6H), 2.48 (br t, J = 5.0 Hz, 4H), 2.34 (s, 3H)

화합물번호 307. 벤조[1,3]디옥솔-5-일메틸-(2-피롤리딘-1-일-퀴나졸린-4-일)-아민Compound 307. Benzo [1,3] dioxol-5-ylmethyl- (2-pyrrolidin-1-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.48(br d, J=3.9 Hz, 2H), 7.45(d, J=8.1Hz, 1H), 6.99(quartet, J=4.1 Hz, 1H), 6.92(s, 1H), 6.86(d, J=7.8 Hz, 1H), 6.76(d, J=7.8 Hz, 1H), 5.95(s, 2H), 5.70(br s, 1H), 4.72(d, J=5.7 Hz, 2H), 3.68(br t, J=6.6 Hz, 4H), 1.97(m, 4H) 1 H NMR (CDCl 3, 300 MHz) δ 7.48 (br d, J = 3.9 Hz, 2H), 7.45 (d, J = 8.1 Hz, 1H), 6.99 (quartet, J = 4.1 Hz, 1H), 6.92 ( s, 1H), 6.86 (d, J = 7.8 Hz, 1H), 6.76 (d, J = 7.8 Hz, 1H), 5.95 (s, 2H), 5.70 (br s, 1H), 4.72 (d, J = 5.7 Hz, 2H), 3.68 (br t, J = 6.6 Hz, 4H), 1.97 (m, 4H)

화합물번호 308. 벤조[1,3]디옥솔-5-일메틸-(2-피페리딘-1-일-퀴나졸린-4-일)-아민Compound 308. Benzo [1,3] dioxol-5-ylmethyl- (2-piperidin-1-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.48(m, 3H), 7.03(m, 1H), 6.85(m, 3H), 5.95(s, 2H), 5.64(br s, 1H), 4.69(t, J=5.4 Hz, 2H), 3.89(m, 4H), 1.64(m, 6H) 1 H NMR (CDCl 3, 300 MHz) δ 7.48 (m, 3H), 7.03 (m, 1H), 6.85 (m, 3H), 5.95 (s, 2H), 5.64 (br s, 1H), 4.69 (t , J = 5.4 Hz, 2H), 3.89 (m, 4H), 1.64 (m, 6H)

화합물번호 309. 벤조[1,3]디옥솔-5-일메틸-(2-몰포린-4-일-퀴나졸린-4-일)-아민Compound 309. Benzo [1,3] dioxol-5-ylmethyl- (2-morpholin-4-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.51(m, 3H), 7.07(t, J=7.4 Hz, 1H), 6.89(s, 1H), 6.85(d, J=7.8Hz, 1H), 6.78(d, J=7.8 Hz, 1H), 5.96(s, 2H), 5.69(br s, 1H), 4.70(d, J=5.4 Hz, 2H), 3.89(m, 4H), 3.78(m, 4H) 1 H NMR (CDCl 3, 300 MHz) δ 7.51 (m, 3H), 7.07 (t, J = 7.4 Hz, 1H), 6.89 (s, 1H), 6.85 (d, J = 7.8 Hz, 1H), 6.78 (d, J = 7.8 Hz, 1H), 5.96 (s, 2H), 5.69 (br s, 1H), 4.70 (d, J = 5.4 Hz, 2H), 3.89 (m, 4H), 3.78 (m, 4H )

화합물번호 310. 벤조[1,3]디옥솔-5-일메틸-[2-(4-메틸-피페라진-1-일)-퀴나졸린-4-일]-아민Compound number 310. Benzo [1,3] dioxol-5-ylmethyl- [2- (4-methyl-piperazin-1-yl) -quinazolin-4-yl] -amine

1H NMR(CDCl3, 300 MHz) δ 7.48(m, 3H), 7.05(t, J=8.1Hz, 1H), 6.89(s, 1H), 6.85(d, J=7.8Hz, 1H), 6.78(d, J=7.8 Hz, 1H), 5.96(s, 2H), 5.68(br s, 1H), 4.70(d, J=5.4 Hz, 2H), 3.95(br t, J=4.8 Hz, 4H), 2.48(br t, J=4.8 Hz, 4H), 2.35(s, 3H) 1 H NMR (CDCl 3, 300 MHz) δ 7.48 (m, 3H), 7.05 (t, J = 8.1 Hz, 1H), 6.89 (s, 1H), 6.85 (d, J = 7.8 Hz, 1H), 6.78 (d, J = 7.8 Hz, 1H), 5.96 (s, 2H), 5.68 (br s, 1H), 4.70 (d, J = 5.4 Hz, 2H), 3.95 (br t, J = 4.8 Hz, 4H) , 2.48 (br t, J = 4.8 Hz, 4H), 2.35 (s, 3H)

화합물번호 311. (2-피롤리딘-1-일-퀴나졸린-4-일)-(3,4,5-트리메톡시-벤질)-아민Compound No. 311. (2-Pyrrolidin-1-yl-quinazolin-4-yl)-(3,4,5-trimethoxy-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.57(br t, J=7.8 Hz, 2H), 7.48(t, J=7.7Hz, 1H), 7.02(t, J=8.0 Hz, 1H), 6.66(s, 2H), 6.11(br s, 1H), 4.74(d, J=5.4 Hz, 2H), 3.84(s, 9H), 3.71(br t, J=6.2 Hz, 4H), 1.98(br t, J=6.9 Hz, 4H) 1 H NMR (CDCl 3, 300 MHz) δ 7.57 (br t, J = 7.8 Hz, 2H), 7.48 (t, J = 7.7 Hz, 1H), 7.02 (t, J = 8.0 Hz, 1H), 6.66 ( s, 2H), 6.11 (br s, 1H), 4.74 (d, J = 5.4 Hz, 2H), 3.84 (s, 9H), 3.71 (br t, J = 6.2 Hz, 4H), 1.98 (br t, J = 6.9 Hz, 4H)

화합물번호 312. (2-피페리딘-1-일-퀴나졸린-4-일)-(3,4,5-트리메톡시-벤질)-아민Compound No. 312. (2-Piperidin-1-yl-quinazolin-4-yl)-(3,4,5-trimethoxy-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.50(m, 3H), 7.03(br t, J=8.0 Hz, 1H), 6.65(s, 2H), 5.71(br s, 1H), 4.72(d, J=5.1 Hz, 2H), 3.91(m, 4H), 3.84(s, 9H), 1.65(m, 6H) 1 H NMR (CDCl 3, 300 MHz) δ 7.50 (m, 3H), 7.03 (br t, J = 8.0 Hz, 1H), 6.65 (s, 2H), 5.71 (br s, 1H), 4.72 (d, J = 5.1 Hz, 2H), 3.91 (m, 4H), 3.84 (s, 9H), 1.65 (m, 6H)

화합물번호 313. (2-몰포린-4-일-퀴나졸린-4-일)-(3,4,5-트리메톡시-벤질)-아민Compound 313. (2-Morpholin-4-yl-quinazolin-4-yl)-(3,4,5-trimethoxy-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.53(m, 3H), 7.11(br t, J=8.4 Hz, 1H), 6.63(s, 2H), 5.74(br s, 1H), 4.72(d, J=5.4 Hz, 2H), 3.85(m, 16H) 1 H NMR (CDCl 3, 300 MHz) δ 7.53 (m, 3H), 7.11 (br t, J = 8.4 Hz, 1H), 6.63 (s, 2H), 5.74 (br s, 1H), 4.72 (d, J = 5.4 Hz, 2H), 3.85 (m, 16H)

화합물번호 314. [2-(4-메틸-피페라진-1-일)-퀴나졸린-4-일]-(3,4,5-트리메톡시-벤질)-아민Compound number 314. [2- (4-Methyl-piperazin-1-yl) -quinazolin-4-yl]-(3,4,5-trimethoxy-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.53(m, 3H), 7.06(m, 1H), 6.64(s, 2H), 5.77(br s, 1H), 4.72(d, J=5.1 Hz, 2H), 3.97(br t, J=4.5 Hz, 4H), 3.85(s, 9H), 2.50(br t, J=5.0 Hz, 4H), 2.36(s, 3H) 1 H NMR (CDCl 3, 300 MHz) δ 7.53 (m, 3H), 7.06 (m, 1H), 6.64 (s, 2H), 5.77 (br s, 1H), 4.72 (d, J = 5.1 Hz, 2H ), 3.97 (br t, J = 4.5 Hz, 4H), 3.85 (s, 9H), 2.50 (br t, J = 5.0 Hz, 4H), 2.36 (s, 3H)

화합물번호 315. (2-피롤리딘-1-일-퀴나졸린-4-일)-(2,4,6-트리메톡시-벤질)-아민Compound 315. (2-Pyrrolidin-1-yl-quinazolin-4-yl)-(2,4,6-trimethoxy-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.46(m, 2H), 7.38(d, J=8.1 Hz, 1H), 6.98(m, 1H), 6.17(s, 2H), 5.84(br s, 1H), 4.81(d, J=5.1 Hz, 2H), 3.85(s, 6H), 3.83(s, 3H), 3.74(br t, J=6.5 Hz, 4H), 1.98(m, 4H) 1 H NMR (CDCl 3, 300 MHz) δ 7.46 (m, 2H), 7.38 (d, J = 8.1 Hz, 1H), 6.98 (m, 1H), 6.17 (s, 2H), 5.84 (br s, 1H ), 4.81 (d, J = 5.1 Hz, 2H), 3.85 (s, 6H), 3.83 (s, 3H), 3.74 (br t, J = 6.5 Hz, 4H), 1.98 (m, 4H)

화합물번호 316. (2-피페리딘-1-일-퀴나졸린-4-일)-(2,4,6-트리메톡시-벤질)-아민Compound 316. (2-Piperidin-1-yl-quinazolin-4-yl)-(2,4,6-trimethoxy-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.41(m, 3H), 6.98(m, 1H), 6.16(s, 2H), 5.86(br s, 1H), 4.80(d, J=5.1 Hz, 2H), 3.97(m, 4H), 3.85(s, 6H), 3.83(s, 3H), 1.65(m, 6H) 1 H NMR (CDCl 3, 300 MHz) δ 7.41 (m, 3H), 6.98 (m, 1H), 6.16 (s, 2H), 5.86 (br s, 1H), 4.80 (d, J = 5.1 Hz, 2H ), 3.97 (m, 4H), 3.85 (s, 6H), 3.83 (s, 3H), 1.65 (m, 6H)

화합물번호 317. (2-몰포린-4-일-퀴나졸린-4-일)-(2,4,6-트리메톡시-벤질)-Compound number 317. (2-morpholin-4-yl-quinazolin-4-yl)-(2,4,6-trimethoxy-benzyl)-

아민Amine

1H NMR(CDCl3, 300 MHz) δ 7.47(m, 3H), 7.02(m, 1H), 6.17(s, 2H), 5.93(br s, 1H), 4.79(d, J=5.1 Hz, 2H), 3.99(m, 4H), 3.86(m, 13H) 1 H NMR (CDCl 3, 300 MHz) δ 7.47 (m, 3H), 7.02 (m, 1H), 6.17 (s, 2H), 5.93 (br s, 1H), 4.79 (d, J = 5.1 Hz, 2H ), 3.99 (m, 4H), 3.86 (m, 13H)

화합물번호 318. [2-(4-메틸-피페라진-1-일)-퀴나졸린-4-일]-(2,4,6-트리메톡시-벤질)-아민Compound number 318. [2- (4-Methyl-piperazin-1-yl) -quinazolin-4-yl]-(2,4,6-trimethoxy-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.45(m, 3H), 6.98(m, 1H), 6.16(s, 2H), 5.91(br s, 1H), 4.80(d, J=5.1 Hz, 2H), 4.01(br t, J=4.7 Hz, 4H), 3.83(s, 6H), 3.79(s, 3H), 2.52(br t, J=5.0 Hz, 4H), 2.04(s, 3H) 1 H NMR (CDCl 3, 300 MHz) δ 7.45 (m, 3H), 6.98 (m, 1H), 6.16 (s, 2H), 5.91 (br s, 1H), 4.80 (d, J = 5.1 Hz, 2H ), 4.01 (br t, J = 4.7 Hz, 4H), 3.83 (s, 6H), 3.79 (s, 3H), 2.52 (br t, J = 5.0 Hz, 4H), 2.04 (s, 3H)

화합물번호 319. (2,4-디메톡시-벤질)-(2-에톡시-퀴나졸린-4-일)-아민Compound number 319. (2,4-dimethoxy-benzyl)-(2-ethoxy-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.60(m, 2H), 7.52(d, J=8.1 Hz, 1H), 7.23(m, 2H), 6.48(m, 2H), 6.11(br s, 1H), 4.78(d, J=5.4 Hz, 2H), 4.51(quartet, J=7.2 Hz, 2H), 3.88(s, 3H), 3.81(s, 3H), 1.47(t, J=7.2 Hz, 3H) 1 H NMR (CDCl 3, 300 MHz) δ 7.60 (m, 2H), 7.52 (d, J = 8.1 Hz, 1H), 7.23 (m, 2H), 6.48 (m, 2H), 6.11 (br s, 1H ), 4.78 (d, J = 5.4 Hz, 2H), 4.51 (quartet, J = 7.2 Hz, 2H), 3.88 (s, 3H), 3.81 (s, 3H), 1.47 (t, J = 7.2 Hz, 3H )

화합물번호 320. 벤조[1,3]디옥솔-5-일메틸-(2-에톡시-퀴나졸린-4-일)-아민Compound number 320. Benzo [1,3] dioxol-5-ylmethyl- (2-ethoxy-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.63(m, 3H), 7.24(m, 1H), 6.82(m, 3H), 5.96(s, 2H), 5.79(br s, 1H), 4.75(d, J=5.4 Hz, 2H), 4.50(quartet, J=7.2 Hz, 2H), 1.46(t, J=7.2 Hz, 3H) 1 H NMR (CDCl 3, 300 MHz) δ 7.63 (m, 3H), 7.24 (m, 1H), 6.82 (m, 3H), 5.96 (s, 2H), 5.79 (br s, 1H), 4.75 (d , J = 5.4 Hz, 2H), 4.50 (quartet, J = 7.2 Hz, 2H), 1.46 (t, J = 7.2 Hz, 3H)

화합물번호 321. (2-이소프로필-퀴나졸린-4-일)-(2-메톡시-벤질)-아민Compound number 321. (2-isopropyl-quinazolin-4-yl)-(2-methoxy-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.01(d, J = 8.1 Hz, 1H), 7.81(d, J = 8.1 Hz, 1H), 7.69(t, J = 7.3 Hz, 1H), 7.43(t, J = 7.4 Hz, 2H), 7.31(m, 1H), 6.93(t, J = 7.0 Hz, 2H), 4.95(d, J = 5.8 Hz, 2H), 3.93(s, 3H), 3,31(m, 1H), 1.41(d, J = 6.8 Hz, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.01 (d, J = 8.1 Hz, 1H), 7.81 (d, J = 8.1 Hz, 1H), 7.69 (t, J = 7.3 Hz, 1H), 7.43 (t , J = 7.4 Hz, 2H), 7.31 (m, 1H), 6.93 (t, J = 7.0 Hz, 2H), 4.95 (d, J = 5.8 Hz, 2H), 3.93 (s, 3H), 3,31 (m, 1H), 1.41 (d, J = 6.8 Hz, 6H)

화합물번호 322. (2,3-디메톡시-벤질)-(2-이소프로필-퀴나졸린-4-일)-아민Compound number 322. (2,3-Dimethoxy-benzyl)-(2-isopropyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.97(d, J=8.2 Hz, 1H), 7.82(d, J=8.3 Hz, 1H), 7.69(t, J=7.3 Hz, 1H), 7.41(t, J=7.6 Hz, 1H), 7.03(m, 2H), 6.89(m, 1H), 4.96(d, J=5.8 Hz, 2H), 3.96(s, 3H), 3.89(3, 3H), 3.30(t, J=7.1 Hz, 1H), 1.79(d, J=6.8 Hz, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.97 (d, J = 8.2 Hz, 1H), 7.82 (d, J = 8.3 Hz, 1H), 7.69 (t, J = 7.3 Hz, 1H), 7.41 (t , J = 7.6 Hz, 1H), 7.03 (m, 2H), 6.89 (m, 1H), 4.96 (d, J = 5.8 Hz, 2H), 3.96 (s, 3H), 3.89 (3, 3H), 3.30 (t, J = 7.1 Hz, 1H), 1.79 (d, J = 6.8 Hz, 6H)

화합물번호 323. (3,5-디메톡시-벤질)-(2-이소프로필-퀴나졸린-4-일)-아민Compound number 323. (3,5-Dimethoxy-benzyl)-(2-isopropyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.21(d, J=6.3 Hz, 1H), 8.02(d, J=8.4 Hz, 1H), 7.63(t, J=7.7 Hz, 1H), 7.37(t, J=7.5 Hz, 1H), 6.65(d, J=2.1 Hz, 2H), 6.36(d, J=2.0 Hz, 1H), 4.90(d, J=5.5 Hz, 2H), 3.75(s, 6H), 3.34(t, J=7.0 Hz, 1H), 1.38(d, J=6.7 Hz, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.21 (d, J = 6.3 Hz, 1H), 8.02 (d, J = 8.4 Hz, 1H), 7.63 (t, J = 7.7 Hz, 1H), 7.37 (t , J = 7.5 Hz, 1H), 6.65 (d, J = 2.1 Hz, 2H), 6.36 (d, J = 2.0 Hz, 1H), 4.90 (d, J = 5.5 Hz, 2H), 3.75 (s, 6H ), 3.34 (t, J = 7.0 Hz, 1H), 1.38 (d, J = 6.7 Hz, 6H)

화합물번호 324. (3,4-디메톡시-벤질)-(2-이소프로필-퀴나졸린-4-일)-아민Compound 324. (3,4-Dimethoxy-benzyl)-(2-isopropyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.17(d, J=6.2 Hz, 1H), 7.97(d, J=8.5 Hz, 1H), 7.62(t, J=7.7 Hz, 1H), 7.34(t, J=7.5 Hz, 1H), 7.12(s, 1H), 7.05(d, J=8.1 Hz, 1H), 6.82(d, J=8.2 Hz, 1H), 4.90(d, J=5.5 Hz, 2H), 3.86(s, 6H), 3.33(t, J=7.1 Hz, 1H), 1.40(d, J=6.7 Hz, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.17 (d, J = 6.2 Hz, 1H), 7.97 (d, J = 8.5 Hz, 1H), 7.62 (t, J = 7.7 Hz, 1H), 7.34 (t , J = 7.5 Hz, 1H), 7.12 (s, 1H), 7.05 (d, J = 8.1 Hz, 1H), 6.82 (d, J = 8.2 Hz, 1H), 4.90 (d, J = 5.5 Hz, 2H ), 3.86 (s, 6H), 3.33 (t, J = 7.1 Hz, 1H), 1.40 (d, J = 6.7 Hz, 6H)

화합물번호 325. (2-이소프로필-퀴나졸린-4-일)-(3,4,5-트리메톡시-벤질)-아민Compound 325. (2-Isopropyl-quinazolin-4-yl)-(3,4,5-trimethoxy-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.22(d, J=6.2 Hz, 1H), 8.00(d, J=8.5 Hz, 1H), 7.64(t, J=7.7 Hz, 1H), 7.36(t, J=7.4 Hz, 1H), 6.79(s, 2H), 4.90(d, J=5.5 Hz, 2H), 3.84(s, 9H), 3.34(t, J=7.2 Hz, 1H), 1.39(d, J=6.7 Hz, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.22 (d, J = 6.2 Hz, 1H), 8.00 (d, J = 8.5 Hz, 1H), 7.64 (t, J = 7.7 Hz, 1H), 7.36 (t , J = 7.4 Hz, 1H), 6.79 (s, 2H), 4.90 (d, J = 5.5 Hz, 2H), 3.84 (s, 9H), 3.34 (t, J = 7.2 Hz, 1H), 1.39 (d , J = 6.7 Hz, 6H)

화합물번호 326. (2,5-디메톡시-벤질)-(2-이소프로필-퀴나졸린-4-일)-아민Compound number 326. (2,5-Dimethoxy-benzyl)-(2-isopropyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.06(d, J=8.1 Hz, 1H), 7.86(d, J=8.0 Hz, 1H), 7.70(t, J=7.3 Hz, 1H), 7.43(t, J=7.4 Hz, 1H), 7.01(s, 1H), 6.80(m, 2H), 4.93(d, J=5.6 Hz, 2H), 3.89(s, 3H), 3.75(s, 3H), 3.36(t, J=7.4 Hz, 1H), 1.40(d, J=6.9 Hz, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.06 (d, J = 8.1 Hz, 1H), 7.86 (d, J = 8.0 Hz, 1H), 7.70 (t, J = 7.3 Hz, 1H), 7.43 (t , J = 7.4 Hz, 1H), 7.01 (s, 1H), 6.80 (m, 2H), 4.93 (d, J = 5.6 Hz, 2H), 3.89 (s, 3H), 3.75 (s, 3H), 3.36 (t, J = 7.4 Hz, 1H), 1.40 (d, J = 6.9 Hz, 6H)

화합물번호 327. (2-이소프로필-퀴나졸린-4-일)-(2,4,6-트리메톡시-벤질)-아민Compound number 327. (2-isopropyl-quinazolin-4-yl)-(2,4,6-trimethoxy-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.09(d, J=8.0 Hz, 1H), 7.73(d, J=8.1 Hz, 1H), 7.65(t, J=7.2 Hz, 1H), 7.41(t, J=7.3 Hz, 1H), 6.31(br, 1H), 6.18(s, 2H), 4.97(d, J=5.3 Hz, 2H), 3.88(s, 9H), 3.34(t, J=7.3 Hz, 1H), 1.42(d, J=6.5 Hz, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.09 (d, J = 8.0 Hz, 1H), 7.73 (d, J = 8.1 Hz, 1H), 7.65 (t, J = 7.2 Hz, 1H), 7.41 (t , J = 7.3 Hz, 1H), 6.31 (br, 1H), 6.18 (s, 2H), 4.97 (d, J = 5.3 Hz, 2H), 3.88 (s, 9H), 3.34 (t, J = 7.3 Hz , 1H), 1.42 (d, J = 6.5 Hz, 6H)

화합물번호 328. (2-벤질-퀴나졸린-4-일)-(2-메톡시-벤질)-아민Compound 328. (2-benzyl-quinazolin-4-yl)-(2-methoxy-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.78(d, J=8.1 Hz, 1H), 7.65(m, 1H), 7.58(d, J=8.1 Hz, 1H), 7.37-7.18(m, 6H), 6.87(d, J=8.4 Hz, 1H), 6.83(t, J=7.2 Hz, 1H), 6.21(br, 1H), 4.81(d, J=5.7 Hz, 2H), 4.20(s, 2H), 3.88(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.78 (d, J = 8.1 Hz, 1H), 7.65 (m, 1H), 7.58 (d, J = 8.1 Hz, 1H), 7.37-7.18 (m, 6H) , 6.87 (d, J = 8.4 Hz, 1H), 6.83 (t, J = 7.2 Hz, 1H), 6.21 (br, 1H), 4.81 (d, J = 5.7 Hz, 2H), 4.20 (s, 2H) , 3.88 (s, 3H)

화합물번호 329. (2-벤질-퀴나졸린-4-일)-(2,3-디메톡시-벤질)-아민Compound number 329. (2-benzyl-quinazolin-4-yl)-(2,3-dimethoxy-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.78(d, J=8.1 Hz, 1H), 7.67(dd, J 1 =6.7 Hz, J 2 =0.9 Hz, 1H), 7.60(d, J=8.4 Hz, 1H), 7.46(d, J=6.9 Hz, 2H), 7.36-7.17(m, 4H), 6.93(t, J=8.1 Hz, 1H), 6.83(m, 2H), 6.22(br, 1H), 4.83(d, J=5.7 Hz, 2H), 4.20(s, 2H), 3.90(s, 3H), 3.86(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.78 (d, J = 8.1 Hz, 1H), 7.67 (dd, J 1 = 6.7 Hz, J 2 = 0.9 Hz, 1H), 7.60 (d, J = 8.4 Hz , 1H), 7.46 (d, J = 6.9 Hz, 2H), 7.36-7.17 (m, 4H), 6.93 (t, J = 8.1 Hz, 1H), 6.83 (m, 2H), 6.22 (br, 1H) , 4.83 (d, J = 5.7 Hz, 2H), 4.20 (s, 2H), 3.90 (s, 3H), 3.86 (s, 3H)

화합물번호 330. (2-벤질-퀴나졸린-4-일)-(3,5-디메톡시-벤질)-아민Compound 330. (2-benzyl-quinazolin-4-yl)-(3,5-dimethoxy-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.89(t, J=9.0 Hz, 2H), 7.62(t, J=7.7 Hz, 1H), 7.48(d, J=7.1 Hz, 2H), 7.31(m, 4H), 6.55(d, J=1.9 Hz, 2H), 6.37(s, 1H), 4.81(d, J=5.3 Hz, 2H), 4.22(s, 2H), 3.73(s, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.89 (t, J = 9.0 Hz, 2H), 7.62 (t, J = 7.7 Hz, 1H), 7.48 (d, J = 7.1 Hz, 2H), 7.31 (m) , 4H), 6.55 (d, J = 1.9 Hz, 2H), 6.37 (s, 1H), 4.81 (d, J = 5.3 Hz, 2H), 4.22 (s, 2H), 3.73 (s, 6H)

화합물번호 331. (2-벤질-퀴나졸린-4-일)-(3,4-디메톡시-벤질)-아민Compound number 331. (2-benzyl-quinazolin-4-yl)-(3,4-dimethoxy-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.11(d, J=6.1 Hz, 1H), 7.91(d, J=8.2 Hz, 1H), 7.52(m, 3H), 7.23(m, 4H), 7.02(s, 1H), 6.92(m, 1H), 6.75(d, J=8.2 Hz, 1H), 4.83(d, J=5.2 Hz, 2H), 4.27(s, 2H), 3.86(s, 3H), 3.69(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.11 (d, J = 6.1 Hz, 1H), 7.91 (d, J = 8.2 Hz, 1H), 7.52 (m, 3H), 7.23 (m, 4H), 7.02 (s, 1H), 6.92 (m, 1H), 6.75 (d, J = 8.2 Hz, 1H), 4.83 (d, J = 5.2 Hz, 2H), 4.27 (s, 2H), 3.86 (s, 3H) , 3.69 (s, 3H)

화합물번호 332. (2-벤질-퀴나졸린-4-일)-(3,4,5-트리메톡시-벤질)-아민Compound number 332. (2-benzyl-quinazolin-4-yl)-(3,4,5-trimethoxy-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.03(d, J=7.6 Hz, 1H), 7.91(d, J=8.4 Hz, 1H), 7.61(t, J=7.7 Hz, 1H), 7.50(d, J=6.8 Hz, 2H), 7.32(t, J=7.6 Hz, 1H), 7.23(m, 3H), 6.66(s, 2H), 4.81(d, J=5.2 Hz, 2H), 4.25(s, 2H), 3.86(s, 9H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.03 (d, J = 7.6 Hz, 1H), 7.91 (d, J = 8.4 Hz, 1H), 7.61 (t, J = 7.7 Hz, 1H), 7.50 (d , J = 6.8 Hz, 2H), 7.32 (t, J = 7.6 Hz, 1H), 7.23 (m, 3H), 6.66 (s, 2H), 4.81 (d, J = 5.2 Hz, 2H), 4.25 (s , 2H), 3.86 (s, 9H)

화합물번호 333. (2-벤질-퀴나졸린-4-일)-(2,4-디메톡시-벤질)-아민Compound number 333. (2-benzyl-quinazolin-4-yl)-(2,4-dimethoxy-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.95(d, J=8.1 Hz, 1H), 7.68(m, 2H), 7.54(m, 2H), 7.40-7.24(m, 4H), 7.10(d, J=8.3 Hz, 1H), 6.45(d, J=2.23 Hz, 1H), 6.35(m, 1H), 4.79(d, J=5.5 Hz, 2H), 4.28(s, 2H), 3.86(s, 3H), 3.81(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.95 (d, J = 8.1 Hz, 1H), 7.68 (m, 2H), 7.54 (m, 2H), 7.40-7.24 (m, 4H), 7.10 (d, J = 8.3 Hz, 1H), 6.45 (d, J = 2.23 Hz, 1H), 6.35 (m, 1H), 4.79 (d, J = 5.5 Hz, 2H), 4.28 (s, 2H), 3.86 (s, 3H), 3.81 (s, 3H)

화합물번호 334. (2-벤질-퀴나졸린-4-일)-(2,5-디메톡시-벤질)-아민Compound 334. (2-benzyl-quinazolin-4-yl)-(2,5-dimethoxy-benzyl) -amine

1H NMRCDCl3, 300 MHz) δ 8.26(d, J=8.3 Hz, 1H), 8.13(d, J=8.2 Hz, 1H), 7.61(m, 3H), 7.40(t, J=7.7 Hz, 1H), 7.24(m, 4H), 7.79(m, 3H), 4.94(d, J=5.4 Hz, 2H), 4.38(s, 2H), 3.85(s, 3H), 3.68(s, 3H) 1 H NMRCDCl 3 , 300 MHz δ 8.26 (d, J = 8.3 Hz, 1H), 8.13 (d, J = 8.2 Hz, 1H), 7.61 (m, 3H), 7.40 (t, J = 7.7 Hz, 1H ), 7.24 (m, 4H), 7.79 (m, 3H), 4.94 (d, J = 5.4 Hz, 2H), 4.38 (s, 2H), 3.85 (s, 3H), 3.68 (s, 3H)

화합물번호 335. (2-벤질-퀴나졸린-4-일)-(2,4,6-트리메톡시-벤질)-아민Compound 335. (2-benzyl-quinazolin-4-yl)-(2,4,6-trimethoxy-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.12(d, J=8.1 Hz, 1H), 7.63(m, 4H), 7.35(m, 4H), 6.17(s, 2H), 4.96(d, J=5.4 Hz, 2H), 4.40(s, 2H), 3.85(s, 9H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.12 (d, J = 8.1 Hz, 1H), 7.63 (m, 4H), 7.35 (m, 4H), 6.17 (s, 2H), 4.96 (d, J = 5.4 Hz, 2H), 4.40 (s, 2H), 3.85 (s, 9H)

화합물번호 336. (2-페닐-퀴나졸린-4-일)-(3,4,5-트리메톡시-벤질)-아민Compound number 336. (2-phenyl-quinazolin-4-yl)-(3,4,5-trimethoxy-benzyl) -amine

화합물번호 337. (2-페닐-퀴나졸린-4-일)-(2,4,6-트리메톡시-벤질)-아민Compound number 337. (2-phenyl-quinazolin-4-yl)-(2,4,6-trimethoxy-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.76(d, J=5.4 Hz, 2H), 7.69(m, 2H), 7.54(m, 3H), 7.41(t, J=7.6 Hz, 1H), 7.28(s, 1H), 6.19(s, 2H), 5.00(d, 2H, J=5.1 Hz), 3.90(s, 9H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.76 (d, J = 5.4 Hz, 2H), 7.69 (m, 2H), 7.54 (m, 3H), 7.41 (t, J = 7.6 Hz, 1H), 7.28 (s, 1H), 6.19 (s, 2H), 5.00 (d, 2H, J = 5.1 Hz), 3.90 (s, 9H)

화합물번호 338. (2-퓨란-2-일-퀴나졸린-4-일)-(2-메톡시-벤질)-아민Compound 338. (2-Furan-2-yl-quinazolin-4-yl)-(2-methoxy-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.01(d, J=8.4 Hz, 1H), 7.70(m, 3H), 7.48(d, J=6.6 Hz, 2H), 7.39(t, J=7.5 Hz, 1H), 7.29(d, J=7.8 Hz, 1H), 6.95(t, J=7.4 Hz, 2H), 6.60(m, 1H), 6.87(br, 1H), 4.97(d, J=5.3 Hz, 2H), 3.93(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.01 (d, J = 8.4 Hz, 1H), 7.70 (m, 3H), 7.48 (d, J = 6.6 Hz, 2H), 7.39 (t, J = 7.5 Hz , 1H), 7.29 (d, J = 7.8 Hz, 1H), 6.95 (t, J = 7.4 Hz, 2H), 6.60 (m, 1H), 6.87 (br, 1H), 4.97 (d, J = 5.3 Hz , 2H), 3.93 (s, 3H)

화합물번호 339. (2-퓨란-2-일-퀴나졸린-4-일)-(3-메톡시-벤질)-아민Compound 339. (2-Furan-2-yl-quinazolin-4-yl)-(3-methoxy-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.01(d, J=8.4 Hz, 1H), 7.78(d, J=8.1 Hz, 1H), 7.67(m, 2H), 7.42(m, 2H), 7.27(m, 2H), 6.87(d, J=2.0 Hz, 1H), 6.58(m, 1H), 6.50(br, 1H), 4.94(d, J=5.2 Hz, 2H), 3.80(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.01 (d, J = 8.4 Hz, 1H), 7.78 (d, J = 8.1 Hz, 1H), 7.67 (m, 2H), 7.42 (m, 2H), 7.27 (m, 2H), 6.87 (d, J = 2.0 Hz, 1H), 6.58 (m, 1H), 6.50 (br, 1H), 4.94 (d, J = 5.2 Hz, 2H), 3.80 (s, 3H)

화합물번호 340. (2-퓨란-2-일-퀴나졸린-4-일)-(4-메톡시-벤질)-아민Compound number 340. (2-Furan-2-yl-quinazolin-4-yl)-(4-methoxy-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.01(d, J=8.3 Hz, 1H), 7.77(d, J=8.1 Hz, 1H), 7.67(t, J=7.2 Hz, 2H), 7.41(m, 4H), 6.90(d, J=8.6 Hz, 2H), 6.59(m, 1H), 6.50(br, 1H), 4.89(d, J=5.5 Hz, 2H), 3.82(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.01 (d, J = 8.3 Hz, 1H), 7.77 (d, J = 8.1 Hz, 1H), 7.67 (t, J = 7.2 Hz, 2H), 7.41 (m) , 4H), 6.90 (d, J = 8.6 Hz, 2H), 6.59 (m, 1H), 6.50 (br, 1H), 4.89 (d, J = 5.5 Hz, 2H), 3.82 (s, 3H)

화합물번호 341. 벤조[1,3]디옥솔-5-일메틸-(2-퓨란-2-일-퀴나졸린-4-일)-아민Compound No. 341.Benzo [1,3] dioxol-5-ylmethyl- (2-furan-2-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.99(d, J=8.3 Hz, 1H), 7.78(d, J=8.1 Hz, 1H), 7.65(m, 2H), 7.41(t, J=5.6 Hz, 2H), 6.94(t, J=7.6 Hz, 2H), 6.78(d, J=7.9 Hz, 1H), 6.57(m, 1H), 6.41(br, 1H), 5.95(s, 2H), 4.85(d, J=5.4 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.99 (d, J = 8.3 Hz, 1H), 7.78 (d, J = 8.1 Hz, 1H), 7.65 (m, 2H), 7.41 (t, J = 5.6 Hz , 2H), 6.94 (t, J = 7.6 Hz, 2H), 6.78 (d, J = 7.9 Hz, 1H), 6.57 (m, 1H), 6.41 (br, 1H), 5.95 (s, 2H), 4.85 (d, J = 5.4 Hz, 2H)

화합물번호 342. (2,3-디메톡시-벤질)-(2-퓨란-2-일-퀴나졸린-4-일)-아민Compound number 342. (2,3-Dimethoxy-benzyl)-(2-furan-2-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.02(d, J=8.2 Hz, 1H), 7.71(m, 3H), 7.52(d, J=2.3 Hz, 1H), 7.39(m, 1H), 7.07(t, J=4.9 Hz, 2H), 6.90(m, 1H), 6.67(br, 1H), 6.60(m, 1H), 4.49(d, J=5.5 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.02 (d, J = 8.2 Hz, 1H), 7.71 (m, 3H), 7.52 (d, J = 2.3 Hz, 1H), 7.39 (m, 1H), 7.07 (t, J = 4.9 Hz, 2H), 6.90 (m, 1H), 6.67 (br, 1H), 6.60 (m, 1H), 4.49 (d, J = 5.5 Hz, 2H)

화합물번호 343. (3,5-디메톡시-벤질)-(2-퓨란-2-일-퀴나졸린-4-일)-아민Compound 343. (3,5-Dimethoxy-benzyl)-(2-furan-2-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.02(d, J=8.3 Hz, 1H), 7.84(d, J=8.2 Hz, 1H), 7.68(m, 2H), 7.45(d, J=3.1 Hz, 1H), 7.38(m, 1H), 6.65(m, 2H), 6.64(br, 1H), 6.57(m, 1H), 6.40(t, J=2.1 Hz, 1H), 4.90(d, J=5.3 Hz, 2H), 3.77(s, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.02 (d, J = 8.3 Hz, 1H), 7.84 (d, J = 8.2 Hz, 1H), 7.68 (m, 2H), 7.45 (d, J = 3.1 Hz , 1H), 7.38 (m, 1H), 6.65 (m, 2H), 6.64 (br, 1H), 6.57 (m, 1H), 6.40 (t, J = 2.1 Hz, 1H), 4.90 (d, J = 5.3 Hz, 2H), 3.77 (s, 6H)

화합물번호 344. (3,4-디메톡시-벤질)-(2-퓨란-2-일-퀴나졸린-4-일)-아민Compound 344. (3,4-Dimethoxy-benzyl)-(2-furan-2-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.00(d, J=8.3 Hz, 1H), 7.79(d, J=8.1 Hz, 1H), 7.66(t, J=2.3 Hz, 2H), 7.47(d, J=3.2 Hz, 1H), 7.36(m, 1H), 7.09(s, 1H), 7.01(m, 1H), 6.86(d, J=8.2 Hz, 1H), 6.59(m, 1H), 6.46(br, 1H), 4.99(d, J=5.3 Hz, 2H), 3.88(s, 3H), 3.85(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.00 (d, J = 8.3 Hz, 1H), 7.79 (d, J = 8.1 Hz, 1H), 7.66 (t, J = 2.3 Hz, 2H), 7.47 (d , J = 3.2 Hz, 1H, 7.36 (m, 1H), 7.09 (s, 1H), 7.01 (m, 1H), 6.86 (d, J = 8.2 Hz, 1H), 6.59 (m, 1H), 6.46 (br, 1H), 4.99 (d, J = 5.3 Hz, 2H), 3.88 (s, 3H), 3.85 (s, 3H)

화합물번호 345. (2-퓨란-2-일-퀴나졸린-4-일)-(3,4,5-트리메톡시-벤질)-아민Compound No. 345. (2-Furan-2-yl-quinazolin-4-yl)-(3,4,5-trimethoxy-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.01(d, J=8.3 Hz, 1H), 7.86(d, J=8.3 Hz, 1H), 7.65(t, J=6.2 Hz, 2H), 7.54(d, J=3.1 Hz, 1H), 7.34(t, J=7.5 Hz, 1H), 6.80(br, 1H), 6.77(s, 2H), 6.60(m, 1H), 4.99(d, J=5.4 Hz, 2H), 3.87(s, 9H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.01 (d, J = 8.3 Hz, 1H), 7.86 (d, J = 8.3 Hz, 1H), 7.65 (t, J = 6.2 Hz, 2H), 7.54 (d , J = 3.1 Hz, 1H), 7.34 (t, J = 7.5 Hz, 1H), 6.80 (br, 1H), 6.77 (s, 2H), 6.60 (m, 1H), 4.99 (d, J = 5.4 Hz , 2H), 3.87 (s, 9H)

화합물번호 346. (2,4-디메톡시-벤질)-(2-퓨란-2-일-퀴나졸린-4-일)-아민Compound 346. (2,4-Dimethoxy-benzyl)-(2-furan-2-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.01(d, J=8.2 Hz, 1H), 7.69(m, 3H),7.51(d, J=4.6 Hz, 1H), 7.38(t, J=7.4 Hz, 2H), 6.60(m, 1H), 6.48(m, 3H), 4.88(d, J=5.4 Hz, 2H), 3.89(s, 3H), 3.81(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.01 (d, J = 8.2 Hz, 1H), 7.69 (m, 3H), 7.51 (d, J = 4.6 Hz, 1H), 7.38 (t, J = 7.4 Hz , 2H), 6.60 (m, 1H), 6.48 (m, 3H), 4.88 (d, J = 5.4 Hz, 2H), 3.89 (s, 3H), 3.81 (s, 3H)

화합물번호 347. (2,5-디메톡시-벤질)-(2-퓨란-2-일-퀴나졸린-4-일)-아민Compound 347. (2,5-Dimethoxy-benzyl)-(2-furan-2-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.01(d, J=8.3 Hz, 1H), 7.70(m, 3H), 7.50(d, J=2.9 Hz, 1H), 7.41(d, J=7.3 Hz, 1H), 7.10(d, J=2.8 Hz, 1H), 6.84(m, 2H), 6.58(m, 1H), 4.94(d, J=5.4 Hz, 2H), 3.89(s, 3H), 3.74(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.01 (d, J = 8.3 Hz, 1H), 7.70 (m, 3H), 7.50 (d, J = 2.9 Hz, 1H), 7.41 (d, J = 7.3 Hz , 1H), 7.10 (d, J = 2.8 Hz, 1H), 6.84 (m, 2H), 6.58 (m, 1H), 4.94 (d, J = 5.4 Hz, 2H), 3.89 (s, 3H), 3.74 (s, 3H)

화합물번호 348. (2-퓨란-2-일-퀴나졸린-4-일)-(2,4,6-트리메톡시-벤질)-아민Compound 348. (2-Furan-2-yl-quinazolin-4-yl)-(2,4,6-trimethoxy-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.01(d, J=8.2 Hz, 1H), 7.67(m, 4H), 7.37(t, J=7.5 Hz, 1H), 6.60(m, 1H), 6.21(br, 1H), 6.17(s, 2H), 4.96(d, J=5.4 Hz, 2H), 3.87(s, 9H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.01 (d, J = 8.2 Hz, 1H), 7.67 (m, 4H), 7.37 (t, J = 7.5 Hz, 1H), 6.60 (m, 1H), 6.21 (br, 1H), 6.17 (s, 2H), 4.96 (d, J = 5.4 Hz, 2H), 3.87 (s, 9H)

화합물번호 349. (2-메톡시-벤질)-(2-티오펜-2-일-퀴나졸린-4-일)-아민Compound No. 349. (2-methoxy-benzyl)-(2-thiophen-2-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.21(d, J=3.3 Hz, 1H), 7.91(d, J=8.3 Hz, 1H), 7.68(m, 2H), 7.52(m, 2H), 7.37(t, J=7.6 Hz, 2H), 7.29(d, J=7.7 Hz, 1H), 7.19(t, J=4.2 Hz, 1H), 6.95(t, J=7.7 Hz, 2H), 6.49(br,1H), 4.98(d, J=5.3 Hz, 2H), 3.95(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.21 (d, J = 3.3 Hz, 1H), 7.91 (d, J = 8.3 Hz, 1H), 7.68 (m, 2H), 7.52 (m, 2H), 7.37 (t, J = 7.6 Hz, 2H), 7.29 (d, J = 7.7 Hz, 1H), 7.19 (t, J = 4.2 Hz, 1H), 6.95 (t, J = 7.7 Hz, 2H), 6.49 (br , 1H), 4.98 (d, J = 5.3 Hz, 2H), 3.95 (s, 3H)

화합물번호 350. (3-메톡시-벤질)-(2-티오펜-2-일-퀴나졸린-4-일)-아민Compound 350. (3-Methoxy-benzyl)-(2-thiophen-2-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.17(d, J=3.2 Hz, 1H), 7.91(d, J=8.3 Hz, 1H), 7.71(m, 2H), 7.47(m, 1H), 7.37(m, 1H), 7.28(m, 1H), 7.16(m, 1H), 7.06(d, J=7.4 Hz, 2H), 6.84(m, 1H), 6.30(br, 1H), 4.94(d, J=5.5 Hz, 2H), 3.79(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.17 (d, J = 3.2 Hz, 1H), 7.91 (d, J = 8.3 Hz, 1H), 7.71 (m, 2H), 7.47 (m, 1H), 7.37 (m, 1H), 7.28 (m, 1H), 7.16 (m, 1H), 7.06 (d, J = 7.4 Hz, 2H), 6.84 (m, 1H), 6.30 (br, 1H), 4.94 (d, J = 5.5 Hz, 2H), 3.79 (s, 3H)

화합물번호 351. (4-메톡시-벤질)-(2-티오펜-2-일-퀴나졸린-4-일)-아민Compound 351. (4-Methoxy-benzyl)-(2-thiophen-2-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.17(d, J=3.1 Hz, 1H), 7.90(d, J=8.5 Hz, 1H), 7.70(m, 2H), 7.46(m, 3H), 7.36(m, 1H), 7.17(t, J=4.3 Hz, 1H), 6.91(d, J=8.5 Hz, 2H), 6.23(br, 1H), 4.90(d, J=5.3 Hz, 2H), 3.82(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.17 (d, J = 3.1 Hz, 1H), 7.90 (d, J = 8.5 Hz, 1H), 7.70 (m, 2H), 7.46 (m, 3H), 7.36 (m, 1H), 7.17 (t, J = 4.3 Hz, 1H), 6.91 (d, J = 8.5 Hz, 2H), 6.23 (br, 1H), 4.90 (d, J = 5.3 Hz, 2H), 3.82 (s, 3H)

화합물번호 352. 벤조[1,3]디옥솔-5-일메틸-(2-티오펜-2-일-퀴나졸린-4-일)-아민Compound number 352. Benzo [1,3] dioxol-5-ylmethyl- (2-thiophen-2-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.10(d, J=3.1 Hz, 1H), 7.88(d, J=8.5 Hz, 1H), 7.69(m, 2H), 7.46(t, J=2.5 Hz, 1H), 7.38(m, 1H), 7.17(m, 1H), 6.96(t, J=7.5 Hz, 2H), 6.80(d, J=7.9 Hz, 1H), 6.11(br, 1H), 5.96(s, 2H), 4.87(d, J=5.3 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.10 (d, J = 3.1 Hz, 1H), 7.88 (d, J = 8.5 Hz, 1H), 7.69 (m, 2H), 7.46 (t, J = 2.5 Hz , 1H), 7.38 (m, 1H), 7.17 (m, 1H), 6.96 (t, J = 7.5 Hz, 2H), 6.80 (d, J = 7.9 Hz, 1H), 6.11 (br, 1H), 5.96 (s, 2H), 4.87 (d, J = 5.3 Hz, 2H)

화합물번호 353. (2,3-디메톡시-벤질)-(2-티오펜-2-일-퀴나졸린-4-일)-아민Compound number 353. (2,3-Dimethoxy-benzyl)-(2-thiophen-2-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.21(d, J=3.2 Hz, 1H), 7.91(d, J=8.2 Hz, 1H), 7.69(m, 2H), 7.49(d, J=4.8 Hz, 1H), 7.36(m, 1H), 7.17(m, 2H), 7.04(m, 1H), 6.90(d, J=7.2 Hz, 1H), 6.45(br, 1H), 5.00(d, J=5.4 Hz, 2H), 3.98(s, 3H), 3.90(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.21 (d, J = 3.2 Hz, 1H), 7.91 (d, J = 8.2 Hz, 1H), 7.69 (m, 2H), 7.49 (d, J = 4.8 Hz , 1H), 7.36 (m, 1H), 7.17 (m, 2H), 7.04 (m, 1H), 6.90 (d, J = 7.2 Hz, 1H), 6.45 (br, 1H), 5.00 (d, J = 5.4 Hz, 2H), 3.98 (s, 3H), 3.90 (s, 3H)

화합물번호 354. (3,5-디메톡시-벤질)-(2-티오펜-2-일-퀴나졸린-4-일)-아민Compound 354. (3,5-Dimethoxy-benzyl)-(2-thiophen-2-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.20(d, J=3.3 Hz, 1H), 7.92(d, J=8.4 Hz, 1H), 7.76(d, J=10.9 Hz, 1H), 7.68(t, J=7.7 Hz, 1H), 7.48(d, J=4.9 Hz, 1H), 7.36(t, J=7.6Hz, 1H), 7.16(m, 1H), 6.66(s, 2H), 6.41(s, 1H), 4.90(d, J=5.4 Hz, 2H), 3.78(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.20 (d, J = 3.3 Hz, 1H), 7.92 (d, J = 8.4 Hz, 1H), 7.76 (d, J = 10.9 Hz, 1H), 7.68 (t , J = 7.7 Hz, 1H), 7.48 (d, J = 4.9 Hz, 1H), 7.36 (t, J = 7.6 Hz, 1H), 7.16 (m, 1H), 6.66 (s, 2H), 6.41 (s , 1H), 4.90 (d, J = 5.4 Hz, 2H), 3.78 (s, 3H)

화합물번호 355. (3,4-디메톡시-벤질)-(2-티오펜-2-일-퀴나졸린-4-일)-아민Compound 355. (3,4-Dimethoxy-benzyl)-(2-thiophen-2-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.19(d, J=3.0 Hz, 1H), 7.91(d, J=8.5 Hz, 1H), 7.67(m, 2H), 7.49(t, J=2.5 Hz, 1H), 7.35(m, 1H), 7.17(m, 1H), 7.09(m, 1H), 7.01(m, 1H), 6.85(d, J=8.1 Hz, 1H), 6.38(br, 1H), 4.89(d, J=5.3 Hz, 2H), 3.88(s, 3H), 3.84(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.19 (d, J = 3.0 Hz, 1H), 7.91 (d, J = 8.5 Hz, 1H), 7.67 (m, 2H), 7.49 (t, J = 2.5 Hz , 1H), 7.35 (m, 1H), 7.17 (m, 1H), 7.09 (m, 1H), 7.01 (m, 1H), 6.85 (d, J = 8.1 Hz, 1H), 6.38 (br, 1H) , 4.89 (d, J = 5.3 Hz, 2H), 3.88 (s, 3H), 3.84 (s, 3H)

화합물번호 356. (2-티오펜-2-일-퀴나졸린-4-일)-(3,4,5-트리메톡시-벤질)-아민Compound 356. (2-thiophen-2-yl-quinazolin-4-yl)-(3,4,5-trimethoxy-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.19(d, J=3.1 Hz, 1H), 7.91(d, J=8.4 Hz, 1H), 7.79(d, J=8.1 Hz, 1H), 7.68(t, J=7.6 Hz, 1H), 7.48(d, J=5.0 Hz, 1H), 7.36(t, J=7.6 Hz, 1H), 7.17(t, J=4.3 Hz, 1H), 6.75(s, 2H), 6.43(br, 1H), 4.88(d, J=5.4 Hz, 2H), 3.85(s, 9H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.19 (d, J = 3.1 Hz, 1H), 7.91 (d, J = 8.4 Hz, 1H), 7.79 (d, J = 8.1 Hz, 1H), 7.68 (t , J = 7.6 Hz, 1H), 7.48 (d, J = 5.0 Hz, 1H), 7.36 (t, J = 7.6 Hz, 1H), 7.17 (t, J = 4.3 Hz, 1H), 6.75 (s, 2H ), 6.43 (br, 1H), 4.88 (d, J = 5.4 Hz, 2H), 3.85 (s, 9H)

화합물번호 357. (2,4-디메톡시-벤질)-(2-티오펜-2-일-퀴나졸린-4-일)-아민Compound number 357. (2,4-Dimethoxy-benzyl)-(2-thiophen-2-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.23(d, J=3.0 Hz, 1H), 7.91(d, J=8.2 Hz, 1H), 7.65(m, 2H), 7.48(t, J=7.6 Hz, 2H), 7.38(d, J=7.9Hz, 1H), 7.19(m, 1H), 6.48(m, 3H), 4.90(d, J=5.4 Hz, 2H), 3.93(s, 3H), 3.80(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.23 (d, J = 3.0 Hz, 1H), 7.91 (d, J = 8.2 Hz, 1H), 7.65 (m, 2H), 7.48 (t, J = 7.6 Hz , 2H), 7.38 (d, J = 7.9 Hz, 1H), 7.19 (m, 1H), 6.48 (m, 3H), 4.90 (d, J = 5.4 Hz, 2H), 3.93 (s, 3H), 3.80 (s, 3H)

화합물번호 358. (2,5-디메톡시-벤질)-(2-티오펜-2-일-퀴나졸린-4-일)-아민Compound 358. (2,5-Dimethoxy-benzyl)-(2-thiophen-2-yl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.22(d, J=3.1 Hz, 1H), 7.91(d, J=8.5 Hz, 1H), 7.69(m, 2H), 7.49(t, J=3.5 Hz, 1H), 7.37(m, 1H), 7.18(m, 2H), 6.81(t, J=4.8 Hz, 2H), 6.52(br, 1H), 4.95(d, J=5.3 Hz, 2H), 3.90(s, 3H), 3.74(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.22 (d, J = 3.1 Hz, 1H), 7.91 (d, J = 8.5 Hz, 1H), 7.69 (m, 2H), 7.49 (t, J = 3.5 Hz , 1H), 7.37 (m, 1H), 7.18 (m, 2H), 6.81 (t, J = 4.8 Hz, 2H), 6.52 (br, 1H), 4.95 (d, J = 5.3 Hz, 2H), 3.90 (s, 3 H), 3.74 (s, 3 H)

화합물번호 359. (2-티오펜-2-일-퀴나졸린-4-일)-(2,4,6-트리메톡시-벤질)-아민Compound number 359. (2-thiophen-2-yl-quinazolin-4-yl)-(2,4,6-trimethoxy-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.28(d, J=3.2 Hz, 1H), 7.93(d, J=8.4 Hz, 1H), 7.65(m, 2H), 7.49(d, J=4.8 Hz, 1H), 7.35(t, J=7.6 Hz, 1H), 7.19(t, J=4.3 Hz, 1H), 6.20(br, 1H), 6.18(s, 2H), 5.00(d, J=5.3 Hz, 2H), 3.88(s, 9H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.28 (d, J = 3.2 Hz, 1H), 7.93 (d, J = 8.4 Hz, 1H), 7.65 (m, 2H), 7.49 (d, J = 4.8 Hz , 1H), 7.35 (t, J = 7.6 Hz, 1H), 7.19 (t, J = 4.3 Hz, 1H), 6.20 (br, 1H), 6.18 (s, 2H), 5.00 (d, J = 5.3 Hz , 2H), 3.88 (s, 9H)

화합물번호 360. (2-메톡시-벤질)-[2-(메톡시-페닐-메틸)-퀴나졸린-4-일]-아민Compound No. 360. (2-Methoxy-benzyl)-[2- (methoxy-phenyl-methyl) -quinazolin-4-yl] -amine

1H NMR(CDCl3, 300 MHz) δ 7.90(d, J=8.4 Hz, 1H), 7.68-7.55(m, 4H), 7.38-7.20(m, 6H), 6.85(m, 2H), 6.24(br, 1H), 5.41(s, 1H), 4.84(d, J=6.0 Hz, 2H), 3.87(s, 3H), 3.50(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.90 (d, J = 8.4 Hz, 1H), 7.68-7.55 (m, 4H), 7.38-7.20 (m, 6H), 6.85 (m, 2H), 6.24 ( br, 1H), 5.41 (s, 1H), 4.84 (d, J = 6.0 Hz, 2H), 3.87 (s, 3H), 3.50 (s, 3H)

화합물번호 361. (3-메톡시-벤질)-[2-(메톡시-페닐-메틸)-퀴나졸린-4-일]-아민Compound 361. (3-Methoxy-benzyl)-[2- (methoxy-phenyl-methyl) -quinazolin-4-yl] -amine

1H NMR(CDCl3, 300 MHz) δ 7.95(d, J=8.3 Hz, 1H), 7.75(d, J=8.1 Hz, 1H), 7.64(m, 3H), 7.28(m, 5H), 6.94(s, 2H), 6.83(d, J=8.1 Hz, 1H), 6.59(br, 1H), 5.42(s, 1H), 4.83(d, J=4.9 Hz, 2H), 3.76(s, 3H), 3.49(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.95 (d, J = 8.3 Hz, 1H), 7.75 (d, J = 8.1 Hz, 1H), 7.64 (m, 3H), 7.28 (m, 5H), 6.94 (s, 2H), 6.83 (d, J = 8.1 Hz, 1H), 6.59 (br, 1H), 5.42 (s, 1H), 4.83 (d, J = 4.9 Hz, 2H), 3.76 (s, 3H) , 3.49 (s, 3H)

화합물번호 362. (4-메톡시-벤질)-[2-(메톡시-페닐-메틸)-퀴나졸린-4-일]-아민Compound No. 362. (4-Methoxy-benzyl)-[2- (methoxy-phenyl-methyl) -quinazolin-4-yl] -amine

1H NMR(CDCl3, 300 MHz) δ 7.93(d, J=8.4 Hz, 1H), 7.70-7.57(m, 4H), 7.39-7.22(m, 6H), 6.81(d, J=8.4 Hz, 2H), 5.89(br, 1H), 5.42(s, 1H), 4.76(d, J=5.4 Hz, 2H), 3.79(s, 3H), 3.50(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.93 (d, J = 8.4 Hz, 1H), 7.70-7.57 (m, 4H), 7.39-7.22 (m, 6H), 6.81 (d, J = 8.4 Hz, 2H), 5.89 (br, 1H), 5.42 (s, 1H), 4.76 (d, J = 5.4 Hz, 2H), 3.79 (s, 3H), 3.50 (s, 3H)

화합물번호 363. 벤조[1,3]디옥솔-5-일메틸-[2-(메톡시-페닐-메틸)-퀴나졸린-4-일]-아민Compound No. 363. Benzo [1,3] dioxol-5-ylmethyl- [2- (methoxy-phenyl-methyl) -quinazolin-4-yl] -amine

1H NMR(CDCl3, 300 MHz) δ 7.95(d, J=8.3 Hz, 1H), 7.81(d, J=8.1 Hz, 1H), 7.64(m, 2H), 7.35(m, 5H), 6.83(m, 2H), 6.70(d, J=7.9 Hz, 1H), 5.93(s, 2H), 5.46(s, 1H), 4.76(d, J=5.1 Hz, 2H), 3.51(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.95 (d, J = 8.3 Hz, 1H), 7.81 (d, J = 8.1 Hz, 1H), 7.64 (m, 2H), 7.35 (m, 5H), 6.83 (m, 2H), 6.70 (d, J = 7.9 Hz, 1H), 5.93 (s, 2H), 5.46 (s, 1H), 4.76 (d, J = 5.1 Hz, 2H), 3.51 (s, 3H)

화합물번호 364. (2,3-디메톡시-벤질)-[2-(메톡시-페닐-메틸)-퀴나졸린-4-일]-아민Compound No. 364. (2,3-Dimethoxy-benzyl)-[2- (methoxy-phenyl-methyl) -quinazolin-4-yl] -amine

1H NMR(CDCl3, 300 MHz) δ 8.00(d, J=8.3 Hz, 1H), 7.69(m, 3H), 7.32(m, 5H), 6.89(m, 3H), 5.50(s, 1H), 4.90(d, J=5.2 Hz, 2H), 3.93(s, 3H), 3.88(s, 3H), 3.51(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.00 (d, J = 8.3 Hz, 1H), 7.69 (m, 3H), 7.32 (m, 5H), 6.89 (m, 3H), 5.50 (s, 1H) , 4.90 (d, J = 5.2 Hz, 2H), 3.93 (s, 3H), 3.88 (s, 3H), 3.51 (s, 3H)

화합물번호 365. (3,5-디메톡시-벤질)-[2-(메톡시-페닐-메틸)-퀴나졸린-4-일]-아민Compound No. 365. (3,5-Dimethoxy-benzyl)-[2- (methoxy-phenyl-methyl) -quinazolin-4-yl] -amine

1H NMR(CDCl3, 300 MHz) δ 7.95(d, J=8.3 Hz, 1H), 7.77(d, 1H, J=8.1 Hz), 7.65(m, 3H), 7.31(m, 5H), 6.60(br, 1H), 6.55(s, 2H), 6.39(d, J=2.0 Hz, 1H), 5.44(s, 1H), 4.81(d, J=5.1 Hz, 2H), 3.75(s, 6H), 3.49(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.95 (d, J = 8.3 Hz, 1H), 7.77 (d, 1H, J = 8.1 Hz), 7.65 (m, 3H), 7.31 (m, 5H), 6.60 (br, 1H), 6.55 (s, 2H), 6.39 (d, J = 2.0 Hz, 1H), 5.44 (s, 1H), 4.81 (d, J = 5.1 Hz, 2H), 3.75 (s, 6H) , 3.49 (s, 3H)

화합물번호 366. (3,4-디메톡시-벤질)-[2-(메톡시-페닐-메틸)-퀴나졸린-4-일]-아민Compound 366. (3,4-Dimethoxy-benzyl)-[2- (methoxy-phenyl-methyl) -quinazolin-4-yl] -amine

1H NMR(CDCl3, 300 MHz) δ 7.94(d, J=8.4 Hz, 1H), 7.78(d, J=8.1 Hz, 1H), 7.68(d, J=6.9 Hz, 2H), 7.58(t, J=7.6 Hz, 1H), 7.33(m, 5H), 6.96(s, 1H), 6.91(t, J=4.1 Hz, 1H), 5.45(s, 1H), 4.80(d, J=5.2 Hz, 2H), 3.88(s, 3H), 3.80(s, 3H), 3.50(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.94 (d, J = 8.4 Hz, 1H), 7.78 (d, J = 8.1 Hz, 1H), 7.68 (d, J = 6.9 Hz, 2H), 7.58 (t , J = 7.6 Hz, 1H), 7.33 (m, 5H), 6.96 (s, 1H), 6.91 (t, J = 4.1 Hz, 1H), 5.45 (s, 1H), 4.80 (d, J = 5.2 Hz , 2H), 3.88 (s, 3H), 3.80 (s, 3H), 3.50 (s, 3H)

화합물번호 367. [2-(메톡시-페닐-메틸)-퀴나졸린-4-일]-(3,4,5-트리메톡시-벤질)-아민Compound number 367. [2- (methoxy-phenyl-methyl) -quinazolin-4-yl]-(3,4,5-trimethoxy-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.95(d, J=8.3 Hz, 1H), 7.83(d, J=8.2 Hz, 1H), 7.63(m, 3H), 7.30(m, 5H), 6.75(br, 1H), 6.64(s, 2H), 5.45(s, 1H), 4.80(d, J=5.2 Hz, 2H), 3.78(s, 9H), 3.48(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.95 (d, J = 8.3 Hz, 1H), 7.83 (d, J = 8.2 Hz, 1H), 7.63 (m, 3H), 7.30 (m, 5H), 6.75 (br, 1H), 6.64 (s, 2H), 5.45 (s, 1H), 4.80 (d, J = 5.2 Hz, 2H), 3.78 (s, 9H), 3.48 (s, 3H)

화합물번호 368. (2,4-디메톡시-벤질)-[2-(메톡시-페닐-메틸)-퀴나졸린-4-일]-아민Compound number 368. (2,4-Dimethoxy-benzyl)-[2- (methoxy-phenyl-methyl) -quinazolin-4-yl] -amine

1H NMR(CDCl3, 300 MHz) δ 7.97(d, J=8.3 Hz, 1H), 7.67(m, 4H), 7.33(m, 5H), 7.18(d, J=8.3 Hz, 1H), 6.48(br, 1H), 6.45(s, 1H), 6.35(m, 1H), 5.50(s, 1H), 4.79(d, J=5.1 Hz, 2H), 8.85(s, 3H), 3.79(s, 3H), 3.52(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.97 (d, J = 8.3 Hz, 1H), 7.67 (m, 4H), 7.33 (m, 5H), 7.18 (d, J = 8.3 Hz, 1H), 6.48 (br, 1H), 6.45 (s, 1H), 6.35 (m, 1H), 5.50 (s, 1H), 4.79 (d, J = 5.1 Hz, 2H), 8.85 (s, 3H), 3.79 (s, 3H), 3.52 (s, 3H)

화합물번호 369. (2,5-디메톡시-벤질)-[2-(메톡시-페닐-메틸)-퀴나졸린-4-일]-아민Compound 369. (2,5-Dimethoxy-benzyl)-[2- (methoxy-phenyl-methyl) -quinazolin-4-yl] -amine

1H NMR(CDCl3, 300 MHz) δ 7.96(d, J=8.3 Hz, 1H), 7.66(m, 4H), 7.34(m, 5H), 6.97(s, 1H), 6.80(t, J=3.8 Hz, 1H), 6.54(br, 1H), 5.47(s, 1H), 4.86(d, J=5.0 Hz, 2H), 3.86(s, 3H), 3.72(s, 3H), 3.50(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.96 (d, J = 8.3 Hz, 1H), 7.66 (m, 4H), 7.34 (m, 5H), 6.97 (s, 1H), 6.80 (t, J = 3.8 Hz, 1H), 6.54 (br, 1H), 5.47 (s, 1H), 4.86 (d, J = 5.0 Hz, 2H), 3.86 (s, 3H), 3.72 (s, 3H), 3.50 (s, 3H)

화합물번호 370. [2-(메톡시-페닐-메틸)-퀴나졸린-4-일]-(2,4,6-트리메톡시-벤질)-아민Compound 370. [2- (methoxy-phenyl-methyl) -quinazolin-4-yl]-(2,4,6-trimethoxy-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.89(d, J=8.1 Hz, 1H), 7.75(dd, J 1 =8.4 Hz, J 2 =1.2 Hz, 2H), 7.63(td, J 1 =6.9 Hz, J 2 =1.2 Hz, 1H), 7.51(d, J=7.2 Hz, 1H), 7.35-7.21(m, 4H), 6.16(s, 2H), 5.98(br, 1H), 5.43(s, 1H), 4.87(d, J=5.4 Hz, 2H), 3.82(s, 3H), 3.80(s, 6H), 3.52(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.89 (d, J = 8.1 Hz, 1H), 7.75 (dd, J 1 = 8.4 Hz, J 2 = 1.2 Hz, 2H), 7.63 (td, J 1 = 6.9 Hz, J 2 = 1.2 Hz, 1H), 7.51 (d, J = 7.2 Hz, 1H), 7.35-7.21 (m, 4H), 6.16 (s, 2H), 5.98 (br, 1H), 5.43 (s, 1H), 4.87 (d, J = 5.4 Hz, 2H), 3.82 (s, 3H), 3.80 (s, 6H), 3.52 (s, 3H)

화합물번호 371. (2-메톡시-벤질)-[2-(1-페닐-에틸)-퀴나졸린-4-일]-아민Compound 371. (2-Methoxy-benzyl)-[2- (1-phenyl-ethyl) -quinazolin-4-yl] -amine

1H NMR(CDCl3, 300 MHz) δ 7.85(d, J=8.6 Hz, 1H), 7.64(m, 2H), 7.56(d, J=7.4 Hz, 2H), 7.30(m, 6H), 6.90(t, J=7.9 Hz, 2H), 6.55(br, 1H), 4.90(d, J=5.4 Hz, 2H), 4.40(d, J=7.0 Hz, 1H), 3.92(s, 3H), 1.79(d, J=7.1 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.85 (d, J = 8.6 Hz, 1H), 7.64 (m, 2H), 7.56 (d, J = 7.4 Hz, 2H), 7.30 (m, 6H), 6.90 (t, J = 7.9 Hz, 2H), 6.55 (br, 1H), 4.90 (d, J = 5.4 Hz, 2H), 4.40 (d, J = 7.0 Hz, 1H), 3.92 (s, 3H), 1.79 (d, J = 7.1 Hz, 3H)

화합물번호 372. (3-메톡시-벤질)-[2-(1-페닐-에틸)-퀴나졸린-4-일]-아민Compound number 372. (3-Methoxy-benzyl)-[2- (1-phenyl-ethyl) -quinazolin-4-yl] -amine

1H NMR(CDCl3, 300 MHz) δ 7.85(d, J=8.6 Hz, 1H), 7.74(d, J=8.1 Hz, 1H), 7.63(m, 1H), 7.51(d, J=7.2 Hz, 2H), 7.25(m, 5H), 6.97(d, J=7.9 Hz, 2H), 6.86(d, J=2.0 Hz, 1H), 4.88(d, J=5.4 Hz, 2H), 4.36(m, 1H), 3.77(s, 3H), 1.75(d, J=7.1 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.85 (d, J = 8.6 Hz, 1H), 7.74 (d, J = 8.1 Hz, 1H), 7.63 (m, 1H), 7.51 (d, J = 7.2 Hz , 2H), 7.25 (m, 5H), 6.97 (d, J = 7.9 Hz, 2H), 6.86 (d, J = 2.0 Hz, 1H), 4.88 (d, J = 5.4 Hz, 2H), 4.36 (m , 1H), 3.77 (s, 3H), 1.75 (d, J = 7.1 Hz, 3H)

화합물번호 373. (4-메톡시-벤질)-[2-(1-페닐-에틸)-퀴나졸린-4-일]-아민Compound 373. (4-Methoxy-benzyl)-[2- (1-phenyl-ethyl) -quinazolin-4-yl] -amine

1H NMR(CDCl3, 300 MHz) δ 7.84(d, J=8.5 Hz, 1H), 7.73(d, J=8.1 Hz, 1H), 7.62(t, J=7.6 Hz, 1H), 7.53(d, J=7.6 Hz, 2H), 7.27(m, 6H), 6.85(d, J=7.6 Hz, 2H), 6.38(br, 1H), 4.81(d, J=5.5 Hz, 2H), 4.40(m, 1H), 3.81(s, 3H), 1.78(d, J=7.3 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.84 (d, J = 8.5 Hz, 1H), 7.73 (d, J = 8.1 Hz, 1H), 7.62 (t, J = 7.6 Hz, 1H), 7.53 (d , J = 7.6 Hz, 2H), 7.27 (m, 6H), 6.85 (d, J = 7.6 Hz, 2H), 6.38 (br, 1H), 4.81 (d, J = 5.5 Hz, 2H), 4.40 (m , 1H), 3.81 (s, 3H), 1.78 (d, J = 7.3 Hz, 3H)

화합물번호 374. 벤조[1,3]디옥솔-5-일메틸-[2-(1-페닐-에틸)-퀴나졸린-4-일]-아민Compound 374. Benzo [1,3] dioxol-5-ylmethyl- [2- (1-phenyl-ethyl) -quinazolin-4-yl] -amine

1H NMR(CDCl3, 300 MHz) δ 7.85(d, J=8.4 Hz, 1H), 7.75(d, J=8.5 Hz, 1H), 7.63(m, 1H), 5.52(d, J=7.5 Hz, 2H), 7.28(m, 4H), 6.85(t, J=6.7 Hz, 2H), 6.73(d, J=7.8 Hz, 1H), 6.49(br, 1H), 5.94(s, 2H), 4.78(d, J=5.4 Hz, 2H), 4.40(m, 1H), 1.78(d, J=7.2 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.85 (d, J = 8.4 Hz, 1H), 7.75 (d, J = 8.5 Hz, 1H), 7.63 (m, 1H), 5.52 (d, J = 7.5 Hz , 2H), 7.28 (m, 4H), 6.85 (t, J = 6.7 Hz, 2H), 6.73 (d, J = 7.8 Hz, 1H), 6.49 (br, 1H), 5.94 (s, 2H), 4.78 (d, J = 5.4 Hz, 2H), 4.40 (m, 1H), 1.78 (d, J = 7.2 Hz, 3H)

화합물번호 375. (2,3-디메톡시-벤질)-[2-(1-페닐-에틸)-퀴나졸린-4-일]-아민Compound 375. (2,3-Dimethoxy-benzyl)-[2- (1-phenyl-ethyl) -quinazolin-4-yl] -amine

1H NMR(CDCl3, 300 MHz) δ 7.85(d, J=8.0 Hz, 1H), 7.65(m, 2H), 7.55(d, J=7.5 Hz, 2H), 7.28(m, 5H), 6.91(m, 3H), 6.54(br, 1H), 4.91(d, J=5.4 Hz, 2H), 4.41(m, 1H), 3.94(s, 3H), 3.89(s, 3H), 1.78(d, J=7.4 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.85 (d, J = 8.0 Hz, 1H), 7.65 (m, 2H), 7.55 (d, J = 7.5 Hz, 2H), 7.28 (m, 5H), 6.91 (m, 3H), 6.54 (br, 1H), 4.91 (d, J = 5.4 Hz, 2H), 4.41 (m, 1H), 3.94 (s, 3H), 3.89 (s, 3H), 1.78 (d, J = 7.4 Hz, 3H)

화합물번호 376. (3,5-디메톡시-벤질)-[2-(1-페닐-에틸)-퀴나졸린-4-일]-아민Compound number 376. (3,5-Dimethoxy-benzyl)-[2- (1-phenyl-ethyl) -quinazolin-4-yl] -amine

1H NMR(CDCl3, 300 MHz) δ 7.84(d, J=8.3 Hz, 1H), 7.74(d, J=8.1 Hz, 1H), 7.63(m, 1H), 7.52(d, J=7.3 Hz, 2H), 7.24(m, 4H), 6.56(s, 2H), 6.41(s, 1H), 4.48(d, J=5.3 Hz, 2H), 4.38(m, 1H), 3.75(s, 6H), 1.78(d, J=7.1 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.84 (d, J = 8.3 Hz, 1H), 7.74 (d, J = 8.1 Hz, 1H), 7.63 (m, 1H), 7.52 (d, J = 7.3 Hz , 2H), 7.24 (m, 4H), 6.56 (s, 2H), 6.41 (s, 1H), 4.48 (d, J = 5.3 Hz, 2H), 4.38 (m, 1H), 3.75 (s, 6H) , 1.78 (d, J = 7.1 Hz, 3H)

화합물번호 377. (3,4-디메톡시-벤질)-[2-(1-페닐-에틸)-퀴나졸린-4-일]-아민Compound 377. (3,4-Dimethoxy-benzyl)-[2- (1-phenyl-ethyl) -quinazolin-4-yl] -amine

1H NMR(CDCl3, 300 MHz) δ 7.83(d, J=8.3 Hz, 1H), 7.75(d, J=8.2 Hz, 1H), 7.62(d, J=7.4 Hz, 1H), 7.53(d, J=7.2 Hz, 2H), 7.25(m, 5H), 6.94(d, J=5.6 Hz, 2H), 6.82(d, J=8.6 Hz, 1H), 6.32(br, 1H), 4.84(d, J=5.4 Hz, 2H), 4.38(m, 1H), 3.89(s, 3H), 3.79(s, 3H), 1.78(d, J=7.1 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.83 (d, J = 8.3 Hz, 1H), 7.75 (d, J = 8.2 Hz, 1H), 7.62 (d, J = 7.4 Hz, 1H), 7.53 (d , J = 7.2 Hz, 2H), 7.25 (m, 5H), 6.94 (d, J = 5.6 Hz, 2H), 6.82 (d, J = 8.6 Hz, 1H), 6.32 (br, 1H), 4.84 (d , J = 5.4 Hz, 2H), 4.38 (m, 1H), 3.89 (s, 3H), 3.79 (s, 3H), 1.78 (d, J = 7.1 Hz, 3H)

화합물번호 378. [2-(1-페닐-에틸)-퀴나졸린-4-일]-(3,4,5-트리메톡시-벤질)-아민Compound number 378. [2- (1-phenyl-ethyl) -quinazolin-4-yl]-(3,4,5-trimethoxy-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.82(t, J=9.2 Hz, 2H), 7.54(m, 2H), 7.27(m, 5H), 6.65(s, 2H), 4.86(d, J=5.4 Hz, 2H), 4.40(m, 1H), 3.79(s, 9H), 1.78(d, J=7.1 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.82 (t, J = 9.2 Hz, 2H), 7.54 (m, 2H), 7.27 (m, 5H), 6.65 (s, 2H), 4.86 (d, J = 5.4 Hz, 2H), 4.40 (m, 1H), 3.79 (s, 9H), 1.78 (d, J = 7.1 Hz, 3H)

화합물번호 379. (2,4-디메톡시-벤질)-[2-(1-페닐-에틸)-퀴나졸린-4-일]-아민Compound No. 379. (2,4-Dimethoxy-benzyl)-[2- (1-phenyl-ethyl) -quinazolin-4-yl] -amine

1H NMR(CDCl3, 300 MHz) δ 7.85(d, J=8.4 Hz, 1H), 7.60(m, 4H), 7.32(m, 3H), 7.21(t, J=6.9 Hz, 2H), 6.48(d, J=2.0 Hz, 1H), 6.39(br, 1H), 6.36(d, J=8.1 Hz, 1H), 4.48(d, J=5.3 Hz, 2H), 4.40(m, 1H), 3.88(s, 3H), 3.82(s, 3H), 1,80(d, J=7.1 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.85 (d, J = 8.4 Hz, 1H), 7.60 (m, 4H), 7.32 (m, 3H), 7.21 (t, J = 6.9 Hz, 2H), 6.48 (d, J = 2.0 Hz, 1H), 6.39 (br, 1H), 6.36 (d, J = 8.1 Hz, 1H), 4.48 (d, J = 5.3 Hz, 2H), 4.40 (m, 1H), 3.88 (s, 3H), 3.82 (s, 3H), 1,80 (d, J = 7.1 Hz, 3H)

화합물번호 380. (2,5-디메톡시-벤질)-[2-(1-페닐-에틸)-퀴나졸린-4-일]-아민Compound 380. (2,5-Dimethoxy-benzyl)-[2- (1-phenyl-ethyl) -quinazolin-4-yl] -amine

1H NMR(CDCl3, 300 MHz) δ 7.83(d, J=8.2 Hz, 1H), 7.63(m, 2H), 7.56(d, J=7.4 Hz, 2H), 7.35(m, 1H), 7.28(m, 2H), 7.19(d, J=7.3 Hz, 1H), 6.98(d, J=2.8 Hz, 1H), 6.82(m, 2H), 6.28(br, 1H), 4.88(d, J=5.4 Hz, 2H), 4.38(m, 2H), 3.88(s, 3H), 3.79(s, 3H), 1.79(d, J=7.1 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.83 (d, J = 8.2 Hz, 1H), 7.63 (m, 2H), 7.56 (d, J = 7.4 Hz, 2H), 7.35 (m, 1H), 7.28 (m, 2H), 7.19 (d, J = 7.3 Hz, 1H), 6.98 (d, J = 2.8 Hz, 1H), 6.82 (m, 2H), 6.28 (br, 1H), 4.88 (d, J = 5.4 Hz, 2H), 4.38 (m, 2H), 3.88 (s, 3H), 3.79 (s, 3H), 1.79 (d, J = 7.1 Hz, 3H)

화합물번호 381. [2-(1-페닐-에틸)-퀴나졸린-4-일]-(2,4,6-트리메톡시-벤질)-아민Compound 381. [2- (1-phenyl-ethyl) -quinazolin-4-yl]-(2,4,6-trimethoxy-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.76(d, J=8.4 Hz, 1H), 7.64-7.50(m, 4H), 7.31-7.24(m, 3H), 7.16(t, J=7.2 Hz, 1H), 6.17(s, 2H), 6.03(br, 1H), 5.02-4.83(m, 2H), 4.31(q, J=7.2 Hz, 1H), 3.83(s, 9H), 1.80(d, J=7.2 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.76 (d, J = 8.4 Hz, 1H), 7.64-7.50 (m, 4H), 7.31-7.24 (m, 3H), 7.16 (t, J = 7.2 Hz, 1H), 6.17 (s, 2H), 6.03 (br, 1H), 5.02-4.83 (m, 2H), 4.31 (q, J = 7.2 Hz, 1H), 3.83 (s, 9H), 1.80 (d, J = 7.2 Hz, 3H)

화합물번호 382. (2-싸이클로프로필-퀴나졸린-4-일)-(2-메톡시-벤질)-아민Compound No. 382. (2-Cyclopropyl-quinazolin-4-yl)-(2-methoxy-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.75(d, J=8.0 Hz, 1H), 7.62(m, 2H), 7.35(m, 3H), 6.93(m, 2H), 6.32(br, 1H), 4.81(d, J=5.4 Hz, 2H), 3.98(s, 3H), 2.19(m, 1H), 1.25(m, 2H), 1.01(m, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.75 (d, J = 8.0 Hz, 1H), 7.62 (m, 2H), 7.35 (m, 3H), 6.93 (m, 2H), 6.32 (br, 1H) , 4.81 (d, J = 5.4 Hz, 2H), 3.98 (s, 3H), 2.19 (m, 1H), 1.25 (m, 2H), 1.01 (m, 2H)

화합물번호 383. (2-싸이클로프로필-퀴나졸린-4-일)-(3-메톡시-벤질)-아민Compound 383. (2-Cyclopropyl-quinazolin-4-yl)-(3-methoxy-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.77-7.61(m, 3H), 7.35-7.24(m, 2H), 6.94(m, 2H), 6.84(dd, J 1 =8.4 Hz, J 2 =2.7 Hz, 1H), 5.93(br, 1H), 4.78(d, J=5.7 Hz, 2H), 3.79(s, 3H), 2.17(m, 1H), 1.17(m, 2H), 0.95(m, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.77-7.61 (m, 3H), 7.35-7.24 (m, 2H), 6.94 (m, 2H), 6.84 (dd, J 1 = 8.4 Hz, J 2 = 2.7 Hz, 1H), 5.93 (br, 1H), 4.78 (d, J = 5.7 Hz, 2H), 3.79 (s, 3H), 2.17 (m, 1H), 1.17 (m, 2H), 0.95 (m, 2H )

화합물번호 384. (2-싸이클로프로필-퀴나졸린-4-일)-(4-메톡시-벤질)-아민Compound 384. (2-Cyclopropyl-quinazolin-4-yl)-(4-methoxy-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.78(d, J=7.9 Hz, 1H), 7.70(m, 2H), 7.35(m, 3H), 6.90(d, J=7.8 Hz, 2H), 5.98(br, 1H), 4.74(d, J=5.4 Hz, 2H), 3.82(s, 3H), 2.20(m, 1H), 1.21(m, 2H), 1.01(m, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.78 (d, J = 7.9 Hz, 1H), 7.70 (m, 2H), 7.35 (m, 3H), 6.90 (d, J = 7.8 Hz, 2H), 5.98 (br, 1H), 4.74 (d, J = 5.4 Hz, 2H), 3.82 (s, 3H), 2.20 (m, 1H), 1.21 (m, 2H), 1.01 (m, 2H)

화합물번호 385. 벤조[1,3]디옥솔-5-일메틸-(2-싸이클로프로필-퀴나졸린-4-일)-아민Compound No. 385. Benzo [1,3] dioxol-5-ylmethyl- (2-cyclopropyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.76(d, J=8.0 Hz, 1H), 7.66(m, 2H), 7.43(m, 1H), 6.84(m, 3H), 5.96(s, 2H), 4.71(d, J=5.4 Hz, 2H), 2.19(m, 1H), 1.20(m, 2H), 1.01(m, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.76 (d, J = 8.0 Hz, 1H), 7.66 (m, 2H), 7.43 (m, 1H), 6.84 (m, 3H), 5.96 (s, 2H) , 4.71 (d, J = 5.4 Hz, 2H), 2.19 (m, 1H), 1.20 (m, 2H), 1.01 (m, 2H)

화합물번호 386. (2-싸이클로프로필-퀴나졸린-4-일)-(2,3-디메톡시-벤질)-아민Compound No. 386. (2-Cyclopropyl-quinazolin-4-yl)-(2,3-dimethoxy-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.74(d, J=7.9 Hz, 1H), 7.64(m, 2H), 7.32(d, J=8.4 Hz, 1H), 6.99(m, 2H), 6.89(m, 1H), 6.32(br, 1H), 4.83(d, J=5.4 Hz, 2H), 3.94(s, 3H), 3.89(s, 3H), 2.18(m, 1H), 1.22(m, 2H), 1.01(m, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.74 (d, J = 7.9 Hz, 1H), 7.64 (m, 2H), 7.32 (d, J = 8.4 Hz, 1H), 6.99 (m, 2H), 6.89 (m, 1H), 6.32 (br, 1H), 4.83 (d, J = 5.4 Hz, 2H), 3.94 (s, 3H), 3.89 (s, 3H), 2.18 (m, 1H), 1.22 (m, 2H), 1.01 (m, 2H)

화합물번호 387. (2-싸이클로프로필-퀴나졸린-4-일)-(3,5-디메톡시-벤질)-아민Compound No. 387. (2-Cyclopropyl-quinazolin-4-yl)-(3,5-dimethoxy-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.76(d, J=7.8 Hz, 1H), 7.66(m, 2H), 7.35(m, 1H), 6.54(s, 2H), 6.39(s, 1H), 6.23(br, 1H), 4.74(d, J=5.4 Hz, 2H), 3.79(s, 6H), 2.18(m, 1H), 1.19(m, 2H), 0.99(m, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.76 (d, J = 7.8 Hz, 1H), 7.66 (m, 2H), 7.35 (m, 1H), 6.54 (s, 2H), 6.39 (s, 1H) , 6.23 (br, 1H), 4.74 (d, J = 5.4 Hz, 2H), 3.79 (s, 6H), 2.18 (m, 1H), 1.19 (m, 2H), 0.99 (m, 2H)

화합물번호 388. (2-싸이클로프로필-퀴나졸린-4-일)-(3,4-디메톡시-벤질)-아민Compound No. 388. (2-Cyclopropyl-quinazolin-4-yl)-(3,4-dimethoxy-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.76(d, J=7.8 Hz, 1H), 7.67(t, J=7.4 Hz, 2H), 7.31(t, J=3.8 Hz, 1H), 6.94(d, J=5.0 Hz, 2H), 6.84(t, J=4.3 Hz, 1H), 6.07 (br, 1H), 4.74(d, J=5.4 Hz, 2H), 3.89(s, 3H), 3.87(s, 3H), 2.20(m, 1H), 1.22(m, 2H), 1.00(m, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.76 (d, J = 7.8 Hz, 1H), 7.67 (t, J = 7.4 Hz, 2H), 7.31 (t, J = 3.8 Hz, 1H), 6.94 (d , J = 5.0 Hz, 2H), 6.84 (t, J = 4.3 Hz, 1H), 6.07 (br, 1H), 4.74 (d, J = 5.4 Hz, 2H), 3.89 (s, 3H), 3.87 (s , 3H), 2.20 (m, 1H), 1.22 (m, 2H), 1.00 (m, 2H)

화합물번호 389. (2-싸이클로프로필-퀴나졸린-4-일)-(3,4,5-트리메톡시-벤질)-아민Compound No. 389. (2-Cyclopropyl-quinazolin-4-yl)-(3,4,5-trimethoxy-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.77-7.64(m, 3H), 7.33(t, J=7.2 Hz, 1H), 6.61(s, 1H), 6.00(br, 1H), 4.72(d, J=5.4 Hz, 2H), 3.84(s, 9H), 2.19(m, 1H), 1.19(m, 2H), 0.98(m, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.77-7.64 (m, 3H), 7.33 (t, J = 7.2 Hz, 1H), 6.61 (s, 1H), 6.00 (br, 1H), 4.72 (d, J = 5.4 Hz, 2H), 3.84 (s, 9H), 2.19 (m, 1H), 1.19 (m, 2H), 0.98 (m, 2H)

화합물번호 390. (2-싸이클로프로필-퀴나졸린-4-일)-(2,4-디메톡시-벤질)-아민Compound number 390. (2-Cyclopropyl-quinazolin-4-yl)-(2,4-dimethoxy-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.73(d, J=8.3 Hz, 1H), 7.62(m, 2H), 7.32(d, J=9.3 Hz, 2H), 6.48(m, 2H), 6.14(br, 1H), 4.73(d, J=5.4 Hz, 2H), 3.89(s, 3H), 3.81(s, 3H), 2.19(m, 1H), 1.25(m, 2H), 1.01(m, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.73 (d, J = 8.3 Hz, 1H), 7.62 (m, 2H), 7.32 (d, J = 9.3 Hz, 2H), 6.48 (m, 2H), 6.14 (br, 1H), 4.73 (d, J = 5.4 Hz, 2H), 3.89 (s, 3H), 3.81 (s, 3H), 2.19 (m, 1H), 1.25 (m, 2H), 1.01 (m, 2H)

화합물번호 391. (2-싸이클로프로필-퀴나졸린-4-일)-(2,5-디메톡시-벤질)-아민Compound No. 391. (2-Cyclopropyl-quinazolin-4-yl)-(2,5-dimethoxy-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.74(d, J=8.5 Hz, 1H), 7.63(m, 2H), 7.33(t, J=7.5 Hz, 1H), 6.98(d, J=2.1 Hz, 1H), 6.81(m, 2H), 6.25(br, 1H), 3.88(s, 3H), 3.78(s, 3H), 2.18(m, 1H), 1.25(m, 2H), 1.01(m, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.74 (d, J = 8.5 Hz, 1H), 7.63 (m, 2H), 7.33 (t, J = 7.5 Hz, 1H), 6.98 (d, J = 2.1 Hz , 1H), 6.81 (m, 2H), 6.25 (br, 1H), 3.88 (s, 3H), 3.78 (s, 3H), 2.18 (m, 1H), 1.25 (m, 2H), 1.01 (m, 2H)

화합물번호 392. (2-싸이클로프로필-퀴나졸린-4-일)-(2,4,6-트리메톡시-벤질)-아민Compound No. 392. (2-Cyclopropyl-quinazolin-4-yl)-(2,4,6-trimethoxy-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.73(d, J=8.3 Hz, 1H), 7.64(m, 1H), 7.53(d, J=6.2 Hz, 1H), 7.29(m, 1H), 2.17(s, 2H), 6.06(br, 1H), 4.82(d, J=5.3 Hz, 2H), 3.87(s, 6H), 3.84(s, 3H), 2.18(m, 1H), 1.30(m, 2H), 1.00(m, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.73 (d, J = 8.3 Hz, 1H), 7.64 (m, 1H), 7.53 (d, J = 6.2 Hz, 1H), 7.29 (m, 1H), 2.17 (s, 2H), 6.06 (br, 1H), 4.82 (d, J = 5.3 Hz, 2H), 3.87 (s, 6H), 3.84 (s, 3H), 2.18 (m, 1H), 1.30 (m, 2H), 1.00 (m, 2H)

화합물번호 393. (2-메톡시-벤질)-(2-프로필-퀴나졸린-4-일)-아민Compound No. 393. (2-Methoxy-benzyl)-(2-propyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.78(d, J=8.2 Hz, 1H), 7.68(m, 2H), 7.44(d, J=7.3 Hz, 1H), 7.38(d, J = 7.0 Hz, 1H), 7.34(m, 1H), 6.95(t, J=7.8 Hz, 2H), 6.24(br, 1H), 4.91(d, J=5.7 Hz, 2H), 3.93(s, 3H), 2.87(t, J=7.7 Hz, 2H), 1.93(m, 2H), 1.04(t, J=7.4 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.78 (d, J = 8.2 Hz, 1H), 7.68 (m, 2H), 7.44 (d, J = 7.3 Hz, 1H), 7.38 (d, J = 7.0 Hz , 1H), 7.34 (m, 1H), 6.95 (t, J = 7.8 Hz, 2H), 6.24 (br, 1H), 4.91 (d, J = 5.7 Hz, 2H), 3.93 (s, 3H), 2.87 (t, J = 7.7 Hz, 2H), 1.93 (m, 2H), 1.04 (t, J = 7.4 Hz, 3H)

화합물번호 394. (3-메톡시-벤질)-(2-프로필-퀴나졸린-4-일)-아민Compound 394. (3-Methoxy-benzyl)-(2-propyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.80(d, J=8.4 Hz, 1H), 7.68(m, 2H), 7.35(m, 2H), 6.99(m, 2H), 6.85(m, 1H), 5.83(br s, 1H), 4.86(d, J=5.1 Hz, 2H), 3.80(s, 3H), 2.86(t, J=7.7 Hz, 2H), 1.90(sixtet, J=7.5 Hz, 2H), 1.02(t, J=7.4 Hz, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.80 (d, J = 8.4 Hz, 1H), 7.68 (m, 2H), 7.35 (m, 2H), 6.99 (m, 2H), 6.85 (m, 1H) , 5.83 (br s, 1H), 4.86 (d, J = 5.1 Hz, 2H), 3.80 (s, 3H), 2.86 (t, J = 7.7 Hz, 2H), 1.90 (sixtet, J = 7.5 Hz, 2H ), 1.02 (t, J = 7.4 Hz, 3H)

화합물번호 395. (4-메톡시-벤질)-(2-프로필-퀴나졸린-4-일)-아민Compound number 395. (4-Methoxy-benzyl)-(2-propyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.79(d, J=8.4Hz, 1H), 7.65(m, 2H), 7.38(m, 3H), 6.88(d, J=8.4Hz, 2H), 5.81(br s, 1H), 4.80(d, J=5.1 Hz, 2H), 3.81(s, 3H), 2.86(t, J=7.8 Hz, 2H), 1.91(sixtet, J=7.5 Hz, 2H), 1.03(t, J=7.5 Hz, 3H) 1 H NMR (CDCl 3, 300 MHz) δ 7.79 (d, J = 8.4 Hz, 1H), 7.65 (m, 2H), 7.38 (m, 3H), 6.88 (d, J = 8.4 Hz, 2H), 5.81 (br s, 1H), 4.80 (d, J = 5.1 Hz, 2H), 3.81 (s, 3H), 2.86 (t, J = 7.8 Hz, 2H), 1.91 (sixtet, J = 7.5 Hz, 2H), 1.03 (t, J = 7.5 Hz, 3H)

화합물번호 396. 벤조[1,3]디옥솔-5-일메틸-(2-프로필-퀴나졸린-4-일)-아민Compound No. 396.Benzo [1,3] dioxol-5-ylmethyl- (2-propyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.80(d, J=7.8Hz, 1H), 7.68(m, 2H), 7.37(t, J=7.5 Hz, 1H), 6.89(m, 2H), 6.78(d, J=7.8 Hz, 1H), 5.95(s, 2H), 5.80(br s, 1H), 4.78(d, J=5.4 Hz, 2H), 2.86(t, J=7.8 Hz, 2H), 1.91(sixtet, J=7.5 Hz, 2H), 1.03(t, J=7.5 Hz, 3H) 1 H NMR (CDCl 3, 300 MHz) δ 7.80 (d, J = 7.8 Hz, 1H), 7.68 (m, 2H), 7.37 (t, J = 7.5 Hz, 1H), 6.89 (m, 2H), 6.78 (d, J = 7.8 Hz, 1H), 5.95 (s, 2H), 5.80 (br s, 1H), 4.78 (d, J = 5.4 Hz, 2H), 2.86 (t, J = 7.8 Hz, 2H), 1.91 (sixtet, J = 7.5 Hz, 2H), 1.03 (t, J = 7.5 Hz, 3H)

화합물번호 397. (2,3-디메톡시-벤질)-(2-프로필-퀴나졸린-4-일)-아민Compound 397. (2,3-Dimethoxy-benzyl)-(2-propyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.76(d, J=8.4Hz, 1H), 7.64(m, 2H), 7.37(t, J=7.2 Hz, 1H), 7.03(d, J=4.8 Hz, 2H), 6.88(t, J=4.8 Hz, 1H), 6.17(br s, 1H), 4.90(d, J=5.7 Hz, 2H), 3.94(s, 3H), 3.89(s, 3H), 2.86(t, J=7.8 Hz, 2H), 1.91(sixtet, J=7.5 Hz, 2H), 1.03(t, J=7.5 Hz, 3H) 1 H NMR (CDCl 3, 300 MHz) δ 7.76 (d, J = 8.4 Hz, 1H), 7.64 (m, 2H), 7.37 (t, J = 7.2 Hz, 1H), 7.03 (d, J = 4.8 Hz , 2H), 6.88 (t, J = 4.8 Hz, 1H), 6.17 (br s, 1H), 4.90 (d, J = 5.7 Hz, 2H), 3.94 (s, 3H), 3.89 (s, 3H), 2.86 (t, J = 7.8 Hz, 2H), 1.91 (sixtet, J = 7.5 Hz, 2H), 1.03 (t, J = 7.5 Hz, 3H)

화합물번호 398. (3,5-디메톡시-벤질)-(2-프로필-퀴나졸린-4-일)-아민Compound 398. (3,5-Dimethoxy-benzyl)-(2-propyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.80(d, J=8.1Hz, 1H), 7.70(m, 2H), 7.38(t, J=7.2 Hz, 1H), 6.57(d, J=2.1 Hz, 2H), 6.41(m, 1H), 5.83(br s, 1H), 4.82(d, J=5.4 Hz, 2H), 3.78(s, 6H), 2.86(t, J=7.8 Hz, 2H), 1.91(sixtet, J=7.5 Hz, 2H), 1.03(t, J=7.5 Hz, 3H) 1 H NMR (CDCl 3, 300 MHz) δ 7.80 (d, J = 8.1 Hz, 1H), 7.70 (m, 2H), 7.38 (t, J = 7.2 Hz, 1H), 6.57 (d, J = 2.1 Hz , 2H), 6.41 (m, 1H), 5.83 (br s, 1H), 4.82 (d, J = 5.4 Hz, 2H), 3.78 (s, 6H), 2.86 (t, J = 7.8 Hz, 2H), 1.91 (sixtet, J = 7.5 Hz, 2H), 1.03 (t, J = 7.5 Hz, 3H)

화합물번호 399. (3,4-디메톡시-벤질)-(2-프로필-퀴나졸린-4-일)-아민Compound 399. (3,4-Dimethoxy-benzyl)-(2-propyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.80(d, J=8.1Hz, 1H), 7.69(m, 2H), 7.37(t, J=7.5 Hz, 1H), 6.97(d, J=7.2 Hz, 2H), 6.85(d, J=8.4 Hz, 1H), 5.81(br s, 1H), 4.81(d, J=5.4 Hz, 2H), 3.88(s, 3H), 3.86(s, 3H), 2.86(t, J=7.8 Hz, 2H), 1.91(sixtet, J=7.5 Hz, 2H), 1.03(t, J=7.5 Hz, 3H) 1 H NMR (CDCl 3, 300 MHz) δ 7.80 (d, J = 8.1 Hz, 1H), 7.69 (m, 2H), 7.37 (t, J = 7.5 Hz, 1H), 6.97 (d, J = 7.2 Hz , 2H), 6.85 (d, J = 8.4 Hz, 1H), 5.81 (br s, 1H), 4.81 (d, J = 5.4 Hz, 2H), 3.88 (s, 3H), 3.86 (s, 3H), 2.86 (t, J = 7.8 Hz, 2H), 1.91 (sixtet, J = 7.5 Hz, 2H), 1.03 (t, J = 7.5 Hz, 3H)

화합물번호 400. (2-프로필-퀴나졸린-4-일)-(3,4,5-트리메톡시-벤질)-아민Compound 400. (2-propyl-quinazolin-4-yl)-(3,4,5-trimethoxy-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.81(d, J=8.3 Hz, 3H), 7.71(m, 2H), 4.40(m, 1H), 6.68(s, 2H), 6.07(br, 1H), 4.82(d, J=5.5 Hz, 2H), 3.86(s, 9H), 2.88(t, J=7.7 Hz, 2H), 1.94(m, 2H), 1.03(t, J=7.4 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.81 (d, J = 8.3 Hz, 3H), 7.71 (m, 2H), 4.40 (m, 1H), 6.68 (s, 2H), 6.07 (br, 1H) , 4.82 (d, J = 5.5 Hz, 2H), 3.86 (s, 9H), 2.88 (t, J = 7.7 Hz, 2H), 1.94 (m, 2H), 1.03 (t, J = 7.4 Hz, 2H)

화합물번호 401. (2,4-디메톡시-벤질)-(2-프로필-퀴나졸린-4-일)-아민Compound number 401. (2,4-Dimethoxy-benzyl)-(2-propyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.78(d, J=8.5 Hz, 1H), 7.64(m, 2H), 7.36(m, 2H), 7.47(m, 2H), 6.14(br, 1H), 4.82(d, J=5.4 Hz, 2H), 3.90(s, 3H), 3.82(s, 3H), 2.87(t, J=7.8 Hz, 2H), 1.96(m, 2H), 1.05(t, J=7.3 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.78 (d, J = 8.5 Hz, 1H), 7.64 (m, 2H), 7.36 (m, 2H), 7.47 (m, 2H), 6.14 (br, 1H) , 4.82 (d, J = 5.4 Hz, 2H), 3.90 (s, 3H), 3.82 (s, 3H), 2.87 (t, J = 7.8 Hz, 2H), 1.96 (m, 2H), 1.05 (t, J = 7.3 Hz, 2H)

화합물번호 402. (2,5-디메톡시-벤질)-(2-프로필-퀴나졸린-4-일)-아민Compound number 402. (2,5-Dimethoxy-benzyl)-(2-propyl-quinazolin-4-yl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.78(d, J=8.1 Hz, 1H), 7.66(m, 2H), 7.37(m, 1H), 7.05(s, 1H), 6.82(m, 2H), 6.29(br, 1H), 4.87(d, J=5.4 Hz, 2H), 3.88(s, 3H), 3.76(s, 3H), 2.86(t, J=7.6 Hz, 2H), 1.95(m, 2H), 1.05(t, J=7.5 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.78 (d, J = 8.1 Hz, 1H), 7.66 (m, 2H), 7.37 (m, 1H), 7.05 (s, 1H), 6.82 (m, 2H) , 6.29 (br, 1H), 4.87 (d, J = 5.4 Hz, 2H), 3.88 (s, 3H), 3.76 (s, 3H), 2.86 (t, J = 7.6 Hz, 2H), 1.95 (m, 2H), 1.05 (t, J = 7.5 Hz, 2H)

화합물번호 403. (2-프로필-퀴나졸린-4-일)-(2,4,6-트리메톡시-벤질)-아민Compound number 403. (2-propyl-quinazolin-4-yl)-(2,4,6-trimethoxy-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 7.76(d, J=8.3 Hz, 1H), 7.60(m, 2H), 7.35(m, 1H), 6.18(s, 2H), 5.98(br, 1H), 4.88(d, J=5.4 Hz, 2H), 3.87(s, 6H), 3.85(3, 3H), 2.88(t, J=7.5 Hz, 2H), 1.98(m, 2H), 1.07(t, J=7.4 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 7.76 (d, J = 8.3 Hz, 1H), 7.60 (m, 2H), 7.35 (m, 1H), 6.18 (s, 2H), 5.98 (br, 1H) , 4.88 (d, J = 5.4 Hz, 2H), 3.87 (s, 6H), 3.85 (3, 3H), 2.88 (t, J = 7.5 Hz, 2H), 1.98 (m, 2H), 1.07 (t, J = 7.4 Hz, 2H)

화합물번호 404. (2-메톡시-벤질)-퀴나졸린-4-일-아민Compound number 404. (2-methoxy-benzyl) -quinazolin-4-yl-amine

1H NMR(CDCl3, 300 MHz) δ 8.74(s, 1H), 7.88(d, J=8.2 Hz, 1H), 7.70(m, 2H), 7.47(m, 2H), 7.32(m, 1H), 6.97(d, J=7.8 Hz, 2H), 6.25(br, 1H), 4.88(d, J=5.5 Hz, 2H), 3.93(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.74 (s, 1H), 7.88 (d, J = 8.2 Hz, 1H), 7.70 (m, 2H), 7.47 (m, 2H), 7.32 (m, 1H) , 6.97 (d, J = 7.8 Hz, 2H), 6.25 (br, 1H), 4.88 (d, J = 5.5 Hz, 2H), 3.93 (s, 3H)

화합물번호 405. (3-메톡시-벤질)-퀴나졸린-4-일-아민Compound number 405. (3-Methoxy-benzyl) -quinazolin-4-yl-amine

1H NMR(CDCl3, 300 MHz) δ 8.73(s, 1H), 7.86(d, J=8.3 Hz, 1H), 7.73(t, J=9.0 Hz, 2H), 7.47(m, 1H), 7.31(m, 1H), 6.99(t, J=7.4 Hz, 2H), 6.87(d, J=8.1 Hz, 1H), 6.01(br, 1H), 4.87(d, J=5.4 Hz, 2H), 3.82(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.73 (s, 1H), 7.86 (d, J = 8.3 Hz, 1H), 7.73 (t, J = 9.0 Hz, 2H), 7.47 (m, 1H), 7.31 (m, 1H), 6.99 (t, J = 7.4 Hz, 2H), 6.87 (d, J = 8.1 Hz, 1H), 6.01 (br, 1H), 4.87 (d, J = 5.4 Hz, 2H), 3.82 (s, 3H)

화합물번호 406. (4-메톡시-벤질)-퀴나졸린-4-일-아민Compound 406. (4-Methoxy-benzyl) -quinazolin-4-yl-amine

1H NMR(CDCl3, 300 MHz) δ 8.71(s, 1H), 7.85(d, J=8.1Hz, 1H), 7.71(m, 2H), 7.45(t, J=7.5 Hz, 1H), 7.34(d, J=8.7 Hz, 2H), 6.90(d, J=8.7 Hz, 1H), 5.88(br s, 1H), 4.80(d, J=5.1 Hz, 2H), 3.82(s, 3H) 1 H NMR (CDCl 3, 300 MHz) δ 8.71 (s, 1H), 7.85 (d, J = 8.1 Hz, 1H), 7.71 (m, 2H), 7.45 (t, J = 7.5 Hz, 1H), 7.34 (d, J = 8.7 Hz, 2H), 6.90 (d, J = 8.7 Hz, 1H), 5.88 (br s, 1H), 4.80 (d, J = 5.1 Hz, 2H), 3.82 (s, 3H)

화합물번호 407. 벤조[1,3]디옥솔-5-일메틸-퀴나졸린-4-일-아민Compound 407. Benzo [1,3] dioxol-5-ylmethyl-quinazolin-4-yl-amine

1H NMR(CDCl3, 300 MHz) δ 8.72(s, 1H), 7.88(d, J=8.4 Hz, 1H), 7.40(m, 2H), 7.48(d, J=7.2 Hz, 1H), 6.90(m, 2H), 6.81(d, J=7.4 Hz, 1H), 5.98(s, 2H), 5.96(br, 1H), 4.78(d, J=5.4 Hz, 2H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.72 (s, 1H), 7.88 (d, J = 8.4 Hz, 1H), 7.40 (m, 2H), 7.48 (d, J = 7.2 Hz, 1H), 6.90 (m, 2H), 6.81 (d, J = 7.4 Hz, 1H), 5.98 (s, 2H), 5.96 (br, 1H), 4.78 (d, J = 5.4 Hz, 2H)

화합물번호 408. (2,3-디메톡시-벤질)-퀴나졸린-4-일-아민Compound number 408. (2,3-dimethoxy-benzyl) -quinazolin-4-yl-amine

1H NMR(CDCl3, 300 MHz) δ 8.70(s, 1H), 7.73(m, 3H), 7.43(m, 1H), 7.04(m, 2H), 6.93(m, 1H), 6.32(br, 1H), 4.89(d, J=5.4 Hz, 2H), 3.95(s, 3H), 3.90(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.70 (s, 1H), 7.73 (m, 3H), 7.43 (m, 1H), 7.04 (m, 2H), 6.93 (m, 1H), 6.32 (br, 1H), 4.89 (d, J = 5.4 Hz, 2H), 3.95 (s, 3H), 3.90 (s, 3H)

화합물번호 409. (3,5-디메톡시-벤질)-퀴나졸린-4-일-아민Compound number 409. (3,5-Dimethoxy-benzyl) -quinazolin-4-yl-amine

1H NMR(CDCl3, 300 MHz) δ 8.71(s, 1H), 7.87(d, J=8.4Hz, 1H), 7.73(m, 2H), 7.47(t, J=7.2 Hz, 1H), 6.40(d, J=2.4 Hz, 2H), 6.41(t, J=2.1 Hz, 1H), 5.93(br s, 1H), 4.81(d, J=5.1 Hz, 2H), 3.79(s, 6H) 1 H NMR (CDCl 3, 300 MHz) δ 8.71 (s, 1H), 7.87 (d, J = 8.4 Hz, 1H), 7.73 (m, 2H), 7.47 (t, J = 7.2 Hz, 1H), 6.40 (d, J = 2.4 Hz, 2H), 6.41 (t, J = 2.1 Hz, 1H), 5.93 (br s, 1H), 4.81 (d, J = 5.1 Hz, 2H), 3.79 (s, 6H)

화합물번호 410. (3,4-디메톡시-벤질)-퀴나졸린-4-일-아민Compound 410. (3,4-Dimethoxy-benzyl) -quinazolin-4-yl-amine

1H NMR(CDCl3, 300 MHz) δ 8.73(s, 1H), 7.87(d, J=8.2 Hz, 1H), 7.75(t, J=7.4 Hz, 2H), 7.47(t, J=7.6 Hz, 1H), 6.97(d, J=7.8 Hz, 2H), 6.86(d, J=8.0 Hz, 1H), 6.08(br, 1H), 4.81(d, J=5.2 Hz, 2H), 3.89(s, 3H), 3.87(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.73 (s, 1H), 7.87 (d, J = 8.2 Hz, 1H), 7.75 (t, J = 7.4 Hz, 2H), 7.47 (t, J = 7.6 Hz , 1H), 6.97 (d, J = 7.8 Hz, 2H), 6.86 (d, J = 8.0 Hz, 1H), 6.08 (br, 1H), 4.81 (d, J = 5.2 Hz, 2H), 3.89 (s , 3H), 3.87 (s, 3H)

화합물번호 411. 퀴나졸린-4-일-(3,4,5-트리메톡시-벤질)-아민Compound number 411. Quinazolin-4-yl- (3,4,5-trimethoxy-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.73(s, 1H), 7.84(m, 1H), 7.78(m, 1H), 7.50(m, 1H), 6.63(d, J=7.8 Hz, 2H), 6.23(br, 1H), 4.80(d, J=5.3 Hz, 2H), 3.85(s, 9H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.73 (s, 1H), 7.84 (m, 1H), 7.78 (m, 1H), 7.50 (m, 1H), 6.63 (d, J = 7.8 Hz, 2H) , 6.23 (br, 1H), 4.80 (d, J = 5.3 Hz, 2H), 3.85 (s, 9H)

화합물번호 412. (2,4-디메톡시-벤질)-퀴나졸린-4-일-아민Compound 412. (2,4-Dimethoxy-benzyl) -quinazolin-4-yl-amine

1H NMR(CDCl3, 300 MHz) δ 8.70(s, 1H), 7.83(d, J=8.3 Hz, 1H), 7.72(m, 2H), 7.44(t, J=7.6 Hz, 1H), 7.32(d, J=8.2 Hz, 1H), 6.48(m, 2H), 6.26(br, 1H), 4.80(d, J=5.4 Hz, 2H), 3.89(s, 3H), 3.82(s, 3H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.70 (s, 1H), 7.83 (d, J = 8.3 Hz, 1H), 7.72 (m, 2H), 7.44 (t, J = 7.6 Hz, 1H), 7.32 (d, J = 8.2 Hz, 1H), 6.48 (m, 2H), 6.26 (br, 1H), 4.80 (d, J = 5.4 Hz, 2H), 3.89 (s, 3H), 3.82 (s, 3H)

화합물번호 413. (2,5-디메톡시-벤질)-퀴나졸린-4-일-아민Compound 413. (2,5-dimethoxy-benzyl) -quinazolin-4-yl-amine

1H NMR(CDCl3, 300 MHz) δ 8.69(s, 1H), 7.84(d, J=8.4Hz, 1H), 7.69(m, 2H), 7.44(t, J=7.2 Hz, 1H), 6.99(d, J=3.0 Hz, 1H), 6.83(m, 2H), 6.29(br s, 1H), 4.85(d, J=5.4 Hz, 2H), 3.88(s, 3H), 3.76(s, 3H) 1 H NMR (CDCl 3, 300 MHz) δ 8.69 (s, 1H), 7.84 (d, J = 8.4 Hz, 1H), 7.69 (m, 2H), 7.44 (t, J = 7.2 Hz, 1H), 6.99 (d, J = 3.0 Hz, 1H), 6.83 (m, 2H), 6.29 (br s, 1H), 4.85 (d, J = 5.4 Hz, 2H), 3.88 (s, 3H), 3.76 (s, 3H )

화합물번호 414. 퀴나졸린-4-일-(2,4,6-트리메톡시-벤질)-아민Compound number 414. Quinazolin-4-yl- (2,4,6-trimethoxy-benzyl) -amine

1H NMR(CDCl3, 300 MHz) δ 8.72(s, 1H), 7.81(d, J=8.1Hz, 1H), 7.69(t, J=7.5 Hz, 1H), 7.60(d, J=8.1Hz, 1H), 7.40(t, J=7.5 Hz, 1H), 6.19(s, 2H), 6.03(br s, 1H), 4.83(d, J=5.1 Hz, 2H), 3.86(s, 6H), 3.84(s, 3H) 1 H NMR (CDCl 3, 300 MHz) δ 8.72 (s, 1H), 7.81 (d, J = 8.1 Hz, 1H), 7.69 (t, J = 7.5 Hz, 1H), 7.60 (d, J = 8.1 Hz , 1H), 7.40 (t, J = 7.5 Hz, 1H), 6.19 (s, 2H), 6.03 (br s, 1H), 4.83 (d, J = 5.1 Hz, 2H), 3.86 (s, 6H), 3.84 (s, 3 H)

화합물번호 415. 4-벤질옥시-2-이소프로필-퀴나졸린Compound number 415. 4-benzyloxy-2-isopropyl-quinazoline

1H NMR(CDCl3, 300 MHz) δ 8.16(d, J=8.1 Hz, 1H), 7.87(s, J=8.4 Hz, 1H), 7.77(m, 1H), 7.54(d, J=7.5 Hz, 2H), 7.49-7.34(m, 4H), 5.66(s, 2H), 3.22(m, 1H), 1.40(d, J=6.9 Hz, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.16 (d, J = 8.1 Hz, 1H), 7.87 (s, J = 8.4 Hz, 1H), 7.77 (m, 1H), 7.54 (d, J = 7.5 Hz , 2H), 7.49-7.34 (m, 4H), 5.66 (s, 2H), 3.22 (m, 1H), 1.40 (d, J = 6.9 Hz, 6H)

화합물번호 416. 4-벤질설파닐-2-이소프로필-퀴나졸린Compound number 416. 4-benzylsulfanyl-2-isopropyl-quinazoline

1H NMR(CDCl3, 300 MHz) δ 8.01(d, J=8.4 Hz, 1H), 7.89(d, J=8.4 Hz, 1H), 7.78(m, 1H), 7.48(m, 3H), 7.35-7.23(m, 3H), 4.67(s, 2H), 3.29(m, 1H), 1.43(d, J=6.9 MHz, 6H) 1 H NMR (CDCl 3 , 300 MHz) δ 8.01 (d, J = 8.4 Hz, 1H), 7.89 (d, J = 8.4 Hz, 1H), 7.78 (m, 1H), 7.48 (m, 3H), 7.35 -7.23 (m, 3H), 4.67 (s, 2H), 3.29 (m, 1H), 1.43 (d, J = 6.9 MHz, 6H)

한편, 본 발명에 따른 상기 화학식 1로 표시되는 화합물은 목적에 따라 여러 형태로 제제화가 가능하다. 다음은 본 발명에 따른 상기 화학식 1로 표시되는 화합물을 활성성분으로 함유시킨 몇몇 제제화 방법을 예시한 것으로 본 발명이 이에 한정되는 것은 아니다.On the other hand, the compound represented by Formula 1 according to the present invention can be formulated in various forms according to the purpose. The following illustrates some formulation methods containing the compound represented by Formula 1 according to the present invention as an active ingredient, but the present invention is not limited thereto.

제조예 1 : 정제의 제조Preparation Example 1 Preparation of Tablet

본 발명의 화합물을 이용하여 다음과 같은 조성으로 경구투여용 정제를 습식 과립법 및 건식과립법을 이용하여 제조하였다.Tablets for oral administration using the compound of the present invention in the following composition were prepared using wet granulation and dry granulation.

[조성][Furtherance]

유효화합물 200 mg, 경질 무수규산 10 mg, 스테아린산 마그네슘 2 mg, 미세결정 셀룰로오즈 50 mg, 전분 글리콜산 나트륨 25 mg, 옥수수 전분 113 mg, 무수에탄올 적량.200 mg of active compound, 10 mg of hard silicic anhydride, 2 mg of magnesium stearate, 50 mg of microcrystalline cellulose, 25 mg of sodium starch glycolate, 113 mg of corn starch, proper amount of ethanol anhydride.

제조예 2 : 연고제의 제조Preparation Example 2 Preparation of Ointment

본 발명의 화합물을 이용하여 다음과 같은 조성으로 연고제를 제조하였다.Using the compound of the present invention was prepared an ointment with the following composition.

[조성][Furtherance]

유효화합물 5 g, 세틸팔미테이트 20 g, 세탄올 40 g, 스테아릴알콜 40 g, 미리스탄이소프로필 80 g, 모노스테아린산 소르비탄 20 g, 폴리솔베이트 60 g, 파라옥시안식향산 프로필 1 g, 파라옥시안식향산 메틸 1 g, 인산 및 정제수 적량Active compound 5 g, cetyl palmitate 20 g, cetanol 40 g, stearyl alcohol 40 g, myristan isopropyl 80 g, monostearic acid sorbitan 20 g, polysorbate 60 g, paraoxybenzoic acid propyl 1 g, para 1 g of methyl oxyanate, phosphoric acid and purified water

제조예 3 : 주사제의 제조Preparation Example 3 Preparation of Injection

본 발명의 화합물을 이용하여 다음과 같은 조성으로 주사제를 제조하였다.Injections were prepared using the compounds of the present invention in the following compositions.

[조성][Furtherance]

유효화합물 100 mg, 만니톨 180 mg, 인산일수소나트륨 25 mg, 주사용 물 2974 mgActive Compound 100 mg, mannitol 180 mg, sodium dihydrogen phosphate 25 mg, water for injection 2974 mg

실험예 1. 포도당 흡수도 분석Experimental Example 1. Analysis of glucose absorption

근육 세포인 C2C12 세포를 10% 송아지 혈청(bovine calf serum)이 들어있는 DMEM(Dulbecco's modified Eagle's medium) 배지에서 세포 배양하였다. 세포의 밀도가 약 85 ∼ 90% 가량 되면 1% 송아지 혈청 배양액으로 치환한 후 6일간 세포 분화를 유도시켰다. 완전히 분화된 세포를 5 mM의 포도당이 포함된 크렙스 링거 완충액(Krebs Ringer Buffer, KRB)으로 3시간 배양한 후 후보 물질을 10 μM 농도가 되게 첨가하여 30분간 방치한 후 0.2 μCi 2-데옥시글루코스를 첨가하고 20분 동안 방치하였다. KRB 완충액을 제거한 후 차가운 PBS로 세 번 세포를 세척한 후 0.5N NaOH를 사용하여 세포를 용해시키고 방사선 계측기를 이용하여 계수율(cpm)을 측정하였다. Muscle cells C2C12 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) medium containing 10% bovine calf serum. When the cell density was about 85-90%, the cells were replaced with 1% calf serum culture and induced cell differentiation for 6 days. The fully differentiated cells were incubated with Krebs Ringer Buffer (KRB) containing 5 mM glucose for 3 hours, then added to 10 μM of the candidate substance for 30 minutes, and then 0.2 μCi 2-deoxyglucose. Was added and left for 20 minutes. After removing the KRB buffer, the cells were washed three times with cold PBS, and then the cells were lysed using 0.5 N NaOH and counted using a radiometer (cpm).

다음 표 2로부터 확인되는 바와 같이, C2C12 세포에 본 발명에 따른 화학식 1로 표시되는 화합물을 처리하였을 경우 대조군에 비하여 근육 세포주에서 포도당의 흡수가 최대 2.8배까지 증가함을 관찰할 수 있었다.As confirmed from the following Table 2, when the C2C12 cells were treated with the compound represented by Formula 1 according to the present invention, it was observed that glucose uptake was increased up to 2.8-fold in muscle cell lines compared to the control group.

화합물 번호Compound number 포도당 흡수도Glucose absorbance 화합물 번호Compound number 포도당 흡수도Glucose absorbance 화합물 번호Compound number 포도당 흡수도Glucose absorbance 1One 1.7 1.7 4141 1.1 1.1 8181 0.9 0.9 22 1.3 1.3 4242 1.1 1.1 8282 1.2 1.2 33 1.2 1.2 4343 1.1 1.1 8383 0.7 0.7 44 1.2 1.2 4444 1.3 1.3 8484 1.0 1.0 55 0.9 0.9 4545 1.1 1.1 8585 1.0 1.0 66 1.4 1.4 4646 1.1 1.1 8686 1.4 1.4 77 1.5 1.5 4747 0.9 0.9 8787 1.0 1.0 88 1.2 1.2 4848 1.0 1.0 8888 1.1 1.1 99 2.0 2.0 4949 1.8 1.8 8989 1.4 1.4 1010 1.5 1.5 5050 1.2 1.2 9090 1.4 1.4 1111 1.0 1.0 5151 1.0 1.0 9191 1.2 1.2 1212 0.8 0.8 5252 1.3 1.3 9292 1.4 1.4 1313 0.7 0.7 5353 1.2 1.2 9393 1.1 1.1 1414 1.2 1.2 5454 1.2 1.2 9494 1.3 1.3 1515 0.8 0.8 5555 1.2 1.2 9595 1.2 1.2 1616 1.3 1.3 5656 1.1 1.1 9696 1.3 1.3 1717 1.2 1.2 5757 1.0 1.0 9797 1.0 1.0 1818 1.0 1.0 5858 1.4 1.4 9898 1.2 1.2 1919 1.4 1.4 5959 1.2 1.2 9999 1.4 1.4 2020 1.9 1.9 6060 1.0 1.0 100100 1.4 1.4 2121 1.2 1.2 6161 1.9 1.9 101101 1.5 1.5 2222 2.6 2.6 6262 1.1 1.1 102102 1.2 1.2 2323 0.8 0.8 6363 1.1 1.1 103103 2.2 2.2 2424 2.8 2.8 6464 1.2 1.2 104104 1.0 1.0 2525 2.6 2.6 6565 1.4 1.4 105105 1.2 1.2 2626 1.7 1.7 6666 1.3 1.3 106106 1.8 1.8 2727 1.0 1.0 6767 0.9 0.9 107107 0.4 0.4 2828 1.1 1.1 6868 1.3 1.3 108108 2.2 2.2 2929 1.6 1.6 6969 1.0 1.0 109109 1.3 1.3 3030 1.8 1.8 7070 1.0 1.0 110110 2.0 2.0 3131 1.1 1.1 7171 1.0 1.0 111111 2.4 2.4 3232 1.1 1.1 7272 1.1 1.1 112112 1.9 1.9 3333 1.2 1.2 7373 1.0 1.0 113113 2.1 2.1 3434 1.3 1.3 7474 0.9 0.9 114114 2.2 2.2 3535 1.91.9 7575 1.3 1.3 115115 2.3 2.3 3636 1.4 1.4 7676 1.0 1.0 116116 2.5 2.5 3737 2.2 2.2 7777 1.4 1.4 117117 1.4 1.4 3838 1.5 1.5 7878 1.4 1.4 118118 2.1 2.1 3939 0.9 0.9 7979 1.1 1.1 119119 2.6 2.6 4040 1.2 1.2 8080 1.0 1.0 120120 1.4 1.4

화합물 번호Compound number 포도당 흡수도Glucose absorbance 화합물 번호Compound number 포도당 흡수도Glucose absorbance 화합물 번호Compound number 포도당 흡수도Glucose absorbance 121121 2.4 2.4 161161 1.1 1.1 201201 1.7 1.7 122122 1.3 1.3 162162 1.3 1.3 202202 1.4 1.4 123123 2.1 2.1 163163 2.5 2.5 203203 2.0 2.0 124124 1.4 1.4 164164 3.4 3.4 204204 1.2 1.2 125125 2.8 2.8 165165 2.5 2.5 205205 1.3 1.3 126126 2.1 2.1 166166 2.8 2.8 206206 1.4 1.4 127127 1.4 1.4 167167 3.2 3.2 207207 2.0 2.0 128128 2.3 2.3 168168 3.6 3.6 208208 2.0 2.0 129129 1.3 1.3 169169 2.5 2.5 209209 1.1 1.1 130130 2.2 2.2 170170 2.4 2.4 210210 0.9 0.9 131131 2.3 2.3 171171 2.2 2.2 211211 1.3 1.3 132132 1.3 1.3 172172 2.6 2.6 212212 2.0 2.0 133133 2.1 2.1 173173 1.3 1.3 213213 1.4 1.4 134134 2.6 2.6 174174 1.2 1.2 214214 2.0 2.0 135135 2.6 2.6 175175 2.7 2.7 215215 2.2 2.2 136136 1.3 1.3 176176 2.4 2.4 216216 2.6 2.6 137137 2.4 2.4 177177 2.8 2.8 217217 1.2 1.2 138138 2.4 2.4 178178 4.2 4.2 218218 2.0 2.0 139139 2.5 2.5 179179 2.9 2.9 219219 2.3 2.3 140140 2.7 2.7 180180 4.1 4.1 220220 2.5 2.5 141141 2.1 2.1 181181 3.1 3.1 221221 1.5 1.5 142142 1.4 1.4 182182 3.1 3.1 222222 1.2 1.2 143143 2.3 2.3 183183 3.3 3.3 223223 1.7 1.7 144144 1.3 1.3 184184 3.2 3.2 224224 1.1 1.1 145145 2.2 2.2 185185 1.4 1.4 225225 1.3 1.3 146146 2.3 2.3 186186 1.0 1.0 226226 1.9 1.9 147147 1.3 1.3 187187 2.4 2.4 227227 1.6 1.6 148148 2.1 2.1 188188 1.0 1.0 228228 2.1 2.1 149149 2.6 2.6 189189 1.3 1.3 229229 1.9 1.9 150150 2.6 2.6 190190 1.2 1.2 230230 1.7 1.7 151151 1.3 1.3 191191 2.4 2.4 231231 1.2 1.2 152152 2.4 2.4 192192 2.1 2.1 232232 1.2 1.2 153153 2.4 2.4 193193 1.3 1.3 233233 1.4 1.4 154154 2.5 2.5 194194 1.4 1.4 234234 1.1 1.1 155155 2.7 2.7 195195 1.2 1.2 235235 1.2 1.2 156156 1.1 1.1 196196 2.1 2.1 236236 1.2 1.2 157157 2.0 2.0 197197 1.3 1.3 237237 0.9 0.9 158158 2.0 2.0 198198 1.4 1.4 238238 1.0 1.0 159159 2.6 2.6 199199 2.1 2.1 239239 0.5 0.5 160160 2.5 2.5 200200 2.7 2.7 240240 1.0 1.0

화합물 번호Compound number 포도당 흡수도Glucose absorbance 화합물 번호Compound number 포도당 흡수도Glucose absorbance 화합물 번호Compound number 포도당 흡수도Glucose absorbance 241241 1.2 1.2 293293 0.6 0.6 364364 1.3 1.3 242242 0.9 0.9 296296 0.9 0.9 368368 1.1 1.1 243243 1.4 1.4 298298 0.6 0.6 369369 1.1 1.1 244244 0.4 0.4 299299 0.8 0.8 370370 1.3 1.3 245245 1.2 1.2 300300 0.9 0.9 371371 1.2 1.2 246246 1.2 1.2 301301 0.8 0.8 372372 1.1 1.1 247247 1.3 1.3 302302 0.7 0.7 373373 1.1 1.1 248248 1.4 1.4 303303 1.0 1.0 374374 1.1 1.1 249249 0.9 0.9 304304 0.8 0.8 375375 1.1 1.1 250250 1.3 1.3 305305 0.8 0.8 376376 1.1 1.1 251251 0.6 0.6 306306 0.8 0.8 377377 1.1 1.1 252252 0.9 0.9 307307 0.8 0.8 378378 0.9 0.9 253253 1.3 1.3 308308 0.8 0.8 379379 1.1 1.1 254254 1.4 1.4 309309 0.8 0.8 380380 1.0 1.0 255255 1.3 1.3 310310 0.9 0.9 381381 1.2 1.2 256256 0.6 0.6 321321 1.2 1.2 382382 1.2 1.2 257257 1.4 1.4 322322 1.4 1.4 383383 1.4 1.4 258258 1.3 1.3 323323 1.1 1.1 384384 1.2 1.2 259259 1.4 1.4 324324 1.3 1.3 387387 1.2 1.2 260260 1.4 1.4 325325 1.2 1.2 388388 1.2 1.2 261261 1.1 1.1 326326 1.2 1.2 389389 1.3 1.3 262262 1.1 1.1 327327 1.3 1.3 390390 1.1 1.1 263263 1.1 1.1 328328 1.4 1.4 391391 1.2 1.2 264264 1.1 1.1 329329 1.8 1.8 392392 1.1 1.1 265265 1.1 1.1 330330 1.2 1.2 394394 1.3 1.3 266266 1.1 1.1 331331 1.2 1.2 395395 1.2 1.2 267267 1.0 1.0 332332 1.1 1.1 396396 1.3 1.3 268268 1.1 1.1 333333 1.2 1.2 397397 1.3 1.3 269269 1.2 1.2 334334 1.1 1.1 398398 1.4 1.4 270270 1.1 1.1 335335 1.1 1.1 399399 1.2 1.2 271271 0.8 0.8 336336 1.3 1.3 404404 2.1 2.1 272272 0.4 0.4 337337 1.3 1.3 405405 2.2 2.2 273273 0.7 0.7 341341 0.8 0.8 406406 2.1 2.1 274274 0.8 0.8 343343 1.3 1.3 407407 1.5 1.5 275275 0.8 0.8 345345 1.3 1.3 408408 1.6 1.6 276276 0.8 0.8 353353 1.2 1.2 409409 1.6 1.6 283283 1.0 1.0 355355 1.2 1.2 411411 1.2 1.2 285285 0.8 0.8 360360 1.4 1.4 412412 1.7 1.7 288288 0.8 0.8 361361 1.3 1.3 413413 1.2 1.2 291291 0.8 0.8 362362 1.2 1.2 414414 1.5 1.5 292292 0.7 0.7 363363 1.3 1.3

실험예 2. 웨스턴 블롯(Western blot)을 이용한 AMPK 효소의 활성 측정Experimental Example 2 Determination of AMPK Enzyme Activity by Western Blot

C2C12 세포 배양 및 분화는 상기 실험예 1과 동일한 조건에서 수행하며 후보 물질의 처리 조건도 동일하게 실행하였다 (50분 동안 10 μM 처리). 이 후 배양액을 제거하고 세포를 PBS 용액으로 두 번 세척 한 후 lysis 완충액(50 mM 트리스 HCl, pH 7.4, 1 % NP-40, 0.25 % 소듐 데옥시콜레이트, 150 mM NaCl, 1 mM EDTA, 1 mM PMSF, 1 mM 소듐 오르쏘바나데이트, 1 mM NaF, 1 μg/mL 아프로티닌, 1 μg/mL 로이펩틴, 1 μg/mL 펩스타틴)를 사용하여 단백질 추출물을 얻었다. AMPK의 활성도는 AMPK의 기질인 아세틸 CoA 카르복시라제의 세린79 잔기의 인산화 정도와 AMPK 활성화 시 필수적으로 동반되는 알파 서브유닛의 트레오닌172 잔기의 인산화 정도를 웨스턴 블롯(Western blot) 분석을 통하여 간접적으로 측정하였다. 단백질의 일정한 정량을 확인하기 위해서 ERK(Extracellular signal regulated protein kinase)의 양을 웨스턴 블롯(Western blot)으로 확인하였다.C2C12 cell culture and differentiation were carried out under the same conditions as in Experimental Example 1 above, and the treatment conditions of the candidates were also performed (10 μM treatment for 50 minutes). Subsequently, the culture medium was removed and the cells washed twice with PBS solution, followed by lysis buffer (50 mM Tris HCl, pH 7.4, 1% NP-40, 0.25% sodium deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM). Protein extracts were obtained using PMSF, 1 mM sodium orthovanadate, 1 mM NaF, 1 μg / mL aprotinin, 1 μg / mL leupeptin, 1 μg / mL pepstatin). AMPK activity was measured indirectly by Western blot analysis of phosphorylation of serine 79 residues of AMPK substrate, acetyl CoA carboxylase, and threonine172 residues of alpha subunits essential for AMPK activation. It was. In order to confirm the constant quantification of protein, the amount of extracellular signal regulated protein kinase (ERK) was confirmed by Western blot.

다음 표 3은 웨스턴 블롯(Western blot)으로 확인한 결과를 나타낸 것으로, 트레오닌172 잔기의 인산화 정도가 3배 이상 증가한 결과에 대해서는 “strong”으로 표기하였고, 트레오닌172 잔기의 인산화 정도가 1 내지 3배 증가한 결과에 대해서는 “mild”로 표기하였고, 트레오닌172 잔기의 인산화 정도가 1배 미만 증가한 결과에 대해서는 “weak”로 표기하였다.The following Table 3 shows the results confirmed by Western blot. For the result of more than three-fold increase in the degree of phosphorylation of threonine 172 residue, it is marked as “strong”, and the degree of phosphorylation of threonine 172 residue is increased by one to three times. The results were marked as "mild" and the results were marked as "weak" for the result of less than 1-fold increase in phosphorylation of threonine 172 residue.

화합물번호Compound number AMPK 효소 활성AMPK Enzyme Activity 화합물 번호Compound number AMPK 효소 활성AMPK Enzyme Activity 화합물 번호Compound number AMPK 효소 활성AMPK Enzyme Activity 1One 6.0a 6.0 a 116116 2.0(strong)2.0 (strong) 178178 5.7(strong)5.7 (strong) 22 4.2a 4.2 a 118118 2.0(strong)2.0 (strong) 179179 3.8(strong)3.8 (strong) 33 3.3a 3.3 a 119119 2.3(strong)2.3 (strong) 180180 3.9(strong)3.9 (strong) 44 3.5a 3.5 a 121121 2.2(strong)2.2 (strong) 181181 3.1(strong)3.1 (strong) 55 4.7a 4.7 a 123123 2.3(strong)2.3 (strong) 182182 2.9(strong)2.9 (strong) 66 4.7a 4.7 a 125125 1.8(strong)1.8 (strong) 183183 2.6(strong)2.6 (strong) 77 4.4a 4.4 a 126126 2.0(strong)2.0 (strong) 184184 1.9(strong)1.9 (strong) 88 3.0a 3.0 a 128128 1.7(strong)1.7 (strong) 187187 0.7(mild)0.7 (mild) 99 5.5a 5.5 a 130130 1.8(strong)1.8 (strong) 191191 5.2(strong)5.2 (strong) 1010 5.3a 5.3 a 131131 1.8(strong)1.8 (strong) 192192 6.5(strong)6.5 (strong) 1111 3.2a 3.2 a 133133 1.3(mild)1.3 (mild) 196196 4.8(strong)4.8 (strong) 1212 4.0a 4.0 a 134134 1.8(strong)1.8 (strong) 199199 2.3(strong)2.3 (strong) 1313 4.2a 4.2 a 135135 2.0(strong)2.0 (strong) 200200 1.5(strong)1.5 (strong) 1414 3.6a 3.6 a 137137 3.1(strong)3.1 (strong) 201201 2.8(strong)2.8 (strong) 1515 2.3a 2.3 a 138138 2.9(strong)2.9 (strong) 203203 3.9(strong)3.9 (strong) 1616 3.1a 3.1 a 139139 2.1(strong)2.1 (strong) 226226 4.3(strong)4.3 (strong) 1717 2.2a 2.2 a 140140 3.1(strong)3.1 (strong) 227227 4.9(strong)4.9 (strong) 1818 6.0a 6.0 a 142142 1.4(mild)1.4 (mild) 228228 7.9(strong)7.9 (strong) 2020 weakweak 143143 2.4(strong)2.4 (strong) 229229 4.7(strong)4.7 (strong) 2222 strongstrong 144144 2.1(strong)2.1 (strong) 230230 4.9(strong)4.9 (strong) 2424 strongstrong 145145 2.7(strong)2.7 (strong) 271271 2.4 2.4 2525 strongstrong 147147 1.8(strong)1.8 (strong) 272272 3.4 3.4 2626 mildmild 148148 1.7(strong)1.7 (strong) 273273 1.5 1.5 2929 mildmild 149149 2.5(strong)2.5 (strong) 274274 1.9 1.9 3030 mildmild 151151 1.8(strong)1.8 (strong) 275275 2.1 2.1 3535 strongstrong 153153 1.3(mild)1.3 (mild) 276276 1.9 1.9 3737 strongstrong 155155 1.3(mild)1.3 (mild) 277277 1.3 1.3 4949 mildmild 163163 2.8(strong)2.8 (strong) 278278 1.2 1.2 6161 weakweak 164164 1.6(mild)1.6 (mild) 279279 1.3 1.3 101101 weakweak 165165 5.2(strong)5.2 (strong) 280280 1.2 1.2 103103 2.6(strong)2.6 (strong) 166166 3.8(strong)3.8 (strong) 281281 0.9 0.9 106106 1.3(mild)1.3 (mild) 167167 6.7(strong)6.7 (strong) 282282 0.9 0.9 108108 2.2(strong)2.2 (strong) 168168 8.4(strong)8.4 (strong) 283283 1.1 1.1 109109 1.9(strong)1.9 (strong) 169169 6.6(strong)6.6 (strong) 284284 1.4 1.4 110110 1.6(strong)1.6 (strong) 170170 8.8(strong)8.8 (strong) 285285 1.6 1.6 111111 1.8(strong)1.8 (strong) 171171 6.6(strong)6.6 (strong) 286286 1.0 1.0 112112 1.7(strong)1.7 (strong) 172172 4.4(strong)4.4 (strong) 287287 1.2 1.2 113113 2.1(strong)2.1 (strong) 175175 4.8(strong)4.8 (strong) 288288 1.7 1.7 114114 2.0(strong)2.0 (strong) 176176 4.4(strong)4.4 (strong) 289289 1.5 1.5 115115 2.3(strong)2.3 (strong) 177177 5.5(strong)5.5 (strong) 290290 1.0 1.0

화합물 번호Compound number AMPK 효소 활성AMPK Enzyme Activity 화합물 번호Compound number AMPK 효소 활성AMPK Enzyme Activity 화합물 번호Compound number AMPK 효소 활성AMPK Enzyme Activity 291291 1.5 1.5 330330 1.7 1.7 380380 1.9 1.9 292292 1.2 1.2 342342 1.0 1.0 381381 4.0 4.0 293293 0.1 0.1 343343 0.8 0.8 382382 2.2 2.2 294294 0.4 0.4 344344 0.4 0.4 383383 2.2 2.2 295295 0.2 0.2 345345 1.1 1.1 384384 2.0 2.0 296296 1.0 1.0 346346 0.8 0.8 385385 2.8 2.8 297297 0.8 0.8 347347 1.2 1.2 386386 1.3 1.3 298298 0.7 0.7 348348 1.6 1.6 387387 1.5 1.5 299299 0.6 0.6 349349 2.1 2.1 388388 2.8 2.8 300300 1.0 1.0 350350 0.6 0.6 389389 2.2 2.2 301301 0.9 0.9 351351 0.7 0.7 390390 3.8 3.8 302302 1.2 1.2 352352 0.5 0.5 391391 7.1 7.1 303303 1.0 1.0 353353 0.8 0.8 392392 2.7 2.7 304304 1.4 1.4 354354 0.6 0.6 393393 1.0 1.0 305305 2.1 2.1 355355 1.1 1.1 394394 4.5 4.5 306306 1.7 1.7 356356 1.4 1.4 395395 7.0 7.0 307307 2.0 2.0 357357 0.7 0.7 396396 7.3 7.3 308308 2.2 2.2 358358 0.8 0.8 397397 6.5 6.5 309309 1.3 1.3 359359 0.9 0.9 398398 7.8 7.8 310310 1.6 1.6 360360 2.2 2.2 399399 4.9 4.9 311311 0.2 0.2 361361 2.1 2.1 400400 0.4 0.4 312312 0.3 0.3 362362 2.6 2.6 401401 1.4 1.4 313313 0.1 0.1 363363 1.4 1.4 402402 0.5 0.5 314314 0.2 0.2 364364 1.2 1.2 403403 1.3 1.3 315315 0.4 0.4 365365 1.1 1.1 404404 1.9 1.9 316316 1.2 1.2 366366 1.6 1.6 405405 2.7 2.7 317317 0.3 0.3 367367 2.2 2.2 406406 1.5 1.5 318318 0.5 0.5 368368 5.9 5.9 407407 1.3 1.3 319319 1.5 1.5 369369 4.5 4.5 408408 3.5 3.5 320320 0.9 0.9 370370 7.7 7.7 409409 3.3 3.3 321321 0.9 0.9 371371 2.8 2.8 410410 1.1 1.1 322322 1.9 1.9 372372 6.3 6.3 411411 1.8 1.8 323323 1.2 1.2 373373 2.1 2.1 412412 8.4 8.4 324324 2.3 2.3 374374 1.9 1.9 413413 1.7 1.7 325325 2.2 2.2 375375 5.2 5.2 414414 2.9 2.9 326326 2.9 2.9 376376 1.1 1.1 415415 1.1 1.1 327327 4.4 4.4 377377 2.3 2.3 416416 0.7 0.7 328328 3.8 3.8 378378 4.7 4.7 329329 4.2 4.2 379379 6.1 6.1 a 세린79 잔기의 인산화 정도를 웨스턴 블롯(Western blot) 분석한 결과. none 세린79잔기와 트레오닌172 잔기의 인산화 정도를 웨스턴 블롯(Western blot) 분석한 결과. a Western blot analysis of phosphorylation of serine 79 residues. none Western blot analysis of phosphorylation of serine 79 residue and threonine 172 residue.

상기 표 3과 첨부도면 도 1과 도 2a 내지 도 2g로부터 확인할 수 있듯이, 본 발명에 따른 상기 화학식 1로 표시되는 화합물을 근육 세포주에 처리하면 AMPK 효소의 활성이 증가함을 관찰할 수 있었다.As can be seen from Table 3 and the accompanying drawings, Figures 1 and 2a to 2g, the activity of the AMPK enzyme was increased when the compound represented by the formula (1) according to the present invention to the muscle cell line.

실험예 3. 모델동물인 db /db 마우스에서 당뇨/비만 예방 및 치료효과.Experimental Example 3. Prevention and treatment of diabetes / obesity in a model animal db / db mouse.

8∼9주 된 db/db 계통의 수컷 마우스(C57BL/Ks)를 실험에 사용하였다. 0.5% 카르복시메틸셀룰로로스(CMC) 용액의 음성대조군, 0.5% 카르복시메틸셀룰로로스(CMC)에 녹인 양성대조군(Rosiglitazone) 및 시험약물은 매일 오후에 경구 혹은 복강투여 하며, 혈당 측정은 꼬리정맥을 절개하여 3∼4일 간격으로 오후에 일정 시간에 투여 직전에 혈당 측정기로 측정하였다. 동물의 체중과 사료 양은 매일 약물 투여직전에 측정하였다.Male mice of 8-9 weeks old db / db strain (C57BL / Ks) were used for the experiment. Negative control of 0.5% carboxymethylcellulose (CMC) solution, positive control (Rosiglitazone) dissolved in 0.5% carboxymethylcellulose (CMC) and test drug are administered orally or intraperitoneally every afternoon. The incision was measured with a blood glucose meter just before administration at a certain time in the afternoon at intervals of 3 to 4 days. Animal weight and feed volume were measured immediately before daily drug administration.

10일 동안 투여 및 혈당측정과 체중측정이 끝난 후, 혈액을 채취하여 혈청을 분리하여 간기능, 신장기능 및 지질검사를 위한 Biochemical parameter 등을 측정한다.After 10 days of administration, blood glucose measurement and weight measurement, blood is collected and serum is separated to measure liver function, kidney function and biochemical parameters for lipid test.

도 3a 및 3b, 도 4a 및 4b, 도 5a, 5b 및 5c, 그리고 도 6a, 6b 및 6c에서 보듯이, 본 발명에 따른 상기 화학식 1로 표시되는 화합물을 복강 또는 경구 투여를 통하여 실험군과 대조군의 혈당과 체중을 측정하여 분석한 결과, 대조군에 비하여 실험군이 혈당 및 체중이 유의하게 감소하는 것으로 보여 당뇨 및 비만의 예방 및 치료효과를 관찰할 수 있었다.As shown in Figures 3a and 3b, 4a and 4b, 5a, 5b and 5c, and 6a, 6b and 6c, the compound represented by the formula (1) according to the invention through the intraperitoneal or oral administration of the experimental group and the control group As a result of measuring blood sugar and body weight, the experimental group showed a significant decrease in blood sugar and body weight compared to the control group, and thus the prevention and treatment effect of diabetes and obesity was observed.

실험예 3. 모델동물인 ob/ob 마우스에서 당뇨/비만 예방 및 치료효과.Experimental Example 3. Prevention and treatment of diabetes / obesity in ob / ob mice as model animals.

실험예 3-1Experimental Example 3-1

웅성 6주령의 ob/ob 마우스를 Harlan으로부터 공급받아 사료와 물을 자유로이 섭취하도록 하며 SK내 동물실에서 일주일간 순화시켰다. 이후 체중을 측정하여(0 day) 각 그룹의 평균무게가 일정하도록 동물을 분배하였다. 실험군은 대조군(Control), 양성대조군(sibutramine), 각 약물군으로 나누었으며, 투여 용량은 양성대조군 15 mg/kg, 각 약물군은 200 mg/kg/10mL로 약물을 용시 제조하여 인슐린 주사기를 이용하여 복강 투여하였다. 또한 투여는 오후 5시에 매일 1회씩 4주간 투여하였다. 대조군은 0.5% 카르복시메킬셀룰로오스(CMC)만을 kg/10mL로 투여하였다.Male 6-week-old ob / ob mice were fed from Harlan and allowed for free intake of feed and water, followed by a week-long purification in an animal room in SK. The animals were then distributed so that the average weight of each group was constant by weighing (0 day). The experimental group was divided into control group, positive control group, and each drug group, and the dosage was 15 mg / kg positive control group, and 200 mg / kg / 10 mL of each drug group. Administered. In addition, the administration was administered once a day for 4 weeks at 5 pm. The control group was administered with only 0.5% carboxymethyl cellulose (CMC) in kg / 10 mL.

4주간 투여하면서 체중을 측정하였으며, 대조군 그룹의 체중과 약물 투여군 그룹의 체중 차이(g)와, 최초 약물투여한 날(0 day)의 체중으로부터 증가하는 체중의 %를 계산하여 약물이 나타내는 체중증가 억제를 대조군 그룹과 비교함으로써 약효를 평가하였다. 또한 사료 섭취량을 측정하여 사료섭취 억제 효과를 관찰하였다. Body weight was measured during 4 weeks of administration, weight gain of the drug was calculated by calculating the difference in body weight (g) between the control group and the drug group and the percentage of weight gain from the weight of the first day of administration (0 day). Drug efficacy was assessed by comparing inhibition with the control group. In addition, the feed intake was measured to observe the effect of inhibiting feed intake.

실험예 3-2Experimental Example 3-2

실험예 1에서 효과를 보인 약물들에 대해 경구투여를 통한 효과 시험을 실시하였다. 실험군 분배, 투여용량 및 투여기간 등은 실험예 3-1과 동일하며, 단 투여 방법만 존데를 이용하여 강제경구 투여를 실시하였다.Drugs showing the effect in Experimental Example 1 was conducted through the effect test through oral administration. Experimental group distribution, dose and administration period are the same as Experimental Example 3-1, except that only the administration method was forced oral administration using Sonde.

도 7a 및 7b, 도 8a 및 8b, 그리고 도 9에서 보듯이, 본 발명에 따른 상기 화학식 1로 표시되는 화합물을 복강 또는 경구 투여를 통하여 실험군과 대조군의 혈당 또는 체중을 측정하여 분석한 결과, 대조군에 비하여 실험군이 혈당 및 체중이 유의하게 감소하는 것으로 보여 당뇨 및 비만의 예방 및 치료효과를 관찰할 수 있었다.As shown in Figure 7a and 7b, Figure 8a and 8b, and Figure 9, the compound represented by the formula (1) according to the present invention by measuring the blood sugar or body weight of the experimental group and the control group through the abdominal cavity or oral administration, the control group Compared to the experimental group, blood sugar and body weight were significantly decreased, and thus the effect of preventing and treating diabetes and obesity was observed.

상술한 바와 같이, 본 발명에 따른 혈당 저하와 체중 감소 효과가 탁월한 여러 화합물들은 당뇨병 및 비만 치료제로 유용하게 사용할 수 있다.As described above, various compounds excellent in blood sugar lowering and weight loss effects according to the present invention can be usefully used as a therapeutic agent for diabetes and obesity.

Claims (7)

다음 화학식 1로 표시되는 퀴나졸린 유도체 또는 약제학적으로 허용 가능한 이의 염 : A quinazoline derivative represented by the following formula (1) or a pharmaceutically acceptable salt thereof: [화학식 1][Formula 1]
Figure 112005078193254-PAT00020
Figure 112005078193254-PAT00020
 상기 화학식 1에서, In Chemical Formula 1, Ra은 수소, (C1-C18)알킬, (C2-C8)알케닐, (C2-C8)알키닐, 할로게노-(C1-C6)알킬, 히드록시-(C1-C6)알킬, (C1-C6)알콕시-(C1-C6)알킬, 시아노-(C1-C6)알킬, 아미노-(C1-C6)알킬, (C1-C6)알킬아미노-(C1-C6)알킬, 디-[(C1-C6)알킬]아미노-(C1-C6)알킬, (C1-C6)알킬티오-(C1-C6)알킬, (C1-C6)알킬설피닐-(C1-C6)알킬 또는 (C1-C6)알킬설포닐-(C1-C6)알킬에서 선택된 치환체이거나, 화학식 -X1-Q1 [여기서, X1는 직접 결합이거나, O, S, SO, SO2, N(R4), CO, CO2, CH(OR4), CON(R4), N(R4)CO, SO2N(R4), N(R4)SO2, C(R4)2O, C(R4)2S, N(R4)C(R4)2 , N(R4)CON(R4), N(R4)CSN(R4)]에서 선택되고, R4은 수소, (C1-C6)알킬, 아릴, 아릴-(C1-C6)알킬, (C3-C7)싸이클로알킬, (C3-C7)싸이클로알 킬-(C1-C6)알킬, (C3-C7)싸이클로알케닐, (C3-C7)싸이클로알케닐-(C1-C6)알킬, 헤테로아릴, 헤테로아릴-(C1-C6)알킬, 헤테로싸이클릴 또는 헤테로싸이클릴-(C1-C6)알킬의 기이고, Q1은 R4 와 동일하거나 상이한 치환기에서 선택될 수 있으며, R a is hydrogen, (C 1 -C 18 ) alkyl, (C 2 -C 8 ) alkenyl, (C 2 -C 8 ) alkynyl, halogeno- (C 1 -C 6 ) alkyl, hydroxy- ( C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy- (C 1 -C 6 ) alkyl, cyano- (C 1 -C 6 ) alkyl, amino- (C 1 -C 6 ) alkyl, ( C 1 -C 6 ) alkylamino- (C 1 -C 6 ) alkyl, di-[(C 1 -C 6 ) alkyl] amino- (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkylthio At-(C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkylsulfinyl- (C 1 -C 6 ) alkyl or (C 1 -C 6 ) alkylsulfonyl- (C 1 -C 6 ) alkyl Is a selected substituent or is of the formula -X 1 -Q 1 wherein X 1 is a direct bond or is O, S, SO, SO 2 , N (R 4 ), CO, CO 2 , CH (OR 4 ), CON (R 4 ), N (R 4 ) CO, SO 2 N (R 4 ), N (R 4 ) SO 2 , C (R 4 ) 2 O, C (R 4 ) 2 S, N (R 4 ) C (R 4 ) 2 , N (R 4 ) CON (R 4 ), N (R 4 ) CSN (R 4 )], and R 4 is hydrogen, (C 1 -C 6 ) alkyl, aryl, aryl- (C 1 -C 6 ) alkyl, (C 3 -C 7 ) cycloalkyl, (C 3 -C 7 ) cycloalkyl- (C 1 -C 6 ) alkyl, (C 3 -C 7 ) cycloalkenyl, (C 3 -C 7 ) cycloalkenyl- (C 1 Is a group of -C 6 ) alkyl, heteroaryl, heteroaryl- (C 1 -C 6 ) alkyl, heterocyclyl or heterocyclyl- (C 1 -C 6 ) alkyl, Q 1 is R 4 and May be selected from the same or different substituents, 그리고, 여기서 Ra 기내에서의 (C2-C6)알킬렌 기에서 인접 탄소 원자는 O, S, SO, SO2 , N(R5), CO, CH(OR5), CON(R5), N(R5)CO, SO2N(R5), N(R5)SO2, C(R5)=C(R5) 및 C≡C에서 선택된 기의 삽입에 의해서 분리될 수 있고, 여기서 R5는 수소 또는 (C1-C6)알킬이고 And wherein adjacent carbon atoms in the (C 2 -C 6 ) alkylene group in the group R a are O, S, SO, SO 2 , N (R 5 ), CO, CH (OR 5 ), CON (R 5 ), N (R 5 ) CO, SO 2 N (R 5 ), N (R 5 ) SO 2 , C (R 5 ) = C (R 5 ) and C≡C can be separated by insertion of a group selected Wherein R 5 is hydrogen or (C 1 -C 6 ) alkyl 여기서 Ra 기내에서의 임의의 CH2=CH- 또는 HC≡C- 기는 말단 CH2= 또는 HC≡ 위치에서 할로게노, 카르복시, 카르바모일, (C1-C6)알콕시카르보닐, N-(C1-C6)알킬카르바모일, N,N-디-[(C1-C6)알킬]카르바모일, 아미노-(C1-C6)알킬, (C1-C6)알킬아미노-(C1-C6)알킬 및 디-[(C1-C6)알킬]아미노-(C1-C6)알킬에서 선택되거나 또는 화학식 Q2-X2-[여기서, X2는 직접 결합이거나, CO 및 N(R6)CO에서 선택되고, 여기서 R6는 수소 또는 (C1-C6)알킬이고, Q2는 아릴, 아릴-(C1-C6)알킬, 헤테로아릴, 헤테로아릴-(C1-C6)알킬, 헤테로싸이클릴 또는 헤테로싸이클릴-(C1-C6)알킬임]의 기에서 선택된 치 환체를 포함할 수 있고,Wherein any CH 2 ═CH— or HC≡C— group in the R a group is halogeno, carboxy, carbamoyl, (C 1 -C 6 ) alkoxycarbonyl, N— at the terminal CH 2 = or HC≡ position (C 1 -C 6 ) alkylcarbamoyl, N, N- di-[(C 1 -C 6 ) alkyl] carbamoyl, amino- (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkylamino, - (C 1 -C 6) alkyl and di - [(C 1 -C 6) alkyl] amino - (C 1 -C 6) alkyl selected from or the formula Q 2 -X 2 - [wherein, X 2 Is a direct bond or is selected from CO and N (R 6 ) CO, wherein R 6 is hydrogen or (C 1 -C 6 ) alkyl, Q 2 is aryl, aryl- (C 1 -C 6 ) alkyl, hetero Aryl, heteroaryl- (C 1 -C 6 ) alkyl, heterocyclyl or heterocyclyl- (C 1 -C 6 ) alkyl], and 여기서 Ra 기내에서의 임의의 CH2 또는 CH3기는 각각의 CH2 또는 CH3기에서 1 이상의 할로게노, (C1-C6)알킬 치환체, 히드록시, 시아노, 아미노, 카르복시, 카르바모일, (C1-C6)알콕시, (C1-C6)알킬티오, (C1-C6)알킬설피닐, (C1-C6)알킬설포닐, (C1-C6)알킬아미노, 디-[(C1-C6)알킬]아미노, (C1-C6)알콕시카르보닐, N-(C1-C6)알킬카르바모일, N,N-디-[(C1-C6)알킬]카르바모일, (C2-C6)알카노일, (C2-C6)알카노일옥시, (C2-C6)알카노일아미노, N-(C1-C6)알킬-(C2-C6)알카노일아미노, N-(C1-C6)알킬설파모일, N,N-디-[(C1-C6)알킬]설파모일, (C1-C6)알칸설포닐아미노 및 N-(C1-C6)알킬-(C1-C6)알칸설포닐아미노에서 선택된 치환체 또는, 화학식 -X3-Q3 [여기서, X3는 직접 결합이거나, O, S, SO, SO2, N(R7), CO, CH(OR7), CON(R7), N(R7)CO, SO2N(R7), N(R7)SO2, C(R7)2O, C(R7)2S, N(R7)C(R7)2, N(R7)CON(R7) 및 N(R7)CSN(R7)에서 선택되고, R7 은 수소, (C1-C6)알킬, 아릴, 아릴-(C1-C6)알킬, (C3-C7)싸이클로알킬, (C3-C7)싸이클로알킬-(C1-C6)알킬, (C3-C7)싸이클로알케닐, (C3-C7)싸이클로알케닐-(C1-C6)알킬, 헤테로아릴, 헤테로아릴-(C1-C6)알킬, 헤테로싸이클릴 또는 헤테로싸이클릴-(C1-C6) 알킬의 기이고, Q3 은 R7와 동일하거나 상이한 치환기에서 선택될 수 있으며Wherein any CH 2 or CH 3 group in the R a group is at least one halogeno, (C 1 -C 6 ) alkyl substituent, hydroxy, cyano, amino, carboxy, carba at each CH 2 or CH 3 group together, (C 1 -C 6) alkoxy, (C 1 -C 6) alkylthio, (C 1 -C 6) alkylsulfinyl, (C 1 -C 6) alkylsulfonyl, (C 1 -C 6) alkylamino, di - [(C 1 -C 6) alkyl] amino, (C 1 -C 6) alkoxycarbonyl, N- (C 1 -C 6) alkyl-carbamoyl, N, N- di - [( C 1 -C 6 ) alkyl] carbamoyl, (C 2 -C 6 ) alkanoyl, (C 2 -C 6 ) alkanoyloxy, (C 2 -C 6 ) alkanoylamino, N- (C 1- C 6 ) alkyl- (C 2 -C 6 ) alkanoylamino, N- (C 1 -C 6 ) alkylsulfamoyl, N, N- di-[(C 1 -C 6 ) alkyl] sulfamoyl, (C 1 -C 6) alkane sulfonyl amino, N- (C 1 -C 6) alkyl, - (C 1 -C 6) alkane sulfonyl amino substituent selected from or the formula -X 3 -Q 3 [where, X 3 is Or a direct bond, O, S, SO, SO 2 , N (R 7 ), CO, CH (OR 7 ), CON (R 7 ), N (R 7 ) CO, SO 2 N (R 7 ), N ( R 7 ) SO 2 , C (R 7 ) 2 O, C (R 7 ) 2 S, N (R 7 ) C (R 7 ) 2 , N (R 7 ) CON (R 7 ) and N (R 7 ) CSN (R 7 ), R 7 is hydrogen, (C 1 -C 6 ) alkyl, aryl, aryl- (C 1 -C 6 ) Alkyl, (C 3 -C 7 ) cycloalkyl, (C 3 -C 7 ) cycloalkyl- (C 1 -C 6 ) alkyl, (C 3 -C 7 ) cycloalkenyl, (C 3 -C 7 ) cyclo Is a group of alkenyl- (C 1 -C 6 ) alkyl, heteroaryl, heteroaryl- (C 1 -C 6 ) alkyl, heterocyclyl or heterocyclyl- (C 1 -C 6 ) alkyl, Q 3 is May be selected from the same or different substituents as R 7 여기서, Ra 상의 치환체내에서의 임의의 아릴, 헤테로아릴 또는 헤테로싸이클릴기는 0 내지 3개의 치환체를 포함할 수 있고, 이 치환체는 동일하거나 상이할 수 있으며, 할로게노, 트리플루오로메틸, 시아노, 니트로, 히드록시, 아미노, 카르복시, 카르바모일, (C1-C6)알킬, (C2-C8)알케닐, (C2-C8)알키닐, (C1-C6)알콕시, (C2-C6)알케닐옥시, (C2-C6)알키닐옥시, (C1-C6)알킬티오, (C1-C6)알킬설피닐, (C1-C6)알킬설포닐, (C1-C6)알킬아미노, 디-[(C1-C6)알킬]아미노, (C1-C6)알콕시카르보닐, N-(C1-C6)알킬카르바모일, N,N-디-[(C1-C6)알킬]카르바모일, (C2-C6)알카노일, (C2-C6)알카노일옥시, (C2-C6)알카노일아미노, N-(C1-C6)알킬-(C2-C6)알카노일아미노, N-(C1-C6)알킬설파모일, N,N-디-[(C1-C6)알킬]설파모일, (C1-C6)알칸설포닐아미노 및 N-(C1-C6)알킬-(C1-C6)알칸설포닐아미노에서 선택되거나 또는, 화학식 -X4-R8 [여기서, X4는 직접 결합이거나, O 및 N(R9)에서 선택되고, 여기서 R9는 수소 또는 (C1-C6)알킬이고, R8은 할로게노-(C1-C6)알킬, 히드록시-(C1-C6)알킬, (C1-C6)알콕시-(C1-C6)알킬, 시아노-(C1-C6)알킬, 아미노-(C1-C6)알킬, (C1-C6)알킬아미노-(C1-C6)알킬, 디-[(C1-C6)알킬]아미노-(C1-C6)알킬, (C2-C6)알카노일아미노-(C1-C6)알킬 또는 (C1-C6)알콕시 카르보닐아미노-(C1-C6)알킬 임]의 기에서 선택되거나, 또는 화학식-X5-Q4 [여기서, X5는 직접 결합이거나 O, CO 및 N(R10)에서 선택되고, 여기서 R10은 수소 또는 (C1-C6)알킬이고, Q4은 아릴, 아릴-(C1-C6)알킬, 헤테로아릴, 헤테로아릴-(C1-C6)알킬, 헤테로싸이클릴 또는 헤테로싸이클릴-(C1-C6)알킬이고, 이것은 1 또는 2개의 치환체를 포함할 수 있으며, 이 치환체는 동일하거나 상이할 수 있으며, 할로게노, (C1-C6)알킬 및 (C1-C6)알콕시에서 선택되는 것임]의 기에서 선택되고,Wherein any aryl, heteroaryl, or heterocyclyl group in the substituent on R a may comprise 0 to 3 substituents, which substituents may be the same or different and include halogeno, trifluoromethyl, cya Furnace, nitro, hydroxy, amino, carboxy, carbamoyl, (C 1 -C 6 ) alkyl, (C 2 -C 8 ) alkenyl, (C 2 -C 8 ) alkynyl, (C 1 -C 6 ) Alkoxy, (C 2 -C 6 ) alkenyloxy, (C 2 -C 6 ) alkynyloxy, (C 1 -C 6 ) alkylthio, (C 1 -C 6 ) alkylsulfinyl, (C 1- C 6 ) alkylsulfonyl, (C 1 -C 6 ) alkylamino, di-[(C 1 -C 6 ) alkyl] amino, (C 1 -C 6 ) alkoxycarbonyl, N- (C 1 -C 6 ) alkyl carbamoyl, N, N- di - [(C 1 -C 6) alkyl] carbamoyl, (C 2 -C 6) alkanoyl, (C 2 -C 6) alkanoyloxy, (C 2 -C 6 ) alkanoylamino, N- (C 1 -C 6 ) alkyl- (C 2 -C 6 ) alkanoylamino, N- (C 1 -C 6 ) alkylsulfamoyl, N, N- di- [ (C 1 -C 6) alkyl] sulfamoyl, (C 1 -C 6) alkane sulfonylamino N- (C 1 -C 6) alkyl, - (C 1 -C 6) alkane sulfonyl selected or in the amino, the formula -X 4 -R 8 [wherein, X 4 is either a direct bond, O or N (R 9 ), Where R 9 is hydrogen or (C 1 -C 6 ) alkyl, R 8 is halogeno- (C 1 -C 6 ) alkyl, hydroxy- (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy- (C 1 -C 6 ) alkyl, cyano- (C 1 -C 6 ) alkyl, amino- (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkylamino- ( C 1 -C 6 ) alkyl, di-[(C 1 -C 6 ) alkyl] amino- (C 1 -C 6 ) alkyl, (C 2 -C 6 ) alkanoylamino- (C 1 -C 6 ) alkyl Or (C 1 -C 6 ) alkoxy carbonylamino- (C 1 -C 6 ) alkyl], or the formula-X 5 -Q 4 wherein X 5 is a direct bond or O, CO and N (R 10 ), wherein R 10 is hydrogen or (C 1 -C 6 ) alkyl, Q 4 is aryl, aryl- (C 1 -C 6 ) alkyl, heteroaryl, heteroaryl- (C 1 -C 6 ) alkyl, heterocyclyl or heterocyclyl- (C 1 -C 6 ) alkyl , Which may comprise one or two substituents, which substituents may be the same or different and are selected from halogeno, (C 1 -C 6 ) alkyl and (C 1 -C 6 ) alkoxy] Is selected from, 그리고, 여기서 Ra 상의 치환체내에서 헤테로싸이클릴기는 1 또는 2개의 옥소 또는 티옥소 치환체를 포함할 수 있으며;And wherein the heterocyclyl group in the substituent on R a may comprise one or two oxo or thioxo substituents; Rb은 수소, (C1-C18)알킬, (C2-C8)알케닐, (C2-C8)알키닐, 할로게노-(C1-C6)알킬, 히드록시-(C1-C6)알킬, (C1-C6)알콕시-(C1-C6)알킬, 시아노-(C1-C6)알킬, 아미노-(C1-C6)알킬, (C1-C6)알킬아미노-(C1-C6)알킬, 디-[(C1-C6)알킬]아미노-(C1-C6)알킬, (C1-C6)알킬티오-(C1-C6)알킬, (C1-C6)알킬설피닐-(C1-C6)알킬 또는 (C1-C6)알킬설포닐-(C1-C6)알킬에서 선택된 치환체이거나, 화학식 -X1-Q1 [여기서, X1는 직접 결합이거나, O, S, SO, SO2, N(R4), CO, CO2(R4), CH(OR4), CON(R4), N(R4)CO, SO2N(R4), N(R4)SO2, C(R4)2O, C(R4)2S, N(R4)C(R4)2 , N(R4)CON(R4), N(R4)CSN(R4)]에서 선택되고, R4은 수소, (C1-C6)알킬, 아릴, 아릴-(C1-C6)알킬, (C3-C7)싸이클로알킬, (C3-C7)싸이클로알킬-(C1-C6)알킬, (C3-C7)싸이클로알케닐, (C3-C7)싸이클로알케닐-(C1-C6)알킬, 헤테로아릴, 헤테로아릴-(C1-C6)알킬, 헤테로싸이클릴 또는 헤테로싸이클릴-(C1-C6)알킬의 기이고, Q1은 R4 와 동일하거나 상이한 치환기에서 선택될 수 있으며, R b is hydrogen, (C 1 -C 18 ) alkyl, (C 2 -C 8 ) alkenyl, (C 2 -C 8 ) alkynyl, halogeno- (C 1 -C 6 ) alkyl, hydroxy- ( C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy- (C 1 -C 6 ) alkyl, cyano- (C 1 -C 6 ) alkyl, amino- (C 1 -C 6 ) alkyl, ( C 1 -C 6 ) alkylamino- (C 1 -C 6 ) alkyl, di-[(C 1 -C 6 ) alkyl] amino- (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkylthio At-(C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkylsulfinyl- (C 1 -C 6 ) alkyl or (C 1 -C 6 ) alkylsulfonyl- (C 1 -C 6 ) alkyl Is a selected substituent or is of the formula -X 1 -Q 1 wherein X 1 is a direct bond or is O, S, SO, SO 2 , N (R 4 ), CO, CO 2 (R 4 ), CH (OR 4 ) , CON (R 4 ), N (R 4 ) CO, SO 2 N (R 4 ), N (R 4 ) SO 2 , C (R 4 ) 2 O, C (R 4 ) 2 S, N (R 4 ) C (R 4 ) 2 , N (R 4 ) CON (R 4 ), N (R 4 ) CSN (R 4 )], and R 4 is hydrogen, (C 1 -C 6 ) alkyl, aryl, Aryl- (C 1 -C 6 ) alkyl, (C 3 -C 7 ) cycloalkyl, (C 3 -C 7 ) cycloalkyl- (C 1 -C 6 ) alkyl, (C 3 -C 7 ) cycloalkenyl , (C 3 -C 7 ) cycloalkenyl - (C 1 -C 6) alkyl, heteroaryl, heteroaryl - (C 1 -C 6) alkyl, heteroaryl or heteroaryl cycle the cycle reel reel - a group of (C 1 -C 6) alkyl, Q 1 is R 4 Wow May be selected from the same or different substituents, 그리고, 여기서 Rb 기내에서의 (C2-C6)알킬렌 기에서 인접 탄소 원자는 O, S, SO, SO2 , N(R5), CO, CH(OR5), CON(R5), N(R5)CO, SO2N(R5), N(R5)SO2, CH=CH 및 C≡C에서 선택된 기의 삽입에 의해서 분리될 수 있고, 여기서 R5는 수소 또는 (C1-C6)알킬이고 And wherein adjacent carbon atoms in the (C 2 -C 6 ) alkylene group in the group R b are O, S, SO, SO 2 , N (R 5 ), CO, CH (OR 5 ), CON (R 5 ), N (R 5 ) CO, SO 2 N (R 5 ), N (R 5 ) SO 2 , CH═CH and C≡C can be separated by insertion of a group wherein R 5 is hydrogen or (C 1 -C 6 ) alkyl 여기서 Rb 기내에서의 임의의 CH2=CH- 또는 HC≡C- 기는 말단 CH2= 또는 HC≡위치에서 할로게노, 카르복시, 카르바모일, (C1-C6)알콕시카르보닐, N-(C1-C6)알킬카르바모일, N,N-디-[(C1-C6)알킬]카르바모일, 아미노-(C1-C6)알킬, (C1-C6)알킬아미노-(C1-C6)알킬 및 디-[(C1-C6)알킬]아미노-(C1-C6)알킬에서 선택되거나 또는 화학식 Q2- X2-[여기서, X2는 직접 결합이거나, CO 및 N(R6)CO에서 선택되고, 여기서 Rb 상의 치환체내에서의 임의의 아릴, 헤테로아릴 또는 헤테로싸이클릴기 R6는 수소 또는 (C1-C6)알킬이고, Q2는 아릴, 아릴-(C1-C6)알킬, 헤테로아릴, 헤테로아릴-(C1-C6)알킬, 헤테로싸이클릴 또는 헤테로싸이클릴-(C1-C6)알킬임]의 기에서 선택된 치환체를 포함할 수 있고,Wherein any CH 2 ═CH— or HC≡C— group in the R b group is halogeno, carboxy, carbamoyl, (C 1 -C 6 ) alkoxycarbonyl, N— at the terminal CH 2 = or HC≡ position (C 1 -C 6 ) alkylcarbamoyl, N, N- di-[(C 1 -C 6 ) alkyl] carbamoyl, amino- (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkylamino, - (C 1 -C 6) alkyl and di - [(C 1 -C 6) alkyl] amino - (C 1 -C 6) alkyl selected from or the formula Q 2 - X 2 - [wherein, X 2 Is a direct bond or is selected from CO and N (R 6 ) CO, wherein any aryl, heteroaryl or heterocyclyl group R 6 in the substituent on R b is hydrogen or (C 1 -C 6 ) alkyl, Q 2 is aryl, aryl- (C 1 -C 6 ) alkyl, heteroaryl, heteroaryl- (C 1 -C 6 ) alkyl, heterocyclyl or heterocyclyl- (C 1 -C 6 ) alkyl] May include a substituent selected from a group, 여기서 Rb 기내에서의 임의의 CH2 또는 CH3기는 각각의 CH2 또는 CH3기에서 1 이상의 할로게노 또는 (C1-C6)알킬 치환체, 또는 히드록시, 시아노, 아미노, 카르복시, 카르바모일, (C1-C6)알콕시, (C1-C6)알킬티오, (C1-C6)알킬설피닐, (C1-C6)알킬설포닐, (C1-C6)알킬아미노, 디-[(C1-C6)알킬]아미노, (C1-C6)알콕시카르보닐, N-(C1-C6)알킬카르바모일, N,N-디-[(C1-C6)알킬]카르바모일, (C2-C6)알카노일, (C2-C6)알카노일옥시, (C2-C6)알카노일아미노, N-(C1-C6)알킬-(C2-C6)알카노일아미노, N-(C1-C6)알킬설파모일, N,N-디-[(C1-C6)알킬]설파모일, (C1-C6)알칸설포닐아미노 및 N-(C1-C6)알킬-(C1-C6)알칸설포닐아미노에서 선택된 치환체 또는, 화학식 -X3-Q3 [여기서, X3는 직접 결합이거나, O, S, SO, SO2, N(R7), CO, CH(OR7), CON(R7), N(R7)CO, SO2N(R7), N(R7)SO2, C(R7)2O, C(R7)2S, N(R7)C(R7)2, N(R7)CON(R7) 및 N(R7)CSN(R7)에서 선택되고, R7 은 수소, (C1-C6)알킬, 아릴, 아릴-(C1-C6)알킬, (C3-C7)싸이클로알킬, (C3-C7)싸이클로알킬-(C1-C6)알킬, (C3-C7)싸이클로알케닐, (C3-C7)싸이클로알케닐-(C1-C6)알킬, 헤테로아릴, 헤테로아릴-(C1-C6)알킬, 헤테로싸이클릴 또는 헤테로싸이클릴-(C1-C6)알킬의 기이고, Q3 은 R7 와 동일하거나 상이한 치환기에서 선택될 수 있으며Wherein any CH 2 or CH 3 group in the R b group is at least one halogeno or (C 1 -C 6 ) alkyl substituent at each CH 2 or CH 3 group, or hydroxy, cyano, amino, carboxy, car Barmoyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) alkylthio, (C 1 -C 6 ) alkylsulfinyl, (C 1 -C 6 ) alkylsulfonyl, (C 1 -C 6 ) alkylamino, di - [(C 1 -C 6) alkyl] amino, (C 1 -C 6) alkoxycarbonyl, N- (C 1 -C 6) alkyl-carbamoyl, N, N- di - [ (C 1 -C 6 ) alkyl] carbamoyl, (C 2 -C 6 ) alkanoyl, (C 2 -C 6 ) alkanoyloxy, (C 2 -C 6 ) alkanoylamino, N- (C 1 -C 6 ) alkyl- (C 2 -C 6 ) alkanoylamino, N- (C 1 -C 6 ) alkylsulfamoyl, N, N- di-[(C 1 -C 6 ) alkyl] sulfamoyl, ( C 1 -C 6) alkane sulfonyl amino, N- (C 1 -C 6) alkyl, - (C 1 -C 6) alkane-sulfonyl-amino or a substituent selected from the formula -X 3 -Q 3 [wherein, X 3 Is a direct bond or O, S, SO, SO 2 , N (R 7 ), CO, CH (OR 7 ), CON (R 7 ), N (R 7 ) CO, SO 2 N (R 7 ), N (R 7 ) SO 2 , C (R 7 ) 2 O, C (R 7 ) 2 S, N (R 7 ) C (R 7 ) 2 , N (R 7 ) CON (R 7 ) and N (R 7 ) CSN (R 7 ), R 7 is hydrogen, (C 1 -C 6 ) alkyl, aryl, aryl- (C 1 -C 6 ) Alkyl, (C 3 -C 7 ) cycloalkyl, (C 3 -C 7 ) cycloalkyl- (C 1 -C 6 ) alkyl, (C 3 -C 7 ) cycloalkenyl, (C 3 -C 7 ) cyclo Is a group of alkenyl- (C 1 -C 6 ) alkyl, heteroaryl, heteroaryl- (C 1 -C 6 ) alkyl, heterocyclyl or heterocyclyl- (C 1 -C 6 ) alkyl, Q 3 is With R 7 May be selected from the same or different substituents, Rb 기내에서의 임의의 아릴, 헤테로아릴 또는 헤테로싸이클릴기는 1, 2 또는 3개의 치환체를 포함할 수 있고, 이 치환체는 동일하거나 상이할 수 있으며, 수소, 할로게노, 트리플루오로메틸, 시아노, 니트로, 히드록시, 아미노, 카르복시, 카르바모일, (C1-C6)알킬, (C2-C8)알케닐, (C2-C8)알키닐, (C1-C6)알콕시, (C2-C6)알케닐옥시, (C2-C6)알키닐옥시, (C1-C6)알킬티오, (C1-C6)알킬설피닐, (C1-C6)알킬설포닐, (C1-C6)알킬아미노, 디-[(C1-C6)알킬]아미노, (C1-C6)알콕시카르보닐, N-(C1-C6)알킬카르바모일, N,N-디-[(C1-C6)알킬]카르바모일, (C2-C6)알카노일, (C2-C6)알카노일옥시, (C2-C6)알카노일아미노, N-(C1-C6)알킬-(C2-C6)알카노일아미노, (C3-C6)알케노일아미노, N-(C1-C6)알킬-(C3-C6)알케노일아미노, (C3-C6)알키노일아미노, N-(C1-C6)알 킬-(C3-C6)알키노일아미노, N-(C1-C6)알킬설파모일, N,N-디-[(C1-C6)알킬]설파모일, (C1-C6)알칸설포닐아미노 및 N-(C1-C6)알킬-(C1-C6)알칸설포닐아미노에서 선택되거나 화학식 -X4-R8 [여기서, X4 은 직접 결합이거나, O 및 N(R9)에서 선택되고, 여기서 R9는 수소 또는 (C1-C6)알킬이고, R8 은 할로게노-(C1-C6)알킬, 히드록시-(C1-C6)알킬, (C1-C6)알콕시-(C1-C6)알킬, 시아노-(C1-C6)알킬, 아미노-(C1-C6)알킬, (C1-C6)알킬아미노-(C1-C6)알킬 또는 디-[(C1-C6)알킬]아미노-(C1-C6)알킬임]의 기에서 선택되거나 또는 화학식-X5-Q4 [여기서, X5는 직접 결합이거나 O, CO 및 N(R10)에서 선택되고, 여기서 R10은 수소 또는 (C1-C6)알킬이고, Q4은 아릴, 아릴-(C1-C6)알킬, 헤테로아릴, 헤테로아릴-(C1-C6)알킬, 헤테로싸이클릴 또는 헤테로싸이클릴-(C1-C6)알킬이고, 이것은 1 또는 2개의 치환체를 포함할 수 있으며, 이 치환체는 동일하거나 상이할 수 있으며, 할로게노, (C1-C6)알킬 및 (C1-C6)알콕시에서 선택되는 것임]의 기에서 선택되고,Any aryl, heteroaryl, or heterocyclyl group in the group R b may contain 1, 2 or 3 substituents, which substituents may be the same or different and include hydrogen, halogeno, trifluoromethyl, cya Furnace, nitro, hydroxy, amino, carboxy, carbamoyl, (C 1 -C 6 ) alkyl, (C 2 -C 8 ) alkenyl, (C 2 -C 8 ) alkynyl, (C 1 -C 6 ) Alkoxy, (C 2 -C 6 ) alkenyloxy, (C 2 -C 6 ) alkynyloxy, (C 1 -C 6 ) alkylthio, (C 1 -C 6 ) alkylsulfinyl, (C 1- C 6 ) alkylsulfonyl, (C 1 -C 6 ) alkylamino, di-[(C 1 -C 6 ) alkyl] amino, (C 1 -C 6 ) alkoxycarbonyl, N- (C 1 -C 6 ) alkyl carbamoyl, N, N- di - [(C 1 -C 6) alkyl] carbamoyl, (C 2 -C 6) alkanoyl, (C 2 -C 6) alkanoyloxy, (C 2 -C 6 ) alkanoylamino, N- (C 1 -C 6 ) alkyl- (C 2 -C 6 ) alkanoylamino, (C 3 -C 6 ) alkenoylamino, N- (C 1 -C 6 ) Alkyl- (C 3 -C 6 ) alkenoylamino, (C 3 -C 6 ) alkynoylamino, N- ( C 1 -C 6 ) alkyl- (C 3 -C 6 ) alkynoylamino, N- (C 1 -C 6 ) alkylsulfamoyl, N, N- di-[(C 1 -C 6 ) alkyl] Sulfamoyl, (C 1 -C 6 ) alkanesulfonylamino and N- (C 1 -C 6 ) alkyl- (C 1 -C 6 ) alkanesulfonylamino or is selected from the formula: -X 4 -R 8 [wherein X 4 is a direct bond or is selected from O and N (R 9 ) wherein R 9 is hydrogen or (C 1 -C 6 ) alkyl and R 8 is halogeno- (C 1 -C 6 ) alkyl, hydroxide hydroxy - (C 1 -C 6) alkyl, (C 1 -C 6) alkoxy - (C 1 -C 6) alkyl, cyano, - (C 1 -C 6) alkyl, amino, - (C 1 -C 6) Alkyl, (C 1 -C 6 ) alkylamino- (C 1 -C 6 ) alkyl or di-[(C 1 -C 6 ) alkyl] amino- (C 1 -C 6 ) alkyl] Or formula -X 5 -Q 4 , wherein X 5 is a direct bond or is selected from O, CO and N (R 10 ), wherein R 10 is hydrogen or (C 1 -C 6 ) alkyl, Q 4 is aryl , Aryl- (C 1 -C 6 ) alkyl, heteroaryl, heteroaryl- (C 1 -C 6 ) alkyl, heterocyclyl or he Interrogating cycle reel - (C 1 -C 6) alkyl, which may include one or two substituents, the substituents may be the same or different, halogeno, (C 1 -C 6) alkyl and (C 1- C 6 ) alkoxy], and 여기서 Rb 상의 치환체내에서 헤테로싸이클릴기는 1 또는 2개의 옥소 또는 티옥소 치환체를 포함할 수 있으며,Wherein the heterocyclyl group in the substituent on R b may comprise one or two oxo or thioxo substituents, 그리고 Rb 기내에서의 임의의 아릴, 헤테로아릴 또는 헤테로싸이클릴기의 동 일하거나 상이한 치환기는 서로 결합하여 화학식 -CH=CH-CH=CH-, -N=CH-CH=CH-, -CH=N-CH=CH-, -CH=CH-N=CH-, CH=CH-CH=N-, -N=CH-N=CH-, -CH=N-CH=N-, -N=CH-CH=N-, -N=N-CH=CH-, -CH=CH-N=N-, -CH=CH-O-, -O-CH=CH-, -CH=CH-S-, -S-CH=CH-, -C(R11)2-C(R11)2-O-, -O-C(R11)2-C(R11)2-, -C(R11)2-C(R11)2-S-, -S-C(R11)2-C(R11)2-, -O-C(R11)2-O-, -O-C(R11)2-C(R11)2-O-, -S-C(R11)2-S-, -S-C(R11)2-C(R11)2-S-, -CH=CH-NH-, -NH-CH=CH-, -C(R11)2-C(R11)2-NH-, -NH-C(R11)2-C(R11)2-, -N=CH-NH-, -NH-CH=N-, -NH-C(R11)2-NH-, -O-CH=N-, -N=CH-O-, -S-CH=N-, -N=CH-S-, -O-C(R11)2-NH-, -NH-C(R11)2-O-, -S-C(R11)2-NH-, -NH-C(R11)2-S-, -O-N=CH-, -CH=N-O-, -S-N=CH-, -CH=N-S-, -O-NH-C(R11)2-, -C(R11)2-NH-O-, -S-NH-C(R11)2-, -C(R11)2-NH-S-, -NH-N=CH-, -CH=N-NH-, -NH-NH-C(R11)2-, -C(R11)2-NH-NH, -N=N-NH- 또는 -NH-N=N-의 기 [여기서, R11은 수소 또는 (C1-C6)알킬]를 형성할 수 있고, And the same or different substituents of any aryl, heteroaryl, or heterocyclyl group in the group R b are bonded to each other to formula -CH = CH-CH = CH-, -N = CH-CH = CH-, -CH = N-CH = CH-, -CH = CH-N = CH-, CH = CH-CH = N-, -N = CH-N = CH-, -CH = N-CH = N-, -N = CH -CH = N-, -N = N-CH = CH-, -CH = CH-N = N-, -CH = CH-O-, -O-CH = CH-, -CH = CH-S-, -S-CH = CH-, -C (R 11 ) 2 -C (R 11 ) 2 -O-, -OC (R 11 ) 2 -C (R 11 ) 2- , -C (R 11 ) 2- C (R 11 ) 2 -S-, -SC (R 11 ) 2 -C (R 11 ) 2- , -OC (R 11 ) 2 -O-, -OC (R 11 ) 2 -C (R 11 ) 2 -O-, -SC (R 11 ) 2 -S-, -SC (R 11 ) 2 -C (R 11 ) 2 -S-, -CH = CH-NH-, -NH-CH = CH-, -C (R 11 ) 2 -C (R 11 ) 2 -NH-, -NH-C (R 11 ) 2 -C (R 11 ) 2- , -N = CH-NH-, -NH-CH = N -, -NH-C (R 11 ) 2 -NH-, -O-CH = N-, -N = CH-O-, -S-CH = N-, -N = CH-S-, -OC ( R 11 ) 2 -NH-, -NH-C (R 11 ) 2 -O-, -SC (R 11 ) 2 -NH-, -NH-C (R 11 ) 2 -S-, -ON = CH- , -CH = NO-, -SN = CH-, -CH = NS-, -O-NH-C (R 11 ) 2- , -C (R 11 ) 2 -NH-O-, -S-NH- C (R 11 ) 2- , -C (R 11 ) 2 -NH-S-, -NH-N = CH-, -CH = N-NH-, -NH-NH-C (R 11 ) 2- , -C (R 11 ) 2 -NH-NH, -N = N-NH- or -N A group of H—N═N—, wherein R 11 may form hydrogen or (C 1 -C 6 ) alkyl; 상기 화학식에서, m은 0, 1, 2, 3 또는 4이고;Wherein m is 0, 1, 2, 3 or 4; 각각의 Rc 기는 동일하거나 상이할 수 있으며, 수소, 할로게노, 트리플루오로메틸, 시아노, 이소시아노, 니트로, 히드록시, 머캅토, 아미노, 포르밀, 카르복 시, 카르바모일, (C1-C6)알킬, (C2-C8)알케닐, (C2-C8)알키닐, (C1-C6)알콕시, (C2-C6)알케닐옥시, (C2-C6)알키닐옥시, (C1-C6)알킬티오, (C1-C6)알킬설피닐, (C1-C6)알킬설포닐, (C1-C6)알킬아미노, 디-[(C1-C6)알킬]아미노, (C1-C6)알콕시카르보닐, N-(C1-C6)알킬카르바모일, N,N-디-[(C1-C6)알킬]카르바모일, (C2-C6)알카노일, (C2-C6)알카노일옥시, (C2-C6)알카노일아미노, N-(C1-C6)알킬-(C2-C6)알카노일아미노, (C3-C6)알케노일아미노, N-(C1-C6)알킬-(C3-C6)알케노일아미노, (C3-C6)알키노일아미노, N-(C1-C6)알킬-(C3-C6)알키노일아미노, N-(C1-C6)알킬설파모일, N,N-디-[(C1-C6)알킬]설파모일, (C1-C6)알칸설포닐아미노 및 N-(C1-C6)알킬-(C1-C6)알칸설포닐아미노, 아릴, 아릴-(C1-C6)알킬, (C3-C7)싸이클로알킬, (C3-C7)싸이클로알킬-(C1-C6)알킬, (C3-C7)싸이클로알케닐, (C3-C7)싸이클로알케닐-(C1-C6)알킬, 헤테로아릴, 헤테로아릴-(C1-C6)알킬, 헤테로싸이클릴 또는 헤테로싸이클릴-(C1-C6)알킬임]의 기에서 선택된다.Each R c group may be the same or different and may be selected from hydrogen, halogeno, trifluoromethyl, cyano, isocyano, nitro, hydroxy, mercapto, amino, formyl, carboxy, carbamoyl, (C 1 -C 6 ) alkyl, (C 2 -C 8 ) alkenyl, (C 2 -C 8 ) alkynyl, (C 1 -C 6 ) alkoxy, (C 2 -C 6 ) alkenyloxy, ( C 2 -C 6) alkynyloxy, (C 1 -C 6) alkylthio, (C 1 -C 6) alkylsulfinyl, (C 1 -C 6) alkylsulfonyl, (C 1 -C 6) alkyl amino, di - [(C 1 -C 6) alkyl] amino, (C 1 -C 6) alkoxycarbonyl, N- (C 1 -C 6) alkyl-carbamoyl, N, N- di - [(C 1- C 6 ) alkyl] carbamoyl, (C 2 -C 6 ) alkanoyl, (C 2 -C 6 ) alkanoyloxy, (C 2 -C 6 ) alkanoylamino, N- (C 1 -C 6 ) alkyl- (C 2 -C 6 ) alkanoylamino, (C 3 -C 6 ) alkenoylamino, N- (C 1 -C 6 ) alkyl- (C 3 -C 6 ) alkenoylamino, (C 3 -C 6 ) alkynoylamino, N- (C 1 -C 6 ) alkyl- (C 3 -C 6 ) alkynoylamino, N- (C 1 -C 6 ) alkylsulfamoyl, N, N- Di-[(C 1 -C 6 ) alkyl] sulfamoyl, (C 1 -C 6 ) alkanesulfonylamino and N- (C 1 -C 6 ) alkyl- (C 1 -C 6 ) alkanesulfonylamino, aryl, aryl- (C 1 -C 6 ) alkyl, (C 3 -C 7 ) cycloalkyl, (C 3 -C 7 ) cycloalkyl- (C 1 -C 6 ) alkyl, (C 3 -C 7 ) cycloalkenyl, (C 3 -C 7 ) cycloalkenyl- (C 1 -C 6 ) alkyl, heteroaryl, heteroaryl- (C 1 -C 6 ) alkyl, heterocyclyl or heterocyclyl- (C 1 -C 6 ) alkyl] Is selected from the group. 여기서 Rc 치환체내에서의 임의의 (C2-C6)알킬렌 기에서 인접 탄소 원자는 O, S, SO, SO2 , N(R12), CO, CH(OR12), CON(R12), N(R12)CO, SO2N(R12), N(R12)SO2 , CH=CH 및 C≡C에서 선택된 기의 삽입에 의해서 분리될 수 있고, 여기서 R12는 수소 또는 (C1-C6)알킬이고, Wherein adjacent carbon atoms in any (C 2 -C 6 ) alkylene group in the R c substituent are O, S, SO, SO 2 , N (R 12 ), CO, CH (OR 12 ), CON (R 12 ), N (R 12 ) CO, SO 2 N (R 12 ), N (R 12 ) SO 2 , CH = CH and C≡C can be separated by insertion of a group, wherein R 12 is hydrogen Or (C 1 -C 6 ) alkyl, 여기서 Rc 치환체내에서의 임의의 CH2=CH- 또는 HC≡C- 기는 말단 CH2= 또는 HC≡위치에서 할로게노, 카르복시, 카르바모일, (C1-C6)알콕시카르보닐, N-(C1-C6)알킬카르바모일, N,N-디-[(C1-C6)알킬]카르바모일, 아미노-(C1-C6)알킬, (C1-C6)알킬아미노-(C1-C6)알킬 및 디-[(C1-C6)알킬]아미노-(C1-C6)알킬에서 선택되거나 또는 화학식 Q5-X6-[여기서, X6는 직접 결합이거나, CO 및 N(R13)CO에서 선택되고, 여기서 R13는 수소 또는 (C1-C6)알킬이고, Q5는 아릴, 아릴-(C1-C6)알킬, 헤테로아릴, 헤테로아릴-(C1-C6)알킬, 헤테로싸이클릴 또는 헤테로싸이클릴-(C1-C6)알킬임]의 기에서 선택된 치환체를 포함할 수 있고,Wherein any CH 2 ═CH— or HC≡C— group in the R c substituent is halogeno, carboxy, carbamoyl, (C 1 -C 6 ) alkoxycarbonyl, N at the terminal CH 2 = or HC≡ position - (C 1 -C 6 ) alkylcarbamoyl, N, N- di-[(C 1 -C 6 ) alkyl] carbamoyl, amino- (C 1 -C 6 ) alkyl, (C 1 -C 6 ) Alkylamino- (C 1 -C 6 ) alkyl and di-[(C 1 -C 6 ) alkyl] amino- (C 1 -C 6 ) alkyl or is selected from the formula Q 5 -X 6- [where X 6 is a direct bond or is selected from CO and N (R 13 ) CO, wherein R 13 is hydrogen or (C 1 -C 6 ) alkyl, Q 5 is aryl, aryl- (C 1 -C 6 ) alkyl, Heteroaryl, heteroaryl- (C 1 -C 6 ) alkyl, heterocyclyl or heterocyclyl- (C 1 -C 6 ) alkyl], and 여기서 Rc 치환체내에서의 임의의 CH2 또는 CH3기는 각각의 CH2 또는 CH3기에서 1 이상의 할로게노 또는 (C1-C6)알킬 치환체, 또는 히드록시, 시아노, 아미노, 카르복시, 카르바모일, (C1-C6)알콕시, (C1-C6)알킬티오, (C1-C6)알킬설피닐, (C1-C6)알킬설포닐, (C1-C6)알킬아미노, 디-[(C1-C6)알킬]아미노, (C1-C6)알콕시카르보닐, N-(C1-C6)알킬카르바모일, N,N-디-[(C1-C6)알킬]카르바모일, (C2-C6)알카노일, (C2-C6)알카노일옥시, (C2-C6)알카노일아미노, N-(C1-C6)알킬-(C2-C6)알카노일아미노, N-(C1-C6)알킬설파모일, N,N-디-[(C1-C6)알킬]설파모일, (C1-C6)알칸설포닐아미노 및 N-(C1- C6)알킬-(C1-C6)알칸설포닐아미노에서 선택된 치환체 또는, 화학식 -X7-Q6 [여기서, X7는 직접 결합이거나, O, S, SO, SO2, N(R14), CO, CH(OR14), CON(R14), N(R14)CO, SO2N(R14), N(R14)SO2, C(R14)2O, C(R14)2S 및 N(R14)C(R14)2에서 선택되고, 여기서 R14은 수소 또는 (C1-C6)알킬이고, Q6는 아릴, 아릴-(C1-C6)알킬, (C3-C7)싸이클로알킬, (C3-C7)싸이클로알킬-(C1-C6)알킬, (C3-C7)싸이클로알케닐, (C3-C7)싸이클로알케닐-(C1-C6)알킬, 헤테로아릴, 헤테로아릴-(C1-C6)알킬, 헤테로싸이클릴 또는 헤테로싸이클릴-(C1-C6)알킬임]의 기에서 선택되는 치환체를 포함할 수 있으며,Wherein any CH 2 or CH 3 group in the R c substituent is at least one halogeno or (C 1 -C 6 ) alkyl substituent at each CH 2 or CH 3 group, or hydroxy, cyano, amino, carboxy, Carbamoyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) alkylthio, (C 1 -C 6 ) alkylsulfinyl, (C 1 -C 6 ) alkylsulfonyl, (C 1 -C 6 ) alkylamino, di-[(C 1 -C 6 ) alkyl] amino, (C 1 -C 6 ) alkoxycarbonyl, N- (C 1 -C 6 ) alkylcarbamoyl, N, N- di- [(C 1 -C 6) alkyl] carbamoyl, (C 2 -C 6) alkanoyl, (C 2 -C 6) alkanoyloxy, (C 2 -C 6) alkanoylamino, N- (C 1- C 6 ) alkyl- (C 2 -C 6 ) alkanoylamino, N- (C 1 -C 6 ) alkylsulfamoyl, N, N- di-[(C 1 -C 6 ) alkyl] sulfamoyl, (C 1 -C 6) alkane sulfonyl amino, N- (C 1 - C 6) alkyl, - (C 1 -C 6) alkane-sulfonyl-amino or a substituent selected from the formula -X 7 -Q 6 [where, X 7 is a direct bond or O, S, SO, SO 2 , N (R 14 ), CO, CH (OR 14 ), CON (R 14 ), N (R 1 4 ) CO, SO 2 N (R 14 ), N (R 14 ) SO 2 , C (R 14 ) 2 O, C (R 14 ) 2 S and N (R 14 ) C (R 14 ) 2 Wherein R 14 is hydrogen or (C 1 -C 6 ) alkyl, Q 6 is aryl, aryl- (C 1 -C 6 ) alkyl, (C 3 -C 7 ) cycloalkyl, (C 3 -C 7 ) Cycloalkyl- (C 1 -C 6 ) alkyl, (C 3 -C 7 ) cycloalkenyl, (C 3 -C 7 ) cycloalkenyl- (C 1 -C 6 ) alkyl, heteroaryl, heteroaryl- ( C 1 -C 6 ) alkyl, heterocyclyl or heterocyclyl- (C 1 -C 6 ) alkyl], and a substituent selected from the group 여기서, Rc 기내에서의 임의의 아릴, 헤테로아릴 또는 헤테로싸이클릴기는 1, 2 또는 3개의 치환체를 포함할 수 있고, 이 치환체는 동일하거나 상이할 수 있으며, 수소, 할로게노, 트리플루오로메틸, 시아노, 니트로, 히드록시, 아미노, 카르복시, 카르바모일, (C1-C6)알킬, (C2-C8)알케닐, (C2-C8)알키닐, (C1-C6)알콕시, (C2-C6)알케닐옥시, (C2-C6)알키닐옥시, (C1-C6)알킬티오, (C1-C6)알킬설피닐, (C1-C6)알킬설포닐, (C1-C6)알킬아미노, 디-[(C1-C6)알킬]아미노, (C1-C6)알콕시카르보닐, N-(C1-C6)알킬카르바모일, N,N-디-[(C1-C6)알킬]카르바모일, (C2-C6)알카노일, (C2-C6)알카노일옥시, (C2-C6)알카노일아미노, N-(C1-C6)알킬-(C2-C6)알카노일아미노, (C3- C6)알케노일아미노, N-(C1-C6)알킬-(C3-C6)알케노일아미노, (C3-C6)알키노일아미노, N-(C1-C6)알킬-(C3-C6)알키노일아미노, N-(C1-C6)알킬설파모일, N,N-디-[(C1-C6)알킬]설파모일, (C1-C6)알칸설포닐아미노 및 N-(C1-C6)알킬-(C1-C6)알칸설포닐아미노에서 선택되거나 화학식 -X8-R15 [여기서, X8은 직접 결합이거나, O 및 N(R16)에서 선택되고, 여기서 R16는 수소 또는 (C1-C6)알킬이고, R15은 할로게노-(C1-C6)알킬, 히드록시-(C1-C6)알킬, (C1-C6)알콕시-(C1-C6)알킬, 시아노-(C1-C6)알킬, 아미노-(C1-C6)알킬, (C1-C6)알킬아미노-(C1-C6)알킬 또는 디-[(C1-C6)알킬]아미노-(C1-C6)알킬 임]의 기에서 선택되거나 또는 화학식 -X9-Q7 [여기서, X9은 직접 결합이거나 O, CO 및 N(R17)에서 선택되고, R17은 수소 또는 (C1-C6)알킬이고, Q7은 1 또는 2개의 치환체를 지닐 수 있는, 아릴, 아릴-(C1-C6)알킬, 헤테로아릴, 헤테로아릴-(C1-C6)알킬, 헤테로싸이클릴 또는 헤테로싸이클릴-(C1-C6)알킬이고, 이 치환체는 동일하거나 상이할 수 있으며, 할로게노, (C1-C6)알킬 및 (C1-C6)알콕시에서 선택되고, Q7 내에서의 임의의 헤테로싸이클릴기는 1 또는 2개의 옥소 또는 티옥소 치환체를 포함할 수 있음]의 기에서 선택되고, Wherein any aryl, heteroaryl, or heterocyclyl group in the R c group may comprise 1, 2 or 3 substituents, which substituents may be the same or different and are hydrogen, halogeno, trifluoromethyl , Cyano, nitro, hydroxy, amino, carboxy, carbamoyl, (C 1 -C 6 ) alkyl, (C 2 -C 8 ) alkenyl, (C 2 -C 8 ) alkynyl, (C 1- C 6 ) alkoxy, (C 2 -C 6 ) alkenyloxy, (C 2 -C 6 ) alkynyloxy, (C 1 -C 6 ) alkylthio, (C 1 -C 6 ) alkylsulfinyl, (C 1- C 6 ) alkylsulfonyl, (C 1 -C 6 ) alkylamino, di-[(C 1 -C 6 ) alkyl] amino, (C 1 -C 6 ) alkoxycarbonyl, N- (C 1- C 6 ) alkylcarbamoyl, N, N- di-[(C 1 -C 6 ) alkyl] carbamoyl, (C 2 -C 6 ) alkanoyl, (C 2 -C 6 ) alkanoyloxy, ( C 2 -C 6) alkanoylamino, N- (C 1 -C 6) alkyl, - (C 2 -C 6) alkanoylamino, (C 3 - C 6) alkenyl alkanoyl amino, N- (C 1 -C 6 ) alkyl- (C 3 -C 6 ) alkenoylamino, (C 3 -C 6 ) alkynoyla Mino, N- (C 1 -C 6) alkyl, - (C 3 -C 6) Al Keno-ylamino, N- (C 1 -C 6) alkyl sulfamoyl, N, N- di - [(C 1 -C 6 ) alkyl] sulfamoyl, (C 1 -C 6 ) alkanesulfonylamino and N- (C 1 -C 6 ) alkyl- (C 1 -C 6 ) alkanesulfonylamino or is selected from the formula -X 8 -R 15 wherein X 8 is a direct bond or is selected from O and N (R 16 ), wherein R 16 is hydrogen or (C 1 -C 6 ) alkyl and R 15 is halogeno- (C 1 -C 6 ) Alkyl, hydroxy- (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy- (C 1 -C 6 ) alkyl, cyano- (C 1 -C 6 ) alkyl, amino- (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkylamino- (C 1 -C 6 ) alkyl or di-[(C 1 -C 6 ) alkyl] amino- (C 1 -C 6 ) alkyl] Is selected from the group or of the formula -X 9 -Q 7 wherein X 9 is a direct bond or is selected from O, CO and N (R 17 ), R 17 is hydrogen or (C 1 -C 6 ) alkyl, Q 7 is 1 or 2, which may have a substituent, aryl, - (C 1 -C 6) alkyl, heteroaryl, heteroaryl- Reels - (C 1 -C 6) alkyl, heteroaryl or heteroaryl cycle the cycle reel reel - and (C 1 -C 6) alkyl, the substituents may be the same or different, halogeno, (C 1 -C 6) alkyl And (C 1 -C 6 ) alkoxy, and any heterocyclyl group in Q 7 may include 1 or 2 oxo or thioxo substituents, and 여기서 Rc 상의 치환체내에서 헤테로싸이클릴기는 1 또는 2개의 옥소 또는 티옥소 치환체를 포함할 수 있으며,Wherein the heterocyclyl group in the substituent on R c may comprise one or two oxo or thioxo substituents, Rc 기내에서의 임의의 아릴, 헤테로아릴 또는 헤테로싸이클릴기의 동일하거나 상이한 치환기는 서로 결합하여 화학식 CH=CH-CH=CH-, -N=CH-CH=CH-, -CH=N-CH=CH-, -CH=CH-N=CH-, CH=CH-CH=N-, -N=CH-N=CH-, -CH=N-CH=N-, -N=CH-CH=N-, -N=N-CH=CH-, -CH=CH-N=N-, -CH=CH-O-, -O-CH=CH-, -CH=CH-S-, -S-CH=CH-, -C(R18)2-C(R18)2-O-, -O-C(R18)2-C(R18)2-, -C(R18)2-C(R18)2-S-, -S-C(R18)2-C(R18)2-, -O-C(R18)2-O-, -O-C(R18)2-C(R18)2-O-, -S-C(R18)2-S-, -S-C(R18)2-C(R18)2-S-, -CH=CH-NH-, -NH-CH=CH-, -C(R18)2-C(R18)2-NH-, -NH-C(R18)2-C(R18)2-, -N=CH-NH-, -NH-CH=N-, -NH-C(R18)2-NH-, -O-CH=N-, -N=CH-O-, -S-CH=N-, -N=CH-S-, -O-C(R18)2-NH-, -NH-C(R18)2-O-, -S-C(R18)2-NH-, -NH-C(R18)2-S-, -O-N=CH-, -CH=N-O-, -S-N=CH-, -CH=N-S-, -O-NH-C(R18)2-, -C(R18)2-NH-O-, -S-NH-C(R18)2-, -C(R18)2-NH-S-, -NH-N=CH-, -CH=N-NH-, -NH-NH-C(R18)2-, -C(R18)2-NH-NH, -N=N-NH- 또는 -NH-N=N-의 기 [여기서, R18은 수소 또는 (C1-C6)알킬]를 형성할 수 있다.The same or different substituents of any aryl, heteroaryl, or heterocyclyl group in the R c group are bonded to each other to form the formula CH = CH-CH = CH-, -N = CH-CH = CH-, -CH = N-CH = CH-, -CH = CH-N = CH-, CH = CH-CH = N-, -N = CH-N = CH-, -CH = N-CH = N-, -N = CH-CH = N-, -N = N-CH = CH-, -CH = CH-N = N-, -CH = CH-O-, -O-CH = CH-, -CH = CH-S-, -S- CH = CH-, -C (R 18 ) 2 -C (R 18 ) 2 -O-, -OC (R 18 ) 2 -C (R 18 ) 2- , -C (R 18 ) 2 -C (R 18 ) 2 -S-, -SC (R 18 ) 2 -C (R 18 ) 2- , -OC (R 18 ) 2 -O-, -OC (R 18 ) 2 -C (R 18 ) 2 -O -, -SC (R 18 ) 2 -S-, -SC (R 18 ) 2 -C (R 18 ) 2 -S-, -CH = CH-NH-, -NH-CH = CH-, -C ( R 18 ) 2 -C (R 18 ) 2 -NH-, -NH-C (R 18 ) 2 -C (R 18 ) 2- , -N = CH-NH-, -NH-CH = N-,- NH-C (R 18 ) 2 -NH-, -O-CH = N-, -N = CH-O-, -S-CH = N-, -N = CH-S-, -OC (R 18 ) 2 -NH-, -NH-C (R 18 ) 2 -O-, -SC (R 18 ) 2 -NH-, -NH-C (R 18 ) 2 -S-, -ON = CH-, -CH = NO-, -SN = CH-, -CH = NS-, -O-NH-C (R 18 ) 2- , -C (R 18 ) 2 -NH-O-, -S-NH-C (R 18 ) 2- , -C (R 18 ) 2 -NH-S-, -NH-N = CH-, -CH = N-NH-, -NH-NH-C (R 18 ) 2- , -C ( R 18) 2 -NH-NH, -N = N-NH- or -NH-N = N- of It may form a [where, R 18 is hydrogen or (C 1 -C 6) alkyl]. 제 1 항에 있어서, 다음 화학식 1-1로 표시되는 것을 특징으로 하는 화합물 :The compound of claim 1, wherein the compound is represented by the following Chemical Formula 1-1: [화학식 1-1][Formula 1-1]
Figure 112005078193254-PAT00021
Figure 112005078193254-PAT00021
 상기 화학식 1-1에서, In Chemical Formula 1-1, X는 직접 결합이거나, O, S, SO, SO2 또는 NR5에서 선택되고, R5는 수소, (C1-C6)알킬, 아릴, 아릴-(C1-C6)알킬, (C3-C7)싸이클로알킬, (C3-C7)싸이클로알킬-(C1-C6)알킬, 헤테로아릴, 헤테로아릴-(C1-C6)알킬, 헤테로싸이클릴 또는 헤테로싸이클릴-(C1-C6)알킬의 기이며;X is a direct bond or is selected from O, S, SO, SO 2 or NR 5 , R 5 is hydrogen, (C 1 -C 6 ) alkyl, aryl, aryl- (C 1 -C 6 ) alkyl, (C 3 -C 7 ) cycloalkyl, (C 3 -C 7 ) cycloalkyl- (C 1 -C 6 ) alkyl, heteroaryl, heteroaryl- (C 1 -C 6 ) alkyl, heterocyclyl or heterocyclyl- A group of (C 1 -C 6 ) alkyl; R1은 수소, (C1-C8)알킬, 할로게노-(C1-C6)알킬, 히드록시-(C1-C6)알킬, (C1-C6)알콕시-(C1-C6)알킬, 아미노-(C1-C6)알킬, (C1-C6)알킬아미노-(C1-C6)알킬, 디-[(C1-C6)알킬]아미노-(C1-C6)알킬 및 (C1-C6)알킬설피닐 중에서 선택된 치환체이거나, 또는 화학식 -X1-Q1 [여기서, X1는 직접 결합이거나, O, S 또는 NR5]에서 선택되고, Q1은 R5와 동일하거나 상이한 치환기에서 선택될 수 있으며,R 1 is hydrogen, (C 1 -C 8 ) alkyl, halogeno- (C 1 -C 6 ) alkyl, hydroxy- (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy- (C 1 -C 6 ) alkyl, amino- (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkylamino- (C 1 -C 6 ) alkyl, di-[(C 1 -C 6 ) alkyl] amino- (C 1 -C 6) alkyl and (C 1 -C 6), or a substituent selected from alkyl sulfinyl, or the formula -X 1 -Q 1 [wherein, X 1 is either a direct bond, O, S or NR 5] from Q 1 may be selected from the same or different substituents as R 5 , 그리고, 여기서 R1 기내에서의 (C2-C6)알킬렌 기에서 인접 탄소 원자는 O, S 및 N(R5)에서 선택된 기의 삽입에 의해서 분리될 수 있고,And wherein adjacent carbon atoms in the (C 2 -C 6) alkylene group of R 1 in flight may be separated by insertion of a group selected from O, S and N (R 5), 여기서 R1 기내에서의 임의의 CH2 또는 CH3기는 각각의 CH2 또는 CH3기에서 1 이상의 할로게노, (C1-C6)알킬 치환체, 히드록시, 아미노, (C1-C6)알콕시 (C1-C6)알킬티오, (C1-C6)알킬설피닐, (C1-C6)알킬아미노 및 디-[(C1-C6)알킬]아미노에서 선택된 치환체를 포함할 수 있고,Wherein any CH 2 or CH 3 group in the R 1 group is at least one halogeno, (C 1 -C 6 ) alkyl substituent, hydroxy, amino, (C 1 -C 6 ) at each CH 2 or CH 3 group Substituents selected from alkoxy (C 1 -C 6 ) alkylthio, (C 1 -C 6 ) alkylsulfinyl, (C 1 -C 6 ) alkylamino and di-[(C 1 -C 6 ) alkyl] amino Can do it, 여기서 R1상의 치환체내에서의 임의의 아릴, 헤테로아릴 또는 헤테로싸이클릴기는 0 내지 3개의 치환체를 포함할 수 있고, 이 치환체는 동일하거나 상이할 수 있으며, 할로게노, 히드록시, 아미노, (C1-C6)알킬, 아릴, 아릴-(C1-C6)알킬, 헤테로아릴, 헤테로아릴-(C1-C6)알킬, 헤테로싸이클릴 또는 헤테로싸이클릴-(C1-C6)알킬, (C1-C6)알콕시, (C1-C6)알킬티오 및 (C1-C6)알킬설피닐 중에서 선택된 치환체를 포함할 수 있고,Wherein any aryl, heteroaryl or heterocyclyl group in the substituent on R 1 may comprise 0 to 3 substituents, which substituents may be the same or different and include halogeno, hydroxy, amino, (C 1 -C 6 ) alkyl, aryl, aryl- (C 1 -C 6 ) alkyl, heteroaryl, heteroaryl- (C 1 -C 6 ) alkyl, heterocyclyl or heterocyclyl- (C 1 -C 6 ) May include a substituent selected from alkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) alkylthio and (C 1 -C 6 ) alkylsulfinyl, 그리고, 여기서 R1 상의 치환체내에서 헤테로싸이클릴기는 1 또는 2개의 옥소 또는 티옥소 치환체를 포함할 수 있으며;And wherein the heterocyclyl group in the substituent on R 1 may comprise one or two oxo or thioxo substituents; R2은 수소, (C1-C18)알킬, (C2-C8)알케닐, 할로게노-(C1-C8)알킬, 히드록시-(C1-C8)알킬, (C1-C8)알콕시-(C1-C8)알킬, 아미노-(C1-C8)알킬, (C1-C8)알킬아미노- (C1-C8)알킬, 디-[(C1-C8)알킬]아미노-(C1-C8)알킬, (C1-C8)알킬설피닐, 아릴, 아릴-(C1-C8)알킬, (C3-C7)싸이클로알킬, (C3-C7)싸이클로알킬-(C1-C8)알킬, 헤테로아릴, 헤테로아릴-(C1-C8)알킬, 헤테로싸이클릴 및 헤테로싸이클릴-(C1-C8)알킬 중의 치환기에서 선택될 수 있으며,R 2 is hydrogen, (C 1 -C 18 ) alkyl, (C 2 -C 8 ) alkenyl, halogeno- (C 1 -C 8 ) alkyl, hydroxy- (C 1 -C 8 ) alkyl, (C 1 -C 8 ) alkoxy- (C 1 -C 8 ) alkyl, amino- (C 1 -C 8 ) alkyl, (C 1 -C 8 ) alkylamino- (C 1 -C 8 ) alkyl, di-[( C 1 -C 8 ) alkyl] amino- (C 1 -C 8 ) alkyl, (C 1 -C 8 ) alkylsulfinyl, aryl, aryl- (C 1 -C 8 ) alkyl, (C 3 -C 7 ) Cycloalkyl, (C 3 -C 7 ) cycloalkyl- (C 1 -C 8 ) alkyl, heteroaryl, heteroaryl- (C 1 -C 8 ) alkyl, heterocyclyl and heterocyclyl- (C 1 -C 8 ) may be selected from substituents in alkyl, 그리고, 여기서 R2 기내에서의 (C2-C6)알킬렌 기에서 인접 탄소 원자는 O, S, N(R5), CO, CH(OR5), CON(R5), N(R5)CO, SO2N(R5), N(R5)SO2 및 CH=CH에서 선택된 기의 삽입에 의해서 분리될 수 있고,And wherein adjacent carbon atoms in the (C 2 -C 6 ) alkylene group in the R 2 group are O, S, N (R 5 ), CO, CH (OR 5 ), CON (R 5 ), N (R 5 ) can be separated by insertion of a group selected from CO, SO 2 N (R 5 ), N (R 5 ) SO 2 and CH═CH, 여기서 R2 기내에서의 임의의 CH2 또는 CH3기는 각각의 CH2 또는 CH3기에서 1 이상의 할로게노, (C1-C6)알킬 치환체, 히드록시, 시아노, 아미노, 카르복시, 카르바모일, (C1-C6)알콕시 (C1-C6)알킬티오, (C1-C6)알킬설피닐, (C1-C6)알킬아미노, 디-[(C1-C6)알킬]아미노, (C1-C6)알콕시카르보닐, N-(C1-C6)알킬카르바모일, N,N-디-[(C1-C6)알킬]카르바모일, 아릴, 아릴-(C1-C6)알킬, (C3-C7)싸이클로 알킬, (C3-C7)싸이클로알킬-(C1-C6)알킬, 헤테로아릴, 헤테로아릴-(C1-C6)알킬, 헤테로싸이클릴 및 헤테로싸이클릴-(C1-C6)알킬기 중에서 선택된 치환체를 포함할 수 있고,Wherein any CH 2 or CH 3 group in the R 2 group is at least one halogeno, (C 1 -C 6 ) alkyl substituent, hydroxy, cyano, amino, carboxy, carba at each CH 2 or CH 3 group Moyl, (C 1 -C 6 ) alkoxy (C 1 -C 6 ) alkylthio, (C 1 -C 6 ) alkylsulfinyl, (C 1 -C 6 ) alkylamino, di-[(C 1 -C 6 ) Alkyl] amino, (C 1 -C 6 ) alkoxycarbonyl, N- (C 1 -C 6 ) alkylcarbamoyl, N, N -di-[(C 1 -C 6 ) alkyl] carbamoyl, Aryl, aryl- (C 1 -C 6 ) alkyl, (C 3 -C 7 ) cycloalkyl, (C 3 -C 7 ) cycloalkyl- (C 1 -C 6 ) alkyl, heteroaryl, heteroaryl- (C It may include a substituent selected from 1 -C 6 ) alkyl, heterocyclyl and heterocyclyl- (C 1 -C 6 ) alkyl group, 여기서 R2상의 치환체내에서의 임의의 아릴, 헤테로아릴 또는 헤테로싸이클릴기는 0 내지 3개의 치환체를 포함할 수 있고, 이 치환체는 동일하거나 상이할 수 있으며, 할로게노, 트리플루오로메틸, 시아노, 니트로, 히드록시, 아미노, 카르복시, 카르바모일, (C1-C6)알킬, 아릴, 아릴-(C1-C6)알킬, 헤테로아릴, 헤테로아릴-(C1-C6)알킬, 헤테로싸이클릴 또는 헤테로싸이클릴-(C1-C6)알킬, (C2-C8)알케닐, (C2-C8)알키닐, (C1-C6)알콕시, (C1-C6)알킬티오, (C1-C6)알킬설피닐, (C1-C6)알킬아미노, 디-[(C1-C6)알킬]아미노, (C1-C6)알콕시카르보닐, N-(C1-C6)알킬카르바모일 및 N,N-디-[(C1-C6)알킬]카르바모일에서 선택된 치환체를 포함할 수 있고,Wherein any aryl, heteroaryl, or heterocyclyl group in a substituent on R 2 may comprise 0 to 3 substituents, which substituents may be the same or different and include halogeno, trifluoromethyl, cyano , Nitro, hydroxy, amino, carboxy, carbamoyl, (C 1 -C 6 ) alkyl, aryl, aryl- (C 1 -C 6 ) alkyl, heteroaryl, heteroaryl- (C 1 -C 6 ) alkyl , Heterocyclyl or heterocyclyl- (C 1 -C 6 ) alkyl, (C 2 -C 8 ) alkenyl, (C 2 -C 8 ) alkynyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) alkylthio, (C 1 -C 6 ) alkylsulfinyl, (C 1 -C 6 ) alkylamino, di-[(C 1 -C 6 ) alkyl] amino, (C 1 -C 6 ) alkoxy Carbonyl, N- (C 1 -C 6 ) alkylcarbamoyl and N, N -di-[(C 1 -C 6 ) alkyl] carbamoyl; 그리고, 여기서 R2 상의 치환체내에서 헤테로싸이클릴기는 1 또는 2개의 옥소 또는 티옥소 치환체를 포함할 수 있으며,And wherein the heterocyclyl group in the substituent on R 2 may comprise one or two oxo or thioxo substituents, 그리고 R2기내에서의 임의의 아릴, 헤테로아릴 또는 헤테로싸이클릴기의 동일하거나 상이한 치환기는 서로 결합하여 화학식 -CH=CH-CH=CH-, -N=CH-CH=CH-, -CH=N-CH=CH-, -CH=CH-N=CH-, CH=CH-CH=N-, -N=CH-N=CH-, -CH=N-CH=N-, -N=CH-CH=N-, -CH=CH-O-, -O-CH=CH-, -CH=CH-S-, -S-CH=CH-, -C(R6)2-C(R6)2-O-, -O-C(R6)2-C(R6)2-, -C(R6)2-C(R6)2-S-, -S-C(R6)2-C(R6)2-, -O-C(R6)2-O-, -O-C(R6)2-C(R6)2-O-, -S-C(R6)2-S-, -S-C(R6)2-C(R6)2-S-, -CH=CH-NH-, -NH-CH=CH-, -C(R6)2-C(R6)2-NH-, -NH-C(R6)2-C(R6)2-, -N=CH-NH-, -NH-CH=N-, -NH-C(R6)2-NH-, -O-CH=N-, -N=CH-O-, -S-CH=N-, -N=CH-S-, -O-C(R6)2-NH-, -NH-C(R6)2-O-, -S-C(R6)2-NH-, -NH-C(R6)2-S-, -N=N-NH- 또는 -NH-N=N-의 기 [여기서, R6는 수소 또는 (C1-C3)알킬기]를 형성할 수 있고; And the same or different substituents of any aryl, heteroaryl, or heterocyclyl group in the R 2 group are bonded to each other to formula -CH = CH-CH = CH-, -N = CH-CH = CH-, -CH = N -CH = CH-, -CH = CH-N = CH-, CH = CH-CH = N-, -N = CH-N = CH-, -CH = N-CH = N-, -N = CH- CH = N-, -CH = CH-O-, -O-CH = CH-, -CH = CH-S-, -S-CH = CH-, -C (R 6 ) 2 -C (R 6 ) 2 -O-, -OC (R 6 ) 2 -C (R 6 ) 2- , -C (R 6 ) 2 -C (R 6 ) 2 -S-, -SC (R 6 ) 2 -C (R 6 ) 2- , -OC (R 6 ) 2 -O-, -OC (R 6 ) 2 -C (R 6 ) 2 -O-, -SC (R 6 ) 2 -S-, -SC (R 6 ) 2 -C (R 6 ) 2 -S-, -CH = CH-NH-, -NH-CH = CH-, -C (R 6 ) 2 -C (R 6 ) 2 -NH-, -NH- C (R 6 ) 2 -C (R 6 ) 2- , -N = CH-NH-, -NH-CH = N-, -NH-C (R 6 ) 2 -NH-, -O-CH = N -, -N = CH-O-, -S-CH = N-, -N = CH-S-, -OC (R 6 ) 2 -NH-, -NH-C (R 6 ) 2 -O-, -SC (R 6 ) 2 -NH-, -NH-C (R 6 ) 2 -S-, -N = N-NH- or -NH-N = N-, wherein R 6 is hydrogen or ( C 1 -C 3 ) alkyl group]; R3 및 R4는 각각 동일하거나 상이할 수 있으며, 수소, 할로게노, 트리플루오로메틸, 시아노, 니트로, 히드록시, 머캅토, 아미노, 포르밀, 카르복시, 카르바모일,(C1-C6)알킬, (C2-C8)알케닐, (C2-C6)알콕시, (C1-C6)알킬티오, (C1-C6)알킬설피닐, (C1-C6)알킬아미노, 디-[(C1-C6)알킬]아미노, (C1-C6)알콕시카르보닐, N-(C1-C6)알킬카르바모일, N,N-디-[(C1-C6)알킬]카르바모일, 아릴, 아릴-(C1-C6)알킬, (C3-C7)싸이클로알킬, (C3-C7)싸이클로알킬-(C1-C6)알킬, 헤테로아릴, 헤테로아릴-(C1-C6)알킬, 헤테로싸이클릴 또는 헤테로싸이클릴-(C1-C6)알킬기에서 선택될 수 있고, R 3 and R 4 may be the same or different, respectively, hydrogen, halogeno, trifluoromethyl, cyano, nitro, hydroxy, mercapto, amino, formyl, carboxy, carbamoyl, (C 1- C 6 ) alkyl, (C 2 -C 8 ) alkenyl, (C 2 -C 6 ) alkoxy, (C 1 -C 6 ) alkylthio, (C 1 -C 6 ) alkylsulfinyl, (C 1 -C 6 ) alkylamino, di-[(C 1 -C 6 ) alkyl] amino, (C 1 -C 6 ) alkoxycarbonyl, N- (C 1 -C 6 ) alkylcarbamoyl, N, N -di- [(C 1 -C 6) alkyl] carbamoyl, aryl, - (C 1 -C 6) alkyl, (C 3 -C 7) cyclo-alkyl, (C 3 -C 7) cyclo-alkyl - (C 1 May be selected from a -C 6 ) alkyl, heteroaryl, heteroaryl- (C 1 -C 6 ) alkyl, heterocyclyl or heterocyclyl- (C 1 -C 6 ) alkyl group, 여기서 R3 및 R4 치환체 내에서의 임의의 CH2 또는 CH3기는 각각의 CH2 또는 CH3기에서 1 이상의 할로게노, 히드록시, 아미노, 카르복시, 카르바모일, (C1-C6)알콕시, (C1-C6)알킬티오, (C1-C6)알킬설피닐, (C1-C6)알킬아미노, 디-[(C1-C6)알킬]아미노, (C1-C6)알콕시카르보닐, N-(C1-C6)알킬카르바모일, N,N-디-[(C1-C6)알킬]카르바모일, 아릴, 아릴-(C1-C6)알킬, (C3-C7)싸이클로알킬, (C3-C7)싸이클로알킬-(C1-C6)알 킬, 헤테로아릴, 헤테로아릴-(C1-C6)알킬, 헤테로싸이클릴 및 헤테로싸이클릴-(C1-C6)알킬기 중에서 선택되는 치환체를 포함할 수 있으며,Wherein any CH 2 or CH 3 group in the R 3 and R 4 substituents is at least one halogeno, hydroxy, amino, carboxy, carbamoyl, (C 1 -C 6 ) group at each CH 2 or CH 3 group Alkoxy, (C 1 -C 6 ) alkylthio, (C 1 -C 6 ) alkylsulfinyl, (C 1 -C 6 ) alkylamino, di-[(C 1 -C 6 ) alkyl] amino, (C 1 -C 6 ) alkoxycarbonyl, N- (C 1 -C 6 ) alkylcarbamoyl, N, N -di-[(C 1 -C 6 ) alkyl] carbamoyl, aryl, aryl- (C 1- C 6 ) alkyl, (C 3 -C 7 ) cycloalkyl, (C 3 -C 7 ) cycloalkyl- (C 1 -C 6 ) alkyl, heteroaryl, heteroaryl- (C 1 -C 6 ) alkyl, It may include a substituent selected from a heterocyclyl and heterocyclyl- (C 1 -C 6 ) alkyl group, 여기서 R3 및 R4 기내에서의 임의의 아릴, 헤테로아릴 또는 헤테로싸이클릴기는 1, 2 또는 3개의 치환체를 포함할 수 있고, 이 치환체는 동일하거나 상이할 수 있으며 할로게노, 트리플루오로메텔, 니트로, 히드록시, 아미노, (C1-C6)알콕시, (C1-C6)알킬티오, (C1-C6)알킬아미노, 디-[(C1-C6)알킬]아미노, (C1-C6)알콕시카르보닐, N-(C1-C6)알킬카르바모일 및 N,N-디-[(C1-C6)알킬]카르바모일기에서 선택되는 치환체를 포함할 수 있으며,Wherein any aryl, heteroaryl or heterocyclyl group in the R 3 and R 4 groups may comprise 1, 2 or 3 substituents, which substituents may be the same or different and may be halogeno, trifluoromethel, Nitro, hydroxy, amino, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) alkylthio, (C 1 -C 6 ) alkylamino, di-[(C 1 -C 6 ) alkyl] amino, (C 1 -C 6 ) alkoxycarbonyl, N- (C 1 -C 6 ) alkylcarbamoyl and a substituent selected from N, N -di-[(C 1 -C 6 ) alkyl] carbamoyl groups You can, 여기서 R3 및 R4 상의 치환체내에서 헤테로싸이클릴기는 1 또는 2개의 옥소 또는 티옥소 치환체를 포함할 수 있다.Wherein the heterocyclyl group in the substituents on R 3 and R 4 may comprise one or two oxo or thioxo substituents. 제 2 항에 있어서,The method of claim 2, 상기 X는 O, S 또는 NR5이고;X is O, S or NR 5 ; R1은 수소원자, C1-C6알킬기, C1-C4할로알킬기, C1-C6알킬하이드록시기, C1-C6알킬설파닐기, 페닐기, 페닐 C1-C8알킬기, 피리딘기, 퓨란기, 티오펜기, C3-C7싸이클로알킬기, 피롤리딘기, 피페리딘기, 몰포린기, 또는 N-(C1-C6)알킬 피페라진기이고;R 1 is a hydrogen atom, a C 1 -C 6 alkyl group, a C 1 -C 4 haloalkyl group, a C 1 -C 6 alkylhydroxy group, a C 1 -C 6 alkylsulfanyl group, a phenyl group, a phenyl C 1 -C 8 alkyl group, A pyridine group, a furan group, a thiophene group, a C 3 -C 7 cycloalkyl group, a pyrrolidine group, a piperidine group, a morpholine group, or an N- (C 1 -C 6 ) alkyl piperazine group; R2는 C1-C18알킬기, C2-C8할로알킬기, C3-C7싸이클로알킬기, (C3-C7)싸이클로알킬 C1-C8알킬기, C2-C8알케닐기, (C3-C7)싸이클로알케닐 C1-C8알킬기, (C1-C8)알킬 C1-C8알콕시알킬기, C1-C8의 하이드록시알킬기, 하이드록시-(C1-C8)알킬-(C1-C8)알콕시알킬기, 페닐기, 페닐 C1-C8알킬기, 디-페닐 C1-C8알킬기, 페닐 C1-C8알킬하이드록시기, 페닐 C1-C8알케닐기, 피페리딘 C1-C8알킬기, N-[페닐-(C1-C6)알킬]피페리딘기, N-(C1-C6)알킬 피페리딘 C1-C8알킬기, 피롤리딘온 N-(C1-C8)알킬기, 나프탈렌 C1-C8알킬기, 몰포린 C1-C8알킬기, 피페라진 C1-C8알킬기, N-(C1-C6)알킬피페라진 C1-C8알킬기, 피리딘 C1-C8알킬기, 피롤리딘 C1-C8알킬기, N-(C1-C6)알킬피롤리딘 C1-C8알킬기, 티오펜 C1-C8알킬기 또는 벤조디옥솔 C1-C8알킬기;R 2 is a C 1 -C 18 alkyl group, a C 2 -C 8 haloalkyl group, a C 3 -C 7 cycloalkyl group, a (C 3 -C 7 ) cycloalkyl C 1 -C 8 alkyl group, a C 2 -C 8 alkenyl group, (C 3 -C 7 ) cycloalkenyl C 1 -C 8 alkyl group, (C 1 -C 8 ) alkyl C 1 -C 8 alkoxyalkyl group, C 1 -C 8 hydroxyalkyl group, hydroxy- (C 1- C 8 ) alkyl- (C 1 -C 8 ) alkoxyalkyl group, phenyl group, phenyl C 1 -C 8 alkyl group, di-phenyl C 1 -C 8 alkyl group, phenyl C 1 -C 8 alkylhydroxy group, phenyl C 1- C 8 alkenyl group, piperidine C 1 -C 8 alkyl group, N- [phenyl- (C 1 -C 6 ) alkyl] piperidine group, N- (C 1 -C 6 ) alkyl piperidine C 1 -C 8 alkyl group, pyrrolidinone N- (C 1 -C 8 ) alkyl group, naphthalene C 1 -C 8 alkyl group, morpholine C 1 -C 8 alkyl group, piperazine C 1 -C 8 alkyl group, N- (C 1 -C 6 ) alkylpiperazine C 1 -C 8 alkyl group, pyridine C 1 -C 8 alkyl group, pyrrolidine C 1 -C 8 alkyl group, N- (C 1 -C 6 ) alkylpyrrolidine C 1 -C 8 alkyl group, Thiophene C 1 -C 8 alkyl group or benzodioxol C 1 -C 8 alkyl group; R3, 및 R4는 각각 수소원자, 니트로기, 또는 C1-C8알콕시기이고; R 3 , and R 4 are each a hydrogen atom, a nitro group, or a C 1 -C 8 alkoxy group; R5는 수소원자, C1-C4알킬기 또는 C1-C8의 하이드록시알킬기이고; R 5 is a hydrogen atom, a C 1 -C 4 alkyl group or a C 1 -C 8 hydroxyalkyl group; 그리고, 상기 C3-C7싸이클로알킬, 페닐, 피페리딘, 나프탈렌, 몰포린, 피리딘, 피롤리딘, 피롤리딘온, 피페라진, 티오펜, 및 벤조디옥솔 중에서 선택된 치환체는 C1-C8알킬기, 할로겐원자, 하이드록시, C1-C8알콕시기, 니트로기, 및 트리플루오로메틸기 중에서 선택된 치환기가 1 내지 3개 치환된 것임을 특징으로 하는 화합물.And the substituent selected from C 3 -C 7 cycloalkyl, phenyl, piperidine, naphthalene, morpholine, pyridine, pyrrolidine, pyrrolidinone, piperazine, thiophene, and benzodioxol is C 1 -C 8 alkyl group, a halogen atom, a compound according to claim hydroxy, C 1 -C 8 alkoxy group, a nitro group, and the tree is a substituent selected from the group fluoro substituted 1-3 that. 제 1 항에 있어서, 상기 화학식 1로 표시되는 화합물이 다음에서 선택된 것임을 특징으로 하는 화합물 :The compound of claim 1, wherein the compound represented by Chemical Formula 1 is selected from: 화합물번호 1. 2-[2-(2-페닐-퀴나졸린-4-일아미노)-에톡시]-에탄올Compound No. 1. 2- [2- (2-phenyl-quinazolin-4-ylamino) -ethoxy] -ethanol 화합물번호 2. 이소프로필-(2-트리클로로메틸-퀴나졸린-4-일)-아민Compound No. 2. Isopropyl- (2-trichloromethyl-quinazolin-4-yl) -amine 화합물번호 3. 싸이클로프로필-(2-트리클로로메틸-퀴나졸린-4-일)-아민Compound No. 3. Cyclopropyl- (2-trichloromethyl-quinazolin-4-yl) -amine 화합물번호 4. (2-피페리딘-1-일-에틸)-(2-트리클로로메틸-퀴나졸린-4-일)-아민Compound No. 4. (2-Piperidin-1-yl-ethyl)-(2-trichloromethyl-quinazolin-4-yl) -amine 화합물번호 5. (1-페닐-에틸)-(2-트리클로로메틸-퀴나졸린-4-일)-아민Compound No. 5. (1-phenyl-ethyl)-(2-trichloromethyl-quinazolin-4-yl) -amine 화합물번호 6. (4-페닐-부틸)-(2-트리클로로메틸-퀴나졸린-4-일)-아민Compound No. 6. (4-phenyl-butyl)-(2-trichloromethyl-quinazolin-4-yl) -amine 화합물번호 7. 프로필-(2-트리클로로메틸-퀴나졸린-4-일)-아민Compound No. 7. Propyl- (2-trichloromethyl-quinazolin-4-yl) -amine 화합물번호 8. (2-에틸설파닐-퀴나졸린-4-일)-이소프로필-아민Compound No. 8. (2-Ethylsulfanyl-quinazolin-4-yl) -isopropyl-amine 화합물번호 9. (2-에틸설파닐-퀴나졸린-4-일)-(3-플루오로-벤질)-아민Compound No. 9. (2-ethylsulfanyl-quinazolin-4-yl)-(3-fluoro-benzyl) -amine 화합물번호 10. (2-에틸설파닐-퀴나졸린-4-일)-[2-(3-플루오로-페닐)-에틸]-아민Compound No. 10. (2-ethylsulfanyl-quinazolin-4-yl)-[2- (3-fluoro-phenyl) -ethyl] -amine 화합물번호 11. (2-에틸설파닐-퀴나졸린-4-일)-(2-몰포린-4-일-에틸)-아민Compound No. 11. (2-Ethylsulfanyl-quinazolin-4-yl)-(2-morpholin-4-yl-ethyl) -amine 화합물번호 12. (2-에틸설파닐-퀴나졸린-4-일)-[2-(3-트리플루오로메틸-페닐)에틸]-아민Compound No. 12. (2-ethylsulfanyl-quinazolin-4-yl)-[2- (3-trifluoromethyl-phenyl) ethyl] -amine 화합물번호 13. (6-니트로-퀴나졸린-4-일)-페닐-아민Compound No. 13. (6-Nitro-quinazolin-4-yl) -phenyl-amine 화합물번호 14. (6,7-디에톡시-퀴나졸린-4-일)-나프탈렌-1-일메틸-아민Compound No. 14. (6,7-Diethoxy-quinazolin-4-yl) -naphthalen-1-ylmethyl-amine 화합물번호 15. (6,7-디에톡시-퀴나졸린-4-일)-(3-몰포린-4-일-프로필)-아민Compound No. 15. (6,7-Diethoxy-quinazolin-4-yl)-(3-morpholin-4-yl-propyl) -amine 화합물번호 16. 알릴-(6,7-디에톡시-퀴나졸린-4-일)-아민Compound No. 16. Allyl- (6,7-diethoxy-quinazolin-4-yl) -amine 화합물번호 17. (6,7-디에톡시-퀴나졸린-4-일)-(2-피리딘-2-일-에틸)-아민Compound No. 17. (6,7-Diethoxy-quinazolin-4-yl)-(2-pyridin-2-yl-ethyl) -amine 화합물번호 18. (4-클로로-벤질)-(6,7-디에톡시-퀴나졸린-4-일)-아민Compound No. 18. (4-Chloro-benzyl)-(6,7-diethoxy-quinazolin-4-yl) -amine 화합물번호 19. 부틸-(2-에틸설파닐-퀴나졸린-4-일)-아민Compound No. 19. Butyl- (2-ethylsulfanyl-quinazolin-4-yl) -amine 화합물번호 20. sec-부틸-(2-에틸설파닐-퀴나졸린-4-일)-아민Compound No. 20. sec- Butyl- (2-ethylsulfanyl-quinazolin-4-yl) -amine 화합물번호 21. (2-에틸설파닐-퀴나졸린-4-일)-이소부틸-아민Compound No. 21. (2-Ethylsulfanyl-quinazolin-4-yl) -isobutyl-amine 화합물번호 22. 벤질-(2-에틸설파닐-퀴나졸린-4-일)-아민Compound No. 22. Benzyl- (2-ethylsulfanyl-quinazolin-4-yl) -amine 화합물번호 23. (2-에틸설파닐-퀴나졸린-4-일)-(1-페닐-에틸)-아민Compound No. 23. (2-Ethylsulfanyl-quinazolin-4-yl)-(1-phenyl-ethyl) -amine 화합물번호 24. (2-에틸설파닐-퀴나졸린-4-일)-(3-메톡시-벤질)-아민Compound No. 24. (2-Ethylsulfanyl-quinazolin-4-yl)-(3-methoxy-benzyl) -amine 화합물번호 25. (2-에틸설파닐-퀴나졸린-4-일)-(4-메톡시-벤질)-아민Compound No. 25. (2-Ethylsulfanyl-quinazolin-4-yl)-(4-methoxy-benzyl) -amine 화합물번호 26. (2-에틸설파닐-퀴나졸린-4-일)-(3-트리플루오로메틸-벤질)-아민Compound No. 26. (2-Ethylsulfanyl-quinazolin-4-yl)-(3-trifluoromethyl-benzyl) -amine 화합물번호 27. 싸이클로헥실-(2-에틸설파닐-퀴나졸린-4-일)-아민Compound No. 27. Cyclohexyl- (2-ethylsulfanyl-quinazolin-4-yl) -amine 화합물번호 28. 싸이클로펜틸-(2-에틸설파닐-퀴나졸린-4-일)-아민Compound No. 28. Cyclopentyl- (2-ethylsulfanyl-quinazolin-4-yl) -amine 화합물번호 29. (2-에틸설파닐-퀴나졸린-4-일)-펜에틸-아민Compound No. 29. (2-Ethylsulfanyl-quinazolin-4-yl) -phenethyl-amine 화합물번호 30. (2-에틸설파닐-퀴나졸린-4-일)-(4-페닐-부틸)-아민Compound No. 30. (2-Ethylsulfanyl-quinazolin-4-yl)-(4-phenyl-butyl) -amine 화합물번호 31. (2-에틸설파닐-퀴나졸린-4-일)-프로필-아민Compound number 31. (2-ethylsulfanyl-quinazolin-4-yl) -propyl-amine 화합물번호 32. (2-에틸설파닐-퀴나졸린4-일)-(3-페닐-프로필)-아민Compound 32. (2-ethylsulfanyl-quinazolin4-yl)-(3-phenyl-propyl) -amine 화합물번호 33. (2-에틸설파닐-퀴나졸린-4-일)-(3-이소프로폭시프로필)-아민Compound 33. (2-Ethylsulfanyl-quinazolin-4-yl)-(3-isopropoxypropyl) -amine 화합물번호 34. (2-에틸설파닐-퀴나졸린-4-일)-(2-메톡시-에틸)-아민Compound number 34. (2-ethylsulfanyl-quinazolin-4-yl)-(2-methoxy-ethyl) -amine 화합물번호 35. (2-에틸설파닐-퀴나졸린-4-일)-나프탈렌-1-일메틸-아민Compound No. 35. (2-Ethylsulfanyl-quinazolin-4-yl) -naphthalen-1-ylmethyl-amine 화합물번호 36. (2-에틸설파닐-퀴나졸린-4-일)-(3-몰포린-4-일-프로필)-아민Compound No. 36. (2-Ethylsulfanyl-quinazolin-4-yl)-(3-morpholin-4-yl-propyl) -amine 화합물번호 37. 벤조[1,3]디옥솔-5-일메틸-(2-에틸설파닐-퀴나졸린-4-일)-아민Compound No. 37.Benzo [1,3] dioxol-5-ylmethyl- (2-ethylsulfanyl-quinazolin-4-yl) -amine 화합물번호 38. (3,5-디메톡시-벤질)-(2-에틸설파닐-퀴나졸린-4-일)-아민Compound No. 38. (3,5-Dimethoxy-benzyl)-(2-ethylsulfanyl-quinazolin-4-yl) -amine 화합물번호 39. (2-에틸설파닐-퀴나졸린-4-일)-(2-플루오로-벤질)-아민Compound No. 39. (2-Ethylsulfanyl-quinazolin-4-yl)-(2-fluoro-benzyl) -amine 화합물번호 40. (2-에틸설파닐-퀴나졸린-4-일)-(1-메톡시메틸-프로필)-아민Compound No. 40. (2-Ethylsulfanyl-quinazolin-4-yl)-(1-methoxymethyl-propyl) -amine 화합물번호 41. (1-벤질-피페리딘-4-일)-(2-에틸설파닐-퀴나졸린-4-일)-아민Compound number 41. (1-benzyl-piperidin-4-yl)-(2-ethylsulfanyl-quinazolin-4-yl) -amine 화합물번호 42. 알릴-(2-에틸설파닐-퀴나졸린-4-일)-아민Compound number 42. Allyl- (2-ethylsulfanyl-quinazolin-4-yl) -amine 화합물번호 43. (2-에틸설파닐-퀴나졸린-4-일)-헥사데실-아민Compound number 43. (2-ethylsulfanyl-quinazolin-4-yl) -hexadecyl-amine 화합물번호 44. (2-에틸설파닐-퀴나졸린-4-일)-(2-피페리딘-1-일-에틸)-아민Compound No. 44. (2-Ethylsulfanyl-quinazolin-4-yl)-(2-piperidin-1-yl-ethyl) -amine 화합물번호 45. (2-에틸설파닐-퀴나졸린-4-일)-(2-피롤리딘-1-일-에틸)-아민Compound No. 45. (2-ethylsulfanyl-quinazolin-4-yl)-(2-pyrrolidin-1-yl-ethyl) -amine 화합물번호 46. (2-에틸설파닐-퀴나졸린-4-일)-(2-피리딘-2-일-에틸)-아민Compound No. 46. (2-Ethylsulfanyl-quinazolin-4-yl)-(2-pyridin-2-yl-ethyl) -amine 화합물번호 47. 2-(2-에틸설파닐-퀴나졸린-4-일아미노)-에탄올Compound No. 47. 2- (2-Ethylsulfanyl-quinazolin-4-ylamino) -ethanol 화합물번호 48. (2-에틸설파닐-퀴나졸린-4-일)-[3-(2-메틸-피페리딘-1-일)-프로필]-아민Compound No. 48. (2-Ethylsulfanyl-quinazolin-4-yl)-[3- (2-methyl-piperidin-1-yl) -propyl] -amine 화합물번호 49. (2-클로로-6-플루오로-벤질)-(2-에틸설파닐-퀴나졸린-4-일)-아민Compound No. 49. (2-Chloro-6-fluoro-benzyl)-(2-ethylsulfanyl-quinazolin-4-yl) -amine 화합물번호 50. 2-[2-(2-에틸설파닐-퀴나졸린-4-일아미노)-에톡시]-에탄올Compound number 50. 2- [2- (2-ethylsulfanyl-quinazolin-4-ylamino) -ethoxy] -ethanol 화합물번호 51. 싸이클로헥실-(2-페닐-퀴나졸린-4-일)-아민Compound No. 51. Cyclohexyl- (2-phenyl-quinazolin-4-yl) -amine 화합물번호 52. (4-페닐-부틸)-(2-페닐-퀴나졸린-4-일)-아민Compound 52. (4-phenyl-butyl)-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 53. (5-페닐-펜틸)-(2-페닐-퀴나졸린-4-일)-아민Compound 53. (5-phenyl-pentyl)-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 54. (4-메틸-벤질)-(2-페닐-퀴나졸린-4-일)-아민Compound number 54. (4-Methyl-benzyl)-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 55. 이소부틸-(2-페닐-퀴나졸린-4-일)-아민Compound number 55. Isobutyl- (2-phenyl-quinazolin-4-yl) -amine 화합물번호 56. 부틸-(2-페닐-퀴나졸린-4-일)-아민Compound No. 56. Butyl- (2-phenyl-quinazolin-4-yl) -amine 화합물번호 57. 나프탈렌-1-일메틸-(2-페닐-퀴나졸린-4-일)-아민Compound No. 57. Naphthalen-1-ylmethyl- (2-phenyl-quinazolin-4-yl) -amine 화합물번호 58. (2-페닐-퀴나졸린-4-일)-피리딘-2-일메틸-아민Compound 58. (2-phenyl-quinazolin-4-yl) -pyridin-2-ylmethyl-amine 화합물번호 59. (1-페닐-퀴나졸린-4-일)-티오펜-2-일메틸-아민Compound 59. (1-phenyl-quinazolin-4-yl) -thiophen-2-ylmethyl-amine 화합물번호 60. 이소프로필-(2-페닐-퀴나졸린-4-일)-아민Compound No. 60. Isopropyl- (2-phenyl-quinazolin-4-yl) -amine 화합물번호 61. (2-페닐-퀴나졸린-4-일)-프로필-아민Compound No. 61. (2-phenyl-quinazolin-4-yl) -propyl-amine 화합물번호 62. (3-이소프로폭시프로필)-(2-페닐-퀴나졸린-4-일)-아민Compound No. 62. (3-Isopropoxypropyl)-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 63. (3-플루오로-벤질)-(2-페닐-퀴나졸린-4-일)-아민Compound No. 63. (3-Fluoro-benzyl)-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 64. (2-페닐-퀴나졸린-4-일)-[2-(3-트리플루오로메틸-페닐)-에틸]-아민Compound No. 64. (2-phenyl-quinazolin-4-yl)-[2- (3-trifluoromethyl-phenyl) -ethyl] -amine 화합물번호 65. 벤조[1,3]디옥솔-5-일메틸-(2-페닐-퀴나졸린-4-일)-아민Compound number 65. Benzo [1,3] dioxol-5-ylmethyl- (2-phenyl-quinazolin-4-yl) -amine 화합물번호 66. (2-페닐-퀴나졸린-4-일)-(3-트리플루오로메틸-벤질)-아민Compound No. 66. (2-phenyl-quinazolin-4-yl)-(3-trifluoromethyl-benzyl) -amine 화합물번호 67. (2-메톡시-에틸)-(2-페닐-퀴나졸린-4-일)-아민Compound number 67. (2-methoxy-ethyl)-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 68. 펜에틸-(2-페닐-퀴나졸린-4-일)-아민Compound number 68. Phenethyl- (2-phenyl-quinazolin-4-yl) -amine 화합물번호 69. 페닐-(2-페닐-퀴나졸린-4-일)-아민Compound number 69. Phenyl- (2-phenyl-quinazolin-4-yl) -amine 화합물번호 70. (4-메톡시-페닐)-(2-페닐-퀴나졸린-4-일)-아민Compound No. 70. (4-methoxy-phenyl)-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 71. (2-페닐-퀴나졸린-4-일)-o-톨릴-아민Compound number 71. (2-phenyl-quinazolin-4-yl) -o-tolyl-amine 화합물번호 72. (4-이소프로필-페닐)-(2-페닐-퀴나졸린-4-일)-아민Compound number 72. (4-Isopropyl-phenyl)-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 73. (2,4-디메틸-페닐)-(2-페닐-퀴나졸린-4-일)-아민Compound No. 73. (2,4-Dimethyl-phenyl)-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 74. (2-페닐-퀴나졸린-4-일)-(4-운데실-페닐)-아민Compound number 74. (2-phenyl-quinazolin-4-yl)-(4-undecyl-phenyl) -amine 화합물번호 75. (4-에틸-페닐)-(2-페닐-퀴나졸린-4-일)-아민Compound number 75. (4-Ethyl-phenyl)-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 76. (4-플루오로-페닐)-(2-페닐-퀴나졸린-4-일)-아민Compound number 76. (4-Fluoro-phenyl)-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 77. (2-메톡시-페닐)-(2-페닐-퀴나졸린-4-일)-아민Compound No. 77. (2-Methoxy-phenyl)-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 78. (2-페닐-퀴나졸린-4-일)-(2,4,6-트리메틸-페닐)-아민Compound number 78. (2-phenyl-quinazolin-4-yl)-(2,4,6-trimethyl-phenyl) -amine 화합물번호 79. (4-부틸-페닐)-(2-페닐-퀴나졸린-4-일)-아민Compound number 79. (4-butyl-phenyl)-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 80. (2-페녹시-페닐)-(2-페닐-퀴나졸린-4-일)-아민Compound No. 80. (2-Phenoxy-phenyl)-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 81. (3-페녹시-페닐)-(2-페닐-퀴나졸린-4-일)-아민Compound No. 81. (3-phenoxy-phenyl)-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 82. (4-페녹시-페닐)-(2-페닐-퀴나졸린-4-일)-아민Compound number 82. (4-Penoxy-phenyl)-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 83. (3-브로모-페닐)-(2-페닐-퀴나졸린-4-일)-아민Compound number 83. (3-Bromo-phenyl)-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 84. 2-메톡시-5-(2-페닐-퀴나졸린-4-일아미노)페놀Compound number 84. 2-methoxy-5- (2-phenyl-quinazolin-4-ylamino) phenol 화합물번호 85. 5-(2-페닐-퀴나졸린-4-일아미노)-펜탄-1-올Compound number 85. 5- (2-phenyl-quinazolin-4-ylamino) -pentan-1-ol 화합물번호 86. 벤질-(2-페닐-퀴나졸린-4-일)-아민Compound number 86. Benzyl- (2-phenyl-quinazolin-4-yl) -amine 화합물번호 87. (1-페닐-에틸)-(2-페닐-퀴나졸린-4-일)-아민Compound number 87. (1-phenyl-ethyl)-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 88. (4-클로로-벤질)-(2-페닐-퀴나졸린-4-일)-아민Compound No. 88. (4-Chloro-benzyl)-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 89. (3,4-디클로로-벤질)-(2-페닐-퀴나졸린-4-일)-아민Compound number 89. (3,4-Dichloro-benzyl)-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 90. (3-메톡시-벤질)-(2-페닐-퀴나졸린-4-일)-아민Compound 90. (3-methoxy-benzyl)-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 91. (2-메톡시-벤질)-(2-페닐-퀴나졸린-4-일)-아민Compound number 91. (2-methoxy-benzyl)-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 92. (3,5-디메톡시-벤질)-(2-페닐-퀴나졸린-4-일)-아민Compound 92. (3,5-Dimethoxy-benzyl)-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 93. (2,3-디메톡시-벤질)-(2-페닐-퀴나졸린-4-일)-아민Compound 93. (2,3-Dimethoxy-benzyl)-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 94. (2-플루오로-벤질)-(2-페닐-퀴나졸린-4-일)-아민Compound 94. (2-Fluoro-benzyl)-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 95. 싸이클로펜틸-(2-페닐-퀴나졸린-4-일)-아민Compound number 95. Cyclopentyl- (2-phenyl-quinazolin-4-yl) -amine 화합물번호 96. sec-부틸-(2-페닐-퀴나졸린-4-일)-아민Compound No. 96. sec- butyl- (2-phenyl-quinazolin-4-yl) -amine 화합물번호 97. 알릴-(2-페닐-퀴나졸린-4-일)-아민Compound number 97. Allyl- (2-phenyl-quinazolin-4-yl) -amine 화합물번호 98. (2-페닐-퀴나졸린-4-일)-(2-트리플루오로메틸-벤질)-아민Compound 98. (2-phenyl-quinazolin-4-yl)-(2-trifluoromethyl-benzyl) -amine 화합물번호 99. 헥사데실-(2-페닐-퀴나졸린-4-일)-아민Compound No. 99. Hexadecyl- (2-phenyl-quinazolin-4-yl) -amine 화합물번호 100. (2-페닐-퀴나졸린-4-일)-(2-피롤리딘-1-일-에틸)-아민Compound No. 100. (2-phenyl-quinazolin-4-yl)-(2-pyrrolidin-1-yl-ethyl) -amine 화합물번호 101. (2-페닐-퀴나졸린-4-일)-(2-피페리딘-1-일-에틸)-아민Compound 101. (2-phenyl-quinazolin-4-yl)-(2-piperidin-1-yl-ethyl) -amine 화합물번호 102. (2-페닐-퀴나졸린-4-일)-(2-피리딘-2-일-에틸)-아민Compound number 102. (2-phenyl-quinazolin-4-yl)-(2-pyridin-2-yl-ethyl) -amine 화합물번호 103. [2-(3-플루오로-페닐)-에틸]-(2-페닐-퀴나졸린-4-일)-아민Compound 103. [2- (3-Fluoro-phenyl) -ethyl]-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 104. (1-메톡시메틸-프로필)-(2-페닐-퀴나졸린-4-일)-아민Compound number 104. (1-methoxymethyl-propyl)-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 105. (1-벤질-피페리딘-4-일)-(2-페닐-퀴나졸린-4-일)-아민Compound number 105. (1-benzyl-piperidin-4-yl)-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 106.(2-몰포린-4-일-에틸)-(2-페닐-퀴나졸린-4-일)-아민Compound number 106. (2-Morpholin-4-yl-ethyl)-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 107. [2-(3,4-디메톡시-페닐)-에틸]-(2-페닐-퀴나졸린-4-일)-아민Compound number 107. [2- (3,4-Dimethoxy-phenyl) -ethyl]-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 108. (2,4-디클로로-벤질)-(2-페닐-퀴나졸린-4-일)-아민Compound 108. (2,4-Dichloro-benzyl)-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 109. (2-클로로-벤질)-(2-페닐-퀴나졸린-4-일)-아민Compound 109. (2-Chloro-benzyl)-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 110. 싸이클로프로필-(2-페닐-퀴나졸린-4-일)-아민Compound No. 110. Cyclopropyl- (2-phenyl-quinazolin-4-yl) -amine 화합물번호 111. (2-페닐-퀴나졸린-4-일)-피리딘-3-일메틸-아민Compound number 111. (2-phenyl-quinazolin-4-yl) -pyridin-3-ylmethyl-amine 화합물번호 112. 2-(2-페닐-퀴나졸린-4-일아미노)-프로판-1-올Compound number 112. 2- (2-phenyl-quinazolin-4-ylamino) -propan-1-ol 화합물번호 113. 2-메톡시-4-[(2-페닐-퀴나졸린-4-일아미노)-메틸]-페놀Compound number 113. 2-methoxy-4-[(2-phenyl-quinazolin-4-ylamino) -methyl] -phenol 화합물번호 114. (2-플루오로-에틸)-(2-페닐-퀴나졸린-4-일)-아민Compound number 114. (2-Fluoro-ethyl)-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 115. (2,3-디클로로-벤질)-(2-페닐-퀴나졸린-4-일)-아민Compound number 115. (2,3-Dichloro-benzyl)-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 116. (3-니트로-벤질)-(2-페닐-퀴나졸린-4-일)-아민Compound No. 116. (3-Nitro-benzyl)-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 117. (1-에틸-피롤리딘-2-일메틸)-(2-페닐-퀴나졸린-4-일)-아민Compound 117. (1-Ethyl-pyrrolidin-2-ylmethyl)-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 118. (3,4-디메톡시-벤질)-(2-페닐-퀴나졸린-4-일)-아민Compound 118. (3,4-Dimethoxy-benzyl)-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 119. (2-페닐-퀴나졸린-4-일)-(2-p-톨릴-에틸)-아민Compound 119. (2-phenyl-quinazolin-4-yl)-(2- p -tolyl-ethyl) -amine 화합물번호 120. [2-(3-메톡시-페닐)-에틸]-(2-페닐-퀴나졸린-4-일)-아민Compound number 120. [2- (3-Methoxy-phenyl) -ethyl]-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 121. (1-에틸-프로필)-(2-페닐-퀴나졸린-4-일)-아민Compound 121. (1-ethyl-propyl)-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 122. [2-(2,5-디메톡시-페닐)-에틸]-(2-페닐-퀴나졸린-4-일)-아민Compound No. 122. [2- (2,5-Dimethoxy-phenyl) -ethyl]-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 123. [2-(4-클로로-페닐)-에틸]-(2-페닐-퀴나졸린-4-일)-아민Compound 123. [2- (4-Chloro-phenyl) -ethyl]-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 124. [2-(4-메톡시-페닐)-에틸]-(2-페닐-퀴나졸린-4-일)-아민Compound 124. [2- (4-methoxy-phenyl) -ethyl]-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 125. (1,3-디메틸-부틸)-(2-페닐-퀴나졸린-4-일)-아민Compound No. 125. (1,3-Dimethyl-butyl)-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 126. [2-(3-클로로-페닐)-에틸]-(2-페닐-퀴나졸린-4-일)-아민Compound 126. [2- (3-Chloro-phenyl) -ethyl]-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 127. [2-(2,4-디클로로-페닐)-에틸]-(2-페닐-퀴나졸린-4-일)-아민Compound 127. [2- (2,4-Dichloro-phenyl) -ethyl]-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 128. [2-(3,4-디플루오로-페닐)-에틸]-(2-페닐-퀴나졸린-4-일)-아민Compound No. 128. [2- (3,4-Difluoro-phenyl) -ethyl]-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 129. (2-페닐-퀴나졸린-4-일)-(3,4,5-트리메톡시-벤질)-아민Compound number 129. (2-phenyl-quinazolin-4-yl)-(3,4,5-trimethoxy-benzyl) -amine 화합물번호 130. (3-메틸-부틸)-(2-페닐-퀴나졸린-4-일)-아민Compound No. 130. (3-Methyl-butyl)-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 131. (2-싸이클로헥스-1-에닐-에틸)-(2-페닐-퀴나졸린-4-일)-아민Compound 131. (2-Cyclohex-1-enyl-ethyl)-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 132. 싸이클로헥실메틸-(2-페닐-퀴나졸린-4-일)-아민Compound No. 132. Cyclohexylmethyl- (2-phenyl-quinazolin-4-yl) -amine 화합물번호 133. (2,2-디페닐-에틸)-(2-페닐-퀴나졸린-4-일)-아민Compound 133. (2,2-Diphenyl-ethyl)-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 134. (2,4-디플루오로-벤질)-(2-페닐-퀴나졸린-4-일)-아민Compound number 134. (2,4-Difluoro-benzyl)-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 135. (2,5-디플루오로-벤질)-(2-페닐-퀴나졸린-4-일)-아민Compound number 135. (2,5-Difluoro-benzyl)-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 136. (3,3-디페닐-프로필)-(2-페닐-퀴나졸린-4-일)-아민Compound 136. (3,3-Diphenyl-propyl)-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 137. [2-(4-브로모-페닐)-에틸]-(2-페닐-퀴나졸린-4-일)-아민Compound number 137. [2- (4-Bromo-phenyl) -ethyl]-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 138. 부틸-메틸-(2-페닐-퀴나졸린-4-일)-아민Compound number 138. Butyl-methyl- (2-phenyl-quinazolin-4-yl) -amine 화합물번호 139. (2-페닐-퀴나졸린-4-일)-(4-트리플루오로메틸-벤질)-아민Compound 139. (2-phenyl-quinazolin-4-yl)-(4-trifluoromethyl-benzyl) -amine 화합물번호 140. [2-(2-플루오로-페닐)-에틸]-(2-페닐-퀴나졸린-4-일)-아민Compound number 140. [2- (2-Fluoro-phenyl) -ethyl]-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 141. (2-페닐-퀴나졸린-4-일)-피리딘-4-일메틸-아민Compound number 141. (2-phenyl-quinazolin-4-yl) -pyridin-4-ylmethyl-amine 화합물번호 142. (2-페닐-퀴나졸린-4-일)-피리딘-2-일메틸-아민Compound 142. (2-phenyl-quinazolin-4-yl) -pyridin-2-ylmethyl-amine 화합물번호 143. (2,3-디메틸-싸이클로헥실)-(2-페닐-퀴나졸린-4-일)-아민Compound 143. (2,3-Dimethyl-cyclohexyl)-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 144. (2,4-디메톡시-벤질)-(2-페닐-퀴나졸린-4-일)-아민Compound 144. (2,4-Dimethoxy-benzyl)-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 145. (3-클로로-벤질)-(2-페닐-퀴나졸린-4-일)-아민Compound 145. (3-Chloro-benzyl)-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 146. 1-페닐-2-(2-페닐-퀴나졸린-4-일아미노)-에탄올Compound No. 146. 1-phenyl-2- (2-phenyl-quinazolin-4-ylamino) -ethanol 화합물번호 147. (2,5-디메톡시-벤질)-(2-페닐-퀴나졸린-4-일)-아민Compound 147. (2,5-Dimethoxy-benzyl)-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 148. (4-브로모-벤질)-(2-페닐-퀴나졸린-4-일)-아민Compound 148. (4-Bromo-benzyl)-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 149. [2-(3,4-디클로로-페닐)-에틸]-(2-페닐-퀴나졸린-4-일)-아민Compound 149. [2- (3,4-Dichloro-phenyl) -ethyl]-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 150. 1-[3-(2-페닐-퀴나졸린-4-일아미노)-프로필]-피롤리딘-2-온Compound number 150. 1- [3- (2-phenyl-quinazolin-4-ylamino) -propyl] -pyrrolidin-2-one 화합물번호 151. [2-(2-클로로-페닐)-에틸]-(2-페닐-퀴나졸린-4-일)-아민Compound 151. [2- (2-Chloro-phenyl) -ethyl]-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 152. 2-[2-(2-페닐-퀴나졸린-4-일아미노)-에틸]-페놀Compound 152. 2- [2- (2-phenyl-quinazolin-4-ylamino) -ethyl] -phenol 화합물번호 153. (3-브로모-벤질)-(2-페닐-퀴나졸린-4-일)-아민Compound 153. (3-Bromo-benzyl)-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 154. (2,6-디메톡시-벤질)-(2-페닐-퀴나졸린-4-일)-아민Compound 154. (2,6-Dimethoxy-benzyl)-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 155. (2-브로모-벤질)-(2-페닐-퀴나졸린-4-일)-아민Compound 155. (2-Bromo-benzyl)-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 156. (3-몰포린-4-일-프로필)-(2-페닐-퀴나졸린-4-일)-아민Compound 156. (3-Morpholin-4-yl-propyl)-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 157. 2-[부틸-(2-페닐-퀴나졸린-4-일)-아미노]-에탄올Compound 157. 2- [butyl- (2-phenyl-quinazolin-4-yl) -amino] -ethanol 화합물번호 158. [2-(4-메틸-피페라진-1-일)-에틸]-(2-페닐-퀴나졸린-4-일)-아민Compound 158. [2- (4-Methyl-piperazin-1-yl) -ethyl]-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 159. 싸이클로펜틸-메틸-(2-페닐-퀴나졸린-4-일)-아민Compound 159. Cyclopentyl-methyl- (2-phenyl-quinazolin-4-yl) -amine 화합물번호 160. (2-페닐-퀴나졸린-4-일)-(2-피페라진-1-일-에틸)-아민Compound No. 160. (2-phenyl-quinazolin-4-yl)-(2-piperazin-1-yl-ethyl) -amine 화합물번호 161. O-(4-니트로-벤질)-N-(2-페닐-퀴나졸린-4-일)-하이드록실아민Compound No. 161. O - (4- nitro-benzyl) -N- (2- phenyl-quinazolin-4-yl) hydroxylamine 화합물번호 162. (4-클로로-페닐)-(2-페닐-퀴나졸린-4-일)-아민Compound 162. (4-Chloro-phenyl)-(2-phenyl-quinazolin-4-yl) -amine 화합물번호 163. 벤질-(2-메틸-퀴나졸린-4-일)-아민Compound number 163. Benzyl- (2-methyl-quinazolin-4-yl) -amine 화합물번호 164. (3-메톡시-벤질)-(2-메틸-퀴나졸린-4-일)-아민Compound 164. (3-methoxy-benzyl)-(2-methyl-quinazolin-4-yl) -amine 화합물번호 165. (4-메톡시-벤질)-(2-메틸-퀴나졸린-4-일)-아민Compound 165. (4-Methoxy-benzyl)-(2-methyl-quinazolin-4-yl) -amine 화합물번호 166. (2-메틸-퀴나졸린-4-일)-(3-트리플루오로메틸-벤질)-아민Compound 166. (2-Methyl-quinazolin-4-yl)-(3-trifluoromethyl-benzyl) -amine 화합물번호 167. (2-메틸-퀴나졸린-4-일)-펜에틸-아민Compound 167. (2-Methyl-quinazolin-4-yl) -phenethyl-amine 화합물번호 168. (2-메틸-퀴나졸린-4-일)-(4-페닐-부틸)-아민Compound 168. (2-Methyl-quinazolin-4-yl)-(4-phenyl-butyl) -amine 화합물번호 169. (2-메틸-퀴나졸린-4-일)-나프탈렌-1-일메틸-아민Compound 169. (2-Methyl-quinazolin-4-yl) -naphthalen-1-ylmethyl-amine 화합물번호 170. 벤조[1,3]디옥솔-5-일메틸-(2-메틸-퀴나졸린-4-일)-아민Compound number 170. Benzo [1,3] dioxol-5-ylmethyl- (2-methyl-quinazolin-4-yl) -amine 화합물번호 171. (3-플루오로-벤질)-(2-메틸-퀴나졸린-4-일)-아민Compound 171. (3-Fluoro-benzyl)-(2-methyl-quinazolin-4-yl) -amine 화합물번호 172. [2-(3-플루오로-페닐)-에틸]-(2-메틸-퀴나졸린-4-일)-아민Compound 172. [2- (3-Fluoro-phenyl) -ethyl]-(2-methyl-quinazolin-4-yl) -amine 화합물번호 173. 2-[2-(2-메틸-퀴나졸린-4-일아미노)-에톡시]-에탄올Compound 173. 2- [2- (2-Methyl-quinazolin-4-ylamino) -ethoxy] -ethanol 화합물번호 174. 2-(2-메틸-퀴나졸린-4-일아미노)-에탄올Compound No. 174. 2- (2-Methyl-quinazolin-4-ylamino) -ethanol 화합물번호 175. 벤질-(2-이소프로필-퀴나졸린-4-일)-아민Compound number 175. Benzyl- (2-isopropyl-quinazolin-4-yl) -amine 화합물번호 176. (2-이소프로필-퀴나졸린-4-일)-(3-메톡시-벤질)-아민Compound number 176. (2-Isopropyl-quinazolin-4-yl)-(3-methoxy-benzyl) -amine 화합물번호 177. (2-이소프로필-퀴나졸린-4-일)-(4-메톡시-벤질)-아민Compound 177. (2-Isopropyl-quinazolin-4-yl)-(4-methoxy-benzyl) -amine 화합물번호 178. (2-이소프로필-퀴나졸린-4-일)-(3-트리플루오로메틸-벤질)-아민Compound 178. (2-Isopropyl-quinazolin-4-yl)-(3-trifluoromethyl-benzyl) -amine 화합물번호 179. (2-이소프로필-퀴나졸린-4-일)-펜에틸-아민Compound number 179. (2-isopropyl-quinazolin-4-yl) -phenethyl-amine 화합물번호 180. (2-이소프로필-퀴나졸린-4-일)-(4-페닐-부틸)-아민Compound number 180. (2-isopropyl-quinazolin-4-yl)-(4-phenyl-butyl) -amine 화합물번호 181. (2-이소프로필-퀴나졸린-4-일)-나프탈렌-1-일메틸-아민Compound number 181. (2-isopropyl-quinazolin-4-yl) -naphthalen-1-ylmethyl-amine 화합물번호 182. 벤조[1,3]디옥솔-5-일메틸-(2-이소프로필-퀴나졸린-4-일)-아민Compound No. 182. Benzo [1,3] dioxol-5-ylmethyl- (2-isopropyl-quinazolin-4-yl) -amine 화합물번호 183. (3-플루오로-벤질)-(2-이소프로필-퀴나졸린-4-일)-아민Compound 183. (3-Fluoro-benzyl)-(2-isopropyl-quinazolin-4-yl) -amine 화합물번호 184. [2-(3-플루오로-페닐)-에틸]-(2-이소프로필-퀴나졸린-4-일)-아민Compound 184. [2- (3-Fluoro-phenyl) -ethyl]-(2-isopropyl-quinazolin-4-yl) -amine 화합물번호 185. 2-[2-(2-이소프로필-퀴나졸린-4-일아미노)-에톡시]-에탄올Compound 185. 2- [2- (2-isopropyl-quinazolin-4-ylamino) -ethoxy] -ethanol 화합물번호 186. 2-(2-이소프로필-퀴나졸린-4-일아미노)-에탄올Compound No.186. 2- (2-Isopropyl-quinazolin-4-ylamino) -ethanol 화합물번호 187. 벤질-(2-tert-부틸-퀴나졸린-4-일)-아민Compound number 187. Benzyl- (2- tert -butyl-quinazolin-4-yl) -amine 화합물번호 188. (2-tert-부틸-퀴나졸린-4-일)-(3-메톡시-벤질)-아민Compound 188. (2- tert -Butyl-quinazolin-4-yl)-(3-methoxy-benzyl) -amine 화합물번호 189. (2-tert-부틸-퀴나졸린-4-일)-(4-메톡시-벤질)-아민Compound number 189. (2- tert -Butyl-quinazolin-4-yl)-(4-methoxy-benzyl) -amine 화합물번호 189. (2-tert-부틸-퀴나졸린-4-일)-(4-메톡시-벤질)-아민Compound number 189. (2- tert -Butyl-quinazolin-4-yl)-(4-methoxy-benzyl) -amine 화합물번호 190. (2-tert-부틸-퀴나졸린-4-일)-(3-트리플루오로메틸-벤질)-아민Compound No. 190. (2- tert -Butyl-quinazolin-4-yl)-(3-trifluoromethyl-benzyl) -amine 화합물번호 191. (2-tert-부틸-퀴나졸린-4-일)-펜에틸-아민Compound 191. (2- tert -Butyl-quinazolin-4-yl) -phenethyl-amine 화합물번호 192. (2-tert-부틸-퀴나졸린-4-일)-(4-페닐-부틸)-아민Compound number 192. (2- tert -butyl-quinazolin-4-yl)-(4-phenyl-butyl) -amine 화합물번호 193. (2-tert-부틸-퀴나졸린-4-일)-나프탈렌-1-일메틸-아민Compound number 193. (2- tert -butyl-quinazolin-4-yl) -naphthalen-1-ylmethyl-amine 화합물번호 194. 벤조[1,3]디옥솔-5-일메틸-(2-tert-부틸-퀴나졸린-4-일)-아민Compound 194.Benzo [1,3] dioxol-5-ylmethyl- (2- tert -butyl-quinazolin-4-yl) -amine 화합물번호 195. (2-tert-부틸-퀴나졸린-4-일)-(3-플루오로-벤질)-아민Compound 195. (2- tert -Butyl-quinazolin-4-yl)-(3-fluoro-benzyl) -amine 화합물번호 196. (2-tert-부틸-퀴나졸린-4-일)-[2-(3-플루오로-페닐)-에틸]-아민Compound number 196. (2- tert -Butyl-quinazolin-4-yl)-[2- (3-fluoro-phenyl) -ethyl] -amine 화합물번호 197. 2-[2-(2-tert-부틸-퀴나졸린-4-일아미노)-에톡시]-에탄올Compound 197. 2- [2- (2- tert -butyl-quinazolin-4-ylamino) -ethoxy] -ethanol 화합물번호 198. 2-(2-tert-부틸-퀴나졸린-4-일아미노)-에탄올Compound 198. 2- (2- tert -butyl-quinazolin-4-ylamino) -ethanol 화합물번호 199. 벤질-(2-싸이클로헥실-퀴나졸린-4-일)-아민Compound number 199. Benzyl- (2-cyclohexyl-quinazolin-4-yl) -amine 화합물번호 200. (2-싸이클로헥실-퀴나졸린-4-일)-(3-메톡시-벤질)-아민Compound No. 200. (2-Cyclohexyl-quinazolin-4-yl)-(3-methoxy-benzyl) -amine 화합물번호 201. (2-싸이클로헥실-퀴나졸린-4-일)-(4-메톡시-벤질)-아민Compound No. 201. (2-Cyclohexyl-quinazolin-4-yl)-(4-methoxy-benzyl) -amine 화합물번호 202. (2-싸이클로헥실-퀴나졸린-4-일)-(3-트리플루오로메틸-벤질)-아민Compound 202. (2-Cyclohexyl-quinazolin-4-yl)-(3-trifluoromethyl-benzyl) -amine 화합물번호 203. (2-싸이클로헥실-퀴나졸린-4-일)-펜에틸-아민Compound 203. (2-Cyclohexyl-quinazolin-4-yl) -phenethyl-amine 화합물번호 204. (2-싸이클로헥실-퀴나졸린-4-일)-(4-페닐-부틸)-아민Compound 204. (2-Cyclohexyl-quinazolin-4-yl)-(4-phenyl-butyl) -amine 화합물번호 205. (2-싸이클로헥실-퀴나졸린-4-일)-나프탈렌-1-일메틸-아민Compound 205. (2-Cyclohexyl-quinazolin-4-yl) -naphthalen-1-ylmethyl-amine 화합물번호 206. 벤조[1,3]디옥솔-5-일메틸-(2-싸이클로헥실-퀴나졸린-4-일)-아민Compound 206. Benzo [1,3] dioxol-5-ylmethyl- (2-cyclohexyl-quinazolin-4-yl) -amine 화합물번호 207. (2-싸이클로헥실-퀴나졸린-4-일)-(3-플루오로-벤질)-아민Compound 207. (2-Cyclohexyl-quinazolin-4-yl)-(3-fluoro-benzyl) -amine 화합물번호 208. (2-싸이클로헥실-퀴나졸린-4-일)-[2-(3-플루오로-페닐)-에틸]-아민Compound 208. (2-Cyclohexyl-quinazolin-4-yl)-[2- (3-fluoro-phenyl) -ethyl] -amine 화합물번호 209. 2-[2-(2-싸이클로헥실-퀴나졸린-4-일아미노)-에톡시]-에탄올Compound 209. 2- [2- (2-cyclohexyl-quinazolin-4-ylamino) -ethoxy] -ethanol 화합물번호 210. 2-(2-싸이클로헥실-퀴나졸린-4-일아미노)-에탄올Compound No. 210. 2- (2-Cyclohexyl-quinazolin-4-ylamino) -ethanol 화합물번호 211. 벤질-(2-벤질-퀴나졸린-4-일)-아민Compound number 211. Benzyl- (2-benzyl-quinazolin-4-yl) -amine 화합물번호 212. (2-벤질-퀴나졸린-4-일)-(3-메톡시-벤질)-아민Compound number 212. (2-benzyl-quinazolin-4-yl)-(3-methoxy-benzyl) -amine 화합물번호 213. (2-벤질-퀴나졸린-4-일)-(4-메톡시-벤질)-아민Compound 213. (2-benzyl-quinazolin-4-yl)-(4-methoxy-benzyl) -amine 화합물번호 214. (2-벤질-퀴나졸린-4-일)-(3-트리플루오로메틸-벤질)-아민Compound number 214. (2-benzyl-quinazolin-4-yl)-(3-trifluoromethyl-benzyl) -amine 화합물번호 215. (2-벤질-퀴나졸린-4-일)-펜에틸-아민Compound 215. (2-benzyl-quinazolin-4-yl) -phenethyl-amine 화합물번호 216. (2-벤질-퀴나졸린-4-일)-(4-페닐-부틸)-아민Compound number 216. (2-benzyl-quinazolin-4-yl)-(4-phenyl-butyl) -amine 화합물번호 217. (2-벤질-퀴나졸린-4-일)-나프탈렌-1-일메틸-아민Compound number 217. (2-benzyl-quinazolin-4-yl) -naphthalen-1-ylmethyl-amine 화합물번호 218. 벤조[1,3]디옥솔-5-일메틸-(2-벤질-퀴나졸린-4-일)-아민Compound 218.Benzo [1,3] dioxol-5-ylmethyl- (2-benzyl-quinazolin-4-yl) -amine 화합물번호 219. (2-벤질-퀴나졸린-4-일)-(3-플루오로-벤질)-아민Compound number 219. (2-benzyl-quinazolin-4-yl)-(3-fluoro-benzyl) -amine 화합물번호 220. (2-벤질-퀴나졸린-4-일)-[2-(3-플루오로-페닐)-에틸]-아민Compound number 220. (2-benzyl-quinazolin-4-yl)-[2- (3-fluoro-phenyl) -ethyl] -amine 화합물번호 221. 2-[2-(2-벤질-퀴나졸린-4-일아미노)-에톡시]-에탄올Compound number 221. 2- [2- (2-benzyl-quinazolin-4-ylamino) -ethoxy] -ethanol 화합물번호 222. 2-(2-벤질-퀴나졸린-4-일아미노)-에탄올Compound 222. 2- (2-benzyl-quinazolin-4-ylamino) -ethanol 화합물번호 223. 벤질-(2-피리딘-2-일-퀴나졸린-4-일)-아민Compound number 223. Benzyl- (2-pyridin-2-yl-quinazolin-4-yl) -amine 화합물번호 224. (3-메톡시-벤질)-(2-피리딘-2-일-퀴나졸린-4-일)-아민Compound number 224. (3-Methoxy-benzyl)-(2-pyridin-2-yl-quinazolin-4-yl) -amine 화합물번호 225. (4-메톡시-벤질)-(2-피리딘-2-일-퀴나졸린-4-일)-아민Compound 225. (4-Methoxy-benzyl)-(2-pyridin-2-yl-quinazolin-4-yl) -amine 화합물번호 226. (2-피리딘-2-일-퀴나졸린-4-일)-(3-트리플루오로메틸-벤질)-아민Compound 226. (2-Pyridin-2-yl-quinazolin-4-yl)-(3-trifluoromethyl-benzyl) -amine 화합물번호 227. 펜에틸-(2-피리딘-2-일-퀴나졸린-4-일)-아민Compound number 227. Phenethyl- (2-pyridin-2-yl-quinazolin-4-yl) -amine 화합물번호 228. (4-페닐-부틸)-(2-피리딘-2-일-퀴나졸린-4-일)-아민Compound number 228. (4-phenyl-butyl)-(2-pyridin-2-yl-quinazolin-4-yl) -amine 화합물번호 229. 나프탈렌-1-일메틸-(2-피리딘-2-일-퀴나졸린-4-일)-아민Compound number 229. Naphthalen-1-ylmethyl- (2-pyridin-2-yl-quinazolin-4-yl) -amine 화합물번호 230. 벤조[1,3]디옥솔-5-일메틸-(2-피리딘-2-일-퀴나졸린-4-일)-아민Compound number 230. Benzo [1,3] dioxol-5-ylmethyl- (2-pyridin-2-yl-quinazolin-4-yl) -amine 화합물번호 231. (3-플루오로-벤질)-(2-피리딘-2-일-퀴나졸린-4-일)-아민Compound number 231. (3-Fluoro-benzyl)-(2-pyridin-2-yl-quinazolin-4-yl) -amine 화합물번호 232. [2-(3-플루오로-페닐)-에틸]-(2-피리딘-2-일-퀴나졸린-4-일)-아민Compound number 232. [2- (3-Fluoro-phenyl) -ethyl]-(2-pyridin-2-yl-quinazolin-4-yl) -amine 화합물번호 233. 2-[2-(2-피리딘-2-일-퀴나졸린-4-일아미노)-에톡시]-에탄올Compound 233. 2- [2- (2-pyridin-2-yl-quinazolin-4-ylamino) -ethoxy] -ethanol 화합물번호 234. 2-(2-피리딘-2-일-퀴나졸린-4-일아미노)-에탄올Compound 234. 2- (2-Pyridin-2-yl-quinazolin-4-ylamino) -ethanol 화합물번호 235. 벤질-(2-피리딘-3-일-퀴나졸린-4-일)-아민Compound number 235. Benzyl- (2-pyridin-3-yl-quinazolin-4-yl) -amine 화합물번호 236. (3-메톡시-벤질)-(2-피리딘-3-일-퀴나졸린-4-일)-아민Compound 236. (3-Methoxy-benzyl)-(2-pyridin-3-yl-quinazolin-4-yl) -amine 화합물번호 237. (4-메톡시-벤질)-(2-피리딘-3-일-퀴나졸린-4-일)-아민Compound 237. (4-Methoxy-benzyl)-(2-pyridin-3-yl-quinazolin-4-yl) -amine 화합물번호 238. (2-피리딘-3-일-퀴나졸린-4-일)-(3-트리플루오로메틸-벤질)-아민Compound 238. (2-Pyridin-3-yl-quinazolin-4-yl)-(3-trifluoromethyl-benzyl) -amine 화합물번호 239. 펜에틸-(2-피리딘-3-일-퀴나졸린-4-일)-아민Compound number 239. Phenethyl- (2-pyridin-3-yl-quinazolin-4-yl) -amine 화합물번호 240. (4-페닐-부틸)-(2-피리딘-3-일-퀴나졸린-4-일)-아민Compound number 240. (4-phenyl-butyl)-(2-pyridin-3-yl-quinazolin-4-yl) -amine 화합물번호 241. 나프탈렌-1-일메틸-(2-피리딘-3-일-퀴나졸린-4-일)-아민Compound number 241. Naphthalen-1-ylmethyl- (2-pyridin-3-yl-quinazolin-4-yl) -amine 화합물번호 242. 벤조[1,3]디옥솔-5-일메틸-(2-피리딘-3-일-퀴나졸린-4-일)-아민Compound 242. Benzo [1,3] dioxol-5-ylmethyl- (2-pyridin-3-yl-quinazolin-4-yl) -amine 화합물번호 243. (3-플루오로-벤질)-(2-피리딘-3-일-퀴나졸린-4-일)-아민Compound number 243. (3-Fluoro-benzyl)-(2-pyridin-3-yl-quinazolin-4-yl) -amine 화합물번호 244. [2-(3-플루오로-페닐)-에틸]-(2-피리딘-3-일-퀴나졸린-4-일)-아민Compound 244. [2- (3-Fluoro-phenyl) -ethyl]-(2-pyridin-3-yl-quinazolin-4-yl) -amine 화합물번호 245. 2-[2-(2-피리딘-3-일-퀴나졸린-4-일아미노)-에톡시]-에탄올Compound 245. 2- [2- (2-pyridin-3-yl-quinazolin-4-ylamino) -ethoxy] -ethanol 화합물번호 246. 2-(2-피리딘-3-일-퀴나졸린-4-일아미노)-에탄올Compound 246. 2- (2-Pyridin-3-yl-quinazolin-4-ylamino) -ethanol 화합물번호 247. 벤질-(2-피리딘-4-일-퀴나졸린-4-일)-아민Compound number 247. Benzyl- (2-pyridin-4-yl-quinazolin-4-yl) -amine 화합물번호 248. (3-메톡시-벤질)-(2-피리딘-4-일-퀴나졸린-4-일)-아민Compound 248. (3-Methoxy-benzyl)-(2-pyridin-4-yl-quinazolin-4-yl) -amine 화합물번호 249. (4-메톡시-벤질)-(2-피리딘-4-일-퀴나졸린-4-일)-아민Compound number 249. (4-Methoxy-benzyl)-(2-pyridin-4-yl-quinazolin-4-yl) -amine 화합물번호 250. (2-피리딘-4-일-퀴나졸린-4-일)-(3-트리플루오로메틸-벤질)-아민Compound 250. (2-Pyridin-4-yl-quinazolin-4-yl)-(3-trifluoromethyl-benzyl) -amine 화합물번호 251. 펜에틸-(2-피리딘-4-일-퀴나졸린-4-일)-아민Compound 251.Phenethyl- (2-pyridin-4-yl-quinazolin-4-yl) -amine 화합물번호 252. (4-페닐-부틸)-(2-피리딘-4-일-퀴나졸린-4-일)-아민Compound 252. (4-phenyl-butyl)-(2-pyridin-4-yl-quinazolin-4-yl) -amine 화합물번호 253. 나프탈렌-1-일메틸-(2-피리딘-4-일-퀴나졸린-4-일)-아민Compound number 253. Naphthalen-1-ylmethyl- (2-pyridin-4-yl-quinazolin-4-yl) -amine 화합물번호 254. 벤조[1,3]디옥솔-5-일메틸-(2-피리딘-4-일-퀴나졸린-4-일)-아민Compound 254. Benzo [1,3] dioxol-5-ylmethyl- (2-pyridin-4-yl-quinazolin-4-yl) -amine 화합물번호 255. (3-플루오로-벤질)-(2-피리딘-4-일-퀴나졸린-4-일)-아민Compound 255. (3-Fluoro-benzyl)-(2-pyridin-4-yl-quinazolin-4-yl) -amine 화합물번호 256. [2-(3-플루오로-페닐)-에틸]-(2-피리딘-4-일-퀴나졸린-4-일)-아민Compound No. 256. [2- (3-Fluoro-phenyl) -ethyl]-(2-pyridin-4-yl-quinazolin-4-yl) -amine 화합물번호 257. 2-[2-(2-피리딘-4-일-퀴나졸린-4-일아미노)-에톡시]-에탄올Compound number 257. 2- [2- (2-pyridin-4-yl-quinazolin-4-ylamino) -ethoxy] -ethanol 화합물번호 258. 2-(2-피리딘-4-일-퀴나졸린-4-일아미노)-에탄올Compound number 258. 2- (2-Pyridin-4-yl-quinazolin-4-ylamino) -ethanol 화합물번호 259. 벤질-[2-(4-클로로-페닐)-퀴나졸린-4-일]-아민Compound number 259. Benzyl- [2- (4-chloro-phenyl) -quinazolin-4-yl] -amine 화합물번호 260. [2-(4-클로로-페닐)-퀴나졸린-4-일]-(3-메톡시-벤질)-아민Compound 260. [2- (4-Chloro-phenyl) -quinazolin-4-yl]-(3-methoxy-benzyl) -amine 화합물번호 261. [2-(4-클로로-페닐)-퀴나졸린-4-일]-(4-메톡시-벤질)-아민Compound number 261. [2- (4-Chloro-phenyl) -quinazolin-4-yl]-(4-methoxy-benzyl) -amine 화합물번호 262. [2-(4-클로로-페닐)-퀴나졸린-4-일]-(3-트리플루오로메틸-벤질)-아민Compound 262. [2- (4-Chloro-phenyl) -quinazolin-4-yl]-(3-trifluoromethyl-benzyl) -amine 화합물번호 263. [2-(4-클로로-페닐)-퀴나졸린-4-일]-펜에틸-아민Compound 263. [2- (4-Chloro-phenyl) -quinazolin-4-yl] -phenethyl-amine 화합물번호 264. [2-(4-클로로-페닐)-퀴나졸린-4-일]-(4-페닐-부틸)-아민Compound number 264. [2- (4-Chloro-phenyl) -quinazolin-4-yl]-(4-phenyl-butyl) -amine 화합물번호 265. [2-(4-클로로-페닐)-퀴나졸린-4-일]-나프탈렌-1-일메틸-아민Compound 265. [2- (4-Chloro-phenyl) -quinazolin-4-yl] -naphthalen-1-ylmethyl-amine 화합물번호 266. 벤조[1,3]디옥솔-5-일메틸-[2-(4-클로로-페닐)-퀴나졸린-4-일]-아민Compound No. 266. Benzo [1,3] dioxol-5-ylmethyl- [2- (4-chloro-phenyl) -quinazolin-4-yl] -amine 화합물번호 267. [2-(4-클로로-페닐)-퀴나졸린-4-일]-(3-플루오로-벤질)-아민Compound number 267. [2- (4-Chloro-phenyl) -quinazolin-4-yl]-(3-fluoro-benzyl) -amine 화합물번호 268. [2-(4-클로로-페닐)-퀴나졸린-4-일]-[2-(3-플루오로-페닐)-에틸]-아민Compound 268. [2- (4-Chloro-phenyl) -quinazolin-4-yl]-[2- (3-fluoro-phenyl) -ethyl] -amine 화합물번호 269. 2-{2-[2-(4-클로로-페닐)-퀴나졸린-4-일아미노]-에톡시}-에탄올Compound number 269. 2- {2- [2- (4-Chloro-phenyl) -quinazolin-4-ylamino] -ethoxy} -ethanol 화합물번호 270. 2-[2-(4-클로로-페닐)-퀴나졸린-4-일아미노]-에탄올Compound 270. 2- [2- (4-Chloro-phenyl) -quinazolin-4-ylamino] -ethanol 화합물번호 271. (2,4-디메톡시-벤질)-(2-이소프로필-퀴나졸린-4-일)-아민Compound 271. (2,4-Dimethoxy-benzyl)-(2-isopropyl-quinazolin-4-yl) -amine 화합물번호 272. (2-벤질-퀴나졸린-4-일)-(2,4-디메톡시-벤질)-아민Compound number 272. (2-benzyl-quinazolin-4-yl)-(2,4-dimethoxy-benzyl) -amine 화합물번호 273. 4-(2,4-디메톡시-벤질옥시)-2-페닐-퀴나졸린Compound number 273. 4- (2,4-Dimethoxy-benzyloxy) -2-phenyl-quinazoline 화합물번호 274. 4-(2,4-디메톡시-벤질설파닐)-2-페닐-퀴나졸린Compound 274. 4- (2,4-Dimethoxy-benzylsulfanyl) -2-phenyl-quinazoline 화합물번호 275. (2-메톡시-벤질)-(2-피롤리딘-1-일-퀴나졸린-4-일)-아민Compound 275. (2-Methoxy-benzyl)-(2-pyrrolidin-1-yl-quinazolin-4-yl) -amine 화합물번호 276. (2-메톡시-벤질)-(2-피페리딘-1-일-퀴나졸린-4-일)-아민Compound 276. (2-Methoxy-benzyl)-(2-piperidin-1-yl-quinazolin-4-yl) -amine 화합물번호 277. (2-메톡시-벤질)-(2-몰포린-4-일-퀴나졸린-4-일)-아민Compound number 277. (2-Methoxy-benzyl)-(2-morpholin-4-yl-quinazolin-4-yl) -amine 화합물번호 278. (2-메톡시-벤질)-[2-(4-메틸-피페라진-1-일)-퀴나졸린-4-일]-아민Compound number 278. (2-Methoxy-benzyl)-[2- (4-methyl-piperazin-1-yl) -quinazolin-4-yl] -amine 화합물번호 279. (3-메톡시-벤질)-(2-피롤리딘-1-일-퀴나졸린-4-일)-아민Compound number 279. (3-Methoxy-benzyl)-(2-pyrrolidin-1-yl-quinazolin-4-yl) -amine 화합물번호 280. (3-메톡시-벤질)-(2-피페리딘-1-일-퀴나졸린-4-일)-아민Compound 280. (3-methoxy-benzyl)-(2-piperidin-1-yl-quinazolin-4-yl) -amine 화합물번호 281. (3-메톡시-벤질)-(2-몰포린-4-일-퀴나졸린-4-일)-아민Compound number 281. (3-methoxy-benzyl)-(2-morpholin-4-yl-quinazolin-4-yl) -amine 화합물번호 282. (3-메톡시-벤질)-[2-(4-메틸-피페라진-1-일)-퀴나졸린-4-일]-아민Compound number 282. (3-Methoxy-benzyl)-[2- (4-methyl-piperazin-1-yl) -quinazolin-4-yl] -amine 화합물번호 283. (4-메톡시-벤질)-(2-피롤리딘-1-일-퀴나졸린-4-일)-아민Compound number 283. (4-Methoxy-benzyl)-(2-pyrrolidin-1-yl-quinazolin-4-yl) -amine 화합물번호 284. (4-메톡시-벤질)-(2-피페리딘-1-일-퀴나졸린-4-일)-아민Compound number 284. (4-Methoxy-benzyl)-(2-piperidin-1-yl-quinazolin-4-yl) -amine 화합물번호 285. (4-메톡시-벤질)-(2-몰포린-4-일-퀴나졸린-4-일)-아민Compound number 285. (4-Methoxy-benzyl)-(2-morpholin-4-yl-quinazolin-4-yl) -amine 화합물번호 286. (4-메톡시-벤질)-[2-(4-메틸-피페라진-1-일)-퀴나졸린-4-일]-아민Compound No. 286. (4-methoxy-benzyl)-[2- (4-methyl-piperazin-1-yl) -quinazolin-4-yl] -amine 화합물번호 287. (2,3-디메톡시-벤질)-(2-피롤리딘-1-일-퀴나졸린-4-일)-아민Compound number 287. (2,3-dimethoxy-benzyl)-(2-pyrrolidin-1-yl-quinazolin-4-yl) -amine 화합물번호 288. (2,3-디메톡시-벤질)-(2-피페리딘-1-일-퀴나졸린-4-일)-아민Compound number 288. (2,3-Dimethoxy-benzyl)-(2-piperidin-1-yl-quinazolin-4-yl) -amine 화합물번호 289. (2,3-디메톡시-벤질)-(2-몰포린-4-일-퀴나졸린-4-일)-아민Compound 289. (2,3-Dimethoxy-benzyl)-(2-morpholin-4-yl-quinazolin-4-yl) -amine 화합물번호 290. (2,3-디메톡시-벤질)-[2-(4-메틸-피페라진-1-일)-퀴나졸린-4-일]-아민Compound number 290. (2,3-Dimethoxy-benzyl)-[2- (4-methyl-piperazin-1-yl) -quinazolin-4-yl] -amine 화합물번호 291. (2,4-디메톡시-벤질)-(2-피롤리딘-1-일-퀴나졸린-4-일)-아민Compound 291. (2,4-Dimethoxy-benzyl)-(2-pyrrolidin-1-yl-quinazolin-4-yl) -amine 화합물번호 292. (2,4-디메톡시-벤질)-(2-피페리딘-1-일-퀴나졸린-4-일)-아민Compound 292. (2,4-Dimethoxy-benzyl)-(2-piperidin-1-yl-quinazolin-4-yl) -amine 화합물번호 293. (2,4-디메톡시-벤질)-(2-몰포린-4-일-퀴나졸린-4-일)-아민Compound number 293. (2,4-Dimethoxy-benzyl)-(2-morpholin-4-yl-quinazolin-4-yl) -amine 화합물번호 294. (2,4-디메톡시-벤질)-[2-(4-메틸-피페라진-1-일)-퀴나졸린-4-일]-아민Compound number 294. (2,4-Dimethoxy-benzyl)-[2- (4-methyl-piperazin-1-yl) -quinazolin-4-yl] -amine 화합물번호 295. (2,5-디메톡시-벤질)-(2-피롤리딘-1-일-퀴나졸린-4-일)-아민Compound 295. (2,5-Dimethoxy-benzyl)-(2-pyrrolidin-1-yl-quinazolin-4-yl) -amine 화합물번호 296. (2,5-디메톡시-벤질)-(2-피페리딘-1-일-퀴나졸린-4-일)-아민Compound No. 296. (2,5-Dimethoxy-benzyl)-(2-piperidin-1-yl-quinazolin-4-yl) -amine 화합물번호 297. (2,5-디메톡시-벤질)-(2-몰포린-4-일-퀴나졸린-4-일)-아민Compound No. 297. (2,5-Dimethoxy-benzyl)-(2-morpholin-4-yl-quinazolin-4-yl) -amine 화합물번호 298. (2,5-디메톡시-벤질)-[2-(4-메틸-피페라진-1-일)-퀴나졸린-4-일]-아민Compound number 298. (2,5-Dimethoxy-benzyl)-[2- (4-methyl-piperazin-1-yl) -quinazolin-4-yl] -amine 화합물번호 299. (3,4-디메톡시-벤질)-(2-피롤리딘-1-일-퀴나졸린-4-일)-아민Compound 299. (3,4-Dimethoxy-benzyl)-(2-pyrrolidin-1-yl-quinazolin-4-yl) -amine 화합물번호 300. (3,4-디메톡시-벤질)-(2-피페리딘-1-일-퀴나졸린-4-일)-아민Compound No. 300. (3,4-Dimethoxy-benzyl)-(2-piperidin-1-yl-quinazolin-4-yl) -amine 화합물번호 301. (3,4-디메톡시-벤질)-(2-몰포린-4-일-퀴나졸린-4-일)-아민Compound 301. (3,4-Dimethoxy-benzyl)-(2-morpholin-4-yl-quinazolin-4-yl) -amine 화합물번호 302. (3,4-디메톡시-벤질)-[2-(4-메틸-피페라진-1-일)-퀴나졸린-4-일]-아민Compound number 302. (3,4-Dimethoxy-benzyl)-[2- (4-methyl-piperazin-1-yl) -quinazolin-4-yl] -amine 화합물번호 303. (3,5-디메톡시-벤질)-(2-피롤리딘-1-일-퀴나졸린-4-일)-아민Compound 303. (3,5-Dimethoxy-benzyl)-(2-pyrrolidin-1-yl-quinazolin-4-yl) -amine 화합물번호 304. (3,5-디메톡시-벤질)-(2-피페리딘-1-일-퀴나졸린-4-일)-아민Compound number 304. (3,5-dimethoxy-benzyl)-(2-piperidin-1-yl-quinazolin-4-yl) -amine 화합물번호 305. (3,5-디메톡시-벤질)-(2-몰포린-4-일-퀴나졸린-4-일)-아민Compound 305. (3,5-Dimethoxy-benzyl)-(2-morpholin-4-yl-quinazolin-4-yl) -amine 화합물번호 306. (3,5-디메톡시-벤질)-[2-(4-메틸-피페라진-1-일)-퀴나졸린-4-일]-아민Compound 306. (3,5-Dimethoxy-benzyl)-[2- (4-methyl-piperazin-1-yl) -quinazolin-4-yl] -amine 화합물번호 307. 벤조[1,3]디옥솔-5-일메틸-(2-피롤리딘-1-일-퀴나졸린-4-일)-아민Compound 307. Benzo [1,3] dioxol-5-ylmethyl- (2-pyrrolidin-1-yl-quinazolin-4-yl) -amine 화합물번호 308. 벤조[1,3]디옥솔-5-일메틸-(2-피페리딘-1-일-퀴나졸린-4-일)-아민Compound 308. Benzo [1,3] dioxol-5-ylmethyl- (2-piperidin-1-yl-quinazolin-4-yl) -amine 화합물번호 309. 벤조[1,3]디옥솔-5-일메틸-(2-몰포린-4-일-퀴나졸린-4-일)-아민Compound 309. Benzo [1,3] dioxol-5-ylmethyl- (2-morpholin-4-yl-quinazolin-4-yl) -amine 화합물번호 310. 벤조[1,3]디옥솔-5-일메틸-[2-(4-메틸-피페라진-1-일)-퀴나졸린-4-일]-아민Compound number 310. Benzo [1,3] dioxol-5-ylmethyl- [2- (4-methyl-piperazin-1-yl) -quinazolin-4-yl] -amine 화합물번호 311. (2-피롤리딘-1-일-퀴나졸린-4-일)-(3,4,5-트리메톡시-벤질)-아민Compound No. 311. (2-Pyrrolidin-1-yl-quinazolin-4-yl)-(3,4,5-trimethoxy-benzyl) -amine 화합물번호 312. (2-피페리딘-1-일-퀴나졸린-4-일)-(3,4,5-트리메톡시-벤질)-아민Compound No. 312. (2-Piperidin-1-yl-quinazolin-4-yl)-(3,4,5-trimethoxy-benzyl) -amine 화합물번호 313. (2-몰포린-4-일-퀴나졸린-4-일)-(3,4,5-트리메톡시-벤질)-아민Compound 313. (2-Morpholin-4-yl-quinazolin-4-yl)-(3,4,5-trimethoxy-benzyl) -amine 화합물번호 314. [2-(4-메틸-피페라진-1-일)-퀴나졸린-4-일]-(3,4,5-트리메톡시-벤질)-아민Compound number 314. [2- (4-Methyl-piperazin-1-yl) -quinazolin-4-yl]-(3,4,5-trimethoxy-benzyl) -amine 화합물번호 315. (2-피롤리딘-1-일-퀴나졸린-4-일)-(2,4,6-트리메톡시-벤질)-아민Compound 315. (2-Pyrrolidin-1-yl-quinazolin-4-yl)-(2,4,6-trimethoxy-benzyl) -amine 화합물번호 316. (2-피페리딘-1-일-퀴나졸린-4-일)-(2,4,6-트리메톡시-벤질)-아민Compound 316. (2-Piperidin-1-yl-quinazolin-4-yl)-(2,4,6-trimethoxy-benzyl) -amine 화합물번호 317. (2-몰포린-4-일-퀴나졸린-4-일)-(2,4,6-트리메톡시-벤질)-아민Compound number 317. (2-Morpholin-4-yl-quinazolin-4-yl)-(2,4,6-trimethoxy-benzyl) -amine 화합물번호 318. [2-(4-메틸-피페라진-1-일)-퀴나졸린-4-일]-(2,4,6-트리메톡시-벤질)-아민Compound number 318. [2- (4-Methyl-piperazin-1-yl) -quinazolin-4-yl]-(2,4,6-trimethoxy-benzyl) -amine 화합물번호 319. (2,4-디메톡시-벤질)-(2-에톡시-퀴나졸린-4-일)-아민Compound number 319. (2,4-dimethoxy-benzyl)-(2-ethoxy-quinazolin-4-yl) -amine 화합물번호 320. 벤조[1,3]디옥솔-5-일메틸-(2-에톡시-퀴나졸린-4-일)-아민Compound number 320. Benzo [1,3] dioxol-5-ylmethyl- (2-ethoxy-quinazolin-4-yl) -amine 화합물번호 321. (2-이소프로필-퀴나졸린-4-일)-(2-메톡시-벤질)-아민Compound number 321. (2-isopropyl-quinazolin-4-yl)-(2-methoxy-benzyl) -amine 화합물번호 322. (2,3-디메톡시-벤질)-(2-이소프로필-퀴나졸린-4-일)-아민Compound number 322. (2,3-Dimethoxy-benzyl)-(2-isopropyl-quinazolin-4-yl) -amine 화합물번호 323. (3,5-디메톡시-벤질)-(2-이소프로필-퀴나졸린-4-일)-아민Compound number 323. (3,5-Dimethoxy-benzyl)-(2-isopropyl-quinazolin-4-yl) -amine 화합물번호 324. (3,4-디메톡시-벤질)-(2-이소프로필-퀴나졸린-4-일)-아민Compound 324. (3,4-Dimethoxy-benzyl)-(2-isopropyl-quinazolin-4-yl) -amine 화합물번호 325. (2-이소프로필-퀴나졸린-4-일)-(3,4,5-트리메톡시-벤질)-아민Compound 325. (2-Isopropyl-quinazolin-4-yl)-(3,4,5-trimethoxy-benzyl) -amine 화합물번호 326. (2,5-디메톡시-벤질)-(2-이소프로필-퀴나졸린-4-일)-아민Compound number 326. (2,5-Dimethoxy-benzyl)-(2-isopropyl-quinazolin-4-yl) -amine 화합물번호 327. (2-이소프로필-퀴나졸린-4-일)-(2,4,6-트리메톡시-벤질)-아민Compound number 327. (2-isopropyl-quinazolin-4-yl)-(2,4,6-trimethoxy-benzyl) -amine 화합물번호 328. (2-벤질-퀴나졸린-4-일)-(2-메톡시-벤질)-아민Compound 328. (2-benzyl-quinazolin-4-yl)-(2-methoxy-benzyl) -amine 화합물번호 329. (2-벤질-퀴나졸린-4-일)-(2,3-디메톡시-벤질)-아민Compound number 329. (2-benzyl-quinazolin-4-yl)-(2,3-dimethoxy-benzyl) -amine 화합물번호 330. (2-벤질-퀴나졸린-4-일)-(3,5-디메톡시-벤질)-아민Compound 330. (2-benzyl-quinazolin-4-yl)-(3,5-dimethoxy-benzyl) -amine 화합물번호 331. (2-벤질-퀴나졸린-4-일)-(3,4-디메톡시-벤질)-아민Compound number 331. (2-benzyl-quinazolin-4-yl)-(3,4-dimethoxy-benzyl) -amine 화합물번호 332. (2-벤질-퀴나졸린-4-일)-(3,4,5-트리메톡시-벤질)-아민Compound number 332. (2-benzyl-quinazolin-4-yl)-(3,4,5-trimethoxy-benzyl) -amine 화합물번호 333. (2-벤질-퀴나졸린-4-일)-(2,4-디메톡시-벤질)-아민Compound number 333. (2-benzyl-quinazolin-4-yl)-(2,4-dimethoxy-benzyl) -amine 화합물번호 334. (2-벤질-퀴나졸린-4-일)-(2,5-디메톡시-벤질)-아민Compound 334. (2-benzyl-quinazolin-4-yl)-(2,5-dimethoxy-benzyl) -amine 화합물번호 335. (2-벤질-퀴나졸린-4-일)-(2,4,6-트리메톡시-벤질)-아민Compound 335. (2-benzyl-quinazolin-4-yl)-(2,4,6-trimethoxy-benzyl) -amine 화합물번호 336. (2-페닐-퀴나졸린-4-일)-(3,4,5-트리메톡시-벤질)-아민Compound number 336. (2-phenyl-quinazolin-4-yl)-(3,4,5-trimethoxy-benzyl) -amine 화합물번호 337. (2-페닐-퀴나졸린-4-일)-(2,4,6-트리메톡시-벤질)-아민Compound number 337. (2-phenyl-quinazolin-4-yl)-(2,4,6-trimethoxy-benzyl) -amine 화합물번호 338. (2-퓨란-2-일-퀴나졸린-4-일)-(2-메톡시-벤질)-아민Compound 338. (2-Furan-2-yl-quinazolin-4-yl)-(2-methoxy-benzyl) -amine 화합물번호 339. (2-퓨란-2-일-퀴나졸린-4-일)-(3-메톡시-벤질)-아민Compound 339. (2-Furan-2-yl-quinazolin-4-yl)-(3-methoxy-benzyl) -amine 화합물번호 340. (2-퓨란-2-일-퀴나졸린-4-일)-(4-메톡시-벤질)-아민Compound number 340. (2-Furan-2-yl-quinazolin-4-yl)-(4-methoxy-benzyl) -amine 화합물번호 341. 벤조[1,3]디옥솔-5-일메틸-(2-퓨란-2-일-퀴나졸린-4-일)-아민Compound No. 341.Benzo [1,3] dioxol-5-ylmethyl- (2-furan-2-yl-quinazolin-4-yl) -amine 화합물번호 342. (2,3-디메톡시-벤질)-(2-퓨란-2-일-퀴나졸린-4-일)-아민Compound number 342. (2,3-Dimethoxy-benzyl)-(2-furan-2-yl-quinazolin-4-yl) -amine 화합물번호 343. (3,5-디메톡시-벤질)-(2-퓨란-2-일-퀴나졸린-4-일)-아민Compound 343. (3,5-Dimethoxy-benzyl)-(2-furan-2-yl-quinazolin-4-yl) -amine 화합물번호 344. (3,4-디메톡시-벤질)-(2-퓨란-2-일-퀴나졸린-4-일)-아민Compound 344. (3,4-Dimethoxy-benzyl)-(2-furan-2-yl-quinazolin-4-yl) -amine 화합물번호 345. (2-퓨란-2-일-퀴나졸린-4-일)-(3,4,5-트리메톡시-벤질)-아민Compound No. 345. (2-Furan-2-yl-quinazolin-4-yl)-(3,4,5-trimethoxy-benzyl) -amine 화합물번호 346. (2,4-디메톡시-벤질)-(2-퓨란-2-일-퀴나졸린-4-일)-아민Compound 346. (2,4-Dimethoxy-benzyl)-(2-furan-2-yl-quinazolin-4-yl) -amine 화합물번호 347. (2,5-디메톡시-벤질)-(2-퓨란-2-일-퀴나졸린-4-일)-아민Compound 347. (2,5-Dimethoxy-benzyl)-(2-furan-2-yl-quinazolin-4-yl) -amine 화합물번호 348. (2-퓨란-2-일-퀴나졸린-4-일)-(2,4,6-트리메톡시-벤질)-아민Compound 348. (2-Furan-2-yl-quinazolin-4-yl)-(2,4,6-trimethoxy-benzyl) -amine 화합물번호 349. (2-메톡시-벤질)-(2-티오펜-2-일-퀴나졸린-4-일)-아민Compound No. 349. (2-methoxy-benzyl)-(2-thiophen-2-yl-quinazolin-4-yl) -amine 화합물번호 350. (3-메톡시-벤질)-(2-티오펜-2-일-퀴나졸린-4-일)-아민Compound 350. (3-Methoxy-benzyl)-(2-thiophen-2-yl-quinazolin-4-yl) -amine 화합물번호 351. (4-메톡시-벤질)-(2-티오펜-2-일-퀴나졸린-4-일)-아민Compound 351. (4-Methoxy-benzyl)-(2-thiophen-2-yl-quinazolin-4-yl) -amine 화합물번호 352. 벤조[1,3]디옥솔-5-일메틸-(2-티오펜-2-일-퀴나졸린-4-일)-Compound 352. Benzo [1,3] dioxol-5-ylmethyl- (2-thiophen-2-yl-quinazolin-4-yl)- 아민Amine 화합물번호 353. (2,3-디메톡시-벤질)-(2-티오펜-2-일-퀴나졸린-4-일)-아민Compound number 353. (2,3-Dimethoxy-benzyl)-(2-thiophen-2-yl-quinazolin-4-yl) -amine 화합물번호 354. (3,5-디메톡시-벤질)-(2-티오펜-2-일-퀴나졸린-4-일)-아민Compound 354. (3,5-Dimethoxy-benzyl)-(2-thiophen-2-yl-quinazolin-4-yl) -amine 화합물번호 355. (3,4-디메톡시-벤질)-(2-티오펜-2-일-퀴나졸린-4-일)-아민Compound 355. (3,4-Dimethoxy-benzyl)-(2-thiophen-2-yl-quinazolin-4-yl) -amine 화합물번호 356. (2-티오펜-2-일-퀴나졸린-4-일)-(3,4,5-트리메톡시-벤질)-아민Compound 356. (2-thiophen-2-yl-quinazolin-4-yl)-(3,4,5-trimethoxy-benzyl) -amine 화합물번호 357. (2,4-디메톡시-벤질)-(2-티오펜-2-일-퀴나졸린-4-일)-아민Compound number 357. (2,4-Dimethoxy-benzyl)-(2-thiophen-2-yl-quinazolin-4-yl) -amine 화합물번호 358. (2,5-디메톡시-벤질)-(2-티오펜-2-일-퀴나졸린-4-일)-아민Compound 358. (2,5-Dimethoxy-benzyl)-(2-thiophen-2-yl-quinazolin-4-yl) -amine 화합물번호 359. (2-티오펜-2-일-퀴나졸린-4-일)-(2,4,6-트리메톡시-벤질)-아민Compound number 359. (2-thiophen-2-yl-quinazolin-4-yl)-(2,4,6-trimethoxy-benzyl) -amine 화합물번호 360. (2-메톡시-벤질)-[2-(메톡시-페닐-메틸)-퀴나졸린-4-일]-아민Compound No. 360. (2-Methoxy-benzyl)-[2- (methoxy-phenyl-methyl) -quinazolin-4-yl] -amine 화합물번호 361. (3-메톡시-벤질)-[2-(메톡시-페닐-메틸)-퀴나졸린-4-일]-아민Compound 361. (3-Methoxy-benzyl)-[2- (methoxy-phenyl-methyl) -quinazolin-4-yl] -amine 화합물번호 362. (4-메톡시-벤질)-[2-(메톡시-페닐-메틸)-퀴나졸린-4-일]-아민Compound No. 362. (4-Methoxy-benzyl)-[2- (methoxy-phenyl-methyl) -quinazolin-4-yl] -amine 화합물번호 363. 벤조[1,3]디옥솔-5-일메틸-[2-(메톡시-페닐-메틸)-퀴나졸린-4-일]-아민Compound No. 363. Benzo [1,3] dioxol-5-ylmethyl- [2- (methoxy-phenyl-methyl) -quinazolin-4-yl] -amine 화합물번호 364. (2,3-디메톡시-벤질)-[2-(메톡시-페닐-메틸)-퀴나졸린-4-일]-아민Compound No. 364. (2,3-Dimethoxy-benzyl)-[2- (methoxy-phenyl-methyl) -quinazolin-4-yl] -amine 화합물번호 365. (3,5-디메톡시-벤질)-[2-(메톡시-페닐-메틸)-퀴나졸린-4-일]-아민Compound No. 365. (3,5-Dimethoxy-benzyl)-[2- (methoxy-phenyl-methyl) -quinazolin-4-yl] -amine 화합물번호 366. (3,4-디메톡시-벤질)-[2-(메톡시-페닐-메틸)-퀴나졸린-4-일]-아민Compound 366. (3,4-Dimethoxy-benzyl)-[2- (methoxy-phenyl-methyl) -quinazolin-4-yl] -amine 화합물번호 367. [2-(메톡시-페닐-메틸)-퀴나졸린-4-일]-(3,4,5-트리메톡시-벤질)-아민Compound number 367. [2- (methoxy-phenyl-methyl) -quinazolin-4-yl]-(3,4,5-trimethoxy-benzyl) -amine 화합물번호 368. (2,4-디메톡시-벤질)-[2-(메톡시-페닐-메틸)-퀴나졸린-4-일]-아민Compound number 368. (2,4-Dimethoxy-benzyl)-[2- (methoxy-phenyl-methyl) -quinazolin-4-yl] -amine 화합물번호 369. (2,5-디메톡시-벤질)-[2-(메톡시-페닐-메틸)-퀴나졸린-4-일]-아민Compound 369. (2,5-Dimethoxy-benzyl)-[2- (methoxy-phenyl-methyl) -quinazolin-4-yl] -amine 화합물번호 370. [2-(메톡시-페닐-메틸)-퀴나졸린-4-일]-(2,4,6-트리메톡시-벤질)-아민Compound 370. [2- (methoxy-phenyl-methyl) -quinazolin-4-yl]-(2,4,6-trimethoxy-benzyl) -amine 화합물번호 371. (2-메톡시-벤질)-[2-(1-페닐-에틸)-퀴나졸린-4-일]-아민Compound 371. (2-Methoxy-benzyl)-[2- (1-phenyl-ethyl) -quinazolin-4-yl] -amine 화합물번호 372. (3-메톡시-벤질)-[2-(1-페닐-에틸)-퀴나졸린-4-일]-아민Compound number 372. (3-Methoxy-benzyl)-[2- (1-phenyl-ethyl) -quinazolin-4-yl] -amine 화합물번호 373. (4-메톡시-벤질)-[2-(1-페닐-에틸)-퀴나졸린-4-일]-아민Compound 373. (4-Methoxy-benzyl)-[2- (1-phenyl-ethyl) -quinazolin-4-yl] -amine 화합물번호 374. 벤조[1,3]디옥솔-5-일메틸-[2-(1-페닐-에틸)-퀴나졸린-4-일]-아민Compound 374. Benzo [1,3] dioxol-5-ylmethyl- [2- (1-phenyl-ethyl) -quinazolin-4-yl] -amine 화합물번호 375. (2,3-디메톡시-벤질)-[2-(1-페닐-에틸)-퀴나졸린-4-일]-아민Compound 375. (2,3-Dimethoxy-benzyl)-[2- (1-phenyl-ethyl) -quinazolin-4-yl] -amine 화합물번호 376. (3,5-디메톡시-벤질)-[2-(1-페닐-에틸)-퀴나졸린-4-일]-아민Compound number 376. (3,5-Dimethoxy-benzyl)-[2- (1-phenyl-ethyl) -quinazolin-4-yl] -amine 화합물번호 377. (3,4-디메톡시-벤질)-[2-(1-페닐-에틸)-퀴나졸린-4-일]-아민Compound 377. (3,4-Dimethoxy-benzyl)-[2- (1-phenyl-ethyl) -quinazolin-4-yl] -amine 화합물번호 378. [2-(1-페닐-에틸)-퀴나졸린-4-일]-(3,4,5-트리메톡시-벤질)-아민Compound number 378. [2- (1-phenyl-ethyl) -quinazolin-4-yl]-(3,4,5-trimethoxy-benzyl) -amine 화합물번호 379. (2,4-디메톡시-벤질)-[2-(1-페닐-에틸)-퀴나졸린-4-일]-아민Compound No. 379. (2,4-Dimethoxy-benzyl)-[2- (1-phenyl-ethyl) -quinazolin-4-yl] -amine 화합물번호 380. (2,5-디메톡시-벤질)-[2-(1-페닐-에틸)-퀴나졸린-4-일]-아민Compound 380. (2,5-Dimethoxy-benzyl)-[2- (1-phenyl-ethyl) -quinazolin-4-yl] -amine 화합물번호 381. [2-(1-페닐-에틸)-퀴나졸린-4-일]-(2,4,6-트리메톡시-벤질)-아민Compound 381. [2- (1-phenyl-ethyl) -quinazolin-4-yl]-(2,4,6-trimethoxy-benzyl) -amine 화합물번호 382. (2-싸이클로프로필-퀴나졸린-4-일)-(2-메톡시-벤질)-아민Compound No. 382. (2-Cyclopropyl-quinazolin-4-yl)-(2-methoxy-benzyl) -amine 화합물번호 383. (2-싸이클로프로필-퀴나졸린-4-일)-(3-메톡시-벤질)-아민Compound 383. (2-Cyclopropyl-quinazolin-4-yl)-(3-methoxy-benzyl) -amine 화합물번호 384. (2-싸이클로프로필-퀴나졸린-4-일)-(4-메톡시-벤질)-아민Compound 384. (2-Cyclopropyl-quinazolin-4-yl)-(4-methoxy-benzyl) -amine 화합물번호 385. 벤조[1,3]디옥솔-5-일메틸-(2-싸이클로프로필-퀴나졸린-4-일)-아민Compound No. 385. Benzo [1,3] dioxol-5-ylmethyl- (2-cyclopropyl-quinazolin-4-yl) -amine 화합물번호 386. (2-싸이클로프로필-퀴나졸린-4-일)-(2,3-디메톡시-벤질)-아민Compound No. 386. (2-Cyclopropyl-quinazolin-4-yl)-(2,3-dimethoxy-benzyl) -amine 화합물번호 387. (2-싸이클로프로필-퀴나졸린-4-일)-(3,5-디메톡시-벤질)-아민Compound No. 387. (2-Cyclopropyl-quinazolin-4-yl)-(3,5-dimethoxy-benzyl) -amine 화합물번호 388. (2-싸이클로프로필-퀴나졸린-4-일)-(3,4-디메톡시-벤질)-아민Compound No. 388. (2-Cyclopropyl-quinazolin-4-yl)-(3,4-dimethoxy-benzyl) -amine 화합물번호 389. (2-싸이클로프로필-퀴나졸린-4-일)-(3,4,5-트리메톡시-벤질)-아민Compound No. 389. (2-Cyclopropyl-quinazolin-4-yl)-(3,4,5-trimethoxy-benzyl) -amine 화합물번호 390. (2-싸이클로프로필-퀴나졸린-4-일)-(2,4-디메톡시-벤질)-아민Compound number 390. (2-Cyclopropyl-quinazolin-4-yl)-(2,4-dimethoxy-benzyl) -amine 화합물번호 391. (2-싸이클로프로필-퀴나졸린-4-일)-(2,5-디메톡시-벤질)-아민Compound No. 391. (2-Cyclopropyl-quinazolin-4-yl)-(2,5-dimethoxy-benzyl) -amine 화합물번호 392. (2-싸이클로프로필-퀴나졸린-4-일)-(2,4,6-트리메톡시-벤질)-아민Compound No. 392. (2-Cyclopropyl-quinazolin-4-yl)-(2,4,6-trimethoxy-benzyl) -amine 화합물번호 393. (2-메톡시-벤질)-(2-프로필-퀴나졸린-4-일)-아민Compound No. 393. (2-Methoxy-benzyl)-(2-propyl-quinazolin-4-yl) -amine 화합물번호 394. (3-메톡시-벤질)-(2-프로필-퀴나졸린-4-일)-아민Compound 394. (3-Methoxy-benzyl)-(2-propyl-quinazolin-4-yl) -amine 화합물번호 395. (4-메톡시-벤질)-(2-프로필-퀴나졸린-4-일)-아민Compound number 395. (4-Methoxy-benzyl)-(2-propyl-quinazolin-4-yl) -amine 화합물번호 396. 벤조[1,3]디옥솔-5-일메틸-(2-프로필-퀴나졸린-4-일)-아민Compound No. 396.Benzo [1,3] dioxol-5-ylmethyl- (2-propyl-quinazolin-4-yl) -amine 화합물번호 397. (2,3-디메톡시-벤질)-(2-프로필-퀴나졸린-4-일)-아민Compound 397. (2,3-Dimethoxy-benzyl)-(2-propyl-quinazolin-4-yl) -amine 화합물번호 398. (3,5-디메톡시-벤질)-(2-프로필-퀴나졸린-4-일)-아민Compound 398. (3,5-Dimethoxy-benzyl)-(2-propyl-quinazolin-4-yl) -amine 화합물번호 399. (3,4-디메톡시-벤질)-(2-프로필-퀴나졸린-4-일)-아민Compound 399. (3,4-Dimethoxy-benzyl)-(2-propyl-quinazolin-4-yl) -amine 화합물번호 400. (2-프로필-퀴나졸린-4-일)-(3,4,5-트리메톡시-벤질)-아민Compound 400. (2-propyl-quinazolin-4-yl)-(3,4,5-trimethoxy-benzyl) -amine 화합물번호 401. (2,4-디메톡시-벤질)-(2-프로필-퀴나졸린-4-일)-아민Compound number 401. (2,4-Dimethoxy-benzyl)-(2-propyl-quinazolin-4-yl) -amine 화합물번호 402. (2,5-디메톡시-벤질)-(2-프로필-퀴나졸린-4-일)-아민Compound number 402. (2,5-Dimethoxy-benzyl)-(2-propyl-quinazolin-4-yl) -amine 화합물번호 403. (2-프로필-퀴나졸린-4-일)-(2,4,6-트리메톡시-벤질)-아민Compound number 403. (2-propyl-quinazolin-4-yl)-(2,4,6-trimethoxy-benzyl) -amine 화합물번호 404. (2-메톡시-벤질)-퀴나졸린-4-일-아민Compound number 404. (2-methoxy-benzyl) -quinazolin-4-yl-amine 화합물번호 405. (3-메톡시-벤질)-퀴나졸린-4-일-아민Compound number 405. (3-Methoxy-benzyl) -quinazolin-4-yl-amine 화합물번호 406. (4-메톡시-벤질)-퀴나졸린-4-일-아민Compound 406. (4-Methoxy-benzyl) -quinazolin-4-yl-amine 화합물번호 407. 벤조[1,3]디옥솔-5-일메틸-퀴나졸린-4-일-아민Compound 407. Benzo [1,3] dioxol-5-ylmethyl-quinazolin-4-yl-amine 화합물번호 408. (2,3-디메톡시-벤질)-퀴나졸린-4-일-아민Compound number 408. (2,3-dimethoxy-benzyl) -quinazolin-4-yl-amine 화합물번호 409. (3,5-디메톡시-벤질)-퀴나졸린-4-일-아민Compound number 409. (3,5-Dimethoxy-benzyl) -quinazolin-4-yl-amine 화합물번호 410. (3,4-디메톡시-벤질)-퀴나졸린-4-일-아민Compound 410. (3,4-Dimethoxy-benzyl) -quinazolin-4-yl-amine 화합물번호 411. 퀴나졸린-4-일-(3,4,5-트리메톡시-벤질)-아민Compound number 411. Quinazolin-4-yl- (3,4,5-trimethoxy-benzyl) -amine 화합물번호 412. (2,4-디메톡시-벤질)-퀴나졸린-4-일-아민Compound 412. (2,4-Dimethoxy-benzyl) -quinazolin-4-yl-amine 화합물번호 413. (2,5-디메톡시-벤질)-퀴나졸린-4-일-아민Compound 413. (2,5-dimethoxy-benzyl) -quinazolin-4-yl-amine 화합물번호 414. 퀴나졸린-4-일-(2,4,6-트리메톡시-벤질)-아민Compound number 414. Quinazolin-4-yl- (2,4,6-trimethoxy-benzyl) -amine 화합물번호 415. 4-벤질옥시-2-이소프로필-퀴나졸린Compound number 415. 4-benzyloxy-2-isopropyl-quinazoline 화합물번호 416. 4-벤질설파닐-2-이소프로필-퀴나졸린Compound number 416. 4-benzylsulfanyl-2-isopropyl-quinazoline 다음 화학식 1로 표시되는 퀴나졸린 유도체, 이의 약제학적으로 허용가능한 염, 또는 이의 프로드럭을 함유하는 것임을 특징으로 하는 당뇨 또는 비만의 치료 및 예방용 약제조성물 :Quinazoline derivative represented by the following formula (1), a pharmaceutically acceptable salt thereof, or a pharmaceutical composition for the treatment and prevention of diabetes or obesity, characterized in that it contains a prodrug thereof: [화학식 1][Formula 1]
Figure 112005078193254-PAT00022
Figure 112005078193254-PAT00022
 상기 화학식 1에서, Ra, Rb, Rc, 및 m은 각각 상기 청구항 1에서 정의한 바와 같다.In Formula 1, R a , R b , R c , and m are as defined in claim 1, respectively. 다음 화학식 1로 표시되는 퀴나졸린 유도체, 이의 약제학적으로 허용가능한 염, 또는 이의 프로드럭을 함유하는 것임을 특징으로 하는 당뇨 치료 및 예방제 :A quinazoline derivative represented by the following formula (1), a pharmaceutically acceptable salt thereof, or a prodrug thereof, comprising: a diabetes treatment and prevention agent [화학식 1][Formula 1]
Figure 112005078193254-PAT00023
Figure 112005078193254-PAT00023
 상기 화학식 1에서, Ra, Rb, Rc, 및 m은 각각 상기 청구항 1에서 정의한 바와 같다.In Formula 1, R a , R b , R c , and m are as defined in claim 1, respectively. 다음 화학식 1로 표시되는 퀴나졸린 유도체, 이의 약제학적으로 허용가능한 염, 또는 이의 프로드럭을 함유하는 것임을 특징으로 하는 비만 치료 및 예방제 :A quinazoline derivative represented by the following formula (1), a pharmaceutically acceptable salt thereof, or a prodrug thereof, comprising: a treatment and prevention agent for obesity [화학식 1][Formula 1]
Figure 112005078193254-PAT00024
Figure 112005078193254-PAT00024
 상기 화학식 1에서, Ra, Rb, Rc, 및 m은 각각 상기 청구항 1에서 정의한 바와 같다.In Formula 1, R a , R b , R c , and m are as defined in claim 1, respectively.
KR1020050134722A 2004-12-31 2005-12-30 Quinazolin Derivatives Effective in Preventing Diabetes and Obesity Ceased KR20060079121A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20040117708 2004-12-31
KR1020040117708 2004-12-31

Publications (1)

Publication Number Publication Date
KR20060079121A true KR20060079121A (en) 2006-07-05

Family

ID=36615173

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020050134722A Ceased KR20060079121A (en) 2004-12-31 2005-12-30 Quinazolin Derivatives Effective in Preventing Diabetes and Obesity

Country Status (4)

Country Link
EP (1) EP1844023A1 (en)
JP (1) JP2008526734A (en)
KR (1) KR20060079121A (en)
WO (1) WO2006071095A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101467996B1 (en) * 2010-04-30 2014-12-11 전북대학교산학협력단 The qhinazoline derivatives which are inhibitor of ADP-ribosyl cyclases
WO2024136338A1 (en) * 2022-12-22 2024-06-27 연세대학교 산학협력단 Composition comprising n-benzylquinazoline-4-amine compound for preventing or treating obesity or lipid-associated metabolic disorders

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2584507C (en) 2004-10-20 2016-04-26 Resverlogix Corp. Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases
EP1861388B1 (en) 2005-03-14 2017-07-05 Saniona A/S Potassium channel modulating agents and their medical use
CA2617213C (en) 2005-07-29 2014-01-28 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
FR2891829A1 (en) * 2005-10-12 2007-04-13 Sanofi Aventis Sa 4-AMINO-QUINAZOLINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF
JP2009519995A (en) * 2005-12-20 2009-05-21 ノイロサーチ アクティーゼルスカブ 2-Pyridin-2-yl-quinazoline derivatives as potassium channel modulators for the treatment of respiratory diseases
PT2118074E (en) 2007-02-01 2014-03-20 Resverlogix Corp Compounds for the prevention and treatment of cardiovascular diseases
WO2008157500A1 (en) * 2007-06-17 2008-12-24 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
US20090023773A1 (en) * 2007-06-27 2009-01-22 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
EP2209778B1 (en) 2007-09-21 2012-08-29 Array Biopharma, Inc. Pyridin-2 -yl-amino-i, 2, 4 -thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
CA2707047C (en) * 2007-12-12 2017-11-28 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds for metabolic disorders
EP2269993B1 (en) 2008-04-23 2013-02-27 Kyowa Hakko Kirin Co., Ltd. 2-aminoquinazoline derivative
WO2009158404A1 (en) 2008-06-26 2009-12-30 Resverlogix Corp. Methods of preparing quinazolinone derivatives
WO2010006115A1 (en) * 2008-07-11 2010-01-14 Myriad Pharmaceuticals, Inc. Pharmaceutical compounds as cytotoxic agents and the use thereof
ES2542835T3 (en) 2009-01-08 2015-08-12 Resverlogix Corporation Compounds for the prevention and treatment of cardiovascular diseases
US9238640B2 (en) 2009-03-18 2016-01-19 Resverlogix Corp. Anti-inflammatory agents
EP2421533B1 (en) 2009-04-22 2018-10-17 Resverlogix Corp. Novel anti-inflammatory agents
PH12012500097A1 (en) * 2009-07-21 2011-01-27 Shanghai Inst Organic Chem Potent small molecule inhibitors of autophagy, and methods of use thereof
NZ598516A (en) 2009-09-03 2013-02-22 Bristol Myers Squibb Co Quinazolines as potassium ion channel inhibitors
PT2773354T (en) 2011-11-01 2019-07-17 Resverlogix Corp Oral immediate release formulations for substituted quinazolinones
ES2661510T3 (en) 2011-12-15 2018-04-02 Novartis Ag Use of inhibitors of PI3K activity or function
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
EP2935253B1 (en) 2012-12-21 2018-08-01 Zenith Epigenetics Ltd. Novel heterocyclic compounds as bromodomain inhibitors
EP2938610A2 (en) * 2012-12-28 2015-11-04 The U.S.A. as represented by the Secretary, Department of Health and Human Services Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof
CA2898018C (en) 2013-02-01 2021-02-09 Wellstat Therapeutics Corporation Substituted quinolin-4-amine compounds and pharmaceutical compositions thereof having anti-inflammatory, antifungal, antiparasitic and anticancer activity
EP2970177A1 (en) 2013-03-15 2016-01-20 Pfizer Inc. Indole compounds that activate ampk
AU2015296322B2 (en) 2014-07-26 2019-09-19 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as CDK inhibitors and uses thereof
CA2969839A1 (en) 2014-12-05 2016-06-09 Subramaniam Ananthan Heterocyclic compounds as biogenic amine transport modulators
US10087148B2 (en) * 2014-12-05 2018-10-02 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer, National Institute Of Health Quinazolines as biogenic amine transport modulators
TWI699355B (en) 2014-12-24 2020-07-21 美商基利科學股份有限公司 Quinazoline compounds
AU2015371257B2 (en) 2014-12-24 2018-09-06 Gilead Sciences, Inc. Isoquinoline compounds for the treatment of HIV
MX2017008520A (en) 2014-12-24 2018-03-01 Gilead Sciences Inc Fused pyrimidine compounds for the treatment of hiv.
EP3268007B1 (en) 2015-03-13 2022-11-09 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
CN106045924B (en) * 2016-07-28 2018-08-14 黑龙江八一农垦大学 A kind of synthetic method of aryl substituted quinazoline amine derivative
CN112566906B (en) 2018-07-26 2024-11-12 多曼治疗学公司 Substituted quinazolinone derivatives and their use as positive allosteric modulators of MGLUR4
CN116323608A (en) 2020-05-19 2023-06-23 卡尔优普公司 AMPK activator
JP2023531726A (en) 2020-06-26 2023-07-25 キャリーオペ，インク． AMPK Activator
EP4236957A4 (en) * 2020-10-30 2024-08-07 Resverlogix Corp. Methods for lowering hba1c level with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor
CZ309449B6 (en) * 2020-12-24 2023-01-25 Ústav experimentální botaniky AV ČR, v. v. i. Quinazoline derivatives as selective cyclooxygenase-1 inhibitors
CN112608302B (en) * 2020-12-28 2022-05-24 郑州大学第一附属医院 Quinazoline derivative for activating target ubiquitination degradation of EGFR protein through low-oxygen reduction and application thereof
CN114315802B (en) * 2021-12-14 2023-06-16 西安医学院 Quinazoline nitrogen-containing heterocyclic derivative, preparation method and application

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3340260A (en) * 1962-12-03 1967-09-05 Ciba Geigy Corp 4-amino-pyrimidines
JPS542325A (en) * 1977-06-07 1979-01-09 Sankyo Co Ltd Agricultural and horticultural pesticide
IL89027A (en) * 1988-01-29 1993-01-31 Lilly Co Eli Quinazoline derivatives, process for their preparation and fungicidal, insecticidal and miticidal compositions containing them
PT100905A (en) * 1991-09-30 1994-02-28 Eisai Co Ltd BICYCLE HYGIENEOUS HETEROCYCLIC COMPOUNDS CONTAINING BENZENE, CYCLOHEXAN OR PYRIDINE AND PYRIMIDINE, PYRIDINE OR IMIDAZOLE SUBSTITUTES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
JP2657760B2 (en) * 1992-07-15 1997-09-24 小野薬品工業株式会社 4-aminoquinazoline derivatives and pharmaceuticals containing them
GB2295387A (en) * 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
DE19756388A1 (en) * 1997-12-18 1999-06-24 Hoechst Marion Roussel De Gmbh New 2-aryl-4-amino-6,7-di:methoxy-quinazoline derivatives useful as guanylate cyclase activators for treating cardiovascular diseases, etc.
KR20010089171A (en) * 1998-08-21 2001-09-29 추후제출 Quinazoline derivatives
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
WO2002062767A1 (en) * 2001-02-07 2002-08-15 Sumitomo Pharmaceuticals Company, Limited Novel quinazoline derivatives
DE10224462A1 (en) * 2002-06-03 2003-12-11 Bayer Ag Use of cGMP stimulating compounds
WO2004087680A1 (en) * 2003-03-31 2004-10-14 Taisho Pharmaceutical Co., Ltd. Novel quinazoline derivatives and methods of treatment related to the use thereof
EP1610774A4 (en) * 2003-04-09 2008-07-16 Exelixis Inc Tie-2 modulators and methods of use
WO2005003100A2 (en) * 2003-07-03 2005-01-13 Myriad Genetics, Inc. 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101467996B1 (en) * 2010-04-30 2014-12-11 전북대학교산학협력단 The qhinazoline derivatives which are inhibitor of ADP-ribosyl cyclases
WO2024136338A1 (en) * 2022-12-22 2024-06-27 연세대학교 산학협력단 Composition comprising n-benzylquinazoline-4-amine compound for preventing or treating obesity or lipid-associated metabolic disorders

Also Published As

Publication number Publication date
EP1844023A1 (en) 2007-10-17
WO2006071095A1 (en) 2006-07-06
JP2008526734A (en) 2008-07-24

Similar Documents

Publication Publication Date Title
KR20060079121A (en) Quinazolin Derivatives Effective in Preventing Diabetes and Obesity
DE60131844T2 (en) 2-AMINO-3- (ALKYL) -PYRIMIDONE DERIVATIVES AS GSK3.BETA. HEMMER
KR100967070B1 (en) Overactive Bladder Therapeutics Using Acetate Acetate Derivatives as Active Ingredients
US8653091B2 (en) Pyrid-2yl fused heterocyclic compounds, and compositions and uses thereof
BG63487B1 (en) The use of heterocyclic compounds
MXPA06007715A (en) (3-oxo-3, 4-dihydro-quinoxalin-2-yl-amino) -benzamide derivatives and related compound as glycogen phosphorylase inhibitors for the treatment of diabetes and obesity.
US9708321B2 (en) Spiro-quinazolinone derivatives and their use as positive allosteric modulators of mGluR4
CN102548983A (en) Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitor
US20080207614A1 (en) Quinazoline derivatives for the treatment and prevention of diabetes and obesity
WO2007048840A1 (en) Novel beta-agonists, process for their preparation and their use as medicaments
KR20030085005A (en) Antipruritics
EP3994138B1 (en) Estrogen-related receptor alpha (erralpha) modulators
KR100807515B1 (en) New compounds
EP1340748B1 (en) Quinazoline derivatives and drugs
KR101676889B1 (en) Phenylimidazole compounds
CN114656472A (en) Pyrazolopyrimidine compound, isomer or salt, and preparation method and application thereof
DE102004021779A1 (en) New beta-agonists, process for their preparation and their use as medicines
US7368454B2 (en) (3,4-dihydro-quinazolin-2-yl)-aryl-amines
JPS6157563A (en) 5-oxypyrimidinone derivative and manufacture
KR900003301B1 (en) Method for preparing 2-piperazinyl-4-phenyl quinazoline derivatives and their salts
US5681843A (en) Parabanic acid derivatives
CN114891003A (en) Novel dihydropyrimidine compounds, intermediates or salts, and preparation method and application thereof
WO2011023722A1 (en) Novel quinoxalinone hepcidin antagonists
KR100556559B1 (en) 2- (4- (4- (4,5-dichloro-2-methylimidazol-1-yl) butyl) -1-piperazinyl) -5-fluoropyrimidine, the preparation method thereof and its Therapeutic use
US7348332B2 (en) (3,4-dihydro-quinazolin-2-yl)-indan-1-yl-amines

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 20051230

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20100813

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 20051230

Comment text: Patent Application

PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20120621

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20120829

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20120621

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I